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Preface to “Recent Advances in HTLV Research 
2015” 
Human T-cell leukemia virus (HTLV) has been foundational in our understanding of the 
molecular pathology of virus-induced cancers. The study of adult T-cell leukemia (ATL) and 
associated neurological pathologies, including HTLV-associated-myelopathy/tropical spastic 
paraparesis (HAM/TSP) continues to enhance our understanding regarding how viruses can cause 
cancer and associated pathologies.  This volume presents the latest advancements in knowledge in the 
study of HTLV replication and pathology, and outlines prospects for future advancement in the field. 
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Abstract: Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus discovered.
Studies on HTLV-1 have been instrumental for our understanding of the molecular pathology of
virus-induced cancers. HTLV-1 is the etiological agent of an adult T-cell leukemia (ATL) and can
lead to a variety of neurological pathologies, including HTLV-1-associated-myelopathy/tropical
spastic paraparesis (HAM/TSP). The ability to treat the aggressive ATL subtypes remains inadequate.
HTLV-1 replicates by (1) an infectious cycle involving virus budding and infection of new permissive
target cells and (2) mitotic division of cells harboring an integrated provirus. Virus replication
initiates host antiviral immunity and the checkpoint control of cell proliferation, but HTLV-1 has
evolved elegant strategies to counteract these host defense mechanisms to allow for virus persistence.
The study of the molecular biology of HTLV-1 replication has provided crucial information for
understanding HTLV-1 replication as well as aspects of viral replication that are shared between
HTLV-1 and human immunodeficiency virus type 1 (HIV-1). Here in this review, we discuss the
various stages of the virus replication cycle—both foundational knowledge as well as current updates
of ongoing research that is important for understanding HTLV-1 molecular pathogenesis as well as in
developing novel therapeutic strategies.
Keywords: deltaretrovirus; antiretroviral; lentivirus
1. Introduction
Human T-cell leukemia virus type 1 (HTLV-1) was independently discovered in 1980 by
two research groups and identified as the etiological agent of an adult T-cell leukemia (ATL) [1,2].
As the first human retrovirus discovered, research on HTLV-1 laid the foundational framework for
subsequent studies of human immunodeficiency virus type 1 (HIV-1), infectious causes of cancer, and
the molecular mechanisms of leukemogenesis [3].
Shortly after the discovery of HTLV-1, another human retrovirus was discovered—human T-cell
leukemia virus type 2, HTLV-2—which closely resembled HTLV-1 in genome structure and nucleotide
sequence [4]. Unlike HTLV-1, HTLV-2 has not been convincingly associated with human pathology.
Nevertheless, both HTLV-1 and HTLV-2 are included in worldwide prevalence estimates. Historically,
it has been estimated that 15–20 million people are infected worldwide [5,6]. A more recent study
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has estimated the number closer to 5–10 million, with the majority of these individuals residing in
Japan and the Caribbean Basin [7]. A third and fourth type of HTLV, human T-cell leukemia virus
type 3 (HTLV-3) and human T-cell leukemia virus type 4 (HTLV-4), have been discovered in central
Africa in the past decade; both are closely related to HTLV-1, and likely share similarities in replication,
pathogenesis and transmission [8,9].
HTLV-1 is the etiological agent of ATL as well as a variety of neurological pathologies,
primarily HTLV-1-associated-myelopathy/tropical spastic paraparesis (HAM/TSP) [10]. Both ATL
and HAM/TSP have a low incidence among HTLV-1 carriers. It is thought that approximately 2%–6%
of patients infected with HTLV-1 will acquire either pathology [11,12]. ATL generally presents after a
long latency in patients infected during childhood. This is in contrast to HAM/TSP, which is associated
with infection later in life [13].
ATL is an aggressive malignancy of the peripheral T-cells and can be divided into four
subtypes—acute, lymphomatous, chronic, or smoldering. Patients with the acute form of ATL have
a prognosis of approximately 6 months—an estimate that has not significantly changed since the
discovery of the disease, despite advances in treatments [14]. Current recommended therapies for ATL
include chemotherapy, monoclonal antibodies, allogeneic bone marrow transplants, and a combination
of interferon-α (IFN-α) and azidothymidine (AZT) [15–18]. Interestingly, the mechanism of action
of the combination of IFN-α and AZT appears to correlate with an induction of cell apoptosis by
phosphorylation of p53 [19].
HAM/TSP is characterized by spasticity and weakness of the legs along with urinary
disturbances [19]. The primary pathology of HAM/TSP is associated with HTLV-1 infection in the
spinal cord leading to inflammation. Unlike ATL, which appears to have a complex and multi-faceted
pathology, the incidence of HAM/TSP has been shown to correlate with HTLV-1 proviral loads as well
as the site of proviral integration [20,21]. Treatment of HAM/TSP is symptom-based and includes
antispasmodic and anti-inflammatory medications [22].
Research into the HTLV-1 life cycle to date has been essential in the discovery and development
of better therapeutic strategies. Here in this review, we highlight what is currently known as well as
recent advances in the study of HTLV-1 replication. The recent advances help to provide further reason
for hope in effective therapeutic options for HTLV-1-infected individuals.
2. HTLV-1 Infectious Replication Cycle
2.1. Attachment and Fusion
HTLV-1 primarily infects CD4+ T-cells but has the potential to infect a wide variety of cells,
including CD8+ T-cells, B-lymphocytes, endothelial cells, myeloid cells, fibroblasts, as well as other
mammalian cells [23–27]. This wide variety of target cells is due in part to the ability of the surface
subunit (SU) of the HTLV-1 envelope glycoprotein (Env) to interact with three widely distributed
cellular surface receptors including the glucose transporter (GLUT1) [28], heparin sulfate proteoglycan
(HSPG) [29], and the VEGF-165 receptor neuropilin-1 (NRP-1) [30]. Once HTLV-1 has attached to the
cell, the membrane fusion process occurs by a series of proposed sequential events between SU and
the target cell receptor proteins (Figure 1A,B) [30,31]. Briefly, the HTLV-1 Env interacts with HSPG
first followed by NRP-1, which results in the formation of a complex. Following this event, GLUT1
associates with the HSPG/NRP-1 complex to initiate the fusion process, through interactions with the
HTLV-1 Env transmembrane (TM) protein, which allows for the HTLV-1 capsid (CA) core containing
the viral genome and viral proteins to be released into the cytoplasm of the permissive target cell
(Figure 1B).
4
Viruses 2016, 8, 31
 
Figure 1. HTLV-1 life cycle. The major steps in the life cycle of HTLV-1 are shown. A mature, infectious
HTLV-1 virion attaches and fuses to the target cell membrane through interaction with the target
cell surface receptors GLUT1/HSPG/NRP-1 via the HTLV-1 envelope surface and transmembrane
domains of the envelope (Env) protein (A). Following fusion, the viral core containing the viral
genomic RNA (gRNA) is delivered into the cytoplasm (B), and during and/or following entry the
gRNA genome undergoes reverse transcription to convert the gRNA into double stranded DNA
(dsDNA) (C). The dsDNA is then transported into the nucleus (D), and it is integrated into the
host genome; (E,F). The provirus is then transcribed by cellular RNA polymerase II (G), as well as
post-transcriptionally modified (H). Both full-length and spliced viral mRNAs are exported from the
nucleus to the cytoplasm (I). The viral proteins are then translated by the host cell translation machinery
(J), and the Gag, Gag-Pol and Env proteins transported to the plasma membrane (PM) along with two
copies of the gRNA genome (K). These viral proteins and gRNA assemble at a virus budding site along
the PM to form an immature virus particle (L). The budding particle releases from the cell surface (M),
and undergoes a maturation process through the action of the viral protease, which cleaves the viral
polyproteins to form an infectious, mature virus particle (N).
It has been demonstrated that GLUT1 plays a key role in both the binding of the SU and the
infection of CD4+ cells [32]. Paradoxically, other retroviruses have mechanisms that decrease surface
expression of their receptors, such as HIV-1 Nef and Vpu [33,34]. The decrease of receptor expression
on the cell surface is thought to prevent both superinfection and intracellular Env-receptor interactions,
which can inhibit proper proteolytic processing of the Env precursor polyprotein. HTLV-1 does not
encode for an accessory protein that reduces surface expression of GLUT1, and it is therefore unclear
how HTLV-1 modulates plasma membrane receptor expression. However, it has been recently shown
that HTLV-1-based virus-like particles (VLPs) produced in cells with high levels of GLUT1 were better
able to fuse with target cells than those produced from cells with low levels of GLUT1 [35]. In 293T cells,
5
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HTLV-1 Env avoids interaction with GLUT1 through the separate intracellular localization of GLUT1
and Env [35]. This recent observation is important because it suggests that separate intracellular
localization of GLUT1 and HTLV-1 Env is required for proper fusion activity of the HTLV-1 Env. This
study may also have implications for HTLV-1 cellular tropism, as CD4+ regulatory T-cells, the primary
viral reservoir for HTLV-1-infected individuals, express GLUT1 at low levels as compared to other
types of CD4+ T-cells [36].
2.2. Reverse Transcription, Nuclear Transport and Integration
The HTLV-1 CA core enters the infected cell and contains two copies of the viral genomic RNA
(gRNA) along with reverse transcriptase (RT), integrase (IN), and the viral protease (PR). Reverse
transcription of HTLV-1 RNA to double-stranded DNA (dsDNA) has not been extensively studied but
likely occurs after virus entry (Figure 1C) [37,38]. It is thought that HIV-1 reverse transcription is linked
to intracellular uncoating of the CA core [39]. Additionally, HIV-1 RT and IN interactions have been
shown to be necessary for production of early reverse transcription products [40]. Complementary
studies with HTLV-1 have yet to be done, so it is unclear whether HTLV-1 CA uncoating correlates with
reverse transcription or if RT-IN interactions occur during early reverse transcription. Recombination
can occur during reverse transcription, and recent evidence from phylogenetic analyses strongly
suggests that recombination played a distinct role in emergence of HTLV-1 in the human population
approximately 4000 years ago [41].
Unlike HIV-1, which is highly sensitive to the effects of the APOBEC family of cytidine deaminases,
HTLV-1 appears less sensitive APOBECs. There is some evidence that APOBEC3G may lead to G-to-A
hypermutation in some HTLV-1 sequences in vivo [42,43], but the overall effect on HTLV-1 sequence
diversity appears to be negligible—perhaps due to the propensity of HTLV-1 to be propagated by clonal
expansion of infected cells rather than replication via reverse transcription. HTLV-1 has been previously
shown to prevent APOBEC3G packaging through an element at the C-terminal nucleocapsid (NC)
region of Gag [44].
The partially disassembled core containing the reverse transcription complex (preintegration
complex) is translocated to the nucleus (Figure 1D) where integration into the host cell chromosome
occurs to form the provirus (Figure 1E,F). It has been found that HTLV-1 integrates into the genome in
the absence of preferred sites [45–50]. Such studies have analyzed hundreds of thousands of HTLV-1
integration sites [51,52] and have not been able to identify HTLV-1 proviral integration site hotspots.
Interestingly, in HTLV-1-induced disease states, the integration sites of HTLV-1 become non-random.
For example, it was recently demonstrated that the clinical diagnosis of HAM/TSP correlates with
proviral integration into transcriptionally active regions [53].
2.3. Viral Gene Transcription
The long terminal repeats (LTRs) of the HTLV-1 provirus contain the necessary promoter and
enhancer elements to initiate RNA transcription (Figure 1G), with the polyadenylation signal located in
the 31LTR [1]. Tax, a non-structural protein and the main driver of viral transcription, potently activates
viral transcription during the early phase of infection by recruiting multiple cellular transcription
factors [54]. Three conserved 21-bp repeat elements, known as the Tax-responsive element 1 (TRE-1),
bind the cyclic AMP response element binding protein (CREB) at the TRE-1 site through its N-terminus
(NTD) [55–61], while the C-terminal domain (CTD) of Tax is believed to promote the transcriptional
initiation and RNA polymerase elongation by directly interacting with the TATA binding protein [5,62].
The Tax-CREB promoter complex recruits the multifunctional cellular coactivators CREB binding
protein (CBP), p300, and the p300/CBP-associated factor to the LTR [63–68].
Recently, several host factors that directly interfere with HTLV-1 viral transcription have been
identified. TCF1 and LEF1 are transcription factors specifically found in T-cells. They antagonize Tax
activity through physical association with Tax, preventing transcription of the viral proteins. In most
HTLV-1-infected cell lines, however, TCF1 and LEF1 expression is low due to downregulation via
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STAT5a, which is activated by Tax [69]. The host protein SIRT1 deacetylase has also been shown to
downregulate HTLV-1 viral transcription by inhibiting Tax. Unlike TCF1 and LEF1, SIRT1 appears to
inhibit Tax-CREB interactions. Interestingly, the well-known SIRT1 activator resveratrol significantly
decreases the transmission of HTLV-1 produced from MT2 cells [70,71]. This suggests that resveratrol
may be a potential therapeutic option for patients infected with HTLV-1 or a prophylactic option
to prevent virus transmission. In addition to these cellular host factors, the facilitate chromatin
transcription (FACT)proteins SUPT16H and SSRP1 have been shown to inhibit both HTLV-1 and
HIV-1 transcription by preventing interaction of HTLV-1 Tax and HIV-1 Tat with their respective viral
LTRs [72].
2.4. Post-Transcriptional Regulation
Rex is a positive post-transcriptional regulator essential for splicing and transport of HTLV-1
mRNA (Figure 1H,I). Rex specifically interacts with the U3 and R regions of the HTLV-1 gRNA known
as the Rex-responsive element (RexRE). During the early stages of viral gene transcription, suboptimal
levels of Rex are present [73], which results in the exclusive export of doubly spliced (tax, rex, p30II, p12,
p13, and hbz) viral mRNAs to the cytoplasm (Figure 1I) [74]. Once Rex accumulates in the nucleus, Rex
reduces splicing of viral mRNA and the singly spliced (env) and unspliced (gag-pro-pol) mRNAs are
then exported from the nucleus to the cytoplasm leading to the production of enzymatic and structural
proteins (Figure 1J) [74]. Rex binds to the RexRE through a highly basic RNA-binding NTD, while
the CTD is important for protein oligomerization [75,76]. Rex also contains an activation domain
containing the nuclear export signal, which targets Rex to the nuclear pore complex in order for Rex to
move between the nucleus and cytoplasm [77,78].
Despite the presence of host cell mechanisms to export doubly spliced RNA, all HTLV-1 mRNA
transcripts, including those that are doubly spliced, have RexREs present. A recent study has shown
that Rex may have a CRM1-dependent role in nuclear export of all HTLV-1 mRNAs, even the doubly
spliced mRNAs that should be exported via host cell mechanisms [79]. These observations suggest that
viral mRNA export is under a more complex regulation than previously thought. Furthermore, another
recent study has suggested that there are three alternatively spliced HTLV-1 transcripts that encode
for novel Rex isoforms, which may also contribute to the regulation of HTLV-1 protein expression
levels [80].
2.5. Viral Protein Translation
As soon as HTLV-1 mRNAs are exported to the cytoplasm, the host protein-synthesis machinery
translates the viral proteins. Presumably, the full-length viral gRNA is either translated or trafficked to
the plasma membrane, where it can dimerize, interact with the Gag polyprotein, and be packaged into
assembling particles (Figure 1K,L) [81]. The doubly spliced and unspliced mRNAs are translated by
free ribosomes to express the enzymatic and structural proteins, respectively, while the singly spliced
mRNA is translated by membrane-bound ribosomes to express Env [45].
Many RNA viruses use a cap-independent mechanism to recruit the 40S ribosomal subunit to an
internal ribosome entry segment (IRES) within the 51UTR of the mRNA, which allows for ribosomal
scanning and protein translation to occur [82–84]. It was thought that HTLV-1 mRNA contains an
IRES element [85] used for the translation of the Gag protein, but another study suggests that a 51
proximal post-transcriptional control element modulates post-transcriptional HTLV-1 gene expression
by interacting with the host RNA helicase A instead of an IRES element, implying that the translation
of the HTLV-1 mRNA is cap-dependent [86]. Interestingly, a recent study has demonstrated that
HTLV-1 translation is inhibited by the drug edeine, a cap-independent translation inhibitor, suggesting
that an IRES element in the 51 UTR recruits the ribosome to the mRNA [87]. Obviously, more research
is needed to firmly establish the mechanism(s) used by HTLV-1 to translate its viral proteins.
7
Viruses 2016, 8, 31
2.6. Gag and Viral RNA Trafficking
Viral particle formation occurs after Gag traffics from the cytoplasm to the plasma membrane
(PM) (Figure 1K). How HTLV-1 Gag translocates from the site of translation to the membrane is poorly
understood. However, it is known that monomeric forms of HTLV-1 Gag exist in the cytoplasm and
are detected at the membrane shortly after the initiation of viral protein translation [88]. This is in
contrast to HIV-1 Gag, where low ordered oligomers are observed in the cytoplasm until micromolar
concentrations are reached prior to detecting oligomeric Gag at the plasma membrane [88]. HIV-1
Gag interacts with many cellular proteins, including cytoskeleton-associated proteins, though their
relationship to HIV-1 Gag trafficking is unclear [89]. HTLV-1-infected cells regulate cytoskeletal
polarization [90], though it is unclear if this is related to Gag trafficking to the plasma membrane.
HTLV-1 Gag nucleocapsid (NC) protein binds to HTLV-1 RNA relatively weakly as compared
to that of other retroviral NC proteins, due in part to the anionic carboxy-terminal domain (CTD) of
the HTLV-1 NC [91]. The HTLV-1 MA has been recently reported to bind RNA, and it was found that
HTLV-2 MA binds RNA at much higher affinity than HTLV-2 NC [92]. This is in direct contrast to
HIV-1, in which NC binds to RNA more strongly than HIV-1 MA [92]. These recent findings highlight
the importance of both the MA and NC domains in viral RNA interactions that are likely critically
important for viral gRNA recognition and gRNA packaging. How HTLV-1 RNA traffics through the
cytoplasm in order to get to the plasma membrane (and to virus budding sites) is poorly understood,
but a recent study with HIV-1 gRNA suggests that the viral gRNA diffuses through the cytoplasm to
the membrane [93]. It is formally possible that HTLV-1 gRNA also diffuses through the cytoplasm to
reach the membrane, but it could also bind to Gag before reaching the membrane (Figure 1I–K). There
is a significant need for future studies in order to better understand these aspects of HTLV-1 replication.
2.7. Assembly, Budding and Maturation
Gag-gRNA, Gag-Gag and Gag-membrane interactions are all required for the assembly and
budding of virus particles (Figure 1L) [94]. Gag forms higher order oligomers by oligomerizing
with other Gag molecules through interactions primarily involving the CA domain and to some
extent the NC domain [95–100]. Once at the PM, virus budding sites are identified and are
characterized by the interaction of HIV-1 MA with lipid-rich [101] assembly sites known as lipid
rafts [102–104]. Membrane binding of HIV-1 Gag is dependent upon interaction of MA with
phosphatidylinositol-(4,5)-bisphosphate PI(4,5)P2 [105]. HTLV-1 Gag has been shown to not have
a preference for binding to PI(4,5)P2, which has implications for how HTLV-1 Gag targets the PM
and identifies virus budding sites [105]. Cellular factors are also recruited to the virus budding sites,
resulting in budding and subsequent release of immature virus particles (Figure 1L,M) [100,106,107].
The viral protease (PR) cleaves the Gag and Pol polyproteins during and shortly after the release of
immature virus particles (Figure 1N) [108]. MA remains closely associated with the PM; CA forms a
capsid shell that contains reverse transcriptase, integrase and the NC-coated gRNA. The mature virus
particle, if infectious, is capable of infecting a permissive target cell (Figure 1N) [109].
3. HTLV-1 Transmission
3.1. Inter-Host Transmission
There are generally three modes of inter-host HTLV-1 transmission described: (1) blood and blood
products, (2) vertical or (3) sexual transmission [110], but the main mode of transmission is thought
to be vertical, i.e. from mother-to-child through breastfeeding [111]. Mother-to-child transmission
rates vary from 5% to 27% for children nursed by infected mothers and correlate with the duration of
breastfeeding [112,113]. While it is not clear precisely how infection occurs through the mucosal and
epithelial barriers of the gastrointestinal tract, it is thought that infected lymphocytes in breast milk
carry the virus into the gut [114]. Once in the gut, either cell-free virus or cells carrying the virus must
pass through the epithelium. A recent study demonstrated in vitro that cell-free HTLV-1 may cross
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the epithelial barrier via transcytosis before infecting subepithelial dendritic cells [115]. The precise
mechanism of transcytosis for HTLV-1 remains unclear. However, studies with HIV-1 have shown
that transcytosis across vaginal epithelial cells occurs via the endocytic recycling pathway [116]. It is
plausible that other mechanism(s) are involved in HTLV-1 infection across the gut epithelial barrier
due to the low infectivity of cell-free virus. While cell-free HIV-1 is generally thought to be much
more infectious than cell-free HTLV-1, it has been suggested that HIV-1-infected lymphocytes more
efficiently infect target cells in the gut than cell-free virus – possibly through the formation of a viral
synapse that induces transcytosis [117]. The role of the virological synapse in these transmission
events has not been carefully studied. It is also not known whether HTLV-1 infected lymphocytes can
transmigrate as a whole cell across the epithelial barrier and infect subepithelial immune cells.
Zoonotic transmission events of simian T-cell leukemia virus type 1 (STLV-1) to humans after
contact with nonhuman primates through bites or bushmeat slaughtering still occur in Africa,
establishing the emergence of new HTLV-1 infections in humans. A recent study found that more
than 8% of individuals bitten by nonhuman primates in Africa are infected with HTLV-1, and virus
transmission cannot be attributed to mother-to-child transmission [118]. The strains of HTLV-1 found
in those infected closely resembled the subtypes of STLV-1 commonly found in the primate species
from which they were bitten [118,119]. In fact, it is likely that the emergence of HTLV-3 and HTLV-4
may be attributable to recent STLV zoonotic transmission events, as STLV-4 is known to be endemic in
African gorillas, and phylogenetic analyses have shown that HTLV-4 is not an ancient human virus
but recently emerged in the human population [120]. While these findings highlight the potential
ongoing role of nonhuman primates as virus reservoirs, they also highlight interest in the virus-host
interactions that facilitate cross-species transmission as well as potential risks in transmission and
emergence of more highly pathogenic types of HTLV. While monkeys in Japan also harbor STLV-1
strains [121], those strains are more highly divergent from the HTLV-1 strains in Japanese patients,
indicating that zoonotic transmission of HTLV-1 may not be a major public health threat in regions
outside of Africa [122].
3.2. Cell-to-Cell Transmission
In general, there are two distinct methods of virus transmission between cells: virus infection
of cells in the absence of cell-to-cell contacts and virus infection involving cell-to-cell contacts.
Most retroviruses can efficiently infect target cells in the absence of cell-to-cell contacts—in which
the virus buds from the cell and infects a target cell through diffusion. HTLV-1 is notorious for being
poorly infectious in the absence of direct cell-to-cell transmission, and co-cultivation of permissive
target cells with virus-producing cells are the most effective means of virus transmission [123].
3.3. Virological Synapses
Immunofluorescence and confocal microscopy were used previously to demonstrate that Gag and
Env proteins are more evenly distributed in isolated T-cells, but once the cell comes into contact
with another cell, cell polarization occurs—impacting the localization of HTLV-1 Gag, Env and the
genomic RNA towards the cell-cell junction. This cell-to-cell junction, termed the virological synapse
(VS), shares many features with the previously described immunological synapse, which includes
features such as ordered talin domains and microtubule organizing center (MTOC) polarization [124].
Cryoelectron tomography studies of HTLV-1 associated VS structures suggest that there is no fusion of
the cell membranes [125]. To the contrary, HTLV-1 transmission occurs via rapid budding and fusion
of the HTLV-1 virus across the VS from the infected to uninfected cell (Figure 2).
It has been reported that the formation of the VS is triggered by HTLV-1 infection and is not
dependent on signaling through the T-cell receptor as is seen in immunological synapses [124]. The VS
forms when the surface adhesion molecule intercellular adhesion molecule-1 (ICAM-1) is engaged
by its ligand lymphocyte function-associated antigen 1 (LFA-1) [90,126]. ICAM-1 then activates the
MEK/ERK pathway, which contributes to MTOC relocation. The HTLV-1 Tax protein, the key virus
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transcription accessory protein, works in synergy with ICAM-1 to facilitate MTOC polarization. While
it is primarily a nuclear protein, Tax can be found in the cytoplasm near the MTOC as well as in the
cell-cell contact region [127]. Tax activates the CREB-signaling pathway during the formation of the
HTLV-1 VS [126]. The CREB pathway increases expression of Gem, a small GTP-binding protein in
the RAS superfamily, which is involved in cytoskeleton remodeling and cell migration [128]. Tax also
appears to upregulate ICAM-1 in HTLV-1-infected cells, indicating that ICAM-1 and Tax appear to
have synergistic roles in HTLV-1 VS formation [129].
y g
Figure 2. HTLV-1 Cell-to-Cell Transmission. Shown in the diagram is a host cell (bottom) that has
anchored itself to a permissive target cell (top) using ICAM-1 and LFA1. The HTLV-1 accessory protein
p8 has been shown to increase the expression of the LFA1 receptors as well as increase the number of
cell-cell synapses, which p8 then traffics through to increase LFA1 in the target cell. Once ICAM-1 is
bound, it triggers a signaling cascade that leads to the relocation of the MTOC. Additionally, HTLV-1
Tax is found bound to Golgi bodies that are attached to the MTOC. This initiates a variety of cell
signaling cascades. For example, one established pathway increases expression of Gem, a protein
that increases cell motility and possibly MTOC relocation. As HTLV-1 Gag is produced, it is found
concentrated at the MTOC. Subsequently, HTLV-1 Gag is found at the sites of cell-cell contacts where
the virus particles bud into the viral synapse formed by the cellular adhesion points. Virus particles
produced can bind receptors for entry into the permissive target cell. The question marks along the
lines with arrows indicate mechanisms of transport or activation that are not well understood.
When comparing HTLV-1 cell-cell transmission to HIV-1 cell-cell transmission, HTLV-1 is more
dependent on cell contact for infectivity. Coculturing of virus-producing cells with permissive
target cells significantly enhances HTLV-1 transmission by several thousand-fold, but only increases
HIV-1 transmission 10–100 hundred-fold [130,131]. Furthermore, disruption of actin and tubulin
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polymerization inhibits HTLV-1 spread to a greater extent than that of HIV-1 spread [131]. Nonetheless,
HIV-1 cell-cell transmission remains a highly relevant form of virus spread in vivo. A recent study
helps to highlight this through the observation that granulocytes (e.g., basophils) may actually capture
HIV-1 and contribute to virus transmission [132].
3.4. Viral Biofilms
In addition to transmission via the VS, HTLV-1 particles have been reported to have the ability to
form a biofilm-like, carbohydrate-rich extracellular structure on the surface of cells. These structures
are composed of collagen, agrin, tetherin, and galectin-3 and may function as a way to concentrate
HTLV-1 particles in a single location to increase the likelihood of infection of a permissive target
cell [133]. A recent report described the creation of antiviral biofilm monoclonal antibodies using
purified biofilms from MT2 cells. It was found that in addition to the structural proteins previously
identified, the antigens CD4, CD150, CD25, CD70, and CD80 were also identified in these viral biofilms.
Tax expression was found to modulate the level of these antigens in the viral biofilm [134].
While it has been observed that dendritic cells may be infected by cell-free HTLV-1 in vitro [31],
a recent study analyzed the infectivity of chronically infected C91PL cell culture supernatant as
compared to purified biofilms in primary human monocyte-derived dendritic cells (MDDCs) and
T lymphocytes. It was found that while MDDCs were more easily infected than were T lymphocytes,
both cell types achieved significantly higher proviral loads when exposed to viral biofilms as opposed
to supernatant-derived virus [135].
4. Monoclonal Expansion of HTLV-1 Infected Cells and Leukemogenesis
While HTLV-1 cell-cell transmission is likely a critical determinant of virus transmission from an
infected individual to a susceptible individual, many studies have established that the primary route of
replication for HTLV-1 in vivo is through mitotic division of host cells and subsequent propagation of
the provirus by clonal expansion. DNA analysis of HTLV-1 sequences from patients in geographically
distinct locations shows very little genetic variation among HTLV-1 isolates [136]. This is likely because
of a low evolutionary rate of 7.06 ˆ 10´7–1.38 ˆ 10´5 substitutions per site per year in the LTR and
env regions [137]. While the HTLV-1 reverse transcriptase has a reduced mutation rate as compared to
HIV-1 reverse transcriptase (7 ˆ 10´6 mutations per target base pair per replication cycle for HTLV-1
as compared to 3.4 ˆ 10´5 for HIV-1), the fourfold difference is likely not sufficient alone to explain
the relative difference in genetic diversity between the two viruses [138,139]. Also, administration
of reverse transcriptase inhibitors was found to not reduce proviral loads, even when administered
shortly after infection [140,141].
The most compelling evidence in favor of a clonal expansion of HTLV-1 proviruses is the clonality
of T-cells in infected individuals. HTLV-1 integrates randomly into the genome [142,143]. When the
HTLV-1 proviral sites are amplified by PCR, it has been consistently found that the T-cells are clonal in
both symptomatic and asymptomatic carriers [144,145]. In some HTLV-1 infected individuals, more
than one in every 1500 peripheral blood mononuclear cells (PBMCs) were found to be clonal [146].
Since HTLV-1 persistence depends to some extent on the clonal expansion of infected T-cells,
it is not surprising that HTLV-1 encodes for gene products that have been found to increase cell
proliferation. The oncogenic potential of HTLV-1 is likely a byproduct of the induction of these cellular
proliferative pathways. In fact, expression of the HTLV-1 basic leucine zipper (HBZ) and Tax proteins
in double transgenic mice was recently shown to be sufficient for the development of lymphoma in the
absence of any other viral genes [147]. Since similar pathways influence both cell immortalization and
cellular transformation, these two processes are difficult to uncouple.
4.1. Tax
Tax has been established to have many roles in the HTLV-1 proliferative cycle, including essential
roles in mediating transcription of HTLV-1 genes as well as the recruitment of the MTOC to sites
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of cell-cell contact. Tax can also interfere with host cell cycle regulation, apoptotic pathways, and
proliferative pathways through a variety of mechanisms. The most commonly studied pathway
through which Tax increases cellular proliferation is via the NF-κB/Rel family of proteins.
4.2. Tax and Canonical NF-κB Signaling
The NF-κB/Rel proteins are transcription factors that share a Rel homology domain responsible
for DNA binding and dimerization. There are five proteins in this family: RelA (p65), RelB, c-Rel,
p105 (processed to p50), and p100 (processed to p52). When the NF-κB pathways are turned off,
NF-κB dimers are bound to the inhibitor of κB (IκB) proteins. Activation of NF-κB can occur through a
canonical pathway in which nuclear localization of NF-κB is induced by inflammatory stimuli such as
tumor necrosis factor (TNF) or through a non-canonical pathway reviewed in [148].
NF-κB is constitutively active in HTLV-1 infected cells, an abnormality due to the tight regulation
of NF-κB by its inhibitor, IκB [149]. IκB kinase (IKK) phosphorylates IκB molecules, leading to the
eventual ubiquitination and degradation of IκB and freeing NF-κB dimers to traffic to the nucleus.
HTLV-1 Tax increases the activity of IKK by regulating a variety of upstream effectors. Tak1 is a kinase
that can phosphorylate and activate IKK. Tax binds directly to Tak1 to form an IKK-Tak1-Tax complex
that appears to increase the efficiency of IKK [150]. Tax can also increase the activity of Tak1 by binding
to Tak1-binding protein 2 (TAB2); the physiological function of this remains unclear [151]. Tax can
also bind directly to TRAF6 and can stimulate its function, leading to the activation of NF-κB through
IKK phosphorylation [152]. Finally, Tax can also stimulate MEKK1, which is an upstream regulator of
TAK1 [153].
In addition to its upstream effects on IKK, Tax also binds directly to an IKK subunit, IKKγ (referred
to as NEMO) [154,155]. IKKγ is a regulatory subunit that modulates IKK activity through an unknown
mechanism [156]. Protein phosphatase 2A (PP2A) is a positive regulator of IKKγ, and PP2A binding
to helix 2 (HLX2) is necessary for proper IKK function [157]. Tax binds IKKγ in a region two heptads
downstream of HLX2 termed coiled-coil region 2 (CCR2). When Tax binds this region, it exposes the
HLX2 domain for PP2A binding and simultaneously inactivates PP2A, preventing it from dissociating,
resulting in IKK being constitutively active [158,159].
Tax also has the ability to form complexes with NF-κB monomers in the cytoplasm. Tax can
bind directly to cytoplasmic RelA (p65) and can induce translocation into the nucleus, leading to high
transcriptional activity [151,160–162]. This particular protein-protein interaction appears to also rely
on the CREB-binding protein (CBP or p300), which facilitates the transcriptional activity of RelA.
A role for Tax that has only recently been described is the recognition and inactivation of the
ubiquitin-editing enzyme A20. This enzyme is a negative regulator of the canonical NF-κB pathway.
It binds with the regulatory protein TAX1BP1 and E3 ligase Itch to form a complex that inactivates
essential NF-κB upstream regulators. Tax binds to TAX1BP1, preventing the interaction of TAX1BP1,
A20, and Itch [163,164].
4.3. Tax and Non-Canonical NF-κB Signaling
Tax is known to facilitate the non-canonical pathway of NF-κB as well as the canonical pathway
traditionally induced by MEKK1 and Tak1. This is an important distinction, as the NF-κB dimers are
distinct for each pathway and increase expression of different gene products. For example, when the
non-canonical pathway is blocked in the presence of Tax, tumorigenesis is significantly delayed in Tax
transgenic mice [165]. IKKα phosphorylates p100, which leads to its ubiquitination and cleavage to
p52. Tax facilitates this process by recruiting IKKα to p100 and inducing cleavage [166,167].
4.4. Tax and Other Cell Proliferative Pathways
In addition to its interaction with NF-κB, HTLV-1 Tax has roles in a variety of other cell
proliferation pathways. In particular, Tax interacts directly or indirectly with cyclin-dependent
kinases (CDK) [168,169], phosphoinositide 3-kinase (PI3K) [170], transforming growth factor β-1
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(TGFβ-1) [171,172], and p53 [173–175]. Through a series of complex interactions, Tax ensures that
HTLV-1 replication occurs.
4.5. Tax Downregulation
Tax plays a key role in the proliferation of T-cells but is known to be a highly immunogenic
protein, and Tax-expressing cells are targeted by cytotoxic T-cells [176,177]. That Tax is expressed only
at early time points helps to avoid immune surveillance. In patients with ATL, tax mRNA transcripts
were only found in 34% of all cases [178], indicating that there are downregulation mechanisms in
place to prevent HTLV-1-infected cells from being destroyed by the immune system.
Several mechanisms regulate the downregulation of Tax expression. Many tax genes become
mutated so that non-functional transcripts are produced [178–180]. Cells containing these tax gene
sequences are more likely to replicate due to decreased immune surveillance. Additionally, the tax
gene is often methylated, leading to gene silencing [178,181]. Finally, the HTLV-1 bZIP factor (HBZ)
works to downregulate transcription of many HTLV-1 genes, including Tax [182].
4.6. HBZ
The HBZ gene is an important HTLV-1 gene that is consistently associated with ATL. HBZ mRNA
transcripts have been found in virtually all ATL cells, and it was shown that HBZ plays a key role
in the proliferation of T-cells [183]. Interestingly, the HBZ mRNA appears to play a different role in
T-cell proliferation than the HBZ protein [183]. In mouse T-cells, an HBZ start codon mutant that
distinguishes between RNA function and protein function was found to increase T-cell proliferation by
inhibiting apoptosis and promoting S-phase entry [184]. HBZ RNA attenuates apoptosis by promoting
the transcription of Survivin, a caspase inhibitor that prevents apoptosis. While HBZ protein promotes
S-phase entry, it can also promote apoptosis through its pro-inflammatory effects [184].
HBZ has been reported to directly or indirectly interact with the following proteins that
are essential in CREB-dependent cellular proliferation: CREB, CBP, ATF-1, and ATF-3 [185–188].
Additionally, HBZ interacts with the Jun family of transcription factors, JunB, JunD, and c-Jun [189–191].
The combined activities of Tax and HBZ are essential for cellular proliferation. Taken together, the
activities of both HBZ and Tax are essential for the transformation of T-cells.
5. Conclusions and Future Directions
As the first human retrovirus discovered in the early 1980s, HTLV-1 has been studied extensively,
yet there is still no treatment or vaccine for HTLV-1 infection. Additionally, ATL and HAM/TSP
treatments are symptom-based and do not directly treat the viral infection. Continued research
on the molecular aspects of HTLV-1 replication will enhance opportunities for the discovery of
potential antiretroviral targets that can be exploited for the development of effective therapeutic
strategies. For example, a recent candidate peptide (HBZ157´´176) has been described for use in
vaccine development [192]. Such observations help to enhance the likelihood for specific forms of
therapeutic intervention for the treatment of HTLV-1 infection.
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Abstract: Different animal models have been proposed to investigate the mechanisms of Human
T-lymphotropic Virus (HTLV)-induced pathogenesis: rats, transgenic and NOD-SCID/γcnull (NOG)
mice, rabbits, squirrel monkeys, baboons and macaques. These systems indeed provide useful
information but have intrinsic limitations such as lack of disease relevance, species specificity or
inadequate immune response. Another strategy based on a comparative virology approach is to
characterize a related pathogen and to speculate on possible shared mechanisms. In this perspective,
bovine leukemia virus (BLV), another member of the deltaretrovirus genus, is evolutionary related to
HTLV-1. BLV induces lymphoproliferative disorders in ruminants providing useful information on the
mechanisms of viral persistence, genetic determinants of pathogenesis and potential novel therapies.
Keywords: BLV; HTLV-1; Tax; microRNA; vaccine; HDAC
1. Introduction
BLV naturally infects cattle, zebu and water buffalo but can also be experimentally transmitted to
sheep, goats or alpaca (Vicugna pacos) [1–3]. In cattle, the most prevalent clinical manifestation is a
benign accumulation of infected B-lymphocytes called persistent lymphocytosis (PL) affecting about
one-third of infected animals [4,5]. In a minority of cases (about 5%–10%), BLV infection can progress
to fatal leukemia/lympoma whose most spectacular consequence is spleen disruption consecutive
to tumor formation [6]. BLV typically persists in less than 1% of peripheral blood cells, leading to an
asymptomatic infection in the majority of infected animals. BLV is transmitted horizontally by direct
contact, iatrogenic procedures or insect bites upon transfer of infected cells from milk, blood and body
fluids from heavily infected dams [7,8].
Among experimental hosts, sheep provide a useful model to address specific questions pertaining
to immunity, viral persistence and pathogenesis. In particular, reverse genetics permitted the
development of a life-attenuated vaccine and a novel therapeutic approach. Main advantages of
the sheep model include a high frequency of leukemia/lymphoma (close to 100%) and a shorter
latency period (typically 2–4 years).
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BLV-associated pathogenesis thus shares a series of features with HTLV-1-induced Adult
T-cell Leukemia (ATLL) but does apparently not include neurodegenerative diseases such as
HTLV-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) [9]. It is assumed that
consumption of raw milk from BLV-infected cattle is not associated with an increased risk of cancer in
human, although the link cannot be formally excluded [10].
The goal of this review is to outline interesting observations in the BLV model that are of interest
to understand HTLV-1 replication and pathogenesis.
2. Viral Oncogenes Drive Proliferation
As deltaretrovirus, BLV carries the classical genes (gag, pro pol and env) that are required
to complete the viral cycle: genesis and budding of a virion, infection of a target cell, reverse
transcription and integration into the host cell chromosome. The BLV provirus also encodes a series of
additional accessory genes as well as microRNAs that modulate viral and/or cellular gene expression
(Figure 1) [11,12]. Among these, Tax and G4 are oncogenes able to promote transformation of primary
rat embryo fibroblasts [13,14]. Tax activates transcription by acting on a triplicate 21 bp enhancer motif
in the 51 the LTR promoter via the CREB/ATF signaling pathway [15,16]. Although, the mechanisms of
cell transformation remain to be further characterized, it is interesting to note that BLV and HTLV-1 Tax
share cellular targets. Both transactivators indeed bind to tristetraprolin (TTP), a post-transcriptional
modulator of TNFα expression [17]. The Tax proteins promote nuclear accumulation of TTP and
restore TNFα expression by inhibiting TTP.
Figure 1. Schematic structure of (a) the bovine leukemia virus (BLV) genome and (b) the viral particle.
Another cellular protein concomitantly targeted by BLV G4 and its ortholog in HTLV-1 (p13) is
farnesyl pyrophosphate synthase (FPPS), an enzyme involved in the mevalonate/squalene pathway
and in synthesis of FPP, a substrate required for prenylation of Ras [18]. In addition FPPS is involved
in synthesis of isoprenoids modulating the membrane fluidity and stability of lipid rafts [19]. Being
localized in the nuclear compartment and in mitochondria, G4 and p13 thus exert evolutionary
conserved functions.
Recently, a proviral region located 31 of the env gene was shown to express microRNAs under the
control of RNA polymerase III promoters (miR on Figure 1) [20]. The BLV microRNAs associate with
Argonaute and mimic cellular analogs (e.g., BLV-miR-B4 for miR-29). BLV microRNAs are transcribed
from a region dispensable for in vivo infectivity but are abundantly expressed in leukemic B cells
26
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(about 40%) [21]. This evidence thus contradicts the dogma that naturally occurring RNA viruses
will not encode miRNAs to avoid unproductive cleavage of their genomes. HTLV-1 does not encode
microRNAs as indicated by deep sequencing. The role of the BLV microRNAs in viral replication,
persistence and disease remains to be further characterized.
BLV thus encodes transformation drivers (Tax, G4) and viral microRNAs likely important
in pathogenesis.
3. Reverse Genetics Reveals the Significance of Viral Sequences in Infection and Replication
Reverse genetics using a cloned BLV provirus has allowed the screening of regions required
for infection, replication and pathogenesis. As expected, large deletions within the gag, pol or env
genes destroy infectivity in vivo. Discrete regions of the viral genome, such as the ITAM motifs of the
envelope transmembrane protein (TM), are particularly important for infection [22]. Contradicting the
concept that retroviral genomes are highly condensed, sequences located between the env gene and
the Tax/Rex boundary are dispensable for infection [23]. In particular, deletion of R3 and G4 preserves
infectivity but affects replication efficiency [24]. Similarly, deletion of HTLV p12I or p13II/p30II, the
orthologs of BLV R3 and G4, impairs replication in macaques. In contrast, the mutations do not affect
viral replication in rabbits, emphasizing the importance of relevant animal models [25]. R3 and G4 are
nevertheless dispensable for pathogenesis, although their integrity contributes to disease frequency
and latency [26].
Reverse genetics also generated unexpected observations, such as replication at wild-type levels
of proviruses expressing fusion-deficient envelope proteins (TM A60V and A64S) [27]. These mutants
are thus in principle unable to undergo an infectious cycle and may replicate preferentially through
mitotic division of the host cell.
Mutations within the LTR further revealed that the viral promoter contained sub-optimal
enhancers (AGACGTCA, TGACGGCA, TGACCTCA) that are essential for viral replication. As
expected, site directed mutagenesis of the enhancers into consensus cyclic-AMP responsive elements
(TGACGTCA) increases promoter efficiency but strongly impairs viral replication [28,29]. The presence
of suboptimal enhancers in all BLV and HTLV-1 isolates suggests an evolutionary conserved mechanism
that may reduce basal transcription and facilitate the escape from immune response.
Collectively, these observations thus emphasize the dichotomy between conclusions drawn from
in vitro experimentations and their relevance in the animal model.
4. A Mutation that Increases Pathogenicity: Potential Hyperpathogenic Strain
Until recently, all mutations introduced in the BLV provirus were silent or at most reduced
replication and pathogenesis in vivo. We recently reported that mutation of a N-linked glycosylation
site (N230) affects the stability of the SU envelope protein and increases cell-to-cell transmission
suggesting that this site restricts infectivity and viral replication [30]. A mutant carrying the N230
mutation replicates faster and is more pathogenic compared to the isogenic wild-type BLV strain. This
observation thus suggests a mechanism of co-evolution restricting excessive pathogenicity that would
indirectly impair mutual persistence of the virus and its host. Occurrence of this type of mutation
may thus represent a potential threat associated with emergence of hyperpathogenic BLV strains and
possibly also of new HTLV variants.
5. In Vivo Kinetics Indicates that BLV-Infected Cells Undergo High Turnover during Chronic
Infection of Sheep
The BLV model has been instrumental to understand the dynamics of cell turnover in vivo.
In principle, lymphocyte homeostasis is the result of a critical balance between cell proliferation and
death. Initial experiments using intravenous injection of bromodeoxyuridine (BrdU) demonstrated
that B-lymphocytes are proliferating significantly faster in BLV-positive asymptomatic and persistently
lymphocytotic sheep than in uninfected controls. In fact, an excess of 0.9% cells are produced by
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proliferation each day and, during leukemia, these rates even rise by up to tenfold [31]. Excess of
cell proliferation was also reported in HTLV-induced HAM/TSP using a similar strategy based on
incorporation of deuterated glucose [32]. In contrast, persistent lymphocytosis in BLV-infected cattle is
characterized by a decreased B cell turnover resulting from a reduction of cell death and an overall
impairment of proliferation, as observed in human chronic lymphocytic leukemia (CLL) [33,34].
Cell dynamics can also be estimated by intravenous injection of carboxyfluorescein diacetate
succinimidyl ester (CFSE) [35]. Since CFSE labels proteins via their NH2 terminal ends, halving of
fluorescence indicates that a cell has undergone cell division. Fitting cell numbers and fluorescence
intensities revealed massive destruction of B-lymphocytes during chronic infection of sheep. In contrast,
lymphocyte trafficking to and from lymphoid organs was unaffected.
Collectively, quantification of the dynamic parameters deduced from BrdU and CFSE kinetics
shows that the excess of proliferation in lymphoid organs is compensated by increased death in
peripheral blood [36]. Ablative surgery demonstrated that the spleen is a major lymphoid tissue
massively destroying BLV-infected cells [37].
BLV chronic infection is thus characterized by a very dynamic equilibrium between a virus
attempting to proliferate under a tight control exerted by the immune response.
6. Massive Depletion of Clones Located in Genomic Transcriptionally Active Sites
during Infection
As retroviruses, BLV and HTLV-1 replicate via an infectious cycle upon expression of progeny
virions as well as by mitotic division of provirus-carrying cells (clonal expansion). High throughput
sequencing of proviral integration sites revealed the relative importance of these two cycles in viral
replication varies during infection [38,39]. The majority of infected clones are created early before the
onset of an efficient immune response. Two months from inoculation, the main replication route is
mitotic expansion of pre-existing infected clones. Initially, BLV proviral integration significantly favors
transcribed regions of the genome. Negative selection then eliminates 97% of the clones detected at
seroconversion and disfavors BLV-infected cells carrying a provirus located close to a promoter or
a gene. Nevertheless, among the surviving proviruses, clone abundance positively correlates with
proximity of the provirus to a transcribed region. Two opposite forces thus operate during primary
infection and dictate the fate of long term clonal composition: (1) initial integration inside genes or
promoters and (2) host negative selection disfavoring proviruses located next to transcribed regions.
7. Tight Control of Virus-Positive Cells by the Immune Response
BLV infection is thus characterized by a massive depletion of provirus-carrying cell clones at early
stages and a very dynamic turnover during chronic infection (Section 5). If the host immune response
tightly controls viral replication, it is predicted that cells expressing viral antigens would be shorter
lived. This question was addressed by comparing the survival rates of two cell pools isolated from
the same donor and labeled with different fluorochromes depending on the absence or the presence
of viral proteins induced ex vivo [40]. As predicted, transient viral expression significantly reduced
the lifespan of BLV-infected lymphocytes. Cyclosporine treatment further supported the concept that
an efficient immune response is required to control virus-expressing cells. This evidence is consistent
with the presence of suboptimal LTR promoters that restrict viral reactivation (see Section 3) enabling
escape from immune mediated destruction.
8. A Therapy Based on Activation of Viral Expression
BLV persistence is thus a very dynamic process characterized by a virus that continuously attempts
to replicate and an active control exerts by the host immune response. As outlined in Section 2, viral
proteins promote infectious and mitotic cycles but also expose the infected cell to immune control.
Evidence for a very strong immune response is supported by the presence of virus-specific cytotoxic
T cells and by high titers of neutralizing antibodies. Persistence of infected cells is thus possible
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providing that viral proteins are not expressed, perhaps under the control of viral microRNAs. In
this context, we evaluated the therapeutic effectiveness of a strategy based on the induction of viral
gene expression using valproic acid (VPA), a lysine deacetylase inhibitor [41,42]. VPA efficiently
induced viral expression in primary cultures and reduced the number of leukemic cells in sheep. This
strategy was then translated to another B cell neoplasm [43] and to HTLV-1 infected patients with
HAM/TSP [44]. The treatment appeared to be safe but unable to permanently reduce proviral loads
over the long term [45]. Instead, combination of VPA and other lysine deacetylase inhibitors with a
standard regimen of ATL (AZT + IFN) is promising in ongoing clinical trials [46,47].
9. Towards an Efficient Vaccine
Except in the European Union, the herd prevalence of BLV worldwide ranges between 30% and
90% [48]. Major economic losses result from leukemia/lymphoma-induced death, reduction in milk
production and custom restrictions. Thus, there is an urgent need for an efficient, safe and cost-effective
vaccine against BLV. Previous vaccine candidates faced problems of efficacy (i.e., only a fraction of
animals were protected), persistence (i.e., rapid decrease of immune protection), cost (e.g., production
of purified proteins) or safety (e.g., genetically modified hybrid viruses). Therefore, we designed
another approach based on a life-attenuated BLV strain harboring multiple deletions and mutations.
The rationale was to delete pathogenic genes (i.e., the oncogenic drivers) while maintaining a low level
of infectivity. After a series of failures, we have identified a deleted BLV provirus that is infectious in
cattle but replicates at very low levels. Inoculation of this vaccine elicits a vigorous anti-BLV immune
response comparable to that of a wild-type infection. The vaccine does not spread to uninfected
sentinels maintained during 7 years in the same herd and could not be detected in colostrum and milk
from experimentally infected cows. Passive antibodies are transmitted to the newborn calves via the
maternal colostrum. This anti-viral passive immunity persists during several months in the calves.
However, the BLV mutant fails to transmit from cows to calves as assessed by nested PCR. In contrast
to HIV, there is no significant sequence variation during infection [49,50]. Finally, vaccinated animals
but not uninfected controls resist challenge by a wild type BLV virus. Trials are currently ongoing to
evaluate the efficacy and safety of the vaccine in large herds in Argentina.
10. Conclusions
Understanding the mechanisms of BLV infection has provided valuable information on viral
transmission, persistence and pathogenesis. In particular, reverse genetics yielded conclusions that
could not be predicted from experiments performed in vitro as exemplified by a provirus containing
an optimized promoter that was nevertheless attenuated. BLV persistence is characterized by a very
dynamic cell turnover, which is rather unusual for a chronic infection. Host immunity is essential
to control viral replication as indicated by surgical spleen ablation. Disruption of viral latency with
epigenetic modulators has therapeutic value in BLV leukemia and may be useful for treatment of ATL.
Finally, availability of an efficient anti-BLV vaccine is informative to develop preventive and curative
measures in HTLV.
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Abstract: The first discovered human retrovirus, Human T-Lymphotropic Virus type 1 (HTLV-1),
is responsible for an aggressive form of T cell leukemia/lymphoma. Mouse models recapitulating
the leukemogenesis process have been helpful for understanding the mechanisms underlying the
pathogenesis of this retroviral-induced disease. This review will focus on the recent advances in
the generation of immunodeficient and human hemato-lymphoid system mice with a particular
emphasis on the development of mouse models for HTLV-1-mediated pathogenesis, their present
limitations and the challenges yet to be addressed.
Keywords: adult T cell leukemia/lymphoma; HTLV-1; humanized mouse models; oncogenesis
1. Introduction
Previously known as RNA tumor viruses upon the identification of numerous avian and murine
leukemia/sarcoma viruses, retroviruses were thus termed after the discovery of the viral reverse
transcriptase in 1970 allowing these viruses to replicate through a DNA intermediate [1,2]. After the
description of retroviruses in non-human primates, the long search of human retroviruses ended with
the identification of human T-lymphotropic virus type 1 (HTLV-1) and human immunodeficiency virus
type 1 (HIV-1) in 1980 and 1983, respectively [3,4].
The description of retroviruses in many species has underlined their broad diversity and revealed
their association with numerous diseases encompassing malignant processes, inflammatory disorders
and immune dysfunctions. Importantly, retroviruses have participated in the discovery of new
cellular and molecular events, opening the field of host-virus interactions in pathological processes.
In vivo investigations carried out with avian and murine retroviruses inoculated in their natural
host (i.e., chickens and mice) have largely contributed to decipher the initiation and development of
numerous diseases. Concerning human retroviruses, experimental studies performed in vitro with
human cells have clarified key events in cell-virus interactions. In vivo studies in small (rats, rabbits
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and mice) and large (monkeys) animals have led to an understanding of transmission, dissemination
and persistence of infection.
Since the time of isolation and characterization of human retroviruses, the advent of transgenic
and immunocompromised mice has provided investigators with new animal models to apprehend
virus-induced diseases. More particularly, immunodeficient mouse strains developing a functional
human hemato-lymphoid system (HHLS) after being transplanted with human hematopoietic stem
cells (HSC) have been helpful for reaching significant achievements in studying HIV and HTLV-1
related diseases [5–7]. Such mouse models fulfill the conditions of reliable animal models ethically
acceptable by society, easy to breed at a low cost and convenient to study the pathological processes
linked to infection by lymphotropic viruses, such as HTLV-1 [8–11].
Infection by HTLV-1, a deltaretrovirus, is endemic in Japan, the Caribbean, Western Africa and
South and Central America. It is estimated that 10 to 20 million individuals are infected worldwide.
Most HTLV-1-infected individuals remain life-long asymptomatic carriers. However, in 3%–5% of
cases, HTLV-1 is etiologically linked to a neoplastic syndrome, the adult T cell leukemia/lymphoma
(ATLL) and to a spectrum of chronic inflammatory disorders, among which the most frequent is
a chronic progressive encephalomyelopathy known as HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP) [12–14].
2. The Leukemogenic Activity of HTLV-1
The main clinical feature of ATLL includes leukemic cells with multi-lobulated nuclei called
“flower cells” which infiltrate various tissues (skin lesions are very common), abnormal high blood
calcium level and opportunistic infections [14]. The CD3+, CD4+, CD8´ and CD25+ phenotype of
ATLL cells indicates that these cells derive from activated helper T cells. It was reported that in 10 of 17
ATLL cases, leukemic cells express forkhead box P3 (FoxP3), a marker of CD4+ and CD25+ regulatory
T (Treg) cells that suppress the proliferation of bystander CD4+ T lymphocytes. Indeed, severe
immunodeficiency and complicated opportunistic infections in ATLL patients may arise in part from
the immunosuppressive properties of ATLL cells [15,16].
Epidemiological surveys have underlined that ATLL preferentially develops after transmission to
neonates through maternal milk. After a prolonged asymptomatic period of 20–40 years, aneuploid
leukemic cells emerge. ATLL has been classified into different subtypes: chronic, smoldering, acute
and lymphoma. During the long chronic phase of infection, the virus is found integrated in the
genome of T lymphocytes (more than 90% are CD4+ T cells). HTLV-1 expression remains undetectable,
because of the development of a strong immune response, chiefly mediated by the anti-virus cytotoxic
T-lymphocyte response (CTL) [17]. Several HTLV-1-positive CD4+ CD25+ T cell clones that progress
from polyclonal to oligoclonal populations are observed. Finally, the outcome of several years of in vivo
selection results in the dominance of one leukemic clone. At that stage, ATLL patients have a poor
prognosis and a median survival time of less than one year. Anti-retroviral treatments, chemotherapies
and stem-cell transplantations often fail to cure the disease [18]. Overall, preventing the infection of
neonates by HTLV-1 infected mothers remains a crucial issue for the eradication of ATLL [19].
3. The Leukemogenic Potential of Tax and HBZ
The 51 LTR of the HTLV-1 provirus has been shown to drive sense transcripts that encode structural
and regulatory proteins and among the latter the Tax (transactivator of pX) protein [20]. Interestingly,
the 31 LTR of the HTLV-1 provirus drives antisense transcription involved in the translation of
another regulatory protein HBZ (HTLV-1 basic leucine zipper factor) [21,22]. Cellular and molecular
studies have emphasized that these two HTLV-1 regulatory proteins are exerting a critical role in
HTLV-1-induced leukemogenesis (Figure 1).
The Tax protein is known to trans-activate the sense transcription from the 51 LTR by interacting
with members of the ATF/CREB (Activating Transcription Factor/Cyclic AMP Response Element
Binding protein) family of transcription factors [23]. Tax is also defined as a modulator of cellular gene
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expression involved in the proliferation of T lymphocytes mainly via the activation of the NFκB and
AP-1 pathways. This protein is able to bypass cell-cycle checkpoints, affects mechanisms involved
in the DNA damage response and apoptosis pathways, and is associated with the accumulation of
genetic and epigenetic alterations and RNA stability modifications [20].
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Figure 1. Activities of HTLV-1 Tax and HBZ regulatory proteins in vitro and in vivo. (A) The scheme of
HTLV-1 genome showing the sense and antisense genes; these genes are flanked by the long terminal
repeats (LTR); (upper part) sense transcripts are initiated in the 51 LTR containing the promoter region
and terminate in the 31 LTR; (lower part) antisense transcripts are initiated in the 31 LTR. Coding exons
for regulatory proteins are presented as orange box for Tax and green box for HBZ; (B) Major roles
of Tax and HBZ regulatory proteins reported from experiments using cell culture (upper panel) or
transgenic mouse models (lower panel).
A variety of transgenic mice have been generated to explore the activity of Tax in the initiation and
development of HTLV-1-associated diseases [42] (Figure 2A). The first Tax transgenic mice, obtained
in 1987 [43], with the tax gene being expressed under the control of the HTLV-1 LTR, resulted in
the development of multicentric mesenchymal tumors with infiltration of granulocytes. This was
the first demonstration that defines Tax as an oncoprotein in vivo. These data were later confirmed
by the observation of an elevated expression of Tax in bone, associated with aberrant cell functions
such as thymic atrophy [44], neurofibromatosis, muscle degeneration, lymphadenopathy, abnormal
bone turnover [45] and mesenchymal tumors [25]. Other transgenic mice were generated in which
tax was placed under the control of different promoters, either viral (Simian virus 40 and Mouse
mammary tumor virus) or cellular (CD4, Ig, Granzyme B, Lck, TET, and CD3ε); for a review, see [46].
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When tax was placed under the control of the Granzyme B (GzmB) promoter, which is expressed
in mature T cells, transgenic mice exhibit large granular lymphocytic leukemia, associated with
splenomegaly and lymphadenopathy, two main clinical features of ATLL [26]. Interestingly, by using
a non-invasive imaging of Tax in GzmB-tax/LTR-luciferase transgenic mice, inflammation and the
subsequent malignancy have been shown to be Tax-dependent through the deregulation of the NF-κB
pathway [47]. The constitutive activation of that pathway is essential in the process of Tax-mediated
oncogenesis underlining that it constitutes an ideal target for therapeutic treatment and that Tax
transgenic mice represent good candidates for preclinical therapeutic in vivo trials.
 
Figure 2. Schematic representation of the protocols used to generate HTLV-1 mouse models.
(A) Generation of a transgenic mouse model. Briefly, the gene of interest is injected into the male
pronucleus of a one-cell embryo. Micro-injected oocytes are introduced into a surrogate female and
carried to term. The resulting offspring will then be screened by PCR and sequenced to find the
transgenic ones; (B) Generation of direct and indirect xenograft mouse models: adult immunodeficient
mice are injected either with cells isolated from ATLL patients (direct xenograft) or with HTLV-1
transformed cells (indirect xenograft); (C) Generation of Human Hemato-Lymphoid System (HHLS)
mouse model: sublethally irradiated newborn immunodeficient mice are engrafted with hematopoietic
stem cells. Those humanized mice are then infected with lethally irradiated HTLV-1 producing T cells
(see Section 5.2.).
When tax was placed under the Lck proximal promoter that restricts its expression to developing
thymocytes, T cell leukemia with characteristic “flower cells” and lymphoma with infiltrating
malignant T lymphocytes highly expressing CD25 are observed [27]. These mice also display
a constitutive activation of the NF-κB pathway and a marked hypercalcemia reminiscent to ATLL
pathology. Collectively, these observations confirm that Tax expressed in immature thymocytes is
sufficient to induce leukemogenesis in transgenic mice.
Yamazaki et al. [28] have used a Tax-transgenic mouse model that reproduces ATLL-like diseases.
They have observed that the transfer of splenic lymphomatous cells to immunodeficient mice is
followed by the regeneration of the original ATLL-like lymphoma. They then detected among
lymphomatous cells the presence of a low number of chemotherapy-resistant stem cells. These cells that
belong to a minor population of CD38´ CD71´ CD117+ hematopoietic progenitor cells were shown
to be only responsible for the recapitulation of lymphoma in immunodeficient mice. This observation
strongly suggests that ATLL leukemic clones exclusively originate in a minor population with stem
cell-like properties.
The second regulatory protein HBZ, encoded by the antisense strand of the HTLV-1 provirus,
has biologically important activities at both the RNA and protein levels [34]. hbz RNA promotes the
proliferation of ATLL cells [29], whereas HBZ protein inhibits Tax-mediated viral transcription [21,31].
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In addition, HBZ has been shown to modulate the AP-1 [48] and the classical NFκB signaling
pathways [36] and to regulate the cell-mediated immune response to virus infection [49]. Nowadays,
it is assumed that HBZ is playing an important role in the oncogenic process since it is able to drive
infected cell proliferation [30,38], to increase hTERT transcription [33,34] and to inhibit apoptosis [37].
In HBZ transgenic mice, hbz RNA promotes CD4+ T cell proliferation [29]. In addition,
HBZ protein was found to induce foxp3 transcription, thus enhancing the number of CD4+FoxP3+
T cells. But a direct interaction between HBZ and FoxP3 proteins leads to an impairment of their
regulatory function. Thus, the expression of HBZ in CD4+ T cells appears to be a key mechanism of
HTLV-1-induced neoplastic and inflammatory diseases involving interferon-gamma (IFN-γ) [35,39,40].
Moreover, transgenic mice, in which hbz is expressed under the control of the CD4 promoter, have
been used to test a new vaccine using a recombinant vaccinia virus expressing HBZ. That vaccine was
able to induce a cytotoxic memory response against CD4+ T cells expressing HBZ [50]. Finally, double
transgenic mice expressing both Tax and HBZ under the control of the CD4 promoter have increased
memory T cells and FoxP3+ Treg cells leading to the development of T cell lymphoma and skin
lesions [41]. This observation underlines that these two regulatory proteins exert a complementary
effect on regulating signaling pathways.
The above observations indicate that the HTLV-1 provirus codes for two main regulatory proteins
displaying an oncogenic potential. The question was raised to determine either if they act in
a synergistic manner or if they are chronologically involved in the initiation, the maintenance and
development of the leukemic process. The latter possibility should be considered since the expression
of Tax is frequently disrupted in ATLL cells as indicated by the detection of Tax transcripts in only ~40%
of ATLL cases [24]. Analyses of HTLV-1 proviruses and transcripts in ATLL cells revealed three ways in
which cells can silence Tax expression: accumulation of nonsense mutations, insertions and deletions
in tax, DNA methylation of the provirus that silences viral transcription and deletion of the proviral
51 LTR. The last modification is especially prevalent in acute forms of ATLL. As Tax is the main
immunogenic antigen, it is hypothesized that silencing of Tax allows infected cells to escape the
CTL response against HTLV-1 [22]. In contrary to Tax, HBZ is expressed all along HTLV-1 infection
and HBZ transcription is observed in all ATLL patients [21]. Accordingly, the leukemogenic process
may be divided in two phases: the first one under the control of Tax that drives the proliferation of
HTLV-1-positive CD4+ CD25+ T cell clones, the second one under the control of HBZ that mediates
the proliferation and the maintenance of these clones.
The observations obtained with transgenic mice have provided valuable information about the
involvement of these two regulatory proteins in HTLV-1-mediated leukemogenesis. However, these
transgenic models do not allow exploring the natural history of HTLV-1 infection, and also the specific
intervention of Tax and HBZ during the development of ATLL in humans.
4. Mouse Models
From Immunodeficiency-
The story of immunodeficient mice strains began fifty years ago with the report of BALB/c
nude athymic mice that lack a fully developed T cell compartment (Figure 3) [51]. In CB17-SCID
(severe combined immunodeficiency) mice, discovered in 1983, mature T and B cells do not develop.
Indeed, these mice carry a spontaneous non-sense mutation in the gene coding the protein kinase
DNA activated catalytic polypeptide (Prkdc), an enzyme necessary for the V(D)J recombination of
the B and T cell receptors. However, innate immunity is still functional due to the presence of
macrophages, antigen-presenting cells and natural killer (NK) cells [52]. Introducing the SCID
mutation onto the non-obese diabetic (NOD) genetic background leads to NOD/SCID mice that
display a severe innate immunodeficiency with neither complement system nor functional dendritic
cells and macrophages. They provide a good in vivo environment for reconstitution with human
HSC [53] (see part “to humanization”). In order to avoid thymic education of human HSC on mouse
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thymus in a MHC(H2)-restricted manner, a targeted mutation into the β2-microglobulin (β2m) gene
was also introduced generating NOD/SCID β2mnull mice lacking the murine immune functions.
Later on, a new strain (BALB/c.Cg-Rag2null) of immunodeficient mice was created by deleting the
recombinase-activating gene 2 (Rag2) in BALB/c mice [54].
 
Figure 3. Mouse models in the study of HTLV-1 leukemogenesis. Transgenic immunocompetent mice
were mainly used to investigate the role of HTLV-1 Tax and HBZ (see pink boxes). From the beginning
of the 1980s, several strains of immunodeficient mice have been isolated and/or developed through the
introduction of various gene mutations (in italics over the blue chronological scale). The tumorigenic
potential of HTLV-1 infected T-cells or of ATLL cells has been studied by engrafting these cells in
immunodeficient mice (xenograft, purple boxes). Likewise, the engraftment of immunodeficient
mice with either human lymphocytes or stem cells or lymphoid tissues has led to the generation of
humanized mice (green boxes), prone to investigate the role of HTLV-1 infection in leukemogenesis
(orange boxes). Hu: humanized; HSC: hematopoietic stem cells; PBL: peripheral blood lymphocytes;
HHLS: human hemato-lymphoid system; BLT: bone marrow-liver-thymus; MITRG and MISTRG:
M-CSF, IL3, TPO, MG-CSF and/or SIRPα (signal regulatory protein α).
The next generation of immunocompromised mice was obtained by disruption of the IL-2 receptor
common gamma chain (γ) gene [67]. These new strains of mice displayed a complete absence of
murine T and B cells as well as NK cells. Currently, three major strains of immunodeficient mice
are commonly used, NSG (NOD.Cg-PrkdcSCID-γnull) [64]; NOG (NODShi.Cg-PrkdcSCID-γnull) [65]
and BRG (BALB/c.Cg-Rag2null γnull) [54]. Their advantages and limitations have been extensively
reviewed earlier [5–7,68,69].
To improve the human innate immune cell development, MITRG mouse models were developed
in which four genes encoding human cytokines (M-CSF, IL3, GM-CSF and TPO) were knocked into
their respective mouse loci in Rag2null γnull mice. In MISTRG mice, an additional transgene encoding
the human signal regulatory protein α (SIRPα) was introduced enabling mouse phagocytes to tolerate
and not to phagocyte engrafted xenogeneic cells [66,70].
38
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-to Humanization
The continuous improvements introduced in creating the immunocompromised mice to favor
an efficient engraftment level of human tissue or cells have been exploited to generate humanized
mouse models that carry a human functional immune system [10]. In this review, the term “humanized
mice” is restricted to severely immunodeficient mice engrafted with human cells and/or tissues
and developing a HHLS. These mice have been shown to be valuable to study human immune cell
development under normal and pathological conditions.
Two humanized (hu) mouse models hu-PBL-SCID and SCID-hu Thy/Liv were described at the
end of the 1980s. The first one is generated through the intraperitoneal inoculation of human peripheral
blood lymphocytes (PBL) [60]. The second mouse model is developed after surgical implantation
of fetal thymus/liver tissue under the renal capsule of SCID mice to form a conjoint thymus-like
organ [61]. Such a model is cumbersome to generate and requires repeated biopsies of the organ.
Furthermore, a wasting graft-versus-host disease develops within weeks after implantation of human
cells, thus limiting experimentation to a few weeks.
Based on these models, another valuable humanized mouse model called “BLT” (Bone marrow,
Liver, Thymus) has been described. NOD/SCID and NSG mice are first implanted with human
fetal thymic and liver tissues and then with autologous human HSC. Several weeks later, they show
long-term systemic repopulation with human T and B cells, monocytes, macrophages and dendritic
cells (DC) [63]. T cells in these mice are educated in the human thymus generating human MHC class
I- and II-restricted adaptive immune responses to Epstein-Barr Virus (EBV) infection and are activated
by human DCs to mount a potent T cell immune response to superantigens. It represents a convenient
model to study many aspects of T cell differentiation and function that could not be studied in vitro.
But, technical, ethical and logistical reasons render this BLT model complex to carry out limiting its
wide usage.
These difficulties sparked interest in the search of new protocols to generate convenient and
efficient generations of humanized mice. Materials and methods used to reconstitute the HHLS in mice
include many factors, such as choice of human tissue and/or cells, route of inoculation, age and gender
of recipient mice and preconditioning regime (irradiation or busulfan) (Figure 2C). Immunodeficient
newborn mice such as NSG and BRG mice transplanted with human purified CD34+ cells develop
three to four months later a robust HHLS, through T cell thymopoiesis and B cell splenic and bone
marrow lymphopoiesis. Interestingly, more T and B cells are found in NSG mice than in BRG ones,
showing that NSG mice are more permissive to human cell engraftment than BRG mice. In fact,
a reduced phagocytosis of human cells by mouse macrophages was observed in NSG mice. That
property may be linked to the mouse SIRPα of the NOD genetic background that better recognizes the
“don’t eat me” signal of human CD47 than that of BALB/c background [54,71,72].
The MITRG/MISTRG immunodeficient mice are highly permissive for human cell engraftment
and show an efficient development of human innate immune cells such as macrophages and NK cells.
However, the increase in human myeloid cells correlated with the presence of human B and T cells at
lower frequencies than in NSG mice. As B cells display an immature phenotype, humoral immune
responses are low as in other strains of HHLS mice [66]. The development of human red blood cells
(RBC) is inefficient, and as macrophages strongly phagocyte mouse RBC, anemia ultimately ensues
two to three weeks after engraftment.
5. The Mouse Modeling of HTLV-1-Induced Leukemogenesis
The immortalization and transformation of HTLV-1 infected CD4+ T cells have been studied with
great limitation in tissue culture and patients. Since ATLL develops through several oncogenic steps in
a small percentage of HTLV-1-infected individuals, animal models of ATLL are urgently needed not
only to understand the in vivo initiation and the progression of the leukemogenic process, but also to
perform preclinical studies of potential therapeutic agents. Attempts to reach these objectives have
been performed through the use of mouse xenograft models and of HHLS mice. In particular, human
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T cells in HHLS mice display a phenotype of quiescent/activated and naive/memory cells and appear
well suited for exploring HTLV-1 pathogenesis.
5.1. Xenogeneic Transplantation Assays
Upon the description of immunocompromised mice, their susceptibility to engraftment with either
HTLV-1-infected cell lines or ATLL cells was evaluated (Figure 2B). These experiments confirmed
that the engraftment efficacy directly correlated with the abrogation level of the murine immune
responses and was dependent on a low NK cell activity, absence of complement activity and impaired
macrophage and antigen presenting cell function [53]. Consequently, during the last twenty years,
these mice were mainly used as xenogeneic engraftment models to apprehend critical aspects of
the multistep development of ATLL [10,73,74]. More particularly, the following observations from
three reports underline that the development of xenograft approaches in immunodeficient mice has
largely contributed to understand kinetics, metastasis, disease progression as well as the origin of
ATLL in vivo.
In immunodeficient mice inoculated with HTLV-1 infected MET-1 cells, T cell leukemia with
tumors in organs such as liver and kidney and an increase of serum calcium level are observed similar
to that in ATLL patients [55]. In these leukemic mice, the increase in serum calcium level correlated with
expression of RANK-L (receptor activator of nuclear factor kappa-light-chain-enhancer of activated
B cells ligand) and with secretion of parathyroid hormone-related protein and interleukin-6. As MET-1
cells expressed both the adhesion molecules CD11a (LFA-1α) and CD49d (VLA-4α) and produced
several matrix metallo-proteinases, these observations underline the importance of these molecules in
the spread of ATLL cells.
In the second study, primary ATLL cells from acute or smoldering ATLL patients were
intravenously transplanted into neonatal NOD/SCID/β2mnull mice [75]. Acute-type ATLL cells
were observed in the peripheral blood and in the lymph nodes of recipients. Engrafted ATLL cells
were dually positive for human CD4 and CD25, and displayed patterns of HTLV-1 integration identical
to those of donors by Southern blot analysis. These cells infiltrated into recipients’ liver, and formed
nodular lesions, recapitulating the clinical feature of each patient. In contrast, in smoldering-type
ATLL cases, multiple clones of ATLL cells were efficiently engrafted in NOD/SCID/β2mnull mice.
When these clones were retransplanted into secondary NOD/SCID/β2mnull recipients, single
HTLV-1-infected clones became predominant, indicating the selection of clones with a dominant
proliferative activity.
The third study has addressed the origin of ATLL cells. Nagai et al. [56] report that ATLL is
sustained by a small population of transformed CD4+ CCR7+ CD45RA+ CD45RO´ CD95+ T memory
stem (TSCM) cells, a unique population with stem cell-like properties, whereas the majority of ATLL
cells are CD45RA´ CD45RO+ conventional memory T cells. Indeed, in both HTLV-1 carriers and
ATLL patients, HTLV-1 provirus was absent in naïve T cells, but was always detected in the three
memory (stem, central and effector) subpopulations. In vitro culture assays performed with highly
purified cells clearly demonstrate that the three memory subpopulations have equal susceptibility
to HTLV-1 infection, since they express at least two cell surface receptors for HTLV-1, the heparan
sulfate proteoglycans and the VEGF-165 receptor Neuropilin 1 [76]. But among the T memory cells,
TSCM cells have a unique potential to self-renew while giving rise to T effector and central memory
cells. Such an observation suggests that ATLL is hierarchically organized in the same manner as the
normal memory T cell compartment. To further demonstrate the role played by TSCM in the initiation
of ATLL, the authors proceeded to xenogeneic transplantation assays and inoculated the three subsets
in adult irradiated NOG and NSG mice. They observed that a low number of TSCM cells efficiently
repopulated identical ATLL clones and replenish downstream central and effector memory T cells,
whereas these two other populations have no such capacities. Taken together, these findings reveal the
phenotypic and functional heterogeneity of ATLL cells and identify that the TSCM population is the
hierarchical apex of ATLL able to reconstitute identical ATLL clones. This study together with that
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of Yamazaki et al. [28] (see part 3) underline that like other cancers, ATLL may be sustained by a rare
population with self-renewal capacity able to support accumulations of genetic abnormalities required
for the development of this HTLV-1-induced disease.
Finally, xenogeneic transplantation assays have been performed to define specific therapeutic
strategies against dysregulated pathways in HTLV-1-induced pathogenesis. Enhanced survival
and reduction of tumor growth can be observed after treatment with inhibitors of NFκB-mediated
pathway [77,78], of Bcl-2 family [79] or of histone deacetylase [10]. As HTLV-1 infection leads to
genetic alterations, a drug inhibiting double strand break repair has been tested in a xenograft mouse
model [80]. Oncolytic therapy using measles virus [81] and antibody therapy blocking CCR4 [82] or
CD30 [83] also lead to increased survival in NOD/SCID and NOG mice inoculated with ATLL or
HTLV-1 infected cells.
5.2. HTLV-1 Infection of Humanized Mice
Faithful recapitulation of ATLL in humanized mice has been challenging but required to further
apprehend the natural history of HTLV-1 infection and to approach the importance of the immune
response in the development and outcome of ATLL [84]. A first attempt to analyze the molecular and
cellular events that control the HTLV-1 induced leukemogenesis was realized by inoculating CD34+
progenitor cells ex vivo infected with HTLV-1 in SCID mice engrafted with human fetal thymus and
liver tissues [57]. An increased expression of the CD25 marker on thymocytes was observed together
with a perturbation of the CD4+ and CD8+ thymocyte subset distribution indicating for the first time
that hematopoietic progenitor cells and thymus may be targeted by HTLV-1 in humans. However,
HTLV-1 infection of these SCID-hu mice failed to induce oncogenesis. In contrast, as reported by
Banerjee et al. [85], NOD-SCID mice inoculated with CD34+ cells ex vivo infected with HTLV-1 have
been shown to develop CD4+ T cell lymphoma. However, inoculation of ex vivo infected CD34+ cells
might represent a bias since the presence of HTLV-1 infected cells among CD34+ cells in ATLL patients
is still a matter of debate [56].
To come closer to the natural infection, we have investigated the in vivo effects of HTLV-1 infection
in HHLS BRG mice [58]. Newborn mice were engrafted with human CD34+ cells and then infected
with lethally irradiated HTLV-1-producing T cells at a time when the three main subpopulations of
human thymocytes have been detected, i.e., within a period of one to two months after engraftment
(Figure 2C). As soon as three months after infection, significant alterations of human T cell development
have been observed, the extent of which correlated with the proviral load. Human T cells from thymus
and spleen were activated, as shown by the expression of the CD25 marker, that correlates with the
presence of tax mRNA and with the increased expression of NFκB dependent genes such as bfl-1,
an anti-apoptotic gene. Five months after HTLV-1 infection, hepato-splenomegaly, lymphadenopathy
and T cell lymphoma/thymoma, in which Tax was detected, were observed in those mice. Thus, in vivo
HTLV-1 infection of HHLS BRG mice perturbs human thymopoiesis at the level of immature cells,
and propels T cell development towards the mature stages [86]. To note that these in vivo observations
confirm results obtained in vitro, showing the ability of Tax to interfere with β-selection, an important
checkpoint of early T cell differentiation in the thymus. These data suggest that the infection of
immature target T cells in the thymus and the immunodeficient environment of these humanized mice
favors the rapid development of a T cell malignancy. Interestingly, these observations suggesting that
target cells of the leukemogenic activity of HTLV-1 are recruited among a stem cell population are in
line with those showing the role played by TSCM in the initiation of ATLL [56].
Lastly, observations using mice that were generated through a different humanization protocol
have been reported [59]. Indeed in that study, sub-lethally irradiated seven-week old NOG mice were
submitted to an intra-bone marrow injection (IBMI) of human cord blood CD133+ cells. Three to
eight months after engraftment, a stable B to T cell ratio was observed in the peripheral blood
of these mice indicating the formation of a robust immune system. Four to five months after
engraftment, these humanized NOG mice were infected by intra-peritoneal injection of lethally
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irradiated HTLV-1-producing T cells. Upon infection, the number of human CD4+ T cells in the
periphery increased rapidly with the presence of abnormal T cells displaying lobulated nuclei
resembling ATLL-specific “flower cells”. Five months later, selective growth of a limited number of
human CD25+ infected T cell clones was observed. Interestingly, HTLV-1-specific T cell mediated
immune responses were induced in some infected mice, suggesting that an adequate thymic education
has occurred in these IBMI-humanized NOG mice. Clearly, it is tempting to speculate that the NOG
background may be at the origin of the development of adaptive immune responses. It is interesting to
note that both Tax and HBZ are expressed in infected humanized mice. This is reminiscent to what
is observed in the early phases of the infection process occurring in patients. However, this dual
Tax/HBZ expression persists in humanized mice, probably because of the lack of an efficient immune
response. Thus, induction of cellular and humoral immune responses against HTLV-1 in infected
IBMI-huNOG mice might represent a valuable approach to investigate the natural history of HTLV-1
infection. It remains to be determined whether this immune response may lead to a down-regulation
of Tax expression in these infected mice.
Collectively, studies performed to recapitulate HTLV-1 induced leukemogenesis in humanized
mice are opening a new chapter in the in vivo understanding of pathological mechanisms mediated by
the T cell lymphotropic virus. In addition, it is now evident that humanized mice represent a promising
preclinical tool to study new therapeutic treatments since the nucleoside analogue reverse transcriptase
inhibitor 31-azido-31deoxy-thymidine (AZT) was found to be effective at suppressing HIV replication
in SCID-hu-mice [62]. Treatments to block the entry or the replication of HTLV-1 could be assessed in
order to serve as a post-exposure way to prevent the persistent infection (Figure 4).
Figure 4. Humanized mice in the development of antiretroviral therapy. A schematic for modeling
HTLV-1 infection and therapeutical approaches (orange and blue boxes) in humanized mice. * AZT,
NFκB drugs and/or siRNA; ** analysis of activated T lymphocytes, of HTLV-1 DNA and RNA to
evaluate the drug efficiency.
Currently, antiretroviral therapies including interferon α (IFN-α), zidovudine (AZT) and As2O3
have been tested as a first-line therapy for ATLL patients [87]. Furthermore, the anti-CCR4 monoclonal
antibody mogamulizumab has been shown to have cytotoxic effects on ATLL cells and is now used in
Japan to treat patients [19]. The demonstration of their ability to clear provirus and the understanding
of the molecular and cellular mechanisms involved in humanized mice should accelerate clinical
approaches for HTLV-1 eradication.
6. HHLS Mouse Models and HTLV-1 Pathogenesis: The Future Is Now
The advent of humanized mice to the HTLV-1 research field has offered a challenging opportunity
to in vivo study ATLL development. Thus far, they have been helpful in elucidating the initial steps
of the leukemogenic process induced by this human retrovirus. Concerning HAM/TSP and other
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immuno-inflammatory disorders associated with HTLV-1 infection, humanized mice have not yet
been very useful mainly because of the lack of a strong immune response. One can speculate that
enhancement of this immune response through new technologies (see paragraph iii) will definitively
contribute to a real improvement in the understanding of these pathologies.
Consequently, advances have to be performed to further optimize this mouse model along these
three possibilities:
(i) To infect humanized mice with molecularly cloned HTLV-1 (unpublished data, Pérès et al.)
opening a new way not only for understanding in detail the HTLV-1-pathogenesis, but
also for delineating the importance of various viral genes on CD4+ T cell transformation
and leukemogenesis. Inducible viral gene expression systems could also improve our
knowledge [88].
(ii) To mimic the way HTLV-1 is delivered (breast-feeding) and disseminated (through dendritic
cells) in the body [89]. One can hypothesize that the gastrointestinal tract can serve as
a secondary site of infection in which infected T cells present in the milk would be able to
infect dendritic cells in the intestine. Clearly, new humanized mouse models engrafted with
appropriate target tissues will be suitable for evaluation of HTLV-1 natural infection.
(iii) To enhance the specific immune response, by using mouse strains transgenic for human
HLAs. For example, in NSG-HLA-A2/HDD mice that possess the human HLA-A2 gene, T cell
education is performed in a human HLA context. In these mice, a functional HLA-restricted
cytotoxic response has been observed after EBV infection [90]. Likewise, in transgenic
NOG/HLA-DR4 mice, T cell homeostasis was differentially regulated in HLA-matched
humanized NOG mice compared with HLA-mismatched control mice. Furthermore, antibody
class switching was induced after immunization of HLA-DR matched mice with exogenous
antigens, underlining that this novel mouse strain will contribute to future studies of human
humoral immune responses [91].
Thus, in the near future, it will be possible to infect humanized mice able to develop a fully
functional human immune system after transgenic expression of human HLA molecules, cytokines
and other species-specific factors and by targeting mouse genes to eliminate host MHC antigens and
other genes to further reduce innate immunity [58]. Recently, new technologies for manipulation of the
mouse genome have been described (CRISP/Cas9, clustered regularly interspaced short palindromic
repeats) and provide exciting opportunities for rapidly generating new genetically modified mice
in order to establish a robust small animal model to study the maintenance and development of
ATLL [92].
In conclusion, together with observations obtained in immunodeficient mice through
transplantation assays, studies performed with HTLV-1-infected mice have documented that the
leukemogenic activity of HTLV-1 appears to be dependent on the infection of immature T cells with
stem cell-like properties. Even when infected, these rare pre-leukemic cells can generate clonal
populations of ATLL cells displaying phenotypic and functional heterogeneity. Therefore, reducing
the number of these pre-leukemic cells in HTLV-1 carriers may represent a promising approach to
prevent the development of ATLL. In that context, humanized mice would be very useful for testing the
chimeric antigen receptor T cell therapy and to eliminate pre-leukemic cells, as recently demonstrated
in refractive acute lymphoblastic leukemia [93].
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Abstract: The tumorvirus human T-cell lymphotropic virus type 1 (HTLV-1), a member of the
delta-retrovirus family, is transmitted via cell-containing body fluids such as blood products, semen,
and breast milk. In vivo, HTLV-1 preferentially infects CD4+ T-cells, and to a lesser extent, CD8+
T-cells, dendritic cells, and monocytes. Efficient infection of CD4+ T-cells requires cell-cell contacts
while cell-free virus transmission is inefficient. Two types of cell-cell contacts have been described to
be critical for HTLV-1 transmission, tight junctions and cellular conduits. Further, two non-exclusive
mechanisms of virus transmission at cell-cell contacts have been proposed: (1) polarized budding
of HTLV-1 into synaptic clefts; and (2) cell surface transfer of viral biofilms at virological synapses.
In contrast to CD4+ T-cells, dendritic cells can be infected cell-free and, to a greater extent, via viral
biofilms in vitro. Cell-to-cell transmission of HTLV-1 requires a coordinated action of steps in the
virus infectious cycle with events in the cell-cell adhesion process; therefore, virus propagation from
cell-to-cell depends on specific interactions between cellular and viral proteins. Here, we review the
molecular mechanisms of HTLV-1 transmission with a focus on the HTLV-1-encoded proteins Tax
and p8, their impact on host cell factors mediating cell-cell contacts, cytoskeletal remodeling, and
thus, virus propagation.
Keywords: HTLV-1; Tax; p8; virus transmission; cell-to-cell transmission; cell-cell contacts; virological
synapse; viral biofilm; cellular conduit
1. Introduction
Human T-cell lymphotropic virus type 1 (HTLV-1), a delta-retrovirus, is the causative agent of
a severe and fatal lymphoproliferative disorder of CD4+ T-cells, adult T-cell leukemia/lymphoma
(ATL), and of a neurodegenerative, inflammatory disease, HTLV-1-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) [1–5]. Up to 5% of infected people develop one of the aforementioned
diseases as a consequence of prolonged viral persistence after a clinical latency period that may last
over decades [6–8]. Although the exact number of infected people is unknown [9], it is estimated that
5–10 million people worldwide are infected with HTLV-1 [10]. Endemic regions for HTLV-1 are Japan,
Melanesia, South America, parts of sub-Saharan Africa, the Caribbean, central parts of Australia, and
the Middle East [10,11]. In Europe, only Romania seems to be an endemic region [10,12,13].
Upon binding to its receptor, which is composed of the widely expressed glucose transporter 1
(Glut-1), neuropilin-1 (NRP-1, BDCA-4), and heparan sulfate proteoglycans (HSPG), HTLV-1 enters
and infects its target cell [14–18]. After uncoating and reverse transcription, HTLV-1 integrates into
the host cell genome and is predominantly maintained in its provirus form (9.1 kb), which is flanked
by long terminal repeats (LTR) in both the 5' and 3' region carrying the viral promoter (reviewed
by [19]). Next to genes common for retroviruses encoding structural proteins Gag, the enzymes
protease, polymerase, integrase, and reverse transcriptase, HTLV-1 encodes regulatory (Tax, Rex) and
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accessory (p12/p8, p13, p30) proteins from the sense strand and the HTLV-1 basic leucine zipper (HBZ)
from the antisense strand [7,19]. Tax and Rex are essential for viral replication. While Tax enhances
viral mRNA synthesis by transactivating the HTLV-1 promoter located in the 5'-LTR, Rex controls the
synthesis of the structural proteins on a post-transcriptional level [20]. The accessory proteins p12/p8,
p13, and p30 are important for viral infectivity and persistence in vivo, but not for virus replication
in vitro [21]. An important role in HTLV-1-induced cellular transformation has been attributed to the
viral oncoprotein Tax, which is sufficient to immortalize T-cells in vitro [19]. During the last decade,
important roles for promoting viral replication and cellular proliferation have been attributed to the
HBZ protein and to HBZ RNA. It is thought that Tax is important for initiating immortalization of
lymphocytes, while HBZ is essential for maintaining the immortalized phenotype [22].
HTLV-1 replicates either by infecting new target cells or by mitotic division and clonal proliferation
of infected cells (for review see [23]). In this article, we review the molecular mechanisms of infectious
HTLV-1 cell-to-cell transmission. We focus on the HTLV-1-encoded proteins Tax and p8, their impact
on host factors mediating cell-cell contacts, cytoskeletal remodeling, and virus transmission.
2. Target Cells of HTLV-1 in Vivo
While HTLV-1 infects several cell types in vitro after binding of the viral envelope (Env) protein to
the HTLV-1 receptor [14–18], CD4+ T-cells are the main and preferential target for HTLV-1 infection
in vivo [24]. Additionally, HTLV-1 proviral DNA can also be detected to a lesser extent in CD8+
T-cells [25–27], dendritic cells (DC) [28], plasmacytoid dendritic cells (pDC) [29], and monocytes [26,30].
A recent study by Melamed et al. has shown that infected CD8+ T-cells constitute about 5% of the
total HTLV-1 proviral load found in peripheral blood mononuclear cells (PBMC) in a cohort of
12 HTLV-1-infected patients [27]. However, in clonally expanded populations of HTLV-1-infected
cells, it seems unlikely that other cell types than CD4+ and CD8+ cells are present because almost
all (99.7%) of the most highly abundant clones were CD4+ or CD8+ cells [27]. Another recent study
reported the presence of HTLV-1 in classical, intermediate, and non-classical monocytes in PBMC of
HTLV-1-infected individuals. HTLV-1 infection altered surface receptor expression, migratory function,
and subset frequency of the monocytes [31]. The authors proposed the model that recruitment of
classical monocytes to inflammation sites is increased in infected patients, which may result in virus
acquisition and enhanced virus dissemination [30]. These ex vivo observations are in contrast to in vitro
observations showing that monocytes are refractory to productive HTLV-1 infection, which initiates
Caspase-3-dependent cell death [32]. Early work has also shown that HTLV-1-infected B-cell clones
can be isolated from ATL patients and that B-cells are targets of HTLV-1 in vitro [31,33–36]. However,
B-cells do not seem to constitute a major viral reservoir in vivo.
3. Routes of Viral Transmission in Vivo
In contrast to human immunodeficiency virus (HIV), cell-free infection of CD4+ T-cells with
HTLV-1 is very inefficient. Free virions can hardly be detected in the blood plasma of infected
individuals and are poorly infectious for most cell types except DC [37–41]. Further, infected
lymphocytes produce a limited amount of viral particles, amongst which 1 out of 105 is infectious [38].
However, transmission is greatly improved upon establishment of cell-cell contacts [40]. Therefore,
efficient virus transmission occurs via cell-containing body fluids such as blood, semen, and breast
milk (for review, see [40]). In endemic regions, HTLV-1 is primarily transmitted from mother to child.
Contrary to HIV, mother-to-child transmission of HTLV-1 predominantly occurs via breast-feeding,
while transplacental transmission or transmission during delivery are rare [40,42,43]. The risk of viral
transmission increases with longer breast-feeding periods and high maternal proviral load. Reduction
in breast-feeding also reduces mother-to-child transmission [44]. Sexual transmission of HTLV-1 occurs
more efficiently from men to women than vice versa [40], and transmission might be enhanced by
other sexually transmitted diseases that cause ulcers and ruptures of the mucosa like syphilis or
Herpes simplex type 2 [45]. Rarely, HTLV-1 can also be transmitted by organ transplantation and
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cause diseases in immunocompromised transplant recipients, like HTLV-1-associated lymphomas or
HAM/TSP after kidney transplantation [46,47]. HTLV-1 is not only transmittable among humans,
but also from non-human primates (NHP) to humans. Recent studies have reported that interspecies
transmission of the simian counterpart STLV-1 through severe bites from NHP is an ongoing event in
Central Africa [48,49].
It is still not settled whether cell-free or cell-associated HTLV-1 accounts for infectivity of the
primary target cell in vivo. Moreover, the first host cell infected by HTLV-1 in vivo and the exact route
of infection are currently unknown [50]. Since antigen-presenting cells such as DC (see Section 5) are
naturally infected with HTLV-1, it is assumed that they could be involved in viral transmission to T-cells
in vivo. To obtain insights into the first steps of HTLV-1 acquisition in vivo, e.g., during mother-to-child
transmission by breastfeeding, Martin-Ladil et al. developed an in vitro model studying the transcytosis
of HTLV-1 across a barrier of enterocytes [51]. Interestingly, the integrity of the epithelial barrier
was maintained during co-culture with HTLV-1-infected lymphocytes, and enterocytes were not
susceptible to HTLV-1 infection. However, free infectious HTLV-1 virions crossed the epithelial
barrier via transcytosis and productively infected human DC located beneath the epithelial barrier [51].
Upon infection, DC could then pass the virus to T-cells. Surprisingly, DC are more susceptible to in vitro
infection with viral biofilms than autologous CD4+ T-cells, underlining their potential importance in
virus dissemination [50].
The study of HTLV-1 infection in vivo has benefitted from small animal models (rabbits, rats, and
mice) and from large animal models (macaques, sheep infected with the related bovine leukemia
virus) [52,53]. Recently, HTLV-1-infected humanized mice that are reconstituted with a functional
human immune system and that develop lymphomas have been described [54]. Humanized mice may
provide the opportunity to visualize HTLV-1 transmission in vivo as it has been shown for transmission
of the related retroviruses murine leukemia virus (MLV) and HIV [55]. Additionally, humanized
mouse models have already been used to show the neutralizing function of anti-Env antibodies in
preventing HTLV-1 transmission in vivo [56].
4. Molecular Mechanisms of HTLV-1 Cell-to-Cell Transmission between CD4+ T-Cells
Cell-cell-mediated virus propagation requires coordination of steps of the virus infectious cycle
with events in the cell-cell adhesion process. Therefore, the mechanism of cell-to-cell transmission
depends on specific interactions between cellular and viral proteins [57]. Thus far, two types of
cell-cell contacts have been described to be critical for HTLV-1 transmission, tight cell-cell contacts
(see Section 4.1) and cellular conduits (see Section 4.2). For transmission at tight cell-cell contacts, two
non-exclusive mechanisms of virus transmission at the virological synapse (VS) have been proposed:
(1) polarized budding of HTLV-1 into synaptic clefts (see Section 4.1.1), and (2) cell surface transfer of
viral biofilms (see Section 4.1.2). Thus far, the mechanism of HTLV-1 transmission via cellular conduits
induced by the viral p8 protein is unclear (see Section 4.2) [58,59]. Independent of the route of HTLV-1
transmission, viral particles are transmitted in confined areas protected from the immune response
of the host. Beyond, cytoskeletal remodeling and cell-cell contacts are a prerequisite for all routes of
virus transmission as interference with both actin and tubulin polymerization strongly reduces HTLV-1
transmission [57,60].
4.1. Transmission at Tight Cell-Cell Contacts
4.1.1. Polarized Budding at the Virological Synapse (VS)
Imaging analysis revealed that HTLV-1 is transmitted from cell-to-cell at the so-called virological
synapse (VS; Figure 1) [60]. The VS is defined as a “virus-induced, specialized area of cell-cell contact
that promotes the directed transmission of the virus between cells” [61].
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Figure 1. The virological synapse (VS). Interactions of intercellular adhesion molecule 1 (ICAM-1; on
HTLV-1-infected T-cells) with lymphocyte function-associated antigen (LFA-1; on target cells), and
signals induced by the viral Tax protein trigger polarization of the microtubule organizing center
(MTOC) towards the cell-cell contact and formation of the VS at the cell-cell contact. Tax is not
only located in the nucleus, but also at the MTOC and in the cell-cell contact region. Tax-induced
CREB signaling (nuclear activity of Tax), the accumulation of Tax at the MTOC, and ICAM-1-induced
Ras/MEK/ERK signaling are important for MTOC polarization. It is assumed that the VS allows for
efficient polarized budding and virus transmission via a synaptic cleft, thus, avoiding recognition of
HTLV-1 by the host immune system. Figure was realized thanks to Servier Medical Art.
Igakura et al. found that HTLV-1 Gag p19, Env, Gag p15 (nucleocapsid, important for incorporation
of the viral RNA into the particle), and viral genomes accumulate at the interface between primary
HTLV-1-infected and uninfected T-cells, followed by viral transfer to the uninfected cell [60].
This transfer was accompanied by polarization of the microtubule organizing center (MTOC) inside the
infected cell towards the target cell. The cytoskeletal protein talin, which is important for cell adhesion,
also accumulated at this specialized cell-cell contact, and inhibition of actin and tubulin polymerization
diminished MTOC polarization [60]. The VS is distinct from the immunologic synapse (IS): contrary
to the IS, where the cytoskeleton of the target cell polarizes towards the cell-cell contact, at the VS,
the polarization of the cytoskeleton occurs inside the infected cell towards the target cell [61]. MTOC
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polarization and formation of the VS require at least two signals, one provided by the viral Tax protein,
the other provided by the cell-cell contact as follows: (1) The presence of Tax located at the MTOC
region and the ability of Tax located in the nucleus to stimulate CREB-dependent signaling pathways;
and (2) cross-linking of intercellular adhesion molecule 1 (ICAM-1) at the cell-cell contact [62,63].
ICAM-1 binds to LFA-1 (lymphocyte function-associated antigen 1) on uninfected cells [63,64] at the
site of the cell-cell contact, and this interaction could contribute to the preferred tropism of HTLV-1 for
CD4+ T-cells. Use of specific inhibitors revealed that the small GTPases Rac1 and Cdc42 are important
for MTOC redistribution [63]. Electron tomography detected that cell membranes of infected and target
cells are closely apposed at the VS, but interrupted by clefts. Gag-positive particles were detected
inside the synaptic cleft, which resembled virions in size and morphology [65], suggesting that virions
are transferred across this cleft to target cells. However, it is still questionable whether these particles
were indeed infectious since no Env was detected at the surface of these particles [65].
Summed up, formation of the VS requires Tax to enhance expression of adhesion proteins
(ICAM-1) in an HTLV-1-infected T-cell in contact with an uninfected T-cell [60]. After engagement of
ICAM-1 on the infected T-cell and LFA-1 on uninfected T-cells, reorganization of the cytoskeleton in
the infected cell occurs. Concomitant with polarization of the MTOC adjacent to the VS, viral proteins
are concentrated in the center of the VS and surrounded by an outer ring of adhesion proteins [60].
Thereafter, it is assumed that viral particles are assembled and acquire the viral Env as they bud from
the infected cell into the synaptic cleft. Upon induction and binding of the HTLV-1 receptor on the
uninfected cell, viral particles cross the VS and enter the uninfected cell [61,66].
Interestingly, polarized assembly and transmission at the VS has also been described for other
retroviruses like HIV and MLV [67–69]. Contrary to HTLV-1, both HIV and MLV can also spread
cell-free. However, viral transmission under conditions of direct cell-cell contact is much more
efficient [67,69]. Yet, the quantitative contribution of transmission via the VS for retroviral spread
remains to be determined due to the lack of specific inhibitors of polarized budding processes. Taken
together, transmission via the VS allows directed transmission of HTLV-1 to target cells whilst avoiding
recognition by the host’s immune response.
4.1.2. Transmission of Viral Biofilms at the VS
After infection of a host, microbes have evolved many issues to be protected from the host immune
system. Bacteria developed an important way to hide from the immune system and to spread inside of
the host by producing an extracellular biofilm, where bacteria are concentrated outside of infected
cells. These distinct environments produced by the microbes themselves are rich in polysaccharides
and carbohydrates [70]. Interestingly, biofilms have also been detected on cells infected with HTLV-1
and hence, were named “viral biofilms” (Figure 2) [71]. Biofilm-like, extracellular viral assemblies are
composed of extracellular matrix (ECM) components and cellular lectins. In viral biofilms, virions are
concentrated in a confined protective environment on the surface of infected cells and are transmitted
to target cells at “virological synapses” [71]. HTLV-1 virions and clusters of viral proteins (Gag,
Env) are accumulated in this specialized ECM on the surface of cells from infected patients and of
chronically-infected cell lines. The biofilm is composed of carbohydrates, components of the ECM like
collagen that form tight extracellular matrices, and the HSPG agrin [71]. Additionally, linker proteins
(galectin-3, tetherin) [71], and O-glycosylated surface receptors (CD43, CD45) are part of the viral
biofilm [72]. Tetherin, which was identified as an antiviral factor, prevents cell-free release of viruses
from infected cells, maybe playing a role in the retention of HTLV-1 at the surface of infected cells [73].
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Figure 2. The viral biofilm. HTLV-1 virions are accumulated in a specialized extracellular matrix
(ECM), the so-called viral biofilm, on the surface of infected cells. The viral biofilm is composed of
carbohydrates, components of the ECM (collagen, agrin), linker proteins (galectin-3, tetherin), and
O-glycosylated surface receptors (CD43, CD45). HTLV-1 particles are concentrated into large, highly
infectious assemblies that cluster towards the cell-cell contact. HTLV-1 is transferred to target cells and
guarded by the biofilm from immune recognition. Figure was realized thanks to Servier Medical Art.
HTLV-1 particles are assembled into large, highly infectious clusters and transferred to
neighboring cells while being guarded by the biofilm from immune recognition [74]. Treatment
with heparin or extensive pipetting removed the viral biofilm and strongly impaired the efficiency
of HTLV-1 spreading to target cells by 80% [71], concluding that the viral biofilm is the major
contributor of T-cell-associated infectivity. However, the involvement of polarized budding in biofilm
formation is not excluded. Compared to the observations at the VS before [60], viral biofilms overlap
cell-cell contacts and bridge the gap between both cell surfaces, rather than filling contact sites [71].
Thus, HTLV-1 transmission may not only occur across synaptic clefts, but also at the periphery
of the cell contact [61]. The biofilm might also function as viral reservoir as viruses are highly
concentrated within these biofilms in close proximity to their target cells. Additionally, cell-free
preparations of viral biofilms infect monocyte-derived DC (MDDC) more efficiently than autologous
CD4+ T-lymphocytes in vitro [50]. The viral biofilm could also both provide a physical protection
for the viral Env protein [50,75] and prevent recognition of Env by neutralizing host antibodies [76].
It is assumed, that after infection of new cells, viruses reprogram the protein expression of the host,
amongst others, to form the viral biofilms [71,76]. Yet, the relative contribution of individual viral
proteins to biofilm formation is not settled [74].
Both MLV and HIV also utilize virus-laden uropods for viral spreading at the VS [77,78].
Briefly, polarization of lymphocytes involves the formation of two distinct poles: (1) the leading
edge, which attaches the cell to the substrate allowing directional movement of the cell; and, on the
opposite side, (2) the uropod, which is mostly involved in cell-cell interactions [79]. The current model
suggests that an infected cell will likely engage target cells to form virological synapses if uropods
make the initial contact with the target cell [78]. Uropods contain adhesion molecules, Env-laden
virions, and adhere to the receptor-expressing target cells, while the leading edge continues to drive
cellular polarization of the migrating cells. Contrary, if the leading edge of a migrating lymphocyte
makes the initial contact with a target cell, the leading edge will continue to migrate and bypass the
target cells [77,78]. Since HTLV biofilms are found as one large or several smaller clusters of viruses
bound to the uropod on isolated infected T-cells [71], the uropod might also participate in the formation
of the VS during transmission of HTLV-1.
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4.2. Transmission via Cellular Conduits
To allow for transmission of HTLV-1 over long distances, the transfer of virions via cellular
conduits induced by the viral p8 protein has been proposed (Figure 3; for details on p8 see Section 6.5).
Briefly, p8 is encoded by the open reading frame I of HTLV-1 located in the pX region as a cleavage
product of the precursor protein p12 [80]. In co-culture assays with HTLV-1 reporter cells, Van Prooyen
and colleagues found that overexpression of p8 rescues the infectivity of p12 knockout molecular
clones, and enhances the infectivity of chronically-infected MT-2 cells [58]. Functionally, p8 increased
T-cell conjugate formation, potentially through LFA-1 clustering on the surface of T-cells. Surprisingly,
overexpression of p8 also enhanced the number and length of cellular conduits among T-cells [58].
Conduits are supposed to be formed by directed outgrowth of a filopodium-like protrusion towards
a neighboring cell. In co-cultures between p8-expressing Jurkat T-cells and untransfected Jurkat T-cells,
p8 was also detectable in untransfected cells, suggesting transfer of p8 via the conduits. The latter
was corroborated by life-cell imaging, which detected fluorescently-labeled Gag and p8 in conduits
between chronically-infected T-cells and uninfected target cells. However, it is not known, whether
p8 and LFA-1 also cluster at the tip of the conduit, or only at the surface of the infected cell. Finally,
transmission electron microscopy showed the presence of viral particles resembling HTLV-1 virions
in shape and morphology either at the contact sites between two conduits, or between a conduit and
a target T-cell [58]. The authors proposed the model that p8 enhances transmission of HTLV-1 by
increasing cellular conduits and polysynapse formation (Figure 3) [58,81].
 
Figure 3. Cellular conduits. The viral accessory protein p12 is proteolytically cleaved into the p8
protein, which increases adhesion of T-cells through lymphocyte function-associated antigen-1 (LFA-1)
clustering. Further, p8 induces polysynapse formation and enhances the number and length of cellular
conduits between T-cells, thereby, enhancing HTLV-1-transmission. p8 is transferred to target cells
through these conduits and it is hypothesized to induce T-cell anergy in the target cell. This might be
a strategy for HTLV-1 to evade the host’s immune surveillance during infection. Host cell proteins that
interact with p8 to enhance conduit formation, p8 transfer, and HTLV-1 transmission are still unknown.
Figure was realized thanks to Servier Medical Art.
In parallel, p8 is transferred to neighboring cells, invades target cells and is suggested to induce
T-cell anergy by decreasing T-cell receptor (TCR) signaling in target cells, which could favor persistence
of HTLV-1 in an immune competent host [58,81]. Taken together, p8-induced virus transmission seems
to be a strategy of the virus to be transmitted via long distances. The presence of viral particles at the
55
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contact site between conduits and target cells leads to the assumption that HTLV-1 buds from the tip of
the conduit towards the target cell via a “mini VS” [58,59]. However, it is not known whether p8 and
LFA-1 also cluster at the tip of the conduit, or only at the surface of the infected cell. Formation of a VS
between conduit and target cell suggests protected transfer of HTLV between cells and is in contrast to
transmission of the related retroviruses HIV and MLV, where isolated viral particles were shown to
surf on filopodial bridges before reaching the target cell [82,83]. For HTLV-1, surfing of isolated viral
particles has not been observed yet [58]. The detailed molecular mechanism by which p8 promotes
HTLV-1 transmission remains unknown. It is conceivable that cellular conduits account for HTLV-1
transmission, as suggested by the authors [58]. Nevertheless, it cannot be excluded that transfer occurs
via virological synapses, polysynapses, syncytia, or viralbiofilms [59].
5. Cell-Free HTLV-1 Transmission to Dendritic Cells (DC)
Antigen-presenting DC and their precursor cells (monocytes) are found to be infected with
HTLV-1 in vivo [28–30]. However, it is not clear whether DC play a role in establishing a chronic
HTLV-1 infection. DC either capture virions and transfer them to target cells (trans-infection), or
they are productively infected and infect other cells themselves (cis-infection) (Figure 4) [39,84].
The lectin DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN) facilitates HTLV-1 binding and
fusion of DC through an ICAM-dependent mechanism [84,85]. During HIV-transmission, most
features previously associated with DC-SIGN-mediated trans-infection of DC are apparently fulfilled
by CD169/Siglec-1 [86], whose role remains to be elucidated for HTLV-1.
Figure 4. Transmission of HTLV-1 via dendritic cells (DC). DC either capture the virus and transmit
it to target cells in the absence of infection (trans-infection), or they are productively-infected
before viral transmission (cis-infection). Productive cell-free infection of DC is achieved in vitro by
highly-concentrated preparations of cell-free HTLV-1 or by viral biofilms. Figure was realized thanks
to Servier Medical Art.
In vitro studies have shown that DC can also be infected cell-free with highly-concentrated
viral supernatants, and these infected DC mediate efficient cell-cell contact-dependent infection and
transformation of CD4+ T-cells [84]. These findings and studies reporting the presence of viral
genomes and proteins suggest a potential role of DC in transmission in vivo during initial acquisition
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of infection [61,84]. Interestingly, DC can be infected cell-free via transcytosis through an epithelial
barrier [51]. The relevance of DC in viral transmission has been further strengthened by recent
findings showing that MDDC are more susceptible to infection with viral biofilms than autologous
CD4+ T-lymphocytes in vitro, which supports the model that infection of DC might be an important
step during primary infection in vivo [50]. Searching the mechanism, Alais et al. found that MDDC
express higher amounts of NRP-1 [50], which is part of the HTLV-1 entry receptor [16]. The study also
revealed that infection of DC with virus-containing biofilm is much more efficient than infection with
concentrated viral supernatants [50]. Thus far, it is not settled whether formation of the viral biofilm is
restricted to lymphocytes, or whether it could also be formed upon DC-infection, or whether it could
be transmitted via DC-mediated trans-infection to other cells. Moreover, infection of DC may also be
required for the establishment and maintenance of HTLV-1 infection in primate species [87]. Since the
maturation of DC is impaired in HTLV-1-infected patients [88,89], DC may not only contribute to viral
dissemination, but also to immune dysregulation observed in HTLV-1-infected patients. Compared
to HTLV-1, productive (cis) infection of DC with HIV is inefficient due to antiviral mechanisms like
the presence of the restriction factor SAMHD1 in DC [86]. Infection of CD4+ T-cells occurs in trans by
DC-captured HIV at the VS [67,90]. It is likely that also HTLV-1 is transmitted from DC to T-cells via
polarized budding at the VS, but this has to be verified experimentally.
6. Viral Proteins Enhancing HTLV-1 Transmission
Amongst the HTLV-1-encoded proteins contributing to HTLV-1 transmission, we briefly sum up
the roles of the structural proteins Env, Gag, and the regulatory protein Rex before we focus on Tax,
which is important for formation of the VS (Figure 1) [60], and on p8, which enhances the number of
cellular conduits between infected and uninfected T-cells (Figure 3) [58].
6.1. Env
Env plays a central role in HTLV-1 cell-to-cell transmission (for review, see [17,40,91–93] since
Env is crucial for HTLV-1 infectivity. Briefly, Env encodes two different proteins, the transmembrane
(TM) and the surface (SU) protein. The precursor protein of Env is highly glycosylated, proteolytically
cleaved into SU and TM proteins, and afterwards transported to the cell membrane to initiate virus
assembly and budding [17,92]. The SU subunit of Env binds to the host cell surface receptors Glut-1,
NRP-1, and to HSPGs to trigger fusion of the membranes both of the virus and the host cell [40]. Env is
also important for formation of the VS [66] and for transmission of HTLV-1 in vitro and in vivo [56,57].
6.2. Gag
The HTLV-1 group specific antigen (Gag, p55) is produced as a single precursor polyprotein.
Upon posttranslational modification and myristoylation, the Gag polyprotein is targeted to the inner
membrane of the cellular plasma membrane [91]. Subsequently, Gag is cleaved by viral proteases into
its functional domains matrix (MA, p19), capsid (CA, p24), and nucleocapsid (NC, p15). Matrix is
important for Gag targeting, membrane binding, and Env incorporation, while capsid interacts with
itself to form the inner core of the virion. Nucleocapsid interacts with the genomic RNA inside the
inner core of the virion. A proper spatial and temporal regulation of viral assembly and budding is
crucial for HTLV-1 transmission [91,94].
6.3. Rex
Among the regulatory proteins, not only Tax, but also Rex is important for viral transmission.
This is corroborated by at least two findings: (1) Use of a Rex-deficient HTLV-1 proviral clone showed
that Rex is important for viral transmission in vivo [91]; (2) The chronically HTLV-1-infected T-cell
line C8166-45, which is Rex-deficient, does not produce viral particles, and is not infectious [95].
Taken together, these results suggest that Rex’s function to enhance trafficking of unspliced and single
spliced RNA is important for ideal viral spread [91].
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6.4. Tax
The regulatory protein Tax is essential for viral replication due to strong enhancement of
viral mRNA synthesis by transactivating the HTLV-1 LTR (U3R) promoter. Further, Tax is
a potent transactivator of cellular transcription and important for initiating oncogenic transformation.
Tax shuttles between the nucleus and the cytoplasm and fulfills most of its functions by
direct protein-protein interactions [6,19,96,97]. Thus far, not only a plethora of Tax interaction
partners [98–100], but also of transcriptionally-induced Tax target genes has been identified [101–105].
The latter is attributed to Tax’s function as activator of several signaling pathways including NF-κB,
CREB, SRF, PI3K/AKT, and AP-1 [19,106].
Tax is important for HTLV-1 cell-to-cell transmission. First insights were obtained by fluorescent
imaging analysis showing that Tax cooperates with ICAM-1 thereby inducing polarization of the
MTOC at the VS (Figure 1) [63]. Use of Tax mutants revealed that Tax-induced CREB signaling is
critical for MTOC polarization [62]. Interestingly, ICAM-1 is also induced by Tax on the surface of
T-cells [107], thus, facilitating the formation of the VS and HTLV-1 transmission. Since engagement
of ICAM-1 by interaction with its ligand LFA-1 on target T-cells is important for formation of the
VS, Tax-induced ICAM-1 expression may also contribute to the T-cell tropism of HTLV-1 [61]. Use
of chemical inhibitors revealed that activity of the small GTPases Cdc42 and Rac1 is critical for
Tax-induced MTOC polarization [63]. Since Tax also complexes with these GTPases, Tax might connect
Rho GTPases to their targets and affect cytoskeleton organization to favor HTLV-1 transmission [98,99].
Imaging-based methods were pioneering in defining the routes of viral transmission and
identifying the localization of viral and cellular proteins involved in transmission. Later, Mazurov et al.
developed an elegant single-cycle replication-dependent reporter system that allows quantitative
evaluation of cell-to-cell transmission by measuring reporter gene expression in newly infected
cells [57]. This system requires transient transfection of (1) plasmids carrying a replication-dependent
reporter gene; and of (2) virus packaging plasmids. The packaging plasmids encode full-length
HTLV-1, or they carry a deletion in the env gene and are pseudotyped with VSV-G (glycoprotein G of
vesicular stomatitis virus). The reporter plasmids consist of a CMV-driven reporter gene in antisense
orientation that is interrupted by a gamma-globin intron in sense orientation. After transcription,
the intron is spliced, but the antisense orientation of the reporter gene precludes translation of the
reporter mRNAs in transfected cells. These minus strand RNAs are packaged into virions. After
infection of new cells, mRNAs are reversely transcribed and reporter gene activity is detectable [57].
Using this system, the authors found that both the cell type and the envelope type are critical for
HTLV-1 cell-to-cell transmission: In co-cultures of transfected Jurkat T-cells with Raji/CD4+ B-cells,
Tax enhanced transmission of HTLV-1 packaged with wildtype Env, but not with HTLV-1 packaged
with VSV-G. [57]. On the contrary, the transmission of HTLV-1 reporter vectors in transfected 293T
cells was not enhanced by Tax, suggesting that different host factors involved in transmission are
induced by Tax in Jurkat T-cells than in 293T cells, possibly due to different signaling pathways being
active in the respective cell type. Tax also enhanced cell-to-cell transmission of HIV reporter vectors,
suggesting that Tax-induced changes in the infected donor cell are also beneficial for other retroviruses
than HTLV-1 [57]. One obstacle when working with these reporter vectors was the lack of sufficient
reporter signals in PBMC [57]. Recently, Mazurov and colleagues improved the reporter vectors by
modifying the splice sites, and by enhancing packaging efficiency of spliced reporter vectors [108].
It will be interesting to see, which Tax-induced signaling pathways and host factors are required for
viral transmission to PBMC.
With regard to pathways important for viral transmission, Tax transcriptionally alters the
expression of cell adhesion and surface molecules [109], leading to cytoskeletal remodeling, and
complexes with proteins involved in cytoskeleton structure and dynamics [99]. Table 1 lists host
factors that are important for HTLV-1-transmission, amongst them are also interaction partners and
transcriptional targets of Tax. Despite the knowledge of various Tax-targets involved in cell-cell
interaction, adhesion and cytoskeletal organization, a comprehensive analysis evaluating the role of
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known and new Tax effectors on virus transmission is still lacking. Moreover, it is still not settled
whether blocking Tax-induced pathways important for MTOC polarization also impairs cell-to-cell
transmission of HTLV-1 reporter vectors.
Table 1. Host cell proteins important for HTLV-1 transmission.
Host Cell Factor Other Name; Protein Function Function in Transmission Modulation by Viral Protein Reference
Cell-Surface Associated Proteins
Agrin HSPG; cross-linker of cell surface receptors biofilm formation [71]
CCL22 chemokine ligand 22; binding to CCR4 attraction of CCR4+ T-cells induced by Tax [110]
CCR4 C-C chemokine receptor type 4 on target cell; attracted by CCL22(from infected cell) [110]
CD43 leukosialin; sialophorin adhesion; biofilm formation [72]
CD45 protein-tyrosine phosphatase adhesion; biofilm formation [72]
CD82 Tetraspanin inhibits syncytium formation interacts with Gag and Env [111,112]
Collagen structural protein of ECM biofilm formation induced by Tax (collagen 1 alpha) [71,113]
DC-SIGN DC-specific ICAM-3-grabbingnonintegrin
syncytium formation (on target cell
DC) [85]
GLUT-1 glucose transporter 1 virus entry interacts with Env [14]
Hsc70 heat shock cognate protein 70 syncytium formation (on target cell) interacts with Env [114]
HSPGs heparan sulfate proteoglycans virus entry interact with Env [16]
ICAM-1 intercellular adhesion molecule 1; CD54 VS formation; MTOC polarization;syncytium formation induced by Tax [60,62,107,115]
ICAM-3 intercellular adhesion molecule 3 syncytium formation [115]
Integrin β2/7 CD18 syncytium formation [115]
LFA-1 lymphocyte function-associated antigen 1 VS formation (target cell); adhesion(infected cell) interacts with p8, p12 (infected cell) [58,60,116]
NRP-1 neuropilin-1 virus entry interacts with Env [16]
SDC-1, SDC-2 Syndecan-1/-2; transmembrane HSPGs virus entry [117]
Talin actin-anchor protein; clusters with LFA-1 VS formation [60]
Tetherin BST2: bone marrow stromal antigen 2;lipid raft associated protein biofilm formation; virus attachment [71,73]
VCAM-1 vascular cell adhesion molecule 1 syncytium formation (on target cell) induced by Tax (on infected cell) [115,118,119]
Cytoskeleton and Associated Factors
Actin structural protein cytoskeleton remodeling; MTOCpolarization; virus release interacts with Tax [57,63,98,99]
Cdc42 cell division cycle 42; small GTPase MTOC polarization interacts with Tax [63,98]
CRMP2 collapsin response mediator protein 2 migration, role in transmissionunclear induced by Tax [120]




induced by Tax [121–123]
Cytoskeleton and Associated Factors
GEM GTP-binding mitogen-induced T-cellprotein
cytoskeleton remodeling; migration;
conjugate formation induced by Tax [124]
Rac1 Ras-related C3 botulinum toxin substrate1; small GTPase MTOC polarization interacts with Tax [63,98]
Tubulin component of microtubule cytoskeleton remodelling; MTOCpolarization [57,63]
γ-Tubulin component of centrosomes and spindlepole bodies
cytoskeleton remodelling; MTOC
polarization interacts with Tax [60,63,99,125]
Signaling Pathways and Associated Factors
CREB cAMP response element-binding protein MTOC polarization interacts with Tax [62,126]








Dlg disks large homolog cell-to-cell fusion interacts with Tax and Env [128,129]
Galectin-3 beta-galactoside-binding lectin, linker protein biofilm formation induced by Tax [71,130]
cAMP: cyclic adenosine monophosphate; CD: cluster of differentiation; DC: dendritic cell; Env: envelope protein
of HTLV-1; ECM: extracellular matrix; GTP: guanosine-51-triphosphate; MTOC: microtubule organizing center;
VLP: virus-like particle; VS: virological synapse.
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6.5. p8
The HTLV-1 p8 protein is a cleavage product of the viral accessory p12 protein encoded from the
open reading frame I. The precursor protein p12 normally localizes to the endoplasmatic reticulum (ER)
and to the golgi apparatus, and its functions have been reviewed earlier [21]. p12 is post-translationally
modified by a two-step proteolytic cleavage: the first cleavage between amino acid (aa) 9/10 removes
an ER-retention signal, which allows trafficking of the protein to the golgi. The second cleavage occurs
between aa 29/30 resulting in the p8 protein [80]. p8 is a 70 aa comprising protein that localizes
to the cytoplasm and is recruited to lipid rafts and the IS upon TCR ligation [131]. p8 enhances
LFA-1-mediated cell adhesion on ICAM-1-coated plates [58]. Earlier work had attributed this function
to p12-induced calcium-signaling and suggested that p12 could promote formation of the VS [116]
until it became clear that p12 is processed to p8 [58,80]. It has been proposed that p8 enhances HTLV-1
transmission by increasing the number and length of cellular conduits among T-cells (see Figure 3 and
Section 4.2). p8-enhanced polysynapse formation and virus transmission from HTLV-1-infected cells
to uninfected T-cells [58] had previously been attributed to the precursor p12 [132,133]. Since p8 is also
transferred to neighboring cells, invades target cells, and can induce T-cell anergy, it is proposed that
p8 favors persistence of HTLV-1 in an immune competent host [58].
Both p8 and p12 form disulfide-linked dimers, and only the monomeric forms of p8 and p12
are palmitoylated at a conserved cysteine residue (C39). Albeit mutation of C39 to alanine abrogates
dimerization and palmitoylation, these modifications are dispensable for p8 to increase adhesion
and viral transmission [134]. In vivo studies in macaques support the notion that p8 and p12 are
important for viral persistence and spread. Moreover, productive infection of monocytes depends
on the expression of p8 and p12 proteins [87,135]. Cellular effectors and interaction partners of p8
other than LFA-1 that mediate conduit formation, p8-transfer, and viral transmission are still unknown.
Interaction partners of p12 have been identified (reviewed by [21,91]), but none of them has been
evaluated for a role in p8 transfer and viral transmission. Therefore, the composition of the host
machinery that mediates transfer of p8 and HTLV-1 to the target cell remains to be determined.
7. Host Factors Involved in HTLV-1 Transmission
HTLV-1 has evolved strategies to manipulate the host cell for its transmission. Not only
protein-protein interactions between viral and cellular proteins, but also specific transcriptional
induction of host cell factors might facilitate viral transmission. Table 1 lists host proteins, that are
involved in HTLV-1 transmission and, if indicated, their manipulation by HTLV-1-encoded proteins.
For the sake of completeness, the table also lists proteins which are important for viral entry and
syncytium formation.
7.1. Cell Surface Receptors and Cell-Cell Contacts
Since cell-cell contacts are a prerequisite for efficient HTLV-1 transmission, it is reasonable that
cell surface receptors are critical for this step. Not only receptors on the target cells—like components
of the HTLV-1 receptor (Glut-1, NRP-1, HSPGs, SDC-1/-2)—are important for viral transmission and
tropism [18,117], but also secreted chemokines that could attract target cells. To attract CCR4+CD4+
target T-cells, Tax expressing HTLV-1-infected T-cells produce large amounts of CCL22. Expression of
CCL2 is stimulated by Tax and block of CCL22 using anti-CCL22 antibodies reduces viral transmission
from HTLV-1-infected cells to CD4+ T-cells [110].
Although a plethora of surface receptors is upregulated in HTLV-1-infected cells [109], only few
of them play a role in virus transmission (Table 1). HTLV-1-induced syncytium formation is affected
by Tax, and receptors like vascular cell adhesion molecule 1 (VCAM-1) or ICAM-1 have been shown
to promote syncytium formation, and to be inducible by Tax [92,115,118,119,136]. For details about
receptors being important for viral entry or syncytium formation, see [17,18,92].
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The viral biofilm on the surface of infected cells contains clusters of virions in a cocoon-like
structure, and its composition is shown in Figure 2. Thus far, it is not known in detail, whether
individual viral proteins are important for biofilm formation. A study by Mazurov et al. indicates
that large aggregates of HTLV-1 assemblies are more infectious than multiple clustered virions on
the surface of infected cells [72]. Their data suggest that heavily O-glycosylated surface receptors
CD43 and CD45 render cells less adhesive and prevent inappropriate cell-cell contacts and thus, favor
the assembly of HTLV-1 particles into large, highly infectious structures on the surface of T-cells.
The authors conclude that a balance between pro- and anti-adhesive molecules on the surface of the
infected T-cell is important for the establishment of the VS and virus transmission [72].
7.2. Components and Regulators of the Cytoskeleton
Transmission of HTLV-1 and formation of the VS strongly depends on the functional integrity of
the cytoskeleton [61]. Experiments using single-cycle replication dependent HTLV-1 reporter vectors
confirmed these findings and showed that block of actin and tubulin polymerization strongly reduces
HTLV-1 cell-to-cell transmission while transmission of HIV was only modestly impaired [57]. Beyond,
Rho GTPases Rac1 and Cdc42, interaction partners of Tax, are involved in MTOC polarization at the
VS [63,98]. However, a quantitative comparison of the contribution of individual cytoskeletal proteins
and associated regulatory proteins on viral transmission has never been performed.
Host factors regulating cellular migration, invasion and conjugate formation could also be
involved in HTLV-1 cell-to-cell transmission by favoring dissemination of infected cells in vivo
(Figure 5). Among proteins enhancing cellular migration (Figure 5A), the Tax-induced small
GTP-binding protein GEM plays an important role in HTLV-1 cell-to-cell transmission [124]. GEM is
expressed in HTLV-1-infected T-cell lines and Tax regulates GEM transcription by recruiting CREB and
CREB-binding protein (CBP) to the GEM-promoter. Interestingly, GEM is also important for conjugate
formation between infected and uninfected T-cells (Figure 5B), which may explain its role in cell-to-cell
transmission [124]. However, it is unknown whether GEM and other targets of Tax are required
for formation of the VS. The semaphorin-signaling transducer collapsin response mediator protein 2
(CRMP2) has originally been identified in the nervous system where it mediates growth cone navigation
induced by semaphorin 3A. Beyond, the phosphoprotein CRMP2 is also involved in cytoskeleton
rearrangement controlling migration of human lymphocytes [137]. Activity of CRMP2 is modulated
by Tax and correlates with migration of infected cells [120]. It is likely that CRMP2 plays a role in
dissemination of infected cells in vivo and could thus enhance the probability to transmit viruses to
uninfected cells. The actin-bundling protein Fascin is a tumor marker that is highly upregulated in
many types of cancer and crucial for invasion and metastasis. We found that Fascin is also important for
invasive migration of HTLV-1-infected cells [121]. Fascin is upregulated in chronically HTLV-1-infected
T-cells and regulated by Tax through NF-κB signaling [121,123]. Interestingly, CRMP2 and Fascin
function downstream of Rho kinases while GEM is an upstream negative regulator of ROCK-I Rho
kinase [124]. Currently, we are investigating the role of Fascin in cell-to-cell transmission [122].
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Figure 5. Host factors regulating cellular migration, invasion and conjugate formation. (A) Proteins
enhancing cellular migration and/or invasion of HTLV-1-infected cells could favor dissemination
of HTLV-1 to target cells. Expression of the Tax-induced small GTP-binding protein GEM enhances
both migration of HTLV-1-infected cells and viral transmission. Activity of CRMP2, a phosphoprotein
involved in cytoskeleton rearrangement, is modulated by Tax and correlates with migration of infected
cells. The actin-bundling protein Fascin is induced by Tax and important for invasive migration of
HTLV-1-infected cells. A role of CRMP2 and Fascin for viral transmission remains to be determined.
Both Rac-1 and Cdc42 are interaction partners of Tax that are crucial for migration and for MTOC
polarization. (B) T-cell conjugate formation, a prerequisite for cell-to-cell transmission depends
on components of the cytoskeleton like the Tax-inducible GEM protein, and on Rac1 and Cdc42.
Additionally, Tax regulates expression of surface receptors (see Table 1), which are important for cell-cell
contact formation, and, potentially, for formation of the VS and HTLV-1 transmission. The influence of
different host factors on polarized budding and formation of the VS remains to be determined. Figure
was realized thanks to Servier Medical Art.
7.3. Signaling Pathways
Tax is a potent activator of different cellular signaling pathways [19] including CREB, PI3K/AKT,
SRF, and NF-κB. However, only little is known about the relative contribution of these signaling
pathways on Tax-induced formation of the VS. Using different Tax-mutants, Nejmeddine et al. found
that CREB signals are important for triggering MTOC polarization, while Ras/MAPK/ERK signals
mediate ICAM-1-induced MTOC polarization [62]. Interestingly, expression of the small GTP-binding
protein GEM, which has been shown to induce conjugate formation between infected and uninfected
T-cells, is also dependent on Tax-induced CREB signaling [124]. However, it remains to be determined
whether GEM is involved in MTOC polarization. The contribution of different signaling pathways to
formation of the viral biofilm or to p8-induced conduits is not known. It is also not settled whether Jak
signaling contributes to p8-mediated virus transmission as has been shown for its precursor p12 [132].
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Overall, the quantitative contribution of individual signaling pathways on different mechanisms of
viral transmission remains an open question.
8. Conclusions
HTLV-1 has evolved several clever strategies to transmit via specialized routes from cell-to-cell,
thus being protected from immune recognition. Significant progress has been made in elucidating
molecular mechanisms of HTLV-1 cell-to-cell transmission. Nonetheless, the relative contribution of
individual pathways on transmission in vivo remains to be determined.
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Abstract: Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia (ATL) and
chronic inflammatory diseases. HTLV-1 bZIP factor (HBZ) is transcribed as an antisense transcript
of the HTLV-1 provirus. Among the HTLV-1-encoded viral genes, HBZ is the only gene that
is constitutively expressed in all ATL cases. Recent studies have demonstrated that HBZ plays
an essential role in oncogenesis by regulating viral transcription and modulating multiple host
factors, as well as cellular signaling pathways, that contribute to the development and continued
growth of cancer. In this article, I summarize the current knowledge of the oncogenic function of
HBZ in cell proliferation, apoptosis, T-cell differentiation, immune escape, and HTLV-1 pathogenesis.
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1. Introduction
Human T-cell leukemia virus type 1 (HTLV-1) is the first identified pathogenic retrovirus that
is etiologically associated with two major diseases: adult T-cell leukemia (ATL) and a progressive
myelopathy called HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [1–4].
Four types of HTLVs, named HTLV-1, HTLV-2, HTLV-3, and HTLV-4, have been characterized [5].
However, their oncogenic properties are different. The HTLV-1 genome, in addition to the structural
genes gag, pol, and env, carries a region at its 3' end, which is designated the pX region, and
encodes several accessory genes, including tax, rex, p12, p21, p30, p13, and HTLV-1bZIP factor (HBZ)
(Figure 1) [6,7]. In the 35 years since the discovery of HTLV-1, researchers have mainly focused on Tax,
a trans-acting viral regulatory protein, due to its pleiotropic functions in viral replication and cellular
transformation [8–10]. However, approximately 60% of ATL cases lack Tax expression because of
genetic and epigenetic changes in the proviral genome of HTLV-1, suggesting that Tax is not essential
for the maintenance of ATL [5,11]. In 2002, a new open reading frame (ORF) was identified on the
minus strand of HTLV-1, corresponding to a region complementary to Tax, which encodes a novel basic
leucine zipper factor named HBZ [6]. Studies have shown that HBZ is consistently expressed in all
ATL cases [12]. In some of the ATL cases, HTLV-1 genes, except HBZ, are mutated by APOBEC3G [13].
Moreover, Tax is an immunodominant antigen of this virus and is the major target of cytotoxic T
lymphocytes (CTLs) [14]. Thus, Tax expression is frequently silenced during the long clinically latent
period of the virus [5,11]. In contrast, the immunogenicity of HBZ protein is low compared with that
of Tax protein [15–17]. The constitutive expression of HBZ, by way of suppressing major HTLV-1
sense genes including Tax, could help the virus escape from the host’s immune surveillance and thus
promote spread of infection [5,18,19]. These observations suggest that the HBZ gene is essential for
cellular transformation and leukemogenesis of HTLV-1. In this review, I will highlight recent advances
in our understanding of how HBZ contributes to HTLV-1 oncogenesis.
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Figure 1. Regulatory and accessory genes encoded by HTLV-1. p12, p13, p30, Rex, p21, and Tax are
transcribed from the 5' long terminal repeat (LTR). HBZ is located on the complementary proviral
strand and transcribed from the 3' LTR. Spliced (s) and unspliced (us) HBZ are shown. Shaded boxes
represent their coding regions.
2. Characteristics of HBZ
2.1. Expression of HBZ in ATL
In order to achieve successful transformation, HTLV-1 uses its genome very efficiently to encode
multiple viral genes. Tax, an HTLV-1 plus strand-encoded viral gene, has been implicated in the
leukemogenesis of HTLV-1 as it has growth-promoting activities and the ability to immortalize various
types of cells in vivo [5,8,9,20]. However, Tax is the major target of CTLs [14]. Thus, ATL cells frequently
lose Tax expression by several mechanisms. First, the 5' LTR of HTLV-1 provirus is reported to be
deleted in 39% of ATL cases, resulting in the loss of Tax in ATL [21,22]. The second mechanism
involves the nonsense mutation, deletion, and insertion of the tax gene in ATL cells [11,23]. The third
mechanism includes DNA hypermethylation and histone modification of the 5' LTR of HTLV-1, which
silences viral gene transcription [24,25]. Therefore, Tax may not be necessary for the development of
ATL. On the contrary, the 3' LTR is conserved and unmethylated in all ATL cases [13,26]. Previous
study demonstrated that the HBZ gene was expressed in all ATL cells and that HBZ gene knockdown
inhibited the proliferation of HTLV-1-infected cells, indicating that HBZ may play a critical role in
HTLV-1-mediated oncogenesis [12]. Sp1 binding sites in the 3' LTR of HTLV-1 have been demonstrated
to be critical for HBZ promoter activity [26]. As Sp1 is a well-known regulator of housekeeping genes,
the transcription of the HBZ gene may be relatively constant.
The expression of HBZ has been correlated with HTLV-1 proviral load [27,28]. Kinetic analyses of
the HBZ transcript in HTLV-1-infected rabbits revealed that HBZ was detected at relatively low levels
early after infection but gradually increased and stabilized, whereas other viral genes were maintained
continuously at a low level [29]. Moreover, there is a correlation between the level of HBZ expression
and the severity of HAM/TSP, indicating that high levels of HBZ may be associated with a greater risk
of HAM/TSP [27].
A 5' RACE experiment identified two different HBZ transcripts in ATL; one is spliced (sHBZ) and
the other is unspliced (usHBZ) (Figure 1) [12,30,31]. The sHBZ gene transcript level was approximately
four times higher than the usHBZ gene transcript [28]. Consistently, the level of the usHBZ protein
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was much lower than that of sHBZ [28]. Furthermore, Western blot analyses could detect only the
sHBZ protein in ATL cell lines [32,33].
2.2. Structure of HBZ
HBZ was first identified as a binding partner for the cAMP-response element binding protein-2
(CREB-2) by yeast two-hybrid screening [6]. Promoters for both the sHBZ and usHBZ genes are
TATA-less [26]. The transcription factor Sp1 has been demonstrated to be important for TATA-less
promoter activity [34,35]. Consistent with these observations, the sHBZ promoter is activated by the
constitutively expressed Sp1 protein [26]. Moreover, Tax can activate the activity of sHBZ and usHBZ
gene promoters through Tax-responsible elements (TREs) in the U3 region of HTLV-1 3' LTR [26,36].
However, Tax-mediated activation of antisense transcription is weaker than its activation of HTLV-1
sense transcription [26]. In addition, Tax-induced HBZ expression is influenced by the integration site
in the host genome [36].
The sHBZ transcript is translated into a polypeptide of 206 amino acids, and the protein product
of usHBZ is 209 amino acids long. Both HBZ isoforms contain three domains: activation domain (AD),
central domain (CD), and basic leucine zipper domain (bZIP) [6,37]. The LXXLL-like motif, which is
located at the N-terminal activation domain, is critical for HBZ-mediated activation of Smad3/TGF-β
pathway through binding to CBP/p300 [38]. There are three nuclear localization signals (NLSs)
that are responsible for the nuclear localization of HBZ protein: two regions in the CD domain and
a basic region in the bZIP domain [37]. A recent study demonstrated that HBZ contains a functional
nuclear export signal (NES) sequence within its N-terminal region and disrupts the cellular autophagic
response in the cytoplasm [39]. The sHBZ and unHBZ proteins differ in only seven amino acids
at their N-terminal AD domains. The expression level of sHBZ is four times higher than that of
usHBZ in ATL cells [28]. It is well known that different post-translational N-terminal modifications of
proteins affect their half-lives. The half-life of sHBZ is much longer than that of usHBZ [26]. Thus,
the N-terminal AD domain differences may be responsible for the distinct protein levels observed.
In addition, Dissinger et al. [40] used an affinity-tagged protein and mass spectrometry method to
identify seven modifications of HBZ protein. However, none of the identified post-translational
modifications affected HBZ stability or its regulation of signaling pathways.
3. Oncogenic Properties of HBZ
3.1. Suppression of Viral Transcription
CREB-2 (ATF-4) was identified as a binding protein to HBZ [6]. Dimerization between HBZ
and CREB-2 prevented CREB-2 from binding to a Tax-responsive element (TxRE) site in the HTLV-1
5' LTR, resulting in the suppression of Tax-mediated HTLV-1 5' LTR activation (Figure 2) [6]. Moreover,
HBZ also represses CREB transcription from a cellular cyclic AMP-responsive element (CRE) in the
cyclin D1 promoter, extending the inhibitory function of HBZ to CREB-dependent transcription of
cellular genes [41]. The bZIP domain of HBZ contributes to this repression. In addition, Clerc et al.
reported that HBZ interacts with p300/CBP and disrupts the interaction between Tax and p300/CBP,
thereby inhibiting the Tax-dependent viral transcription [42]. Two LXXLL-like motifs located within
the NH2-terminal region of HBZ mediate the interaction specifically through the KIX domain of the
p300/CBP coactivator [42]. The two LXXLL motifs in the AD domain of HBZ promote binding to the
mixed-lineage leukemia (MLL) surface of the KIX domain [43]. Formation of this interaction inhibits
binding of MLL to the KIX domain while enhancing the binding of the transcription factor c-Myb to
the opposite surface of KIX [43].
3.2. Promotion of T-Cell Proliferation
The development and continued growth of cancers involves altered rates of cell
proliferation [44,45]. Multiple studies have demonstrated that HBZ plays critical roles in ATL
73
Viruses 2016, 8, 34
leukemogenesis through pleiotropic actions, which include the promotion of cell proliferation [18,19].
Satou et al. reported that the HBZ gene enhances proliferation of T cells in vitro and in vivo [12].
Stable expression of HBZ gene increases Kit 225 cell proliferative capacity. Furthermore, repression
of HBZ expression in ATL cell lines by shRNA inhibited the growth of ATL cells. Mutant analyses
showed that HBZ promoted proliferation of T cells as a messenger RNA [12]. Growth-promoting
activity was observed only in the cells expressing sHBZ and not in usHBZ-expressing cells [26].
Moreover, the percentage of CD4+ T lymphocytes increased in splenocytes of HBZ transgenic (HBZ-Tg)
mice, and HBZ-expressing T-cells proliferated more rapidly than those of non-transgenic mice [12,46].
In NOD/SCIDγc´{´ (NOG) mice, HBZ-expressing SLB-1 cells engrafted to form solid tumor masses,
but tumor formation was reduced significantly in animals challenged with HBZ-knockdown SLB-1
cells [32]. Thus, these data collectively indicate that HBZ expression enhances the proliferative capacity
of HTLV-1-infected cells and plays a critical role in cell survival.
Figure 2. Oncogenic function of HBZ. HBZ fulfills its oncogenic functions mainly through regulating
HTLV-1 5' LTR transcription and modulating a variety of cellular signaling pathways that are related
to cell growth, apoptosis, immune escape, T-cell differentiation, and HTLV-1 pathogenesis. Detailed
descriptions can be found in the text.
Recently, Mitobe et al. reported that HBZ RNA increased the number of CD4+ T cells and
attenuated cell death by activating the transcription of the survivin gene, which inhibits apoptosis
(Figure 2). Moreover, the first 50 base pairs of the HBZ coding sequence are required for RNA-mediated
cell proliferation [47].
Accumulating evidence suggests that the HBZ protein modulates cell growth through forming
heterodimers with several host factors, such as C/EBPα and ATF3 (Figure 2) [48,49]. C/EBPα has
emerged as an important negative regulator of cell proliferation in different cancers. In ATL cells, HBZ
overcame the suppressive effect of C/EBPα on cell growth, leading to cell proliferation. A suggested
underlying mechanism is that HBZ inhibits C/EBPα signaling activation by interacting with C/EBPα
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and diminishes its DNA binding capacity [48]. ATF3, an HBZ-binding protein, is constitutively
expressed in ATL cell lines and fresh ATL cases. HBZ attenuates the negative effects of ATF3, allowing
ATF3 to promote the proliferation of ATL cells by mechanisms that upregulate the expression of genes
that are critical for mediating the cell cycle and cell death [49].
Increasing evidence has demonstrated that microRNAs (miRNA) play critical roles in the
development of cancer [50]. In ATL, expression profiling of microRNA revealed that oncogenic
miRNAs, including miR-17 and miR-21, are overexpressed in HTLV-1-infected T cells. These two
miRNAs are post-transcriptionally upregulated by HBZ, and HBZ/miRNA-mediated downregulation
of OBFC2A expression triggers both cell proliferation and genomic instability (Figure 2) [51].
Polakowski et al. reported that HBZ activates expression of neurotrophin BDNF. Moreover, HBZ
promotes a BDNF/TrkB autocrine/paracrine signaling loop in HTLV-1-infected T cells, leading to the
survival of these cells (Figure 2) [52].
In addition, HBZ suppresses the canonical Wnt pathway while enhancing the proliferation and
migration of ATL cells by increasing expression of the noncanonical Wnt5a. These observations suggest
that perturbation of the Wnt signaling pathways by HBZ is associated with the leukemogenesis of
ATL (Figure 2) [53].
HBZ suppresses AP-1 signaling pathway, which is mediated by c-Jun and JunB [54–56]. However,
HBZ can activate JunD-induced transcription by forming heterodimers with JunD, resulting in the
activation of JunD-dependent cellular genes including human telomerase reverse transcriptase (hTERT)
(Figure 2) [57–59]. The activation of telomerase by HBZ may contribute to the maintenance of
leukemic cells.
3.3. Suppression of Cellular Apoptosis and Senescence
Defective apoptosis represents a major causative factor in the development and progression of
cancer [44,45]. HTLV-1 suppresses apoptosis of infected cells by the interactions of viral proteins with
host factors [60]. HBZ has been demonstrated to inhibit the transcription of a proapoptotic gene Bim,
resulting in the decreased activation-induced cellular apoptosis. By interacting with FoxO3a, which is
a transcriptional activator of the Bim gene, HBZ attenuates the DNA binding ability of FoxO3a and
sequesters the inactive form of FoxO3a in the nucleus. Further study has identified that HBZ inhibited
the expression of Bim by epigenetic alterations and histone modifications in the Bim promoter region.
Thus, it may be advantageous for HBZ to suppress the apoptosis of ATL cells (Figure 2) [61].
Tax-induced nuclear factor-κB (NF-κB) activation plays a central role in HTLV-1-mediated
transformation of human T cells [62,63]. However, hyper-activation of NF-κB by Tax triggers a
defense mechanism that induces cellular senescence [64]. By contrast, HBZ delays or prevents the
onset of Tax-induced cellular senescence by down-regulating NF-κB signaling (Figure 2). Zhao et al.
reported that HBZ protein selectively inhibits Tax-mediated classical NF-κB activation by inhibiting
p65 DNA binding capacity and by promoting expression of the PDLIM2 E3 ubiquitin ligase, which
results in p65 degradation [65]. Inhibition of p65 acetylation by HBZ also contributes to the repression
of the classic NF-κB pathway [66]. A recent study demonstrated that HBZ maintains viral latency by
down-regulating Tax-mediated NF-κB activation and by inhibiting Rex-induced expression of viral
proteins [67]. Taken together, these observations suggest that HBZ modulates Tax-mediated viral
replication and NF-κB activation, thus allowing HTLV-1-infected cells to proliferate and persist.
In ATL, HBZ-mediated suppression of the classical NF-κB pathway decreases the expression
of some genes associated with innate immunity and inflammatory responses [65]. NF-κB signaling is
a well-established mediator of host immunity [68]. Therefore, HTLV-1 may facilitate escape from the
host immune attack by suppressing the classical NF-κB pathway in such a manner.
Current data support the view that Tax may facilitate cell proliferation and survival in the early
stage of HTLV-1 infection through activating NF-κB pathway. Nevertheless, Tax protein is the main
target of the host’s CTLs. Therefore, it is plausible that in the late stages of leukemogenesis, ATL cells
that lack Tax expression are selected to emerge. In these cells, NF-κB-inducing kinase (NIK), a known
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activator of NF-κB, may replace Tax to maintain the constitutive activation of NF-κB, a hallmark of
leukemic ATL cells [69]. At this stage, the mitogenic activity of HBZ may be required to maintain the
proliferative nature of leukemic cells. This comprehensive scenario indicates that Tax and HBZ may
cooperate for the long-term development and maintenance of leukemic cells in ATL.
3.4. Induction of Regulatory T-Cell Differentiation
Similar to regulatory T cells (Tregs), leukemic cells of ATL possess a CD4+CD25+ phenotype. The
forkhead box P3 (FoxP3) is critical for the function of Tregs [5]. FoxP3 expression by HTLV-1 infected
T cells is seen in two-thirds of ATL cases [70]. Previous reports indicate that the development and
function of Tregs require the TGF-β signaling [71]. Notably, HTLV-1 infected T cells, unlike Tregs,
are resistant to growth-inhibitory effect of TGF-β, thus the active TGF-β pathway does not impair
the leukemic growth of ATL cells [72–75]. Recently, we observed that HBZ interacted with Smad2/3,
key components of the TGF-β pathway, to form a ternary complex of HBZ/Smad3/p300 that enhanced
TGF-β/Smad transcriptional responses in a p300-dependent manner. The enhancement of TGF-β
signaling by HBZ results in the overexpression of Foxp3 in naïve T cells [38]. Increased CD4+Foxp3+
Treg cells were also observed in HBZ-transgenic mice (Figure 2). Furthermore, a luciferase assay
validated that HBZ induces transcription of the Foxp3 gene. Thus, HBZ-induced Foxp3 expression
could be a mechanism for the increase of Foxp3+ Treg cells in vitro and in vivo [46].
Numerous viruses have developed strategies to modulate TGF-β signaling using viral proteins.
Examples include hepatitis B virus pX; hepatitis C virus core protein, NS3 and NS5; Kaposi
sarcoma-associated herpesvirus K-bZIP; and Epstein-Barr virus LMP1 [76–79]. Like HBZ, the HBV
pX and severe acute respiratory syndrome N protein enhance the transcriptional responses of TGF-β.
Curiously, these viruses seem to employ a common strategy to nullify the TGF-β signaling by having
their viral proteins bind to Smad proteins [76–78].
3.5. Impaired Cell-Mediated Immunity
Impaired cell-mediated immunity has been demonstrated in HTLV-1 carriers and ATL patients,
causing frequent opportunistic infections by various pathogens [80]. However, the mechanism by
which HTLV-1 causes immune deficiency has not been well studied. Sugata et al. observed that HBZ
transgenic mice were highly susceptible to intravaginal infection with herpes simplex virus type 2
(HSV-2) and displayed decreased immune responses to primary and secondary infection with Listeria
monocytogenes (LM). The production of IFN-γ by CD4+ T cells was shown to be suppressed in HBZ-Tg
mice [81]. Previous studies have reported that HBZ suppresses host cell signaling pathways that
are critical for T-cell immune response, such as the NF-κB, AP-1, and NFAT (Figure 2) [46,54,56,65].
Indeed, HBZ suppresses IFN-γ transcription through interaction with NFAT and c-Jun. Thus, HBZ
inhibits cell-mediated immunity in vivo by interfering with the host cell signaling pathway, suggesting
important roles for HBZ in HTLV-1-induced immunodeficiency.
3.6. Induction of T-Cell Lymphoma and Systemic Inflammation
To study the function of HBZ in vivo, Satou et al. generated transgenic mice expressing HBZ under
the control of the mouse CD4 promoter/enhancer, which induces HBZ gene expression specifically
in CD4+ T cells [46]. Similar to HTLV-1 infected individuals, the majority of HBZ transgenic mice
spontaneously developed chronic inflammation in the skin and lungs. Infiltration of CD3+CD4+ T cells
into the dermis and epidermis in the lesions of HBZ-Tg mice was apparent. Moreover, one-third
of HBZ-Tg mice developed T-cell lymphomas after a long latent period [46,82]. As observed in
HTLV-1-infected individuals, more effector/memory and regulatory CD4+ T cells were detected in
the HBZ transgenic mice. However, the function of CD4+Foxp3+ Treg cells in HBZ transgenic mice
was impaired, whereas their proliferation increased. As a mechanism, HBZ impairs the suppressive
function of Treg cells by binding to Foxp3 and NFAT (Figure 2) [46]. Further studies demonstrated
that HBZ-mediated inflammation is closely linked to oncogenesis in CD4+ T cells and that IFN-γ is
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an accelerator of HBZ-induced inflammation [83]. Yamamoto-Taguchi et al. reported that iTreg cells
increased in HBZ-Tg mice and that Treg cells of HBZ-Tg mice tend to lose Foxp3 expression, leading to
increased IFN-γ-expressing proinflammatory cells [84]. Cell adhesion and migration are enhanced in
the CD4+ T cells of HBZ-Tg mice. Thus, HBZ seems to impair various functions of conventional and
regulatory T cells and thereby critically contributes to the development of inflammation in vivo.
3.7. Differences between HBZ and APH-2
HTLV-1 and HTLV-2 are closely related human retroviruses that have been studied
extensively [85,86]. HTLV-1 is associated with ATL and a variety of immune-mediated disorders
including HAM/TSP. In contrast, HTLV-2 is much less pathogenic, with only a few cases of variant
hairy cell leukemia and neurological disease reported. Similar to HBZ, HTLV-2 also generates an
antisense transcript, termed APH-2 (antisense protein of HTLV-2) [87,88]. While most components of
HTLV-1 and HTLV-2, including Tax-1 and Tax-2, show high degree of conservation, APH-2 exhibits less
than 30% homology to HBZ. Although APH-2 does not harbor a bZIP domain, it can suppress
Tax2-mediated viral transcription by interacting with CREB, similar to the effects displayed by
HBZ [87]. APH-2 expression was found to correlate with the proviral load in HTLV-2-infected carriers;
however, APH-2 did not appear to promote T cell proliferation and lymphocytosis. Arnold et al.
reported that HBZ is not required for efficient infectivity or HTLV-1-mediated immortalization of
primary human T lymphocytes in vitro [89]. However, HBZ enhanced infectivity and persistence of
HTLV-1 in inoculated rabbits, indicating that HBZ is not required for cellular immortalization but
enhances infectivity and persistence in vivo [32]. Unlike HBZ, APH-2 is dispensable for enhancing viral
replication and persistent infection in the rabbit animal model [90]. In addition, APH-2 could contribute
to the lower virulence of HTLV-2 [90]. Thus, the antisense transcripts of HTLV-1 and HTLV-2 exhibit
different functions in vivo, and further studies are necessary to clarify their distinct pathobiologies.
4. Perspectives
It has been 35 years since the discovery of HTLV-1. Numerous studies have focused on elucidating
the molecular mechanisms by which HTLV-1-encoded viral proteins induce viral replication, cellular
transformation, and oncogenesis. Tax is thought to have an important role in the leukemogenesis of
HTLV-1 because of its pleiotropic functions. However, Tax expression is frequently lost during the
development of ATL suggesting that Tax may not be essential for this process. By contrast, HBZ is the
only viral gene that is constitutively expressed in ATL cases and thus is a plausible player to critically
control the ATL leukemogenesis. In addition, APOBEC3G frequently introduces mutations to HTLV-1
genes before proviral integration but HBZ seems to be spared from this alteration. As discussed in this
review, current findings support the view that HBZ is indispensable for leukemogenesis by HTLV-1.
Further studies are needed to elucidate the precise molecular mechanisms by which HBZ induces
oncogenesis so that novel therapies targeting HBZ could be developed.
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Abstract: More than thirty years have passed since human T-cell leukemia virus type 1 (HTLV-1) was
described as the first retrovirus to be the causative agent of a human cancer, adult T-cell leukemia
(ATL), but the precise mechanism behind HTLV-1 pathogenesis still remains elusive. For more
than two decades, the transforming ability of HTLV-1 has been exclusively associated to the viral
transactivator Tax. Thirteen year ago, we first reported that the minus strand of HTLV-1 encoded for
a basic Zip factor factor (HBZ), and since then several teams have underscored the importance of this
antisense viral protein for the maintenance of a chronic infection and the proliferation of infected cells.
More recently, we as well as others have demonstrated that HBZ has the potential to transform cells
both in vitro and in vivo. In this review, we focus on the latest progress in our understanding of HBZ
functions in chronicity and cellular transformation. We will discuss the involvement of this paradigm
shift of HTLV-1 research on new therapeutic approaches to treat HTLV-1-related human diseases.
Keywords: human T-cell leukemia virus type 1; adult T-cell leukemia; HTLV-1 bZip Factor; Valproate
1. Introduction
Thirty years ago, human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus
to be identified and is now known as the causative agent of a very aggressive form of leukemia
termed adult T-cell leukemia (ATL). It was isolated in the early 1980s, first in the United States [1] and
then in Japan [2,3]. Currently, HTLV-1 infects approximately 15 million individuals worldwide [4].
HTLV-1 is the etiological agent of both ATL and a slowly progressive neurologic disorder called
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). [5,6]. The role of HTLV-1 in
HAM/TSP will not be discussed here. Below, we summarize and update insights relevant to human
leukemogenesis induced by HTLV-1.
2. HTLV-1 Infectivity and Spread in vivo
Like any animal retrovirus, the HTLV-1 proviral genome encodes for the structural genes, gag, pol
and env, and is bordered by two long terminal repeat sequences (LTR) [7]. The 51 LTR serves as the
main promoter for viral transcription. HTLV-1 is defined as a complex retrovirus because its genome
also contains a region termed the pX region, which it located between the env gene and the 31-LTR and
contains genes encoding regulatory viral factors, Tax, Rex, p12I, p13II, p30II and p21I. Furthermore, the
minus strand of pX has been found to produce an antisense transcript, encoding HBZ [8–11] (Figure 1).
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Figure 1. Structure of the HTLV-1 provirus: The human T-cell leukemia virus type 1 (HTLV-1) genome
encodes for three structural proteins, Gag, Pol, and Env, and complex regulatory proteins such as
Tax, which not only activates viral replication, but also induces the expression of several cellular
genes. The in vivo expression of these viral proteins is suppressed by cytotoxic T lymphocyte (CTL)
activity. HTLV-1 basic Zip factor (HBZ), produced by a minus-strand mRNA, likely plays a role in viral
replication and T-cell proliferation as it is steadily expressed in most HTLV-1-infected cells and primary
adult T-cell leukemia (ATL) cells, whereas Tax is not.
In vitro, HTLV-1 can infect a large variety of cells, including T- and B-cells, fibroblasts,
macrophages, and dendritic cells [12]. These observations indicate that the receptor is common
and expressed on a large number of cells. Studies show that glucose transporter 1 (Glut-1), heparan
sulfate proteoglycans (HSPGs), and neuropilin-1 (NRP-1) are three proteins involved in the mechanism
of HTLV-1 entry [13–15]. The current view on the entry event of HTLV-1 suggests that the virus first
interacts with HSPG and then forms complexes with NRP-1 followed by an association with Glut-1
at the cell surface before final membrane fusion and entry into the cell. However, how these factors
cooperate with each other requires further study. It is interesting to note that, despite the ubiquitous
distribution of these membrane proteins, in vivo, the HTLV-1 provirus is mainly detected in CD4+ and
in CD8+ T-cells [16]. There is nonetheless evidence that cellular receptors play an important role in
determining the cellular tropism of HTLV-1 [17]. Thus, the differential outcome of HTLV-1 on CD4+
and CD8+ cell proliferation may be more important in dictating the apparent specificity for CD4+ cells
than is receptor-binding and differences related to cellular entry [18].
In vivo, HTLV-1 is primarily transmitted by cell-to-cell contact, and not by cell-free virions [19].
Upon contact with an uninfected cell, HTLV-1-infected cells will transiently express high levels
of Tax and intercellular adhesion molecule-1 (ICAM-1) to form a virological synapse [20] or a viral
biofilm [21]. Enveloped viral particles can transfer through this synapse, thus propagating infection [22].
Recently, it has been reported that HTLV-1 cell-to-cell transmission is ten thousand times more
efficient than cell-free infection, while, in comparison, similar experiments have shown that for
human immunodeficiency virus type 1 (HIV-1) infection, this difference is only twofold [23]. However,
the importance of in vivo cell-to-cell spread is tempered by findings that the administration of reverse
transcriptase inhibitors (RTI) to HTLV-1-infected patients with HAM/TSP does not markedly influence
the provirus load [24], and that RTI treatment immediately after HTLV-1 infection in vivo does not
change subsequent proviral load. Thus, viral replication itself does not appear to be critical for
the maintenance of persistent infection; rather, the proliferation of HTLV-1-infected cells seems to
determine viral burden at the carrier state. In this regard, the viral strategy to increase the number of
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infected cells by promoting cellular proliferation is meaningful. Indeed, a long-standing observation is
that HTLV-1 induces clonal proliferation of infected cells in vivo [18,25,26].
3. HTLV-1, Chronicity and Host Immune Response
In order to induce chronic infection, viruses need to establish an equilibrium between viral
virulence and the host immunity [27]. Accordingly, human retroviruses, such as HTLV-1, have
evolved several strategies to control the host immune system and temper viral replication, one of
which is to directly deregulate the major histocompatibility complex (MHC) [27]. The function of
MHC molecules is to bind peptide fragments derived from pathogens and display them on the
cell surface for recognition by the appropriate T-cells. The consequences are often deleterious to
the pathogen—virus-infected cells are killed and B-cells are activated to produce antibodies that
eliminate or neutralize extracellular pathogens. Thus, there is a strong selective pressure in favor
of any virus that has evolved mechanism allowing them to escape presentation of its antigens by
MHC molecules. In its pX region, HTLV-1 encodes an accessory protein, p12 that interacts with MHC
class I heavy chains, and leads to its degradation by the proteasome [28]. In HTLV-1-infected host,
chronically activated cytotoxic T lymphocyte (CTL) response [29–31] and high titer of anti-HTLV-1
antibodies, mostly directed against the Tax protein [32–34], strongly support the idea that Tax is
the main immunogenic target. Indeed, in vivo depletion of Tax-expressing CD4+ T-cells leads to
moderate HTLV-1 replication [35]. CD8+ CTLs are in part responsible for this phenomenon because
their depletion enhances Tax expression in vivo [35]. Furthermore, when a histone deacetylase inhibitor,
valproate, was used to reactivate tax transcription in HTLV-infected host, their proviral load became
reduced [36–38]. A similar observation of valproate-induced reduction of Simian T-Cell Leukemia Virus
(STLV) proviral load has been also reported in a simian model [39]. Thus host’s CTL response targets
Tax-expressing cells, thereby reducing the number of infected cells in vivo. In fact, the HTLV-1 proviral
load appears to be maintained, when an equilibrium is established with the immune response, allowing
the maintenance and the proliferation of HTLV-1-infected cells [40]. While Tax is frequently targeted by
CTL in HTLV-1 infection [32–34], the frequency of HBZ-specific CTL is low and could only be detected
in 25%–40% of infected individuals [41,42]. However, in a systematic study, MacNamara et al. [42]
showed that protective alleles A*0201 and C*0801 bound HBZ-derived peptides with significantly
higher affinity in comparison to alleles which were associated with disease progression (B*5401).
However, further analyses demonstrated that asymptomatic carriers ACs had human leukocyte
antigen (HLA) alleles which bound HBZ peptides significantly more strongly than patients with
HAM/TSP, and that this difference in binding was not simply attributable to A*0201, C*0801, and
B*5401 [41,42].
In order to escape the host immune response, a proportion of cells that express Tax must
subsequently shut down its expression. Recently, various molecular mechanisms accounting for
suppression of Tax expression have been suggested, implicating viral—Rex [43], the pX protein p30
II [44] and HBZ [8]—and cellular proteins—histone deacetylases [45] and GLI-2/THP [46]. In each
study, these data only indicate a partial rather than a complete shutdown of proviral transcription.
Importantly, the extent of suppression of viral expression in natural HTLV-1 infection is not yet
known. However, even partial suppression should provide significant survival advantage to an
HTLV-1-infected cell since these cells might be less prone to elimination by the immune system, which
would be particularly dependent on CTL activity. Furthermore, impairment of CTL surveillance may
similarly allow HTLV-1-transformed leukemic cells to survive and proliferate [47,48].
4. Multifaceted Processes in the Transformation of Infected Cells
Over time, a subset (2%–6%) of HTLV-1-infected individuals will develop ATL [49]. One of the
current models is that the Tax oncoprotein confers survival and proliferative properties to infected
cells (Figure 1) [50–52]. Tax is post-translationally modified by phosphorylation, ubiquitination, and
acetylation [53–59]. These post-translational modifications have been shown to be important for Tax
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function [54,58]. Expression of Tax alone has been postulated to be sufficient for immortalization,
but not transformation, of human T-cells [60,61]. The in vivo transforming capacity of Tax has been
extensively investigated using transgenic mouse models; results suggest that Tax expression can
solely drive in vivo tumor formation [62–64]. However, frequent appearance of type 2 defective
proviruses (i.e., lacking the 51 LTR and the Tax gene) in ATL cells lead into questioning these
current models [65–67]. Investigation of the mechanisms underlying the generation of these defective
proviruses by Miyazaki et al. [67] showed that 41% of type 2 defective proviruses lacking 51 LTR were
formed before proviral integration. Since Tax expression alone is not enough to transform primary
human cells in vitro [60,61,68], it is likely that, similar to human papillomavirus E6 and E7, which
cooperate for the development of tumors [69], tax functions cooperatively with other HTLV-1-encoded
genes in HTLV-1 to induce human leukemogenesis [63]. Further studies are required to better clarify
the roles of the Tax in ATL onset.
5. HTLV-1 Antisense HBZ Transcripts and Viral Pathogenesis
While HTLV-1 plus strand (sense) contains transcripts driven from the 51 LTR, the 31 LTR produces
an antisense transcript, which encodes a protein called HTLV-1 basic Zip factor , HBZ (Figure 1) [7].
The promoter for the hbz gene is contained in the U5 sequence of the 31 LTR [7]. Analyses showed
that HTLV-1 LTR possess a bidirectional transcriptional activity. Interestingly, Sp1 sites within this
region are critical for the control of bidirectional and HBZ transcription [70,71]. While tax transcripts
are detected in few transformed ATL cells, hbz mRNA is present in all ATL cells [72–74].
Through its basic Zip (bZIP) domain, the HBZ protein has been described to interact
with transcription factors the cAMP-response element binding proteins (CREB, CREB-2), the
cAMP-responsive element modulator (CREM-Ia) the activating transcription factor ATF-1 [75],
c-Jun [76,77], JunB [78], and JunD [79], and was originally reported to suppress Tax-mediated viral
transcription [8]. Furthermore, HBZ selectively inhibits the classical nuclear factor-kappa B (NF-κB)
pathway by inhibiting DNA binding of p65 and promoting its degradation [80]. On the other hand,
Tax has been shown to rather activate both classical and alternative NF-κB pathways [81]. Since the
two pathways differentially control the expression of genes with anti-apoptotic functions in lymphoma
cell lines [82], preferential activation of the alternative pathway by Tax and HBZ might be implicated
in the proliferation of ATL cells. Interestingly, a previous study had suggested that the hbz mRNA
itself is also important for the induction of proliferation of HTLV-1-infected cells [9]. Moreover, it
has been shown that HTLV-1 molecular clones harboring a mutation in the leucine zipper domain
of HBZ exhibit reduced proviral load compared to wild type virus when inoculated into rabbits [83].
Furthermore, HBZ has been reported to increase the activity of human telomerase reverse transcriptase
(hTERT) [84]. Collectively, all of the available data support that HBZ protein and RNA play important
roles in promoting viral replication and cellular proliferation [85].
Genetic instability in infected cells might allow them to escape strong CTL response, and
further protect them from clonal dominance [86]. On the other hand, HTLV-1-triggered alterations
in cellular gene expression have been proposed to amount to a mutator phenotype that promotes
leukemogenesis [87]. Thus far, Tax has been recognized as the main source of HTLV-1-associated genetic
instability. In a recent study, Vernin et al. [88] showed that HBZ promotes onco-miR expression as well
as DNA-strand breaks by downregulating the expression of OBFC2A protein via posttranscriptional
activation of miR17 and miR21. OBFC2A intervenes with ATM signaling and subsequently activates
DNA repair and cell-cycle checkpoints [88]. In their study, Vernin et al. further suggested that
preleukemic phenotypes of HTLV-1-positive CD4+ T cells is portrayed by an oncogenic miRNA profile
that is promoted by HBZ [88].
The transforming capacity of HBZ has been clearly demonstrated in vitro and in vivo using HBZ
transgenic (Tg) mice [89,90]. Using the 51 LTR deleted K304089 molecular clone [10], Gazon et al. have
demonstrated that, in murine cells, HBZ expression on its own drives cellular proliferation and colony
formation in soft agar [90]. Furthermore, in vivo studies showed that CD4+ Foxp3-positive T-cells from
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HBZ-Tg mice had similar effector/memory [89] and regulatory phenotypes to infected CD4+ T cells
from ATL patients or HTLV-1-infected carriers [91,92] In this study by Satou et al., transgenic mice
expressing Tax under the same promoter as the HBZ-Tg mice did not display any changes in their Treg
phenotype [89]. These data suggest that HBZ, rather than Tax, is responsible for conferring a specific
phenotype to HTLV-1-infected cells and ATL cells.
The interplay between Tax and HBZ in T-cell transformation might then be explained by the
fact that the former would be needed to initiate transformation while the latter would be required to
maintain the transformed phenotype of ATL cells at a time point when Tax expression is extinguished.
However, when taking into consideration the accumulating evidence on HBZ functions, the notion that
Tax only can initiate cellular transformation via its ability to induce genetic instability may require some
revision. Indeed, it has been clearly established that HBZ is responsible for the specific phenotype,
function and proliferation of HTLV-1-infected CD4+ T-cells and ATL cells, and that, in addition to
Tax, HBZ plays an important role in the oncogenic activity of HTLV-1 (Figure 2). Furthermore, the
long latent period observed by Satou et al. before the onset of T-cell lymphomas in HBZ-Tg mice
suggests that additional epigenetic alterations in CD4+ T-cells are necessary for the development of
T-cell lymphomas in HBZ-Tg mice as well as for ATL [89]. In conclusion, functions recently attributed
to HBZ provide novel insights into the interaction between HTLV and its host and may be exploited to
treat and prevent HTLV-1-induced diseases.
Figure 2. Model for ATL development. HTLV-1 is transmitted in a cell-to-cell fashion via a virological
synapse. After infection, HTLV-1 promotes clonal proliferation of infected cells by pleiotropic actions of
Tax and other viral proteins. Tax is considered crucial for the oligoclonal maintenance and expansion of
HTLV-1-infected cells during the early phase but is only transiently expressed by HTLV-1-infected cells.
Proliferation of HTLV-1-infected cells is controlled by cytotoxic T-cells in vivo. Thereafter, continuing
expression of HBZ is followed by genetic/epigenetic loss of function of tumor suppressor genes and
modulation of micro RNA levels. After a long latent period, ATL develops in about 5% of asymptomatic
carriers. Diverse genetic abnormalities are acquired during the progression to ATL from an indolent to
an aggressive disease form.
6. Therapeutic Approaches for ATL
ATL is an incurable and poorly treatable disease. Despite advances in both chemotherapy and
supportive care, median survival time of patients remains less than one year [93]. As pointed out by
Yamada and Tomonaga [94], an important amount of knowledge in molecular biology and oncogenesis of
ATL has accumulated but has not yet been translated into improved prognosis of affected patients [94].
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In fact, it has been reported that the prognosis of indolent subtypes, chronic and smoldering ATL, was
4.1 years, which is poorer than previously thought [95]. Therapeutic approaches using interferon-α
combined with zidovudine have nonetheless been reported to be highly effective treatments for indolent
ATL and, as they have been extensively reviewed, will not be further detailed here [96–98].
6.1. Chemotherapy
In Europe, US and Brazil, the recommended treatment of patients with acute or lymphoma-type
ATL is based on the use of combined chemotherapy, as a first line therapy: cyclophosphamide,
adriamycin, vincristine, and prednisolone (CHOP). 46.5% of patients treated with CHOP exhibit
partial remission (PR), while only ~20% are achieving complete remission (CR) [99]. Intensification
of CHOP with etoposide, vindesine, ranimustine, and mitoxantrone resulted in CR for 35.8% of
ATL patients [100]. However, the median survival was only 8–8.5 months in these studies with
predicted survivals of 13% after three years. In Japan, the first line of combined chemotherapy
against ATL consists of VCAP-AMP-VECP) (i.e; vincristine, cyclophosphamide, doxorubicin, and
prednisone (VCAP), doxorubicin, ranimustine, and prednisone (AMP), and vindesine, etoposide,
carboplatin, and prednisone (VECP)) [101–103]. It has in fact been shown that the CR rate was
better with VCAP-AMP-VECP (40%) than biweekly CHOP (~20%) and that a three-year survival
rate of patients treated with VCAP-AMP-VECP therapy improved by 24% (versus 13% with CHOP
treatment) [104]. The two main obstacles to combined chemotherapy are (1) the inherent drug
resistance to chemotherapeutic agents observed in ATL cells [49] and (2) the profoundly weakened and
immunodeficient state of ATL patients. Overall, ATL survival with various chemotherapy regimens
is poor, with survival ranging between 5.5 and 13 months in several cohorts of patients, and more
predominantly in patients with acute leukemia or lymphoma. At the moment, this approach does not
represent a prospect for a cure.
6.2. Molecular Targeted Therapy
As an alternative to chemotherapy, a number of studies have addressed the potential use of
nucleoside analogues for the treatment of ATL. The purine analog 21-deoxycoformycin (DCF) that
inhibits adenosine deaminase has been studied. In a phase II study using DCF, two CR (8%) and one
PR (4%) cases were reported among 25 patients with ATL [105]. Unfortunately, these response rates are
significantly lower than those with CHOP-based chemotherapy. Using DCF in conjunction with CHOP,
52% of ATL patients achieved CR, but the median survival of patients was only 7.4 months [106].
Interestingly, another study reported that a patient presenting resistant acute ATL had an improved
and lasting partial response when treated with another adenosine analog, 21-chlorodeoxyadenosine
(cladribine) [107]. However the follow-up phase II study showed very limited benefit with this
compound. It is nonetheless important to note that all patients under treatment showed resistant ATL
prior to treatment in this study and therefore represented a poor prognosis group [108].
Parallel approaches, using analogs or inhibitors of topoisomerase, such as irinotecan
hydrochloride (CPT-11) [109], a bis (2,6-dioxopiperazine) analog (MST-16) [110], Menogaril [111]
or all-trans-retinoic acid (ATRA) [112,113], an analog of vitamin A have been similarly tested. The most
promising results were obtained with the MST-16 treatment. In a cohort constituted of 21 acute-type
ATL patients, treatment resulted in one CR and five PR. Among eight lymphoma-type ATL patients,
two PR cases were identified, while out of two chronic-type ATL patients, one was diagnosed as
being in CR while the other, as being in PR. Remissions were achieved within 23 days and lasted over
two months (median, 68 days) [110]. These results do not clearly represent an improvement over
conventional chemotherapy and further studies with MST-16 are needed.
Gene expression governed by epigenetic changes is crucial for the pathogenesis of cancer. Histone
deacetylases are enzymes that are involved in the remodeling of chromatin and play a key role in
the epigenetic regulation of gene expression. The use of histone deacetylase inhibitors (HDACi) to
treat ATL has recently attracted attention. The HDACi LBH589 (panobinostat) exhibited significant
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anti-ATL activity by activating a novel RAIDD-caspase-2 pathway in mice and by modulating the
expression of Tax and CCR4 [114]. However, a phase II study using panobinostat for cutaneous T-Cell
Lymphoma (CTCL) and indolent ATL patients had to be terminated because of severe side effects and
appearance of ulcers in patients with ATL [115].
Depsipeptide (HFR901228), another HDACi induces apoptosis in all tested HTLV-1-infected cell
lines and in primary cells from patients with acute ATL, through a reduction of NF-κB and AP-1
transactivation activity, and downregulation of B-cell lymphoma-extra large (Bcl-xL) and cyclin D2
expression. Partial inhibition of tumor growth following transplantation of HTLV-1-infected cells, was
seen in a severe combined immunodeficiency (SCID) mouse model [116]. Further studies are needed
to evaluate the efficacy of HFR901228.
Sodium valproate (VPA) is another HDCAi under investigation, which is widely prescribed for
the treatment of epilepsy, bipolar mood disorders, and migraine, and which shows HDACi activity
among several other potential antitumor properties [117]. VPA is also being investigated for its
inclusion in maintenance therapy after chemotherapy [118]. More importantly, dramatic clearance of
both lymphoma and leukemic cells has been demonstrated in Bovine Leukemia Virus-induced B-cell
malignancy in sheep upon treatment [37,119]. In a recent study, Belrose et al. [38] analyzed the impact of
VPA treatment on the expression profile of Tax and HBZ in freshly cultured cells from HTLV-1-infected
patients. It was then proposed that VPA relieved the epigenetic control over Tax expression, thereby
exposing latently HTLV-1-infected cells to the immune response. Indeed, in the presence of VPA, Tax
expression kinetics were profoundly modified, with Tax mRNA levels increasing constantly over time,
suggesting dysregulation of the processes responsible for the control of its expression in lymphocytes
from HAM/TSP patients, but not from asymptomatic carriers. One interesting finding from the Belrose
et al. study was that VPA strongly impaired the expression of HBZ [38]. The authors suggested that
the opposite effect of VPA on Tax and HBZ expression might be caused by the nature of HDAC
complexes present on the 51- and 31-HTLV-1 promoters in relation to their selective down-modulating
properties. Alternatively, it cannot be excluded that activation of sense transcription by Tax and
VPA might have impaired antisense transcription, either by competition for transcription factors
or interference with its initiation. Indeed, Cavanagh et al. [10] have showed that, by deleting the
51-LTR, sense transcription has a negative impact on antisense transcription (i.e., from the 31-LTR) [10].
Interestingly, despite increased Tax expression, Belrose et al. did not observe the expected increase in
proviral load (PVL) in VPA-treated samples from HAM/TSP. Instead, a significant decrease of the PVL
in VPA-treated samples from acute ATL patients was observed, suggesting a decrease in the percentage
of ATL cells [120]. Using VPA to augment the level of histone acetylation and increase HTLV-1 gene
expression in cultured cells from HAM/TSP patients, Mosley et al. [121] demonstrated that, while the
level of Tax expression doubled after overnight treatment, the rate of CD8+ T-cell-mediated lysis of
Tax-expressing cells was reduced by 50% [121]. VPA thus appeared to inhibit CD8+ T-cell-mediated
cell from killing itself. These observations indicate that HDCAis may reduce the efficiency of CTL
surveillance of HTLV-1. Further studies are needed to evaluate the use of HDIs in nonmalignant cases
of HTLV-1 infection. Taken together, these observations strongly suggest that HBZ is a very interesting
therapeutic target and that a therapy using VPA as part of the management of patients with acute and
lymphoma ATL should be considered for the prevention of progression of chronic and smoldering
ATL. Should a protective effect be shown, the long-standing safety profile of this compound would
justify a prospective study in which its efficacy in preventing ATL in patients considered to be at high
risk of disease is evaluated [122].
6.3. Immunotherapy
Another alternative approach is to target ATL cells using specific markers on the surface of the
malignant cells with monoclonal antibodies. One of the first potential tested target is the interleukin
(IL)-2alpha receptor α chain, CD25. Indeed, ATL cells express high level of CD25 on their surface.
In their recent phase I/II trial on 34 patients with ATL, Berkowitz et al. [123] reported that daclizumab,
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a humanized monoclonal antibody which blocks IL-2 binding by recognizing CD25 on ATL cells, was
associated with effective clinical responses in patients with indolent disease, although no beneficial
responses were observed in patients with acute or lymphomatous subtypes of ATL [123]. The finding
that daclizumab has antitumor activity and demonstrates a potential in achieving long-term responses
in patients with the indolent form of ATL, suggest that immunotherapy offers a therapeutic option to
prevent indolent diseases to develop into aggressive ATL [123].
Another target for immuno-based therapy against ATL is the CC chemokine receptor 4 (CCR4).
CCR4 is principally expressed on regulatory T-cells (Tregs) and helper T-cells (Th), where it functions
in inducing homing of these leukocytes to sites of inflammation. Tregs play an essential role in
maintaining immune balance; however, in malignancy, Tregs impair host antitumor immunity and
provide a favorable environment for tumors to grow [49]. Furthermore, ATL cells express high levels
of CCR4 on their surface [124]. Mogamulizumab (KW-0761) is the first approved glyco-engineered
therapeutic monoclonal antibody to target CCR4. 30% of patients with acute forms of ATL (5 out
of 15) treated with Mogamulizumab showed a positive response [125]. Several ongoing clinical trials
in Japan are investigating if combining Mogamulizumab with a chemotherapy treatment could be
beneficial [126–128].
6.4. Stem Cell Transplantation
As a treatment strategy for ATL, allogeneic hematopoietic stem cell transplantation (allo-HSCT) with
reduced intensity conditioning regimens (RIC) was prospectively evaluated. Several teams have reported
the safety and feasibility of allo-HSCT with RIC using peripheral blood stem cells from an HLA-matched
sibling donor in patients with acute ATL, who achieved remission after chemotherapy [129–131]. These
studies showed that the overall survival (OS) at three years after allo-HSCT with RIC treatment ranged
from 33% to 49% [132]. Interestingly, a significant decrease of the proviral load was also reported in many
of these patients. These findings suggest that cell-mediated immunity to HTLV-1 was augmented in these
patients, which might account for the efficacy of this therapy. In fact, Graft-versus-host disease (GVHD) is
a good prognostic factor for ATL patients [130], indicating that an immune attack by donor lymphocytes is
critical for the efficacy of treatment. Kanda et al. [133] reported that grade I/II acute GVHD was associated
with a longer OS. Beneficial effects of allo-HSCT on non-Japanese ATL patients were recently confirmed
by a retrospective study from the European Group for Blood and Marrow Transplantation's Lymphoma
Working Party [134].
7. Perspectives and Conclusions
Although new therapeutic options are emerging, treatment of ATL patients remains challenging.
The initial pathogenic event for ATL is HTLV-1 genomic integration; however, additional genetic
alterations have also been implicated in ATL pathogenesis. Umino et al. [135] reported on the
importance of clonal heterogeneity of ATL cells involving different genomic alterations; they further
demonstrated that these cells originated from a common cell. It was suggested that approximately 70%
of ATL cases undergo clonal evolution, and that genetic instability may contribute to the accumulation
of genomic alterations [135]. In fact, the existence of multiple clones with genomic instability is one
factor that renders ATL cells resistant to conventional chemotherapy. Even if a proportion of cells are
killed by chemotherapy, new resistant clones likely emerge. Therefore, allo-HSCT might be efficient in
curing ATL patients by eliminating HTLV-1-integrated recipient ATL clones through strong immune
response, and subsequent replacement of the hematopoietic system with donor cells.
Whole genome sequencing revealed that carriers have 103 to 104 distinct clones with different
HTLV-1 integration sites, and that most clones harbored one copy of HTLV-1 proviral DNA [136]. This
indicates that HTLV-1 carriers potentially have 103 to 104 malignant clones. If the number of infected
cells increases, there is a greater possibility that malignant transformation might occur. In order to
reduce the number of pre-malignant cells in HTLV-1 carriers and thus prevent the development of ATL,
treatment with HDAC inhibitors seems to be a promising strategy. Indeed vorinostat (suberoylanilide
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hygroxamic acid: SAHA), panobinostat (LBH-589) and MS-275 have been demonstrated to impede
the growth of HTLV-1-infected cell lines and freshly isolated infected cells [137]. Furthermore, as
reported by Belrose et al. [38], the link between VPA-induced apoptosis of HTLV-1-infected cell lines,
decrease of proviral load in freshly isolated infected cells and loss of HBZ expression indicates that
HBZ is a promising therapeutic target. However, further studies are needed to clarify the effect of
HDACi on HBZ, although the inclusion of HDACi in clinical trials for the treatment of ATL is expected.
Nevertheless, to increase the likehood of discovery of a cure for ATL, rigorous investigation remains
necessary for optimizing therapeutic combinations, preventing ATL development in HTLV-1 carriers,
and reducing the number of HTLV-1 carriers.
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Abstract: Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by
human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%–5% of
HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama
classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy
has been reportedly promising, particularly in patients with indolent type ATLL; however, the
prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve
treatment outcomes have been focused on the development of prognostic stratification and improved
dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy,
allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy.
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1. Introduction
Adult T-cell leukemia/lymphoma (ATLL) was first described in 1977 by Uchiyama et al. [1],
as a distinct clinical entity frequently observed in southwestern Japan. The causative agent of
ATLL is the retrovirus human T-cell leukemia virus type I (HTLV-1) [2], which also causes several
immune-associated diseases, including HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [3]. ATLL develops in approximately 3%–5% of HTLV-1 carriers and has a dismal
prognosis. However, the clinical manifestations and the course of disease in ATLL patients vary
to a great extent. Therefore, recent efforts to improve treatment outcomes in ATLL patients have
been focused on the development of prognostic stratification and therapeutic modalities. In this
review, recent advances in ATLL treatment including antiviral therapy, chemotherapy, allogeneic
hematopoietic stem cell transplantation (allo-HSCT), and molecular targeted therapy are discussed.
2. Diagnosis and Prognostic Factors for ATLL
ATLL diagnosis is based on clinical features, serum anti-HTLV-1 antibody, and ATLL cell
morphology. The clonality of ATLL as a mature T-cell malignancy is confirmed by identification
of the monoclonal integration of HTLV-1 proviral DNA in malignant cells by Southern blot analysis.
The quantification of HTLV-1 integration site clonality has been recently developed through deep
sequence analysis [4]. A high proviral load in HTLV-1 carriers is suggested to be associated with the
development of ATLL, although HTLV-1 proviral load is not used as a diagnostic criterion of ATLL. In
1991, the Japan Clinical Oncology Group (JCOG) proposed the Shimoyama classification that defines
four clinical subtypes: acute, lymphoma, chronic, and smoldering (Table 1) [5]. The classification is
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based on the presence of organ involvement, leukemic manifestation, high lactate dehydrogenase
(LDH) and hypercalcemia that altogether reflect the prognosis and natural history of the disease.
Chronic-type ATLL can be further divided into favorable and unfavorable types based on LDH, blood
urea nitrogen, and albumin concentration. Further, acute, lymphoma, and unfavorable chronic types
are defined as aggressive-type ATLL, while favorable chronic and smoldering types are defined as
indolent-type ATLL [6]. For the last two decades, this clinical classification has been widely used as a
guide in ATLL treatment.
Table 1. Diagnostic criteria and classification (the Shimoyama classification).
Smoldering Chronic Lymphoma Acute
Anti-HTLV-I antibody + + + +
Lymphocyte (ˆ109/L) <4 ě4 † <4 *
Abnormal T lymphocytes ě5% +‡ ď1% +‡
Flower cells with T-cell marker Occasionally Occasionally No +
LDH ď1.5 N ď2 N * *
Corrected Ca2+ (mEq/L) <5.5 <5.5 * *
Histology-proven lymphadenopathy No * + *
Tumor lesion
Skin § * * *
Lung § * * *
Lymph node No * Yes *
Liver No * * *
Spleen No * * *
Central nervous system No No * *
Bone No No * *
Ascites No No * *
Pleural effusion No No * *
Gastrointestinal tract No No * *
HTLV-I, human T-lymphotropic virus type-I; LDH, lactate dehydrogenase; N, normal upper limit.
* No essential qualification except terms required for other subtype(s); † Accompanied by T-lymphocytosis
(3.5 ˆ 109/L or more); ‡ In case abnormal T-lymphocytes are less than 5% in peripheral blood, histology-proven
tumor lesion is required; § No essential qualification if other terms are fulfilled, but histology-proven malignant
lesion(s) is required in case abnormal T-lymphocytes are less than 5% in peripheral blood.
Although the prognosis of aggressive ATLL is dismal, there is marked diversity among patients.
A prognostic index for acute- and lymphoma-type ATLL (ATL-PI) has been proposed based on a
retrospective analysis of 807 newly diagnosed patients between January 2000 and May 2009 in Japan [7].
Ann Arbor stage (I–II vs. III–IV), Eastern Cooperative Oncology Group performance status (ECOG
PS; 0–1 vs. 2–4), age, serum albumin, and soluble interleukin-2 receptor (sIL-2R) were statistically
significant prognostic factors. A simplified ATL-PI was as follows: prognostic score; +2 (Ann Arbor
stage = III or IV); +1 (ECOG PS > 1); +1 (age > 70); +1 (albumin < 35 g/L); and +1 (sIL2R > 20,000
U/mL). Scores from 0 to 2 were categorized as low risk, 3 to 4 as intermediate risk, and 5 to 6 as high
risk. The median overall survival times (MST) were 16.2 months in low-risk patients, 7.0 months in
intermediate-risk patients, and 4.6 months in high-risk patients. However, the Shimoyama classification
and ATL-PI were established based on retrospectively collected data; thus, the patient characteristics,
such as the type of treatment and prognostic factors, were not comparable between groups. The
JCOG prognostic index (JCOG-PI) has recently been established based on data from 276 patients with
aggressive ATLL in three prospective JCOG trials, which identified poor PS and hypercalcemia as
significant prognostic factors [8]. In patients with corrected calcium of <2.75 mmol/L and a PS of 0 or
1 (moderate risk), the MST and five-year overall survival (OS) were 14 months and 18%, respectively; in
patients with corrected calcium of ě2.75 mmol/L and/or a PS of 2–4 (high-risk), the MST and five-year
OS were eight months and 4%, respectively. The JCOG-PI may be useful in identifying aggressive
ATLL patients with dismal prognosis. Assessment by both ATL-PI and JCOG-PI will certainly be useful
in identifying patients with extremely poor prognosis among aggressive ATLL cases. In addition,
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several biomarkers, such as CC chemokine receptor 4 (CCR4), lung resistance-related protein, and p53
mutations, have been reported [9,10]; however, so far, prognostic models and biomarkers that are able
to identify patients who may not need allogeneic hematopoietic stem cell transplantation (allo-HSCT)
do not exist. Thus, further investigation is needed to establish robust prognostic models.
3. Treatment for ATLL
The treatment strategy for ATLL patients is based on the clinical subtype according to the
Shimoyama classification [5,9–11]. The watchful waiting strategy or interferon-α (IFN-α)/zidovudine
(AZT) are usually reserved for patients with indolent-type ATLL, whereas chemotherapy, allo-HSCT,
and newer therapeutic agents are preferred for patients with aggressive-type ATLL. In Europe and the
USA, antiviral therapy using IFN-α/AZT is the standard treatment for leukemic-type ATL. Importantly,
a subset of patients with indolent type ATLL experience skin lesions that can be treated with either
skin-directed therapy, such as topical steroids, ultraviolet light, and radiation, or systemic therapy,
such as steroids, oral retinoids, or single agent chemotherapy. The current treatment strategies are
summarized in Table 2.
Table 2. Treatment strategy for adult T-cell leukemia/lymphoma (ATLL).
1. Indolent-type ATLL: Smoldering- or favorable chronic-type
(1) Watchful waiting for asymptomatic patients
(2) Interferon-α (IFN-α)/zidovudine (AZT) or watchful waiting for symptomatic patients
(3) Skin lesion:
Local therapy; Topical steroids, Ultraviolet light, Radiation
Systemic therapy; Steroids, Oral retinoids, Single agent chemotherapy
2. Aggressive-type ATLL: Unfavorable chronic-, lymphoma- or acute-type
(1) Chemotherapy:
VCAP-AMP-VECP
CHOP or less-toxic regimen for elderly patients
(2) VCAP-AMP-VECP + mogamulizumab
(3) Allogeneic hematopoetic stem cell transplantation (allo-HSCT)
(4) IFN-α/AZT (except for lymphoma-type)
3. Relapse or refractory ATLL
(1) Mogamulizumab
(2) Allo-HSCT
(3) New agents under clinical trial:
Brentuximab vedotin, Bortezomib, Lenalidomide, Panobinostat, Forodesine
Pralatrexate, Denileukin diftitox
(4) Vaccine (autologous dendritic cells with tax-peptide)
VCAP-AMP-VECP: vincristine, cyclophosphamide, doxorubicin, and prednisolone (VCAP); doxorubicin,
ranimustine, and prednisolone (AMP); and vindesine, etoposide, carboplatin, and prednisolone (VECP). CHOP:
doxorubicin, cyclophosphamide, vincristine and prednisone.
3.1. Interferon-α and Zidovudine
Combined IFN-α/AZT has been reported effective as an ATLL treatment [12]. An international
consensus meeting recommended the IFN-α/AZT combination or watchful waiting in patients
with indolent ATLL [13]. A meta-analysis of 254 ATLL patients, including 116 patients with acute
type, 100 with lymphoma type, 18 with chronic type, and 11 with smoldering type, reported that
patients with acute-, chronic-, and smoldering leukemic-type ATLL had better outcomes with first-line
antiviral therapy alone, whereas chemotherapy was more effective in patients with lymphoma-type
ATLL [14]. Specifically, the five-year OS of patients with chronic and smoldering indolent-type ATLL
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was 100% with antiviral therapy. Overall, the meta-analysis concluded that first-line antiviral therapy
improved the survival of ATLL patients. JCOG has started a phase III study comparing IFN-α/AZT
with watchful waiting to determine any potential benefits from early intervention in patients with
indolent-type ATLL.
3.2. Chemotherapy
To date, several chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisolone) and EPOCH (VP-16, prednisolone, vincristine, cyclophosphamide,
doxorubicin) have been assessed in patients with aggressive ATLL [15]. Particularly, since 1978,
the JCOG-Lymphoma Study Group (JCOG-LSG) has played a central role in the development of
chemotherapy regimens for ATLL patients [16]. Most recently, JCOG-LSG conducted a randomized
clinical trial (JCOG9801) to compare the modified LSG15 (mLSG15) regimen with a biweekly CHOP
regimen (CHOP14) in untreated patients with aggressive-type ATLL [17]. The original LSG15, i.e.,
VCAP-AMP-VECP, regimen sequentially consisted of vincristine, cyclophosphamide, doxorubicin, and
prednisolone (VCAP); doxorubicin, ranimustine, and prednisolone (AMP); and vindesine, etoposide,
carboplatin, and prednisolone (VECP). The mLSG15 regimen replaced one course of VCAP-AMP-VECP
from the original LSG15 regimen with intrathecal administration of methotrexate and prednisone as
prophylaxis against central nervous system relapse. The CHOP14 regimen consisted of doxorubicin,
cyclophosphamide, vincristine and prednisone. The complete remission (CR) rate of 40% with mLSG15
was significantly better than the CR rate of 25% observed with CHOP14. The three-year OS rates
were 24% and 13% for mLSG15 and CHOP14 regimens, respectively; however, the difference between
the two groups was not statistically significant. In Japan, mLSG15, which has been recommended
as the first-line treatment for aggressive-type ATLL at an international consensus meeting [13], is
feasible as a standard regimen in patients with aggressive ATLL who are less than 56 years old.
However, the mLSG15 regimen is not routinely available throughout the world due to restricted
use of the medications such as ranimustine and vindesine. In addition, the 13-month MST with
mLSG15 is unsatisfactory compared with other hematological malignancies. Currently, there are no
salvage chemotherapy options established for patients with relapsed or refractory ATLL, and further
investigation is needed.
3.3. Allogeneic Hematopoietic Stem Cell Transplantation
Allo-HSCT has become an important curative treatment modality in patients with aggressive-type
ATLL during the last decade; however, intensified chemotherapy and autologous HSCT has
not been successful [18]. Since Utsunomiya et al. [19] reported successful outcomes in
10 ATLL patients receiving allo-HSCT in 2001, the number of ATLL patients receiving allo-HSCT
has been increasing. In earlier cases, patients received allo-HSCT almost always from human leukocyte
antigen (HLA)-matched related donors (MRD) with full-intensity conditioning (FIC) [19–21]. Along
with the well-developed Japanese marrow donor program/cord blood bank and improvements in
supportive care, unrelated bone marrow (UBM) and umbilical cord blood (UCB) have been increasingly
used as alternative donor sources [22–25]. In addition, with the introduction of reduced-intensity
conditioning (RIC), the number of allo-HSCT has been steadily increasing [26]; so far, i.e., by 2015,
more than 1500 ATLL patients have received allo-HSCT in Japan. According to donor sources, the
three-year OS rate was 41% in patients with MRD and 39% with UBM in a nationwide survey [27].
In contrast, the outcomes of allo-HSCT from UCB were unsatisfactory with the three-year OS rate of
17%, partially due to the overlap of the study period that was around 2005, with the developmental
phase of allo-HSCT from UCB in adult patients. The recently updated data on ATLL patients showed
that the three-year OS of allo-HSCT from UCB remained at 20.6% compared with the three-year
OS rates of 34.4% and 37.1% with allo-HSCT from MRD and UBM, respectively [28]. It is certainly
challenging to directly compare outcomes from different donor sources because the graft source
selection is strongly influenced by donor availability. Nevertheless, the outcomes of CBT in ATLL
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patients continue to be unsatisfactory due to the high transplant-related mortality (TRM) of 46.1%.
Novel interventions will be required, particularly during the early phase, to reduce TRM and control
for graft-versus-host disease (GVHD) in patients receiving allo-HSCT from UCB [29,30]. Although most
allo-HSCT outcomes have been reported in Japanese ATLL patients, the European Group for Blood
and Marrow Transplantation’s Lymphoma Working Party has recently shown similar results with
allo-HSCT in ATLL patients in western countries [31]. However, most of these findings were based
on retrospective analysis and patients with heterogeneous backgrounds, including chemosensitive
and refractory diseases at transplantation. An ongoing prospective study is assessing the safety and
efficacy of RIC followed by allo-HSCT in ATLL patients who achieved remission at transplantation
and are stratified according to donor source. Okamura et al. [32,33] first reported that the five-year
OS of allo-HSCT from MRD was 34% in this prospective study. Other prospective trials assessing
RIC followed by allo-HSCT from UBM and UCB are also ongoing. In particular, the three-year OS of
allo-HSCT from both MRD and UBM was approximately 30%, indicating that allo-HSCT is a curative
treatment. However, survival rates of allo-HSCT have not dramatically improved during the last
decade. The major risk factor affecting the survival of ATLL patients receiving allo-HSCT is disease
status at transplantation. Based on the incidence rate of ATLL, about 80%–90% of ATLL patients are
not able to receive allo-HSCT mostly due to disease resistance to chemotherapy. Therefore, further
efforts are needed to increase the response rate prior to allo-HSCT.
3.4. Novel Agents
One recent promising therapeutic progress in ATLL is the introduction of mogamulizumab for the
treatment of patients with relapsed or refractory ATLL. Mogamulizumab is an anti-CCR4 monoclonal
antibody that markedly enhances antibody-dependent cellular cytotoxicity through high-affinity
binding to effector cells. CCR4 is selectively expressed on regulatory T-cells and T-helper type 2 (Th2)
cells and is expressed on the surface of most ATLL cells. In addition, CCR4 expression is highly
associated with poorer prognosis. Based on the data of tolerability in a phase I study, [34] a phase
II study for relapsed ATLL was subsequently conducted wherein 1.0 mg/kg of mogamulizumab
as a single agent was intravenously administered once a week for eight weeks [35]. The overall
response rate (ORR) was reported to be 50%. The median progression-free survival (PFS) was
5.2 months, and the OS was 13.7 months. Based on these results, mogamulizumab use was approved
in Japan on March 2012, although mogamulizumab use is not available outside of Japan except
in clinical trials. A second, randomized phase II clinical trial in newly diagnosed patients with
aggressive ATLL has recently demonstrated that the CR rate was higher at 52% with mLSG15 in
combination with mogamulizumab compared to 33% with mLSG15 alone, whereas there was no
statistical difference in survival [36]. Since these responses were reported not to be long-lasting,
allo-HSCT is still needed for a cure even with the introduction of mogamulizumab. Concurrently,
mogamulizumab has been expected to serve as a bridge to transplantation to achieve better disease
control during allo-HSCT and to improve survival. However, care should be taken with the use of
mogamulizumab in patients with allo-HSCT as CCR4 is expressed not only on tumor cells but also in
normal regulatory T-cells and Th2 cells. In a non-transplantation setting, severe skin reactions, such as
Steven–Johnson syndrome have been reported [37]. Moreover, rare side effects after the administration
of mogamulizumab, such as diffuse panbronchiolitis [38] and colitis [39], have recently been reported.
In patients with allo-HSCT, the mogamulizumab treatment may accelerate GVHD by eradicating
T-cells. Therefore, the safety and benefits of mogamulizumab both before and after allo-HSCT should
be evaluated, and further clinical experience and accumulation of data is necessary [40,41]. To that end,
a multicenter prospective observational study is now underway to evaluate the safety and efficacy of
mogamulizumab use in ATLL patients with relapsed or refractory disease even after allo-HSCT. In
addition to mogamulizumab, clinical trials are underway to determine the efficacy of other novel agents,
including brentuximab vedotin, bortezomib, lenalidomide, panobinostat, forodesine, pralatrexate,
and denileukin diftitox [9,42]. So far, it seems to be difficult to improve the dismal prognosis of ATLL
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through these novel agent monotherapies. However, in future study, it is important to determine how
new agents should be combined with conventional chemotherapy and allo-HSCT.
3.5. Immunotherapy
Allo-HSCT is a curative treatment approach in ATLL patients, partly through its graft-versus-ATLL
(GvATLL) effect as described before. Grade I/II (mild to moderate) acute GVHD has been shown
to be associated with improved survival rates [43,44]. The discontinuation of immunosuppressive
agents or donor lymphocyte infusion was also effective in ATLL patients who relapsed even after
allo-HSCT [45,46]. In addition, Tax- or HBZ-specific T-cells have been shown to play an important role
in inducing a potent GvATLL effect [47,48]. The vaccine, which was developed by pulsing Tax peptide
into autologous dendritic cells, was effective in ATLL patients [49]; a clinical trial is ongoing for the
evaluation of this vaccine with mogamulizumab in Japan.
4. Conclusions
The prognosis of ATLL patients, despite an increase in the variety and potency of therapeutic
options, has undeniably remained poor, and many obstacles still exist [50]. In future efforts, through
studies that uncover the molecular mechanisms underlying ATLL, new treatment protocols integrating
antiviral therapy, chemotherapy, allo-HSCT, and molecular targeted agents with optimized dosing and
timing need to be developed.
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Abstract: Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus associated with human
diseases, such as adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/Tropic spastic
paraparesis (HAM/TSP). As a retrovirus, its life cycle includes a step where HTLV-1 is integrated
into the host genomic DNA and forms proviral DNA. In the chronic phase of the infection, HTLV-1
is known to proliferate as a provirus via the mitotic division of the infected host cells. There are
generally tens of thousands of infected clones within an infected individual. They exist not only in
peripheral blood, but also in various lymphoid organs. Viral proteins encoded in HTLV-1 genome
play a role in the proliferation and survival of the infected cells. As is the case with other chronic
viral infections, HTLV-1 gene expression induces the activation of the host immunity against the
virus. Thus, the transcription from HTLV-1 provirus needs to be controlled in order to evade
the host immune surveillance. There should be a dynamic and complex regulation in vivo, where
an equilibrium between viral antigen expression and host immune surveillance is achieved. The
mechanisms regulating viral gene expression from the provirus are a key to understanding the
persistent/latent infection with HTLV-1 and its pathogenesis. In this article, we would like to review
our current understanding on this topic.
Keywords: HTLV-1 2; provirus 3; retroviral latency
1. Introduction
It has been estimated that Human T-cell leukemia virus type 1 (HTLV-1) has been infecting
humans for several thousand years [1]. In ancient times, prior to the advent of blood transfusions or
drug abuse, the virus spread either by vertical transmission, from mother to child via breast-feeding, or
by horizontal transmission mainly from man to woman, through sexual intercourse. HTLV-1 generally
induces de novo infection not via free viral particles but via cell-to-cell contact between infected and
uninfected cells [2–4]. The presence of infected lymphocytes in breast milk or sperm is pivotal for
de novo infection. In the case of vertical transmission, infected individuals acquire the virus during
infancy and need to carry the virus for decades, before they are able to transfer the virus to their
children. Also, infected women need to remain healthy for decades in order to become pregnant, in
spite of the persistent HTLV-1 infection in their bodies. To achieve such a long-term persistent infection
without having severe health problems, HTLV-1 seems to have developed a strategy to achieve an
asymptomatic condition by minimizing the effect of viral infection on our vital systems. At the same
time, as with other viruses that cause persistent infections, HTLV-1 needs to evade the host immune
surveillance [5].
The main routes of de novo HTLV-1 infection are cell-to-cell transmission and/or extracellular
biofilm-like-structure-mediated transmission [2,4]. In either case, the virus produces viral proteins
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that are necessary for reverse transcription and integration of the viral DNA into the host cellular
DNA. HTLV-1 is required to keep a latent state in the chronic phase of infection, but it also needs
to reactivate viral gene expression for de novo infection. This implies that the virus makes use of a
reversible system to switch from the latent phase of infection to the active phase, where viruses are
produced. For example, when the infected cells are transferred from mother to child, proviruses in
the infected lymphocytes contained in the breast-milk would be transcriptionally reactivated, and
producing infectious viral particles or inducing cell-to-cell transmission. Since an anti-virus immunity
has not been established yet in the new host during the initial phase of infection, the virus would be
able to spread via de novo infection (Figure 1).
Figure 1. Schematic figure of Human T-cell leukemia virus type 1 (HTLV-1) infection from the initial to
the chronic phase of infection. (A) During the initial phase of infection, before an anti-virus immunity
has been established, de novo infection should be more dominant than the clonal expansion of infected
cells. In the chronic phase of infection, antiviral immunity removes infected cells with high viral antigen
expression. HTLV-1 increases the viral copy number by clonal expansion of the infected cells. There
is sporadic viral antigen expression, which should maintain the activity of the anti-viral immunity.
(B) Change in the distribution of infected clones with different antigen expression. In the initial phase,
the proportion of infected clones with high Tax expression is high, because there is little anti-viral
immunity. After the establishment of an anti-viral immunity, clones with high antigen expression are
eliminated by the host immune system.
In a typical asymptomatic carrier, approximately 2% of peripheral mononuclear cells are infected
with HTLV-1 [6], which is far more frequent when compared with the proviral load of HIV-1 in patients
undergoing anti-retroviral therapy [7]. We can also observe cytotoxic T-lymphocytes (CTLs) specific for
HTLV-1 antigens in asymptomatic carriers as well as in HTLV-1-associated myelopathy/Tropic spastic
paraparesis (HAM/TSP) patients, suggesting that even in the absence of clinical symptoms there is
a balance between the host immune surveillance and the persistent viral infection [8,9]. Therefore,
to understand the regulatory mechanisms acting on HTLV-1 provirus integrated within the host
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genomic DNA is a key to elucidate the virological and pathophysiological aspect of HTLV-1 infection,
including the mechanisms leading to transformation of the infected cells or the establishment of chronic
inflammatory diseases.
2. Structure of Human T-cell Leukemia Virus Type 1 (HTLV-1)
HTLV-1 is a delta-type retrovirus [10,11]. Viral RNA is reverse-transcribed, integrated into the
genomic DNA of the host cell, and thereafter remains as a provirus. The size of the proviral genome
is approximately 9000 base pairs (bp) [12]. As is the case with other retroviruses, there are identical
sequences, long terminal repeats (LTRs), at both ends of the provirus. The 51-LTR is the promoter for the
transcripts in the sense orientation, whereas the 31-LTR is the promoter for antisense transcription. Most
of the viral structural genes, such as gag, pol, and env are encoded in the 51 side of the provirus in the
sense orientation, as is commonly observed in other retroviruses [13]. However, a unique characteristic
of HTLV-1, also shared with the bovine leukemia virus (BLV), another delta-type retrovirus, is the
presence of the pX region, which is located in the 31 side of the provirus. There are two regulatory
proteins, Tax and Rex, encoded in the pX region. Tax, the most intensively characterized viral protein,
is a strong transactivator of HTLV-1 51-LTR. Rex is another positive regulator for the expression of viral
antigens, which controls the nuclear export of viral mRNAs. There are several accessory proteins also
encoded in the sense orientation in the pX region, including p13, p30, p12, p27, p21Rex and p8 [14–18].
In addition, HTLV-1 bZIP factor (HBZ) is encoded in the pX region in the anti-sense orientation [19].
HTLV-1 very efficiently utilizes its small genome via alternative splicing and bidirectional
transcription. The regulatory and accessory viral proteins coordinately control viral antigen expression,
contributing to achieve a persistent infection with HTLV-1.
3. Regulation of the 51- and 31-LTR Promoter Regions of HTLV-1 Provirus
There is sense- and antisense-transcription from HTLV-1 provirus, driven by sequences contained
in the LTRs that serve as promoters. The sequence of the 51- and 31-LTRs is identical, so the directionality,
sense or anti-sense orientation, confers the different promoter activity on the 51- and 31-LTRs. There is a
DNA sequence found in the promoter region of some genes (TATA-box) in the sense orientation of the
LTR, but not in the anti-sense orientation. Promoters containing a TATA-box structure generally exhibit
high-plasticity in their promoter activity, whereas TATA-less promoters show low transcriptional
plasticity [20,21]. In line with this notion, the plus strand of the 51-LTR, a TATA-box-containing
promoter, shows variable activity, whereas the minus strand of the 31-LTR, a TATA-less promoter,
shows a relatively stable promoter activity [22]. A recent study has shown that HTLV-1 LTR possesses
a bidirectional transcriptional activity and that Tax could preferentially activate the sense transcription
with no or limited effect on the antisense transcription in a reporter plasmid system [23]. It is well
known that the sense transcription from the 51-LTR is significantly induced in the presence of Tax.
There are three copies of imperfect repeats of a 21 bp sequence called TRE (Tax-response element) that
is responsive to the transactivation mediated by the viral protein Tax. Tax is a strong positive regulator
of sense transcription from the 51-LTR [12,24,25].
A recent interesting study has further extended our understanding on how both sense and
antisense transcriptions are regulated within the provirus. They showed that sense transcription
from the 51-LTR did not interfere with antisense transcription from the 31-LTR and vice versa [26].
They further showed that the cell cycle arrest induced by Tax expression might inhibit Tax-mediated
activation of the sense transcription without affecting antisense transcription. As the authors pointed
out, the mechanism may play a role in HTLV-1 latency. The 51-LTR is regulated by cellular signaling
pathways, such as the T-cell receptor (TCR)-mediated one, in addition to the viral regulatory/accessory
proteins. TCR stimulation in combination with Tax strongly enhances HTLV-1 gene expression [27].
On the other hand, there are several negative regulatory systems acting on the 51-LTR during
transcription, translation, and even post-translation phases. HTLV-1 p30 has the potential to inhibit
the interaction between Tax and p300, resulting in suppression of the 51-LTR [28,29]. p30 additionally
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enhances the retention of mRNA in the nucleus and suppresses viral antigen expression [30]. HTLV-1
p13 is also known to exert an inhibitory effect on the physical interaction between Tax and p300 [15].
Furthermore, HBZ competes with Tax for cAMP response element binding (CREB) protein and p300
binding, so HBZ suppresses the 51-LTR [19,31,32]. The minus strand of the 31-LTR is the promoter of
the spliced form of HBZ [33,34] and is controlled by Sp-1 and Jun-D [22,35]. The unspliced form of
HBZ is transcribed from the promoter located within the pX region [22].
In summary, there is convergent transcription, in the sense- and antisense-orientations, and
various viral transcripts with alternative splicing within HTLV-1 provirus. Growing evidence so
far indicates that HTLV-1 maintains an equilibrium between viral antigen expression and the host
immune surveillance by controlling both sense and antisense transcription, viral regulatory and
accessory proteins’ expression, and host cellular mechanisms, such as cellular-signaling pathways and
cell cycling.
4. In Vitro and in Vivo Proviral Transcription Show Different Patterns
4.1. HTLV-1-Associated Cell Lines and adult T-cell Leukemia (ATL)-Derived Cell Lines
It has been reported that there is clearly a distinct level of proviral expression in vitro and in vivo.
Even among cell lines infected with HTLV-1, there is a wide variation in transcription level. The
distinct viral gene expression should be the consequence of different cellular transformation processes
occurring during in vitro culture or in infected individuals. In vitro T-cell immortalization by HTLV-1
is induced by a high expression level of Tax protein. As shown in previous studies, high level of
tax expression is sufficient to induce immortalization of T cells [36–38]. Because there is no immune
surveillance in in vitro cell culture, viral antigen expression does not confer survival disadvantage
on infected cells. In contrast, adult T-cell leukemia (ATL) cell lines derived from ATL patients are
generated after a long latent period in vivo in the presence of anti-virus immune surveillance [3,39].
In the leukemogenesis of ATL in vivo, the process of transformation depends not only on HTLV-1
infection but also on several other factors, such as escape from the host immune surveillance [40,41], as
well as genetic and epigenetic abnormalities of the host genome [42–50]. As a consequence of immune
pressure, ATL cell lines generally have very low or no Tax expression [39,41].
4.2. Fresh Peripheral Blood Mononuclear Cells (PBMC) from Infected Individuals
Transcripts with sense orientation from the 51-LTR are generally barely detectable, if not at all,
in PBMCs freshly isolated from infected individuals [41,51]. In contrast, antisense transcripts from
the 31-LTR are constitutively detectable in fresh PBMCs [34,52]. Most viral antigens are encoded in
the sense transcripts from the 51-LTR, so infected cells with high expression of viral antigens would
be eliminated by the host immune surveillance. This is quite consistent with the idea that selective
pressure by the host immune system is evident in naturally infected individuals. There are several
mechanisms related to suppression of the 51-LTR, including deletion of the 51-LTR and mutations in
tax gene, a strong transactivator of the 51-LTR [40,41]. In addition, epigenetic mechanisms acting on
the 51-LTR also contribute to the silencing effect, a point which we will discuss about in detail below.
Antisense transcripts are known to encode the viral antigen HBZ [19]. A possible explanation why HBZ
can be expressed in vivo is its low immunogenicity. A previous report demonstrated that the amino
acid sequence of HBZ possesses substantially low immunogenicity [53]. Another important piece of
evidence about proviral expression is that ex vivo culture induces expression of viral proteins [54–56].
Although we do not know the exact mechanism for the in vivo silencing, it is generally accepted that
HTLV-1 expression is silenced but the virus keeps its capacity to re-start production of viral particles.
Recent interesting studies have shown the kinetics of the sense and antisense proviral transcription
during ex vivo culture, suggesting the existence of a time-dependent regulatory mechanism of HTLV-1
provirus, which should be important at the initial phase of infection [57–59].
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4.3. RNA-seq of Fresh ATL Cells
Recently Kataoka et al. published the results of a comprehensive and genome-wide sequencing
analysis of fresh ATL cells from several hundreds of ATL cases in Japan [47]. The RNA-seq analysis
detected not only transcription from the human genome, but also from HTLV-1 provirus integrated
into the host genome of ATL cells. In line with previous reports, sense transcripts from the 51-LTR
were frequently suppressed, whereas antisense transcripts were detectable in all the ATL cases
they analyzed [34,52]. Minus strand transcripts encode HBZ protein and the transcript itself has
a function [19,34,60]. Accumulating evidence has suggested that HBZ plays an important role in
persistent infection and pathogenesis of HTLV-1 [61,62]. Interestingly, some antisense transcripts
do not terminate at the polyadenylation site of HBZ, but there are read-through transcripts into the
flanking host genomic regions [34,47,63]. Although we do not know the function of such read-through
transcripts, the pattern of transcript and role of proviral transcription should be far more complicated
than that of our current understanding.
5. Epigenetic Regulation of HTLV-1 Provirus
HTLV-1 provirus is integrated into the cellular DNA, chromatinized, and affected by genomic
and epigenomic circumstances nearby the integration site [64–67]. An important characteristic of
epigenetic regulation is that the epigenetic state is generally not static but variable depending on
intra-cellular and/or extra-cellular conditions. For example, histone modifications are dynamically
laid down and removed by chromatin-modifying enzymes [68,69]. As we discussed above, HTLV-1
has to be transcriptionally repressed but, at the same time, maintaining an ability to reactivate the
proviral expression to achieve continuous infection within human beings. HTLV-1 should utilize
a reversible epigenetic mechanism of the host cell to achieve a transiently suppressed condition of
HTLV-1 provirus.
5.1. DNA Methylation of HTLV-1 Provirus
DNA methylation is a key mechanism to control gene expression of the host cells. Based on
sequence analyses, HTLV-1 LTRs contain CpG islands, which are defined based on their high percentage
of GC content (a GC percentage greater than 50%) and the length of the region (more than 200 bp) [70].
CpG islands are frequently present in gene promoter regions of the host cells and play a role in
nucleosomal positioning and transcriptional regulation. DNA hypermethylation of CpG islands in
promoter regions is associated with gene silencing. In the case of HTLV-1, DNA hypermethylation is
what controls the activity of the 51-LTR both in latently infected cell lines and ATL cells [54,71,72]. In
contrast, the 31-LTR is rarely methylated, suggesting that selective DNA methylation occurs in HTLV-1
provirus [41,71,73]. Since the sequence of the 51- and the 31-LTRs is identical, there should be some
mechanism that induces selective DNA methylation of the 51-LTR (or selective hypomethylation of
31-LTR). That is a key question that remains to be answered about HTLV-1 infection.
5.2. Histone Modifications in HTLV-1 Provirus
The nucleosome is the fundamental unit of chromatin, and it is composed of an octamer of the
four core histones (H3, H4, H2A, and H2B). Around 147 bp of DNA wrap around each histone octamer.
The histone tails are modified by acetylation, methylation, phosphorylation, and ubiquitylation [68].
These modifications function as platforms for the recruitment of specific effector proteins, such as
transcriptional factors, chromatin remodelers and the general transcription apparatus, including
RNA Polymerase II (RNA Pol II) [74]. Thus, histone modifications are a critical determinant for
gene transcription [69]. The viral protein Tax, together with the phosphorylated CREB, recruits
both CBP and p300 to the 51-LTR [75], resulting in histone acetylation and eviction of nucleosomes,
thus contributing to a strong sense transcription from the 51-LTR [76,77]. Tax also interacts with
the chromatin remodeling complex, changes nucleosome positioning, and induces transcriptional
112
Viruses 2016, 8, 171
activation from the 51-LTR [78,79]. These findings are thought to be molecular mechanisms inducing
strong sense-transcription in in vitro cell cultures, where there is abundant Tax expression. The
Tax-mediated strong transcription from the 51-LTR is the case in vitro but not in vivo, as discussed above.
In order to characterize the pattern of histone modifications in vivo, we have to analyze fresh
ATL cells without doing any ex vivo culture. There are some reports on histone acetylation and
methylation of ATL cells. The previous data suggested that histone acetylation is detectable both in
51- and 31-LTRs [80,81]. We recently demonstrated that H3K9ac is high in the 31-LTR but very low in
the 51-LTR in the ATL-derived cell line ED [39,67]. Another histone modification, H3K4me3, a mark
of active promoter regions, also shows a similar distribution pattern as H3K9ac. In a proportion of
fresh ATL cells and ATL cell lines, H3K9ac and H3K4me3 are detectable at the 51-LTR, although the
distribution is limited only to the 51-LTR. On the other hand, the active histone marks around the
31LTR are not limited to the LTR region, but extend to the pX region, suggesting different histone
modifications between 51- and 31-LTRs [67].
In general, there are two categories of promoters, active and poised promoters [82]. Active
promoters exhibit active histone marks both on the promoter region and downstream of the
transcriptional start site, suggesting the movement of RNA Pol II starts at the promoter and moves into
the gene body [74]. In contrast, poised promoters show limited distribution of H3K9ac and H3K4me3
at promoter regions. Taken together these data suggest that RNA Pol II might be present at both 51-
and 31-LTRs. But, while the 51-LTR is a poised promoter, the 31-LTR functions as an active one. This is
consistent with the pattern of transcription where the 31-LTR is constitutively active but the 51-LTR
is generally suppressed. Also, poised RNA Pol II is ready to start transcription. The possibility of a
poised RNA Pol II at the 51-LTR would also explain why fresh PBMCs, isolated from HTLV-1-infected
individuals, start to express Tax after a very short time in ex vivo culture.
Most studies on histone modifications of HTLV-1 have, so far, been limited to the promoter
regions, 51- and 31-LTRs. However transcription is a biological event with multiple steps, including
transcriptional initiation, elongation, and termination [83]. To understand the whole picture of
transcriptional regulation, we need to analyze all processes of the transcription. Recent technological
advances, such as chromatin immunoprecipitation sequencing (ChIP-seq) analysis will be able to
provide more evidence on the epigenetic regulation of HTLV-1.
5.3. Insulator Region within HTLV-1 Provirus
As mentioned above, there is a significant difference in the transcriptional activity and the
epigenetic characteristics of the 51 and the 31 regions of HTLV-1 provirus. Since the size of the provirus
is just about 9000 bp, there should be a positive regulatory mechanism to maintain such distinct
transcriptional activity within the provirus [67]. We have recently reported that the insulator-binding
protein CTCF (CCCTC-binding factor) directly binds to HTLV-1 provirus. Insulator regions are
functional genomic regions that delimit an epigenetic border between transcriptionally active and
inactive regions [84]. CTCF is also the most characterized insulator-binding protein, which is well
conserved from flies to humans, and plays a fundamental role in the higher order chromatin structure
of the genome [85,86]. Histone modifications, such as H3K4me3, H3K36me3, and H3K9ac, are
significantly changed at the insulator region of HTLV-1. These data suggest that HTLV-1 utilizes this
host insulator-binding molecule to maintain the appropriate pattern of proviral transcription to achieve
persistent infection in infected individuals (Figure 2).
Another function of CTCF is chromatin loop formation by homodimerization [87]. CTCF,
in concert with Cohesin, regulates the proximity of promoters and enhancers, and controls the
transcriptional activity of genes [88–90]. This suggests the possibility that HTLV-1 provirus can
form chromatin looping with distant host genomic sites through its CTCF-binding site. Therefore,
CTCF-mediated chromatin looping with the host genome is another possible mechanism to regulate
proviral expression. It is very interesting that some gamma herpes viruses, such as Epstein-Barr virus
(EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), also use CTCF to switch the pattern of
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viral gene expression [91,92]. As is the case with HTLV-1, EBV is known as a virus with different
in vitro and in vivo pattern of viral gene transcription [93]. A previous report demonstrated that CTCF
plays a role in determining promoter usage at different latency states in EBV infection [92]. EBV is
generally not integrated into the host genome, but HTLV-1 is integrated as a step of the viral life cycle of
retroviruses. Thus integration of HTLV-1 generates ectopic CTCF-binding sites in the human genome.
This could induce aberrant chromatin structure and gene transcription of the host genome [67,94].
Figure 2. Schematic figure of mechanisms regulating HTLV-1 provirus, in vitro and in vivo.
(A) Schematic figure of HTLV-1 provirus in vitro or during the initial phase of infection in vivo. Tax
and viral structural proteins can be expressed, because there is little immune surveillance against the
viral antigens. (B) Schematic figure of HTLV-1 provirus during the chronic phase of infection in vivo.
HTLV-1 maintains a distinct transcription pattern between 51 long terminal repeat (LTR) and 31-LTR
by recruiting the host insulator protein CTCF. The insulator region of HTLV-1 provirus is thought to
prevent the spread of heterochromatin from 51-LTR to 31-LTR. This could also induce chromatin looping
with the host’s CTCF-binding sites.
6. Integration Site and Its Role in Proviral Transcription
In principle, each infected clone has a different integration site (IS). IS data has been used to
identify clonality of HTLV-1-infected cells. According to technological advances in DNA detection
and sequencing, current analysis of clonality of infected cells is becoming far more accurate and
quantitative than before [64,95–99]. Application of modified PCR and DNA sequencing enables us
to determine the exact position of the viral integration site within the host genome. Novel DNA
sequencing technologies have also enabled the characterization of the nature of HTLV-1 integration
landscape with high resolution [66]. Now, we can characterize the distribution of integration sites and
quantify the degree of clonal expansion of each individual infected cell with extremely high resolution
by using next-generation sequencing technology. We know there are approximately ten of thousands
of infected clones in a typical infected individual [66].
The distribution of HTLV-1 integration sites in the infected individuals is determined by two key
factors, i.e., initial integration-targeting and preferential survival of infected clones in vivo. There is clear
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difference in HTLV-1 IS between in vitro-infected samples and in vivo-infected clinical samples [64].
This idea is consistent with a recent report on the clonality analysis of cells infected with BLV, another
member of the delta type retroviruses. The study showed significant depletion of BLV proviral clones
located in transcriptionally active genomic sites during primary infection [100]. The data suggests
that transcriptionally active regions are preferentially targeted by BLV integration, but the provirus
integrated in transcriptionally active regions tends to express a viral antigen, which should result in
removal by the host immune surveillance. During persistent infection in vivo, the infected clone that
has an advantage in escaping from the host immune surveillance would be able to live for a long
time. Although there is no clear hot spot of IS associated with development of ATL, there are some
tendencies as listed below [64,65].
(i) HTLV-1 tends to be integrated into open chromatin.
(ii) Infected clones with ISs within a gene and with the same orientation as the host gene tend to expand.
(iii) Presence of a transcription factor- or histone modifier-binding site, such as Brg1 and STAT-1, near
the IS can affect the frequency of spontaneous Tax expression in ex vivo culture.
The data has also demonstrated that spontaneous Tax expression in ex vivo culture is inversely
correlated with clonal abundance of infected clones, suggesting that Tax expression is not necessarily
related with clonal expansion of infected cells in vivo [65]. Taken together, all these findings have
demonstrated that the IS plays a role in proviral gene transcription.
7. Deletions and Mutations in HTLV-1 Proviral Genome
Compared with HIV-1 provirus, the HTLV-1 genome is highly conserved, which is evidence for
the idea that HTLV-1 maintains its viral copy number via clonal expansion of infected cells rather
than de novo infection with viral particles, in which error-prone reverse transcriptase generates genetic
mutations in the viral genome [101]. Even so, evidence on deletions of HTLV-1 proviral genome has
been provided [102–105] by several reports on defective HTLV-1 proviruses. There are two types, type
1 and type 2, of defective proviruses. Type 1 defective proviruses lack genomic segments within the
provirus, whereas the type 2 lack the 51-LTR [104]. Both types of defective proviruses should have less
capacity to produce viral antigens than the complete ones, so the presence of the defective provirus
is thought to be a consequence of selection by the host immune surveillance. Genetic mutations of
the viral genome encoding viral genes were also reported previously. Furukawa et al. showed the
presence of point mutations with a premature stop codon in tax gene in ATL patients [40]. Fan et al.
performed a comprehensive analysis and found that there are mutations in various viral genes but
not in the HBZ gene [106]. Such deletions and mutations of the provirus should significantly affect
expression of viral genes.
8. Closing Remarks
Recent HTLV-1 research has made substantial progress in proviral regulation, but there are several
issues that remain to be addressed. For example, the evidence we have so far is the result of analyzing
a population of infected cells or ATL cells, so we cannot exclude the possibility that a part of the
infected cells sporadically expresses plus-strand transcripts like Tax at the single-cell level. Also, it
is still unclear how much the maintenance of ATL cells depends on HTLV-1 provirus. It is obvious
that genetic and epigenetic alterations associated with oncogenesis in the host genome play a central
role in the leukemogenesis of ATL [42–50]. Given that the incidence of T-cell malignancy in peripheral
CD4 T cell is quite low in the absence of HTLV-1 infection, HTLV-1 does play a role in ATL generation
in HTLV-1 infection. Intermittent expression of Tax possibly accelerates genomic and epigenomic
abnormalities in the host cellular genome [25,107]. Continuous antisense transcription from the
31-LTR supports the proliferation of ATL cells [34,52], which gives the host cells more of a chance
to accumulate genomic and epigenomic alterations [3,13,61]. A wide variability of leukemogenesis
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among individual ATL cases is likely to exist. Further investigations are required to elucidate the role
of proviral transcription in HTLV-1 pathogenesis.
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Abstract: Human T-cell leukemia virus (HTLV)-1 is a human retrovirus and the etiological agent
of adult T-cell leukemia/lymphoma (ATLL), a fatal malignancy of CD4/CD25+ T lymphocytes.
In recent years, cellular as well as virus-encoded microRNA (miRNA) have been shown to deregulate
signaling pathways to favor virus life cycle. HTLV-1 does not encode miRNA, but several studies
have demonstrated that cellular miRNA expression is affected in infected cells. Distinct mechanisms
such as transcriptional, epigenetic or interference with miRNA processing machinery have been
involved. This article reviews the current knowledge of the role of cellular microRNAs in virus
infection, replication, immune escape and pathogenesis of HTLV-1.
Keywords: human; HTLV-I infections; T-lymphotrophic virus 1; leukemia-lymphoma; adult T-cell;
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1. Introduction
The transmission of the human T-cell leukemia virus (HTLV-1) retrovirus requires close contact
with infected T cells, and occurs from mother to child, predominantly through breastfeeding
as well as through sexual contact and blood transfusion [1,2]. The HTLV-1 infection is also
associated with other diseases, such as: a chronic and progressive neurologic disorder named
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), polymyositis, infective
dermatitis, HTLV-1-associated arthropathy, and HTLV-1-associated uveitis [2,3]. According to the
Shimoyama classification, adult T-cell leukemia/lymphoma (ATLL) can be distinguished into four
subtypes: smoldering, chronic and acute leukemic forms and ATLL lymphoma [4]. The overall survival
of ATLL with different regimens of chemotherapy is poor, ranging between 5.5 and 13 months in
patients presenting acute leukemia or lymphoma [5]. HTLV-1 mediates T lymphocyte transformation
using a multistep process in which the virus promotes genomic instability, accumulation of genetic
defects, and chronic proliferation of infected cells [6]. The genome of HTLV-1 encodes common
retrovirus structural and enzymatic proteins, Gag, Pro, Pol, and Env, and additional accessory and
regulatory proteins such as Tax, Rex, P30, p12, p13, and HTLV-1 basic leucine zipper factor protein
(HBZ). Tax and HBZ regulatory proteins have been reported to play a central role in regulation of viral
and cellular genes that lead to proliferation of infected cells [7]. Tax is a transcriptional trans-activator
that promotes the expression of genes linked to the 5′ long terminal repeat promoter (LTR) element
of the HTLV-1 genome [8]. Tax induces genomic instability [9] and promotes cell-cycle progression,
survival and growth of HTLV-1-positive T cells [10]. HBZ is involved in the proliferation of infected
cells in vitro and in vivo and plays an essential role in oncogenesis mediated by HTLV-1 in late stages
of the disease when Tax is not expressed [11]. Consistently, HBZ was found to be expressed in
ATLL cells through the whole period of ATLL development, suggesting that it might be involved
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in maintenance of HTLV-1-transformed cells [12]. Rex is a post-transcriptional regulator of viral
expression, which activates viral replication in the early phase of HTLV-1 infection by promoting the
nuclear export of HTLV-1 mRNA [13]. Several studies have shown altered expression of microRNAs
(miRNAs) in HTLV-1/ATLL cell lines and primary peripheral blood mononuclear cells (PBMCs) from
ATLL patients, suggesting that miRNA deregulation is involved in HTLV-1 infection and adult T-cell
leukemia/lymphoma pathogenesis. MicroRNAs play an essential role in a wide range of biological
processes, including development, differentiation, cell cycle, apoptosis and oncogenesis [14–16].
2. MiRNA Biogenesis
MicroRNAs (miRNAs) are small, non-coding RNA molecules that transcriptionally regulate
gene expression. The first miRNA identified in animals is Lin-4, discovered in 1993 by Ambros
and colleagues. Lin-4 was identified as heterochronic genes in Caenorhabditis elegans involved in
cell fate [17,18]. Subsequent studies have shown the involvement of miRNAs in different biological
processes, including tumorigenesis by targeting oncogenes or tumor suppressor genes [16]. MiRNA
sequences are localized in different genomic contexts. Some miRNAs are encoded by exon; however,
the majority are encoded by the intronic region of non-coding and coding transcripts [19]. MiRNAs
are transcribed by the RNA polymerase II or III into the nucleus as primary miRNAs (pri-miRNAs).
Pri-miRNAs are normally over 1 kilobase and contain a local steam-loop structure in which mature
miRNA sequences are included. The nuclear RNase III Drosha recognized and processed pri-miRNAs
into a hairpin-shaped RNA of nearly 65 nucleotides in length, named precursor miRNAs (pre-miRNAs).
After transport to the cytoplasm by the RanGTP-dependent dsRNA-binding protein Exportin 5,
pre-miRNAs are processed by the cytoplasmic RNase III Dicer, liberating a mature 20–24 nucleotide
long duplex. Argonaute family proteins, AGO, and Trans-Activation Responsive RNA-Binding
Protein (TARBP2), together with the duplex form a complex named RNA-Induced Silencing Complex
(RISC) [19,20]. One strand of the duplex, called guide strand, is incorporated into the RISC complex
while the other strand, named passenger strand, is targeted for degradation [21]. Apart from the
canonical miRNA biogenesis described above, different alternative mechanisms, which bypass Drosha
processing, were described [22]. MiRNAs can be generated through non-canonical pathways, wherein
the precursor miRNAs are cleavaged by Dicer. Mirtrons represent an example of miRNA processed by
a non-canonical pathway. They are generated from intron lariats serving as pri-miRNAs, which
is processed by Spliceosome that function as Drosha, to release pre-miRNAs [22,23]. MiRNAs
bind complementary sequences usually localized at 3′UTR of messenger RNA and guide RISC to
target mRNA. MiRNAs used different mechanisms to regulate post-transcriptional gene expression:
inhibition of translation and/or messenger RNA degradation. The repression of many miRNA targets
is frequently associated with their destabilization. Degradation of target mRNA is characterized by
gradual shortening of the mRNA poly-Adenine tail, which is catalyzed by the exosome or exonuclease
XRN1. MiRNAs might also induce gene silencing by interfering with protein translation [24]. Several
pieces of evidence show that miRNA silencing is observed with either no change in the mRNA level
or with a significantly smaller decrease of mRNA compared to the protein level [25,26]. Deregulated
MiRNAs in HTLV-1 context will be discussing in the next section of the review.
3. MiRNA Profile in HTLV-1-Transformed Cell Lines and ATLL Patients
Four studies have characterized miRNA expression profiles in HTLV-1/ATLL cell lines and ATLL
patients. Pichler [27] and colleagues chose the phenotype of regulatory T cells (Treg) as a starting point
to study miRNA expression in HTLV-1-transformed cells. The authors have selected and analyzed
the expression of a set of miRNAs characteristic of murine Treg and downregulated in different
tumors. The analysis identified five deregulated miRNAs: miR-21, miR-24, miR-146a, and miR-155
were found upregulated, whereas miR-223 was downregulated. Bellon [28] and colleagues analyzed
miRNA profiles from ATLL patients compared to HTLV-1-negative donors by using microarray. The
results were confirmed by Real Time (RT)-PCR of mature miRNAs in uncultured ATLL cells and
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HTLV-1-transformed cell lines. Microarray analysis and RT-PCR demonstrated downregulation of
miR-181a, miR-132 and miR-125a and upregulation of miR-155 and miR-142-3p. This study identifies
two miRNAs differently expressed in vitro and in vivo. MiR-150 and miR-223 were both upregulated
in uncultured ATLL cells and downregulated in HTLV-1-transformed cell lines. Yeung [29] and
colleagues examined miRNA profiles in several ATLL-derived cell lines and primary peripheral blood
mononuclear cells (PBMCs) from acute ATLL patients using miRNA microarray. Several HTLV-1/ATLL
cell lines and four ATLL patients were studied. Thirteen miRNAs were found to be upregulated and
thirty downregulated among the different cell lines. In parallel, 22 upregulated and 22 downregulated
miRNAs were identified in acute ATLL patients. Among those, miR-9, miR-17-3p, miR-20b, miR-93,
miR-130b and miR-18a were found to be induced; in contrast, miR-1, miR-144, miR-126, miR-130a,
miR-199a, miR-338, miR-432, miR-335 and miR-337 were found to be downregulated. Yamagishi and
colleagues [30] studied the miRNA expression signature in primary ATL cells by using microarray
analysis compared to CD4+ T cells from healthy donors. The results show that 59 of the miRNAs
tested were found with a decrease in ATL primary cells. Among them, miR-31 was the one most
profoundly repressed.
4. HTLV-1 Interferes with Cellular miRNA Machinery
The dysregulation of miRNA pathways has been reported across several viruses, including HIV,
Ebola, Epstein–Barr, Influenza, HBV, HCV, Adenovirus, and HTLV-1 [31–38]. Drosha was reported
to be downregulated in HTLV-1-infected cell lines, HTLV-1-transfected cells, and infected primary
cells [38]. Van Duyne [38] and colleagues proposed that HTLV-1 deregulates the cellular RNAi pathway,
including miRNAs, by suppressing the function and degrading Drosha (Figure 1).
The authors have demonstrated a direct interaction between the Tax oncoprotein and Drosha,
which is responsible for its downregulation. The N-terminal region of Tax presents two putative motifs,
the Zinc finger motif and leucine-zipper-like region, which interact with Drosha. The Tax N-terminal
region is reported to interact with the proteasome complex. Van Duyne and colleagues demonstrated
that the binding between Tax and Drosha leads to its degradation mediated by proteasome complex.
In addition, Drosha increases HTLV-1 replication and is not efficient in processing miRNAs when Tax
is expressed, suggesting that the dysregulation of miRNA machinery might be involved in the rate of
HTLV-1 infection [38]. The HTLV-1 regulatory protein, Rex, is reported to directly interact with Dicer.
Abe [39] and colleagues have demonstrated that Rex suppresses the ribonuclease-directed processing
activity of Dicer, protecting against the cleavage Rex-mRNA (Figure 1). Inhibition of Dicer activation
might represent an additional mechanism used by HTLV-1 to deregulate cellular miRNA expression.
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Figure 1. Human T-cell leukemia virus HTLV-1 interferes with cellular miRNA machinery. MiRNAs
are transcribed by the RNA polymerase II or III into the nucleus as primary miRNAs (pri-miRNAs)
from coding or non-coding part of genes. The nuclear RNase III Drosha recognized and processed
pri-miRNAs into a hairpin-shaped RNA, named precursor miRNAs. Pre-miRNAs are transported to
the cytoplasm by Exportin 5, and processed by the cytoplasmic RNase III Dicer in the mature miRNA
duplex. The duplex forms a complex named RNA-Induced Silencing Complex (RISC). MiRNAs bind
complementary sequences usually localized at 3′UTR of messenger RNA and this binding results in the
inhibition of translation and/or messenger RNA degradation. HTLV-1 deregulates the cellular miRNA
pathway by suppressing the function of Drosha and Dicer. Tax directly interacts with Drosha and the
binding leads to Drosha degradation mediated by proteasome complex. The regulatory protein, Rex, is
reported to directly interact with Dicer. Rex suppresses the ribonuclease-directed processing activity of
Dicer, protecting against the cleavage Rex-mRNA.
5. MiRNAs Target the HTLV-1 Genome
The cellular environment has an essential role in virus infection and replication. Many cellular
genes prevent replication and virus dissemination by acting as innate immunity factors. However,
viruses have evolved strategies to avoid activation of an antiviral state: virus-derived miRNAs can
enhance viral gene expression, replication, and infectivity [40] or suppress the IFN response [41]. The
genome of the Epstein–Barr virus (EBV), Kaposi sarcoma-associated herpesvirus (KSHV), human
cytomegalovirus (hCMV) and bovine leukemia virus (BLV) encodes for virus-derived miRNAs [42–45].
BLV shares many characteristics in disease pathogenesis with HTLV-1 and is associated with the
development of B-cell tumors. Kincaid and colleagues [45] show that BLV is capable of producing
miRNAs in vitro. A subsequent study demonstrated that BLV encodes a conserved cluster of miRNAs
located in a specific BLV proviral region, which is essential for in vivo infectivity [46]. BLV has different
common features in genomic organization with HTLV-1, however HTLV-1-encoded miRNAs have not
been reported. Cellular miRNAs can promote virus replication or negatively regulate virus expression
and infectivity [47]. MiR-28, miR-125b, together with miR-150, miR-223 and miR-382 target 3′ ends
of HIV-1 messenger, promoting viral latency [47]. Bai and colleagues identified a binding site in the
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HTLV-1 genome for miR-28-3p and demonstrated a mechanism used by a cellular miRNA to prevent
HTLV-1 gene expression and viral transmission (Figure 2) [48].
MiR-28-3p was found to target a sequence localized within the viral gag/pol HTLV-1 mRNA
and reduced viral replication and gene expression. MiR-28-3p-expressing cells are characterized by
reduced levels of HTLV-1 gag p19 and p24 products and they are resistant to infection. MiR-28-3p
expression leads to abortive infection by inhibiting HTLV-1 reverse transcription and preventing the
formation of the pre-integration complex. MiR-28-3p suppresses HTLV-1 expression and infection;
this is consistent with the high levels of miR-28-3p reported in resting T cells and their inability to be
infected by HTLV-1 without prior activation. Bai and colleagues [48] demonstrated a natural feedback
loop that regulated miR-28-3p expression in response to virus infection. It is well established that
de novo infection in T cells activates the interferon anti-viral response. MiR-28-3p expression was found
to be induced after IFN-α or - γ stimulation, suggesting that miR-28-3p might contribute to restricting
virus expansion to neighboring cells by reducing local inflammation and the initial establishment of
latent infection. The miR-28-3p site is highly conserved in HTLV-1 subtypes B and C, at nearly 90%.
However, the subtype 1A, Japanese ATK-1, presents a natural polymorphism (T to C substitution)
within the miR-28-3p target site. The mutation is silent and more resistant to miR-28-3p inhibition
of viral replication. Bai and colleagues [48] proposed a model where the modulation of miR-28-3p
expression affected HTLV-1 virus spreading. Virus particles can transiently activate resting T cells by
reducing miR-28-3p expression and favoring infection. Because IFN response is a potent inducer of
miR-28-3p expression, the initial antiviral response might backfire, helping to protect newly infected
cells from being eliminated by the immune system.
Figure 2. MiR-28-3p targets the HTLV-1 genome. The figure illustrates a natural feedback loop that
regulated cellular miRNA expression in response to virus infection. MiR-28-3p suppresses HTLV-1
expression by targeting a sequence localized within the viral gag/pol HTLV-1 sequence. MiR-28-3p
expression leads to abortive infection by inhibiting HTLV-1 reverse transcription and preventing the
formation of the pre-integration complex.
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6. MiRNAs Promote Cell Proliferation
6.1. MiR-146a
MiR-146a has a central role in the regulation of immune response and its expression is induced by
NF-κB signaling. MiR-146a is deregulated in different cancers. A high level of expression was reported
in papillary thyroid carcinoma, anaplastic thyroid cancer, breast cancer, glioblastoma and cervical
cancer [49–53]. In contrast, low-expressing levels were described in pancreatic carcinoma, gastric
cancer, prostate cancer, acute myeloid leukemia (AML), myeloblastic syndrome and chronic myeloid
leukemia (CML) [54–59]. MiR-146a was found to be upregulated in HTLV-1-transformed cell lines [27].
Ectopic expression of Tax in HTLV-1-negative T cells, Jurkat, induced miR-146a expression. Promotor
analysis showed a 15-fold activation of miR-146a by Tax [60], suggesting that HTLV-1 infection might
be involved in the regulation of miR-146a expression. Pichler [27] and colleagues used a mutated form
of Tax and dominant active NF-κB inhibitor to show that miR-146a transactivation is mediated by
NF-κB (Figure 3).
Figure 3. MiRNAs promote cell proliferation. MiR-155 and miR-146a were found elevated in
HTLV-1-infected cells in vitro. Tax induces the transcription factors NF-κB and AP-1, which promote
miR-155 expression by binding the miRNA promoter. This binding resulted in an increased
expression of the B-cell integration cluster (BIC) gene whose transcript is processed into miR-155.
The interferon regulatory factor-4, IRF4, which is induced in HTLV-1-infected cells, promotes
BIC/miR-155 expression. NF-κB also mediates miR-146a transactivation; both miRNAs enhance
cellular growth in HTLV-1-infected cells. MiR-150 and miR-223 are differentially regulated in ATLL
samples and in HTLV-1-transformed cells. MiR-150 and miR-223 were found upregulated in acute
ATLL patients and downregulated in HTLV-1-transformed cell lines. MiR-150 and miR-223 target
the STAT1 3′UTR. Inhibition of STAT1 expression, through miR-150, miR-223 reduced proliferation
of HTLV-1-transformed and ATLL-derived cell lines. MiR-150 and miR-223, by decreasing STAT1
expression and dampening STAT1-dependent signaling in human T cells, regulated proliferation in an
HTLV-1 context.
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Tomita et al. [60] also reported an NF-κB binding site on the miR-146a gene. In addition, it has been
described as having a suppressive effect of miR-146a on NF-κB signaling [51]. This might represent
a negative feedback loop, which seems to be ineffective in HTLV-1-infected cells. MiR-146a has also
been shown to induce proliferation in several human cancers, including cervical cancer [53], breast
cancer cells [61], gastric cancer cells [62] and mesenchymal stem cells (MSCs) [63]. Consistent with this
report, treatment with an anti-miR-146a inhibitor suppressed the proliferation of HTLV-1-transformed
cell lines but not uninfected T-cell lines. In addition, overexpression of miR-146a increased the growth
of HTLV-1-transformed cell lines [27]. Because overexpression of miR-146a has also been described in
an EBV context, Tomita [60] and colleagues suggested that miR-146a up-regulation might represent a
common mechanism in the pathogenesis of persistent viruses. Wang et al. [64] identified 622 putative
target genes of miR-146a that are predicted by using different prediction programs. Gene ontology
analysis shows that these genes are involved in the inhibition of cell growth and promotion of apoptosis,
and this partially explains the role of miR-146a in the proliferation of HTLV-1-transformed cells.
6.2. MiR-155
MiR-155 has been implicated in normal hematopoiesis [65], immune response [66], and in the
carcinogenesis of different human tumors [67,68]. Mouse studies have reported that transgenic
overexpression of miR-155 results in the increased frequency of tumor formation [69]. Overexpression
of miR-155 was found in breast cancer [70], pancreatic cancer [71], lung cancer [72], B-cell
lymphoma [67], MALT lymphoma [73] and acute myeloid leukemia (AML) [74]. MiR-155 was found
elevated in HTLV-1-infected cells in vitro and in vivo [28,75], suggesting that this miRNA might play an
important role in the biology and pathogenesis of HTLV-1. Babar [76] and colleagues used an inducible
knock-in mouse model to show that miR-155 induction in the lymphoid tissue led to disseminated
lymphoma. In contrast, reduction of miR-155 resulted in the decrease of tumor size. In humans,
Calin [77] and colleagues identified a miRNA signature associated with progression and prognosis
in chronic lymphocytic leukemia (CLL) and showed an association between miR-155 upregulation
and poor prognosis. Several lymphoma-associated viruses, including the Epstein-Barr virus, Kaposi
sarcoma-associated herpesvirus and Marek’s disease virus, are characterized by overexpression of
miR-155 [73,78], suggesting that HTLV-1 infection might be responsible for the induction of miR-155 in
infected T cells. MiR-155 upregulation has been reported in HTLV-1 cell lines and ATLL patients [28,75].
Tomita [75] and colleagues demonstrated that transcription factors NF-κB and AP-1 induced miR-155
expression by binding the miRNA promoter in an HTLV-1 context (Figure 3). This binding resulted
in an increased expression of the B-cell integration cluster (BIC) gene whose transcript is processed
into miR-155 (Figure 3). Tomita and colleagues demonstrated that miR-155 overexpression enhanced
the growth in HTLV-1-transformed cells. Consistently, treatment with anti-miR-155 reduced the
proliferation of these cells and had no effect on HTLV-1-negative T cells. Wang [79] and colleagues
demonstrated that interferon regulatory factor-4, IRF4, which is reported to be oncogenic [80], induces
BIC/miR-155 expression in HTLV-1-transformed cells (Figure 3). In normal lymphocytes, IRF4 is
involved in cellular proliferation and differentiation [80]. In mature human CD4+ T cells, IRF4 is
essential for cytokine production and survival [81,82]. Several studies show that IRF4 is overexpressed
in HTLV-1-transformed and primary ATLL/L cells and associated with poor prognosis [81–83],
suggesting that IRF4 might be involved in HTLV-1 pathogenesis. Wang and colleagues show that
depletion of IRF4 drastically reduced cell proliferation of HTLV-1-transformed cell lines, suggesting that
the IRF4/miR-155 pathway might play a central role in the malignant proliferation of HTLV-1-infected
cells [80]. In addition, miR-155 is reported to target Tumor Protein 53-Induced Nuclear Protein 1
(TP53INP1) in liver cancer stem cells [84], which promotes cell cycle arrest and apoptosis, suggesting a
possible mechanism that could enhance cellular proliferation in an HTLV-1 context.
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6.3. MiR-150 and MiR-223
MiR-150 and miR-223 were reported to be differentially regulated in HTLV-1-transformed cells
and in ATLL samples. MiR-150 and miR-223 were found upregulated in acute ATLL patients and
downregulated in HTLV-1-transformed cell lines, suggesting that different selective pressure in vitro
and in vivo might regulate the expression of those miRNAs. MiR-150 can have either oncogenic or
tumor suppressor activity in different human tumors. It is overexpressed in chronic lymphocytic
leukemia (CLL) [85,86] and downregulated in chronic myeloid leukemia (CML) [87,88], acute
lymphoblastic leukemia (ALL) [89] and mantle cell lymphoma (MCL) [90]. Additional studies show
that miR-150 promotes the proliferation and migration in lung cancer by targeting SRC kinase signaling
inhibitor 1 (SRCIN1) and SRC activity [91]. In contrast, miR-150 expression was reported to inhibit cell
migration and invasion in breast cancer [92,93]. C-MYB, NOTCH3, CBL, EGR2, AKT2 and DKC1 are
established targets of miR-150 [94–98]. MiR-223 was reported to be differentially regulated in human
cancers; it is downregulated in hepatocellular carcinoma, B-cell chronic lymphocytic leukemia (B-CLL),
acute myeloid leukemia (AML), gastric MALT lymphoma and recurrent ovarian cancer [99–103]. In
contrast, miR-223 is upregulated in T-cell acute lymphocytic leukemia (T-ALL), EBV-positive diffuse
large B-cell lymphoma, and metastatic gastric cancer [104–108]. FBXW7/Cdc4, RhoB, STMN1, E2F1,
STAT3, C/EBPβ, FOXO1 and NFI-A are validated targets of miR-223 [106–111]. It has previously
been shown that E2F1 represses the miR-223 promoter [110–112]. Interestingly, viral HBZ mRNA
increases the expression and transcriptional activity of E2F1. HBZ expression is consistently increased
in ATLL cells in vivo [11]. These observations can partially explain the differential regulation of miR-223
in vitro and in vivo. MiR-150 and miR-223 target the STAT1 3′UTR in an HTLV-1 context (Figure 3).
STAT1 plays an essential role in immune modulatory functions, anti-viral responses, apoptosis and
anti-proliferative responses [113]. In addition, several studies have shown that STAT1 can also act as
a potent tumor promoter for leukemia development [114] and that many T-ALL leukemic cells are
dependent upon the TYK2-STAT1-BCL2 pathway for continued survival [115]. Inverse correlation
between STAT1 expression and miR-150 and miR-223 was identified in HTLV-1-transformed and
IL-2-independent ATLL-derived cells [116]. IL-2-dependent ATLL cells display a high level of miR-150
expression, but low miR-223, suggesting that miR-150 might be regulated through the IL-2 signaling
pathway. Absence of IL-2 signaling results in miR-150 downregulation in IL-2-dependent ATLL cells.
In contrast, IL-2 stimulation in IL-2-independent ATLL-derived cells leads to miR-150 induction. This
evidence suggests that miR-150 is regulated by the IL-2 signaling pathway. It was reported that
ATLL tumor cells in vivo produce IL-2 or IL-15 and express IL-2 receptor alpha chain, CD25. These
observations partially explain the higher levels of miR-150 in ATLL patients compared with HTLV-1
cell lines. Despite the miR-150 and miR-223 overexpression in freshly isolated ATLL samples, STAT1
was found to be induced in a majority of ATLL samples, suggesting that miR-150 and miR-223 cannot
efficiently suppress STAT1 expression in ATLL patient cells. STAT1 has been reported to have tumor
promoting activities. Inhibition of STAT1 expression, through miR-150, miR-223 or directly by shRNA
targeting, reduced proliferation of HTLV-1-transformed and ATLL-derived cell lines. MiR-150 and
miR-223, by decreasing STAT1 expression and dampening STAT1-dependent signaling in human T
cells, regulated proliferation in an HTLV-1 context.
7. MiRNAs Induce Resistance to Apoptosis
7.1. MiR-31
Yamagishi [30] and colleagues identified miR-31 as one of the most profoundly repressed
miRNAs in primary ATLL cells. MiR-31 is reported as a tumor suppressor and correlates inversely
with metastasis in breast cancer [117]. MiR-31 in vivo targets several genes, such as Fzd3, ITGA5,
MMP16, RDX, RhoA, WAVE3 and integrin α5 subunit, that contribute to cell migration and metastatic
invasion [117,118]. The Polycomb protein complex has been reported to be a strong suppressor of
miR-31 in breast cancer and adult T-cell leukemia [30,117]. Polycomb group proteins are overexpressed
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in ATLL cells [119] and have an important role in cellular development and regeneration by controlling
histone methylation, especially at histone H3 Lys27 (H3K27), which induces chromatin compaction.
The Polycomb family is associated with cancer phenotypes and malignancy in breast cancer, prostate
cancer, bladder tumors, and other neoplasms [120,121]. MiR-31 negatively regulates NF-κB-inducing
kinase (NIK) expression and activity in adult T-cell leukemia and other cancers [30]. NIK has an
important role in tumor progression and the aggressive phenotypes of various cancers. It is well
established that the NIK level directly regulates NF-κB activity in various cell types [122]. Constitutive
activation of the nuclear factor NF-κB is observed in the ATLL cell lines and primary isolated tumor
cells from ATLL patients [123]. NF-κB activation contributes to cell propagation and anti-apoptotic
responses in ATLL [124]. An inverse correlation has been reported between the expression level
of miR-31 and NIK in ATLL patients. Rescue of miR-31 represses NF-κB expression and leads
to increased proliferation and apoptosis resistance. The inhibition of NF-kB promotes tumor cell
death in HTLV-1-transformed cells and primary ATLL cells. The model proposed by Yamagishi and
colleagues show that the Polycomb group regulates miR-31 expression and leads to NF-κB activation
via NIK-miR-31 regulation and apoptosis resistance in HTLV-1 context (Figure 4). The downregulation
of miR-31 might play an important role in ATLL pathogenesis.
 
Figure 4. MiRNAs induce resistance to apoptosis. MiR-31 is one of the most profoundly repressed
miRNAs in primary ATLL cells. The Polycomb protein complex is overexpressed in ATLL cells
and suppresses miR-31 expression. MiR-31 negatively regulates NF-κB-inducing kinase (NIK) and
leads to apoptosis resistance. MiR-130b and miR-93 are upregulated in HTLV-1 cell lines and ATLL
patients and both target Tumor protein p53-inducible nuclear protein (TP53INP1). TP53INP1 is a
tumor suppressor gene that has anti-proliferative and pro-apoptotic activities via both p53-dependent
and p53-independent means. TP53INP1 has in its 3′ UTR two binding sites for miR-93 and two sites
for miR-130b.
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7.2. MiR-130b and MiR-93
Microarray analyses demonstrated that miR-130b and miR-93 were consistently upregulated in
HTLV-1 cell lines and ATLL patients and both target Tumor protein p53-inducible nuclear protein,
TP53INP1 [29]. MiR-130b was found to be deregulated in several human cancers. Overexpression of
miR-130b has been reported in colorectal cancer, gastric cancer, bladder cancer, cutaneous malignant
melanoma, and head and neck squamous cell carcinoma [125–128]. In contrast, miR-130b is
downregulated in papillary thyroid carcinoma, ovarian cancer and endometrial cancer [129–132].
Identified targets of miR-130b are STAT3, PTEN and TGF-b1 [133–135]. MiR-93 belongs to the
miR-106b-25 cluster, which also includes miR-106b and miR-25 [136]. The miR-106b-25 cluster is
overexpressed in neuroblastoma, multiple myeloma, and lung, prostate and gastric tumors [136–138].
Reported targets of miR-93 are PTEN, VEGF, ITGB8, DAB2 and LATS2 [139–143]. TP53INP1 is a tumor
suppressor gene that has anti-proliferative and pro-apoptotic activities via both p53-dependent [144]
and p53-independent means [145]. TP53INP1 has in its 3′ UTR two binding sites for miR-93 and two
sites for miR-130b. Yeung [29] and colleagues have shown that transfection of antagomirs against
miR-93 and miR-130b into an HTLV-1-transformed cell line increased the expression of TP53INP1 and
decreased cellular viability by promoting apoptosis (Figure 4). These results show that TP53INP1
has anti-proliferative properties and can be regulated by miR-130b and miR-93. Transfection of
miR-93 or miR-130b in HTLV-1-negative T-cell lines reduced TP53INP1 expression and increased
cellular proliferation. It has been reported that loss of TP53INP1 correlates with the development of
cancers [146,147] and its induction promotes G1 cell cycle arrest and apoptosis [144,145,148]. This
evidence suggests that up-regulation of miR-130b and miR-93 reduces TP53INP1 levels in ATLL cells
and promotes cellular proliferation. TP53INP1 is also able to reduce cell migration in pancreatic cancer
cells [149] and this might be significant because it is well established that HTLV-1 infection promotes
T-lymphocyte migration [150].
8. MiRNAs Promote Chromatin Remodeling
The Tax protein promotes HTLV-1 gene expression by its interaction with the long terminal repeat
(LTR) or U3 region of the viral promoter [151,152]. To activate the transcription, Tax recruits the
p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF), which bind two
different regions of Tax, resulting in histone acetylation and chromatin remodeling (Figure 5) [153–158].
Rahman [157] and colleagues identified the chromatin remodeling factors, p300 and p/CAF, as a
target of miR-149 and miR-873. MiR-149 has been reported to have a role as an oncogene and
tumor suppressor in different human cancers [158,159]. Downregulation of miR-149 has been
described in prostatic cancer, astrocytomas and renal carcinoma [160–162]. In contrast, miR-873
was found to be suppressed in colorectal cancer, glioblastoma and breast cancer [163–165]. Recent
evidence has established the role of miR-873 in cell proliferation, tumor growth and tamoxifen
resistance in breast cancer [165]. MiR-149 and miR-873 were found to be profoundly downregulated
in HTLV-1-transformed cell lines, MT-2, compared to an uninfected control, Jurkat [157]. To
verify that miR-149 and miR-873 could target p/CAF and p300, the authors over-expressed these
miRNAs in HTLV-1-transformed cells and observed a significant reduction in the expression of
chromatin-remodeling enzymes. In addition, the cell culture supernatant was analyzed for viral
protein p19 before and after transfection. The results show a decrease in the levels of viral progeny
production in cells transfected with miR-149 and miR-873, suggesting that these miRNAs, by targeting
chromatin remodeling factors p/CAF and p300, might play a role in HTLV-1 infection and pathogenesis
(Figure 5).
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Figure 5. MiR-149 and miR-873 promote chromatin remodeling. The Tax protein promotes HTLV-1
gene expression by its interaction with the long terminal repeat (LTR) or U3 region of the viral
promoter. To activate the transcription, Tax recruits the p300/CREB-binding protein (p300/CBP)
and p300/CBP-associated factor (P/CAF), which bind two different regions of Tax, resulting
in histone acetylation and chromatin remodeling. MiR-149 and miR-873 are downregulated in
HTLV-1-transformed cell lines and target the chromatin remodeling factors p300 and p/CAF.
9. MiRNAs Induce Genetic Instability
MiRNA expression analysis in CD4+ lymphocytes, derived from HAM/TSP patients, has
identified a high expression level of miR-17 and miR-21 [166]. Spry 1, Spry 2, PTEN, TPM1 and Pdcd4
have been reported to be miR-21 targets, suggesting its central role in cell proliferation, apoptosis, and
invasion [167–171]. MiR-17, instead, is the main effector of the miR-17-92 cluster component, which
has been identified as a member of the miRNA signature in solid tumors [172]. MiR-17 regulates
E2F1 and c-Myc, p21, PTEN and BIM expression [173–176], suggesting its potential functions in cell
migration, invasion and proliferation. Vernin [166] and colleagues identified OBFC2A as a potential
target of miR-17 and miR-21 in an HTLV-1 context. OBFC2A encodes for hSSB2, which is involved in
the ATM signaling pathway, the activation of the cell cycle checkpoint and promotes DNA repair. The
down-regulation of OBFC2A and a positive correlation between miR-17, miR-21 and HBZ expression
has been reported in HTLV-1-infected cells [166]. Vernin and colleagues suggested that HBZ inactivates
OBFC2A via miR-17 and miR-21, promoting genetic instability and cell proliferation (Figure 6).
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Figure 6. MiRNAs induce genetic instability. MiR-17 and miR-21 are upregulated in an HTLV-1 context.
HBZ inactivates OBFC2A via miR-17 and miR-21, promoting genetic instability and cell proliferation.
OBFC2A encodes for hSSB2, which is involved in the ATM signaling pathway, the activation of the cell
cycle checkpoint and promotes DNA repair.
The authors have shown that ectopic expression of HBZ does not decrease cellular growth
in DNA-damaged cells. HBZ-expressing cells continued to proliferate when treated with a
DNA-damaging agent, neocarzinostatin. This phenotype can be reversed by ectopic expression of
OBFC2A, which leads to a decrease of proliferation rates and restores the DNA damage response. This
evidence suggested a potential role of miR-17 and miR-21 in genetic instability and cell proliferation in
HTLV-1-infected cells.
10. Conclusions and Prospective
The role of miRNAs in HTLV-1 infection and ATLL pathogenesis is beginning to emerge. Available
evidence shows a complex interplay between cellular miRNA machinery and virus infection. HTLV-1
inhibits proteins involved in biogenesis and maturation of cellular miRNAs, resulting in a perturbation
of the expression profile of host miRNAs. In this review, we focused on miRNAs, which are involved in
virus production, establishment of latency, tumor cell transformation and proliferation. A potential role
of MiRNA modulation could represent a therapeutic approach for ATLL patients. The combination
delivery of miRNAs with chemotherapy drugs might provide a promising strategy to overcome
chemo-resistance. Different studies have shown that co-delivery of miRNA and chemotherapeutic
agents are effective to inhibit tumor growth by targeting genes, which are involved in tumor cell
proliferation and/or survival [177–179]. In addition, in combination with antitumor drugs, miRNAs
might have an important role by targeting genes involved in drug resistance, thus overcoming the
chemo-resistance in ATLL patients.
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Abstract: Human T-lymphotropic virus type-1 (HTLV-1) infection is associated with adult
T-cell leukemia/lymphoma (ATL). Tropical spastic paraparesis/HTLV-1-associated myelopathy
(PET/HAM) is involved in the development of autoimmune diseases including Rheumatoid Arthritis
(RA), Systemic Lupus Erythematosus (SLE), and Sjögren’s Syndrome (SS). The development of
HTLV-1-driven autoimmunity is hypothesized to rely on molecular mimicry, because virus-like
particles can trigger an inflammatory response. However, HTLV-1 modifies the behavior of CD4+
T cells on infection and alters their cytokine production. A previous study showed that in patients
infected with HTLV-1, the activity of regulatory CD4+ T cells and their consequent expression
of inflammatory and anti-inflammatory cytokines are altered. In this review, we discuss the
mechanisms underlying changes in cytokine release leading to the loss of tolerance and development
of autoimmunity.
Keywords: Human T-lymphotropic virus type-1 (HTLV-1); immune response; autoimmunity
1. Introduction
The etiology of autoimmune diseases is unknown, but it is clear that the interaction between
genes and the environment is an important step in breaking immune tolerance to self-antigens. This
can lead to inflammation and destruction of specific tissues and organs. Although host genetic
background contributes to autoimmunity, research indicates that infectious agents are one of most
important environmental factors responsible for the development of autoimmune diseases [1–3].
Chronic inflammatory responses to infections have been associated with the initiation and exacerbation
of autoimmune diseases [1,4,5].
Human T-lymphotropic virus type-1 (HTLV-1) is associated to a number of diseases, such as
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and autoimmune diseases
such as the Sjögren’s Syndrome (SS), arthropathies, and uveitis, which are often related to changes
in the immune response [6–9]. The HTLV-1 virus infects CD4+ T lymphocytes, and can modify the
cell function. CD4+ T lymphocytes are the central acquired immune response regulators. Changes in
their behavior can trigger inflammatory reactions that can break immune system tolerance, leading
to autoimmunity. In this review, we discuss immunological changes in HTLV-1 infection and its
association with autoimmune diseases.
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2. Human T-lymphotropic Virus Type-1 (HTLV-1)
Human T-lymphotropic virus type-1 (HTLV-1) is classified as a complex type C retrovirus
belonging to the genus Deltaretrovirus, family Retroviridae, and subfamily Orthoretrovirinae [10,11].
The morphological structure of this virus is similar to other retroviruses; the capsid contains two
simple RNA strands together with the reverse transcriptase and integrase enzymes. These enzymes
are important for insertion of the virus into the host genome, resulting in a provirus [12–15].
The virus genome contains structural and functional genes, such as the gag, pro/pol, and env
that are flanked by two long terminal repeat (LTR) regions. Additionally, the pX region was
identified in the region between the env gene and the 31-LTR region. The pX region codes for the
Tax (p40), REX (p27), p12, p13, p21, and p30 regulatory proteins that are involved in viral infection
and proliferation. Tax is a phosphoprotein that exerts an essential role in viral transcription and cell
behavior transformation [16–19]. It has pleiotropic functions that occur on a very wide spectrum of
interactions with cellular proteins. Tax can modify signal transduction pathways of the host–cell that
induce the transcription factors NF-κB, cAMP response element binding (CREB), Serum response
factor (SRF) and activator protein 1 (AP-1) [12,13,20–22].
Recently, another gene was identified, hbz (HTLV-1 b-ZIP factor), that codes for a protein involved
in the pathogenesis of the virus together with Tax. HBZ can function in two different molecular forms,
mRNA and protein. In mRNA form, it can promote cell proliferation by positive regulation of E2F1.
HBZ protein can down-regulate Tax expression and can interact directly with c-Jun and c-Jun-B [23,24].
HTLV-1 infection is associated with several diseases, primarily with adult T-cell lymphoma
(ATL) and HAM/TSP. HAM/TSP patients present a series of immunological dysfunctions, including
spontaneous proliferation of HTLV-infected T CD4+ lymphocytes, an increase in the migratory
capacity of circulating leukocytes, and increased production of inflammatory cytokines—particularly
neurotoxic cytokines such as IFN-γ and TNF-α—in affected regions along the spinal cord [6,16,25–28].
In HAM/TSP patients, there is a predominance of Th1 cytokines (IFN-γ) and a reduction in Th2
cytokines (IL-4 and IL-10), this is likely to cause greater circulation of immune cells between peripheral
blood and the central nervous system (CNS), leading to inflammation of the nervous tissue [29–31].
Among the several existing theories related to HAM/TSP development, the most widely accepted is
that it is a virally induced, cytotoxic, demyelinating inflammatory process of a chronic and progressive
nature. The lymphocytes are activated during spastic paraparesis; when they cross the blood–brain
barrier, the inflammatory process initiates in the CNS, resulting in lesions [10,15,26,32,33]. Another
theory is direct cytotoxicity mechanism, where HTLV-1-cytotoxic CD8+ T cell cross the blood-brain
barrier and destroy HTLV-1 infected glia cells by cytotoxicity or cytokine production. The last theory
suggests that autoimmunity mechanism can cause lesions by molecular mimicry. A host neuronal
protein seems to be similar to Tax protein from the virus, which can cause immune cross-reaction,
leading to CNS inflammation [6,10,34,35].
3. Immunological Changes in HTLV-1-Infected Patients
Patients infected with HTLV-1 may develop a number of associated diseases, such as HAM/TSP,
or other autoimmune diseases such as the Sjögren’s Syndrome (SS), arthropathies, and uveitis, which
are often related to changes in the immune response [7–9,35]. These changes may occur due to infection
of the CD4+ T lymphocytes by HTLV-1.
HTLV-1-infected CD4+ T lymphocytes exhibit altered signaling cascades and transcription factor
activation, leading to changes in cell behavior [7–9,16,36,37].
Many studies have reported that the HTLV-1 Tax protein affects several transcription factors
including CREB/ATF, NF-κB, AP-1, SRF, and Nuclear factor of activated T-cells (NFAT), as well as
a number of signaling cascades involving PDZ domain-containing proteins such as Rho-GTPases
and Janus kinase (JAK)/signal transducer and activator of transcription (STAT), thus altering the
transforming growth factor-β (TGF-β) cascades. These factors are involved in cell proliferation and
activation, including expression of cytokines and activation of viral proteins [17–19,38–41].
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The expression of forkhead/winged helix transcription factor (FOXP3), which is an important
transcription factor, has also been reported to be altered in patients infected with HTLV-1. FOXP3
is an essential transcription factor for the differentiation, function, and homeostasis of regulatory T
cells (Tregs). Irregularities in the expression of FOXP3 may lead to loss of immune tolerance and the
probable development of autoimmune diseases [41,42].
Previous studies have demonstrated that an increase in FOXP3 expression in patients that
developed ATL leads to an exacerbated Treg function, resulting in increased production of IL-10
and TGF-β, which in turn triggers the immunosuppression phenotype observed in these patients. In
contrast, studies performed with patients that developed HAM/TSP showed a decrease in FOXP3
expression and in the production of the IL-10 and TGF-β cytokines responsible for suppression of
the immune response [31,36,43–45]. This loss of suppressive function may lead to an exacerbation
of the disease process, since inflammation is not controlled and the inflammatory process is
perpetuated. A study performed by Yamano et al. [31] showed that persistent activation of the
immune response, induced by Tax, in patients with HAM/TSP may be associated with a decrease in
the expression of CD4+CD25+FOXP3+ T cells that possess a suppressive function and an accumulation
of CD4+CD25+FOXP3´ T cells that can exacerbate the pathogenic process of HAM/TSP. The authors
demonstrated that in patients with HAM/TSP, there was an increase in the sub-population of
IFN-γ-producing T cells with a CD4+CD25+FOXP3´ phenotype and that this increase correlated
with the clinical severity of HAM/TSP.
Changes in signaling pathways and transcription factor activation caused by viral proteins play
an important role in modifying immune response homeostasis, resulting in a cytokine environment
that may influence the immune cells phenotype. The effect of the environment may lead to autocrine
and paracrine activation and thus influence T cell differentiation and homeostasis. IFN-γ can stimulate
the production of Th1 cells, while the presence of IL-4 leads to the differentiation of Th2 cells. Several
studies have shown that the presence of these cytokines triggers the activity of known suppressors
of cytokine signaling (SOCS) family proteins, which are able to inhibit the recruitment of STATs or
the activation of JAKs. SOCS play a role in the maturation, differentiation, and maintenance of T
lymphocytes [46–48]. SOCS-1 was shown to inhibit the activation of pathways stimulated by IFN-γ
and IL-4, whereas SOC3 is important for maintaining the Th2 phenotype. Previous studies performed
with HAM/TSP patients have demonstrated increased SOC-1 and decreased SOC-3 levels, suggesting
a tendency towards the Th1 response [49].
The HTLV-1-infected CD4+ T lymphocytes of HAM/TSP patients exhibit spontaneous
proliferation, in addition to an increased production of proinflammatory cytokines such as IFN-γ,
TNF-α, IL-1, and IL-6; neurotoxic cytokines such as IFN-γ and TNF-α, in particular, are found at high
concentrations in the spinal fluid of HAM/TSP patients [9,16,50,51]. These findings demonstrate that
infected individuals have an immune response characteristic of the Th1 phenotype (IFN-γ and TNF-α)
and a decrease in the Th2 profile (IL-4 and IL-10) [30,31,45].
Toulza et al. [43] observed that individuals with HAM/TSP had similar IL-10 levels as healthy
individuals and that the TGF-β levels were significantly lower compared to the control group; this in
turn could result in a decrease in the Treg cell-mediated suppressive function and thus contribute to
the exacerbation of inflammation.
4. HTLV-1 and Autoimmunity
HTLV-1 infection leads to changes in the systemic immune response even in asymptomatic
patients [36,52–57]. The regulation of the immune response is carefully organized so that the organism
suffers no damage and that homeostasis is maintained. This is ensured via clonal selection that occurs
during lymphocyte development concomitant with the destruction of the autoreactive cells [58] and
the development of Treg cells. Treg cells are able to inhibit the proliferation of T cells in vitro and
regulate the activity of CD4+ and CD8+ T cells in vivo. There are two major types of Treg cells, naturally
occurring cells and cells produced in the periphery [59].
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During the development of autoimmunity, there is a loss of tolerance to self-antigens, causing
an inflammatory response that attacks organs and tissues of the individual. The pathogenesis of
autoimmune diseases is generally studied in the context of T helper cells and the balance between the
Th1 and Th2 responses. Thus, it has been observed that some diseases such as Rheumatoid Arthritis
(RA) fit the Th1 profile, in which a cell-mediated response occurs, while others such as Systemic
Lupus Erythematosus (SLE) fit the Th2 profile, involving antibodies and immunocomplexes in their
physiopathology [60]. However, during the development of autoimmunity, there is a combination
of several factors that are not only immunological, but also genetic and environmental [61,62].
Of these environmental factors, infections are of great importance, since they act as a trigger for
autoimmunity [63,64].
The association between autoimmunity and HTLV-1 infection has been previously described;
however, the mechanisms underlying this association are not yet fully understood. Many studies
have indicated that molecular mimicry could be the trigger for the development of certain diseases.
However, as previously described, HTLV-1 can result in several immune response anomalies since it
infects CD4+ T lymphocytes and alters their behavior (Figure 1) [65,66].
 
Figure 1. Possible mechanisms involved in HTLV-1 association with autoimmunity.
5. Rheumatoid Arthritis
RA is a chronic and incapacitating disease that affects 1% of the world’s population. Although
the etiopathology of the disease is not fully understood, it is characterized by chronic polyarthritis that
may lead to the destruction of articulation if not properly treated [67–71]. During the early stages of
RA, the cytokines expressed in the synovium are mainly IL-2, 4, 13, 15, and 17. Once the disease is
established, expression of IFN-γ, TNF-α, and IL-10 is observed, with low-level expression of IL-2, -4,
-5, and -13. Furthermore, there is a correlation between serum cytokines and disease progression [72,73].
The development and progression of RA depends on the migration of the T lymphocytes into the
synovium. Previous studies have observed proliferation of the synovium and T cell infiltration in
HTLV infected patients that develop RA. Several studies reported the presence of HTLV proviral DNA
in synovial liquid and tissue cells and that T cells in both the synovium and synovial cells were infected
with HTLV-1. Nishioka et al. [74] also reported the expression of Tax mRNA in synovial cells from
HTLV-I-associated arthropathy patients. Tax may induce cell proliferation, as well as the production
of inflammatory cytokines. In addition, similar to what occurs in HAM/TSP, there is a migration
of lymphocytes into the CNS. This migration may be associated with the viral load of the patient,
as demonstrated by Yakova et al. [75]. These authors observed that patients infected with HTLV-1
that had RA or connective tissue disease had a higher viral load compared to asymptomatic patients;
however, it was similar to the viral load of patients that developed HAM/TSP. Moreover, the viral
load in the synovium was higher in RA patients [74–79].
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6. Sjögren’s Syndrome
SS is defined as a systemic autoimmune disorder, manifesting primarily as xerostomia (dry
mouth) and xerophthalmia (dry keratoconjunctivitis) due to the lymphocytic infiltration of the salivary
and lachrymal glands, which in turn leads to the destruction of the ducts. Furthermore, antinuclear
antibodies (ANA) and other self-antibodies, such as anti-SS-A (Ro) and SS-B (La), are also found in these
patients. Disease development is also associated with genetic and hormonal factors [80,81]. Several
viral infections, such as HTLV-1, may also be associated with the occurrence of this disease. A number
of studies have reported a high prevalence of HTLV-1 in SS patients [82,83]. Nakamura et al. [84]
reported a high prevalence of anti-HTLV-1 IgA in the salivary glands of SS patients. Another interesting
related factor is the level of mononuclear infiltrate in SS patients infected with HTLV-1; SS patients
with HTLV-1 show higher infiltrate levels compared with SS patients not infected with HTLV-1 [82–84].
7. Systemic Lupus Erythematosus
SLE is a systemic autoimmune disease of unknown etiology. This disease progresses with
polymorphic clinical manifestations and periods of exacerbation and remission. Disease development
is associated with a genetic predisposition and environmental factors, such as exposure to sunlight
and viral infection [85–88].
The association between HTLV-1 and SLE is still controversial [89–91]. One possible mechanism
proposed for this association is a process of molecular mimicry through the endogenous sequence
related to HTLV-1 (HRES-1) in the development of SLE. This could trigger the production of
self-antibodies, leading to the formation of immunocomplexes that are deposited in the tissues;
this in turn could cause complement fixation and inflammation, which are pathogenic characteristics
of SLE [92]. Other studies have demonstrated the expression of HTLV-1 antigens in the mononuclear
cells present in the peripheral blood of individuals with SLE and infected with HTLV-1, following three
or more days of in vitro culturing. This indicates the occurrence of viral replication in SLE patients,
which could explain the high seropositivity for HTLV-1 and HTLV-2 observed in these patients [93].
8. Conclusions
Several studies have described HTLV-1 infection in the context of autoimmune diseases, although
this subject is still under debate. Molecular mimicry has been hypothesized as a possible mechanism;
however, HTLV-1-promoted altered cytokine release is critically involved in breaking tolerance.
HTLV-1-induced changes in the activity of regulatory CD4 T-cell molecules affect the homeostasis of
cytokines, including IFN- γ, TNF-α, TGF-β and IL-10, and disrupt the balance in inflammatory and
anti-inflammatory responses, leading to the loss of tolerance and the development of autoimmunity.
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Abstract: Human T-cell Lymphotropic Virus type 1 (HTLV-1) is a human retrovirus that infects at
least 5–10 million people worldwide, and is the etiological agent of a lymphoproliferative malignancy;
Adult T-cell Leukemia/Lymphoma (ATLL); and a chronic neuromyelopathy, HTLV-1 Associated
Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), as well as other inflammatory diseases
such as infective dermatitis and uveitis. Besides sexual intercourse and intravenous transmission,
HTLV-1 can also be transmitted from infected mother to child during prolonged breastfeeding. Some
characteristics that are linked to mother-to-child transmission (MTCT) of HTLV-1, such as the role
of proviral load, antibody titer of the infected mother, and duration of breastfeeding, have been
elucidated; however, most of the mechanisms underlying HTLV-1 transmission during breast feeding
remain largely unknown, such as the sites of infection and cellular targets as well as the role of milk
factors. The present review focuses on the latest findings and current opinions and perspectives on
MTCT of HTLV-1.
Keywords: human; HTLV-1; intestinal barrier; retrovirus; breastfeeding
1. Introduction
Human T-cell Leukemia Virus Type 1 (HTLV-1) infects at least 5–10 million people worldwide,
mainly in highly endemic areas such as southern Japan, West/Central Africa, the Caribbean region,
and parts of South America and Melanesia [1]. HTLV-1 infection is mostly associated with two distinct
diseases: a lymphoproliferation, Adult T cell Leukemia/Lymphoma (ATLL), and an inflammatory
neurological disease, tropical spastic paraparesis or HTLV-1 associated myelopathy (HAM/TSP).
Additionally, HTLV-1 is associated with other inflammatory diseases such as infective dermatitis, some
uveitis and some myositis. Although HTLV-1 preferentially infects CD4+ T cells [2], CD8+ T-cells
may play an important role as reservoir in the host [3], and to a lesser extent, infected monocytes
and B lymphocytes, dendritic cells, and endothelial cells may be found [4,5]. Different modes of
transmission have been identified for HTLV-1: (1) sexual contact; (2) transfusion of contaminated
blood; and (3) from mother to child (MTCT) [6]. In each case, such a transmission involves the transfer
of infected body fluid (semen, blood, and milk, respectively). In the case of MTCT, cohort studies
on HTLV-1 infected carriers indicate that infection during childhood is a potent risk factor for the
development of ATLL [7]. It is now clear that HTLV-1 MTCT mainly involves prolonged breastfeeding,
Viruses 2016, 8, 40 154 www.mdpi.com/journal/viruses
Viruses 2016, 8, 40
as demonstrated by epidemiological, virological and experimental data. However, the mechanisms of
such a transmission remain largely unknown. For instance, the nature of the infected cells present in
the milk, the anatomical sites of viral entry through the mucosa, the first cellular targets of infection,
the role of anti-HTLV-1 antibodies present in breast milk, and the role of other milk factors that may
influence MTCT have not been completely addressed. The present review focuses on such mechanisms,
current studies and perspectives.
2. Evidence of HTLV-1 MTCT during Breastfeeding
First evidence of HTLV-1 transmission from infected mother to children during lactation has been
brought by epidemiological studies. HTLV-1 infection was more prevalent among breastfed children
than bottle-fed children in Japan [8,9], with a rate of seroconversion of 15.7% among children that
had been breastfed for 12 months, compared to 3.6% for bottle-fed children for similar period [10].
Moreover, there is a correlation between MTCT rate and breastfeeding duration. Thus, in a prospective
study in Jamaica, Wiktor et al. [11] reported that breastfeeding beyond 12 months was associated with
a transmission rate of 32%, compared to a transmission rate of 9% for shorter breastfeeding durations.
Similarly, Takahashi et al. [12] showed that a six-month duration of breastfeeding was a critical point in
the rate of seroconversion, since rates of 4.4% and 14.4% were found for children that had been breastfed
for periods under six months or over seven months, respectively. A major piece of evidence supporting
HTLV-1 transmission through breastfeeding has been brought in the 1980s in Japan, where Hino and
coworkers started a pilot study to screen pregnant women in Nagasaki Prefecture for anti-HTLV-1
antibodies (for a review, see [13]). HTLV-1 prevalence was around 4%. Interestingly, HTLV-1 prevalence
among the elder children of the HTLV-1 carrier mothers was approximately 20%, and mothers of the
HTLV-1 positive children were usually HTLV-1 positive (92%), thus showing evidence of MTCT. More
importantly, in 1987, the ATLL Prevention Program Nagasaki, which aimed to refrain seropositive
mothers from breastfeeding in the Nagasaki Prefecture, resulted in a huge reduction of HTLV-1 MTCT
from 20.3% to 2.5% [14]. The major importance of breastfeeding in HTLV-1 MTCT was later confirmed
in other areas [15]. Of note, this residual rate (2.5%) of MTCT in the absence of breastfeeding raised
the possibility of minor secondary routes, such as contamination during delivery, or intrauterine
transmission. This latter route remains controversial, since contradictory studies on the presence of
HTLV-1 in cord-blood samples from seropositive babies have been reported [16–18].
From a virological point of view, it is known that many retroviruses may be transmitted via
breast milk, such as Moloney murine leukemia virus [19,20], Mouse Mammary Tumor Virus [21], or
Caprine Arthritis Encephalitis Virus [22]. Concerning HTLV-1, viral antigens [23], and antibodies
to HTLV-1 were found in the milk of seropositive mothers [24]. The proviral load in breast milk is
strongly predictive of the risk of MTCT, increasing from 4.7/1000 person-months for a provirus load in
milk lower than 0.18% to 28.7/1000 person-months for a provirus load higher than 1.5% [25].
From an experimental point of view, oral inoculation of peripheral blood lymphocytes isolated
from ATLL patients to adult common marmosets (Callithrix jacus) was able to induce seroconversion
within 2.5 months, and the virus was detected in the animal peripheral blood lymphocytes [26].
This study also demonstrated that 5.6 ˆ 107 cells from ATLL patients were sufficient to infect these
animals. Similarly, oral inoculation of concentrated fresh milk from HTLV-1 seropositive mothers
in the same animal model could transmit the infection [27]. Oral transmission of HTLV-1 could be
likewise observed in other animal models. Oral inoculation of four rabbits for eight weeks with an
HTLV-1-infected rabbit lymphoid cell line resulted in the seroconversion of one animal, and it was
possible to generate from this animal a lymphoid cell line productively infected with HTLV-1 [28].
Similarly, oral inoculation of HTLV-1-infected lymphoid cell line (i.e., MT-2) to rats induced a persistent
HTLV-1 infection in the absence of both humoral and cellular immune responses [29].
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3. The Mechanisms of HTLV-1 MTCT
Altogether, these data indicate that breastfeeding is a major route for HTLV-1 MTCT. However,
the mechanisms of HTLV-1 passage through the digestive tract remain largely unknown.
A first point to address concerns the source of HTLV-1 infection in breast milk. It is known that
cell-to-cell contact is required for efficient viral transmission in vivo [30] as well as in vitro [31,32], except
for dendritic cells that can be infected directly with cell-free HTLV-1 virions [33]. Cell free virions have
not been detected so far in breast milk, thus the potential source of infection in breast milk may come
from infected cells, such as lymphocytes, macrophages, or breast epithelial mammary cells. Since
it has been estimated that breastfed children ingest an average of 108 leucocytes a day, considering
prolonged breastfeeding [34,35], infected lymphocytes could provide a strong source of infection in
milk [36]. HTLV-1 infected mononuclear cells can be found in the milk from seropositive mothers
during early lactation [23,37]. Of note, cellular components in breast milk can be found even after
long-term lactation (over 5 years) [38], even if the ratio between the different cell types varies along
the time: for example, the major part of cells in mother’s early milk and colostrum is constituted of
macrophages [39]. It has been found that leukocytes and epithelial cells from the mammary gland are
susceptible to HTLV-1 infection [38]. This observation was confirmed by the evidence that mammary
basal epithelial cells can be productively infected with HTLV-1 and are able to transfer infection to
peripheral blood lymphocytes [40,41]. In addition, in a case report of an ATLL male patient with
pseudogynecomasty, breast biopsy revealed the presence of mammary epithelial cells productively
infected with HTLV-1 [42]. Such data support the hypothesis that basal and/or luminal epithelial
cells may constitute a reservoir of HTLV-1 infectivity. The importance of mammary epithelial cells in
viral transmission during lactation has also been evoked for Bovine Leukemia Virus (BLV), another
deltaretrovirus that is transmitted from BLV-infected cows to calves during lactation [43]. Whatever
the cell types involved, this can provide a more or less continuous source of infection.
A second question concerning the mechanisms of HTLV-1 transmission through the digestive
tract is the anatomical site of viral entry. Up until now, no studies have addressed this question; in fact,
animal models studies (marmoset, rabbit, and rat) on oral inoculation of HTLV-1 were mainly focused
on seroconversion, progression towards an ATLL-like disease, and immune status of the host. Among
the different possible sites of entry, the palatine tonsils and gut seem to be of particular importance
due to their enrichment in possible targets (lymphoid cells and M cells), their function in antigen
sampling [44] and their structure. Moreover, although it does not constitute a proof of viral entry,
HTLV-1 may be retrieved in these structures, as shown in the tonsils for HTLV-1 infected humans [45],
in the intestine and mesenteric lymph nodes of squirrel monkeys inoculated intravenously with
HTLV-1 [46] and in Gut-Associated-Lymphoid Tissues from orally inoculated rabbits [47]. Whatever
the primary sites of HTLV-1 passage/infection, tonsils and/or gut, the virus encounters an epithelium,
pluristratified or monostratified, respectively. This allows in vitro studies using classical models of
human epithelial cell monolayers.
Very few in vitro studies have been published concerning the mechanisms of passage of HTLV-1
across the intestinal barrier. In 1992, Zacharopoulos et al. [48] indicated that a human enterocytic
cell lines (i.e., I407) was susceptible to HTLV-1 infection in vitro, as shown by electron microscopy,
in situ hybridization, and PCR amplification. However, it was unclear if the cells were fully
differentiated as no data on the epithelium integrity and tight junctions were shown. In contrast, our
laboratory performed studies on the susceptibility of three different human enterocytic cell lines on
compartmentalized culture devices, with assessment of the enterocyte differentiation: existence of
a tight epithelial barrier was checked by electron and confocal microscopy, and the trans-epithelial
resistance was measured [49]. In this study, as summarized in Figure 1, it was demonstrated that
HTLV-1 infected lymphocytes were unable to disrupt the epithelial barrier integrity or infect human
enterocytes, in contrast to previous studies on a blood–brain barrier model in human brain endothelial
cells [5,50]. However, it was shown that HTLV-1 virions were able to cross the epithelial barrier by
transcytosis mechanism, and productively infect underlying human dendritic cells [49].
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Figure 1. Hypothetical mechanisms of HTLV-1 (Human T-cell Lymphotropic Virus type 1 ) passage
through the intestinal epithelium.
HTLV-1-infected lymphocytes, once they have crossed the mucus layer, could either pass through
the epithelium via M cells, or in-between enterocytes (paracellular passage), to reach the lamina
propria where potential targets of HTLV-1 infection, such as T lymphocytes (and/or dendritic cells
and B lymphocytes) are located. From in vitro studies [49], the infection of enterocytes or the epithelial
layer disruption seems to be excluded. Another possibility, suggested in the same study, could be viral
transcytosis through the enterocyte, with infection of underlying dendritic cells.
Interestingly, viral transcytosis through enterocytes was observed only in the presence of HTLV-1
infected lymphocytes, and not in the case of purified virions. Such a mechanism of viral transcytosis
is reminiscent of previous work showing transcytosis of HIV across an epithelial barrier, without
infection of enterocytes, and subsequent infection of macrophages or CD4 lymphocytes located to
the basal side of the epithelium [51]. These in vitro results highlight one of the potential mechanisms
proposed for HTLV-1 passage, which are summarized in Figure 1.
4. Determinants of HTLV-1 MTCT
Studies on HTLV-1 MTCT determinants have focused mainly on genetic host factors,
immunological host factors, lactation duration and milk components.
The genetic host factors that control HTLV-1 infection by breastfeeding have been investigated
by Plancoulaine et al. [52], who began in the 1990s a large epidemiological study in endemic villages
of French Guiana. The authors found a dominant major gene predisposing to HTLV-1 infection, in
addition to the expected familial correlations due to the transmission routes (mother to child and
spouse to spouse) [53]. Previous studies had shown that HLA (Human Leukocyte Antigen) genes
distribution was different for ATLL or HAM/TSP patients compared to asymptomatic carriers (for
example, see [54]), but the study by Plancoulaine et al. [53] indicated a genetic predisposition for
HTLV-1 infection itself for 1.5% of the population, which concerned almost all infected children
under 10 years of age, i.e., infected through breastfeeding. Further studies allowed mapping a major
susceptibility locus for HTLV-1 infection during childhood to chromosome 6q27 [55].
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Concerning the immunological factors involved in HTLV-1 MTCT, the role of maternal
anti-HTLV-1 antibodies may appear controversial. Such studies have to take into account the duration
of breastfeeding, since the protective role of anti-HTLV-1 antibodies has been demonstrated in a rabbit
model of infection, where passive immunization was shown to prevent milk-borne transmission of
HTLV-1 to offspring [56]. Moreover, it has been shown in vitro that the addition of HTLV-1 serum
cord blood plasma is able to prevent the infection of human neonatal lymphocytes when co-cultured
with breast-milk cells of HTLV-1 carrier mothers [12]. However, it has been suggested that higher
anti-HTLV-1 antibodies titer in the serum of the mother, as well as the presence of anti-Tax antibodies, is
associated with a higher risk of children infection [11,52,57–59]. However, a high anti-HTLV-1 antibody
titer in the serum may be correlated with a high provirus load in PBMCs, which is a risk factor for
HTLV-1 MTCT [57]. In an analysis including the provirus load in maternal PBMCs, the presence of
anti-Tax antibodies and the anti-HTLV-1 titers, it was found that a higher maternal proviral load and a
higher anti-HTLV-1 antibody titer were independently associated with a higher risk of HTLV-1 MTCT,
whereas the presence of anti-Tax antibodies was not [60].
Another point to take into account concerns the other milk components that may influence
HTLV-1 MTCT transmission. As an example, it has been shown that lactoferrin, an iron-binding milk
glycoprotein, was able to enhance HTLV-1 replication, by transcriptional activation of HTLV-1 Long
Terminal Repeat (LTR), the viral promoter [61]. This effect on HTLV-1 infection seems to be specific
since lactoferrin did not show any effect on HIV-1 LTR, and was even able to inhibit HIV-1 infection,
probably by interfering with viral fusion and entry steps [61]. As an interesting example of “positive
feedback”, the same authors further demonstrated that lactoferrin expression was up-regulated during
HTLV-1 infection, probably in a paracrine manner involving Tax-induced NF-κB activation [62].
5. Ongoing Research on HTLV-1 MTCT and Perspectives
One of the major remaining questions on MTCT concerns the sites of primary passage/infection
of HTLV-1 in the digestive tract. The mechanisms of HTLV-1 infection after oral inoculation should be
addressed in vivo using a humanized mouse as a model of HTLV-1 infection [63–65], in complement to
the rabbit model. In particular, combination of histopathological studies and bioluminescence imaging
will allow determining the preferential sites of HTLV-1 entry (palatine tonsils, and/or gut). In parallel,
the use of transgenic, knock-out, and knock-in mice depleted for different cell types (M cells, dendritic
cells, and macrophages) will allow assessing the role of the different cell types in the first steps of
infection. These studies will also benefit from an in vitro approach, such as differentiation of M cells
from enterocytic cell lines, on compartmentalized culture devices, as already done to show the role of
these cells in virus transport across the epithelium [66]. Combination of in vivo/in vitro studies will
also allow delineating the role of factors such as milk components (e.g., lactoperoxidase), the proviral
load, and the antibody titer in HTLV-1 transport through the intestinal epithelium.
Another perspective concerns the comprehension of the role of breastfeeding duration on HTLV-1
MTCT. It seems rather clear that such a role corresponds to a combination of the cumulative viral
input, the changes over time in milk composition in infected cell types, maternal antibodies, and the
immune status and maturation of the neonate’s gut. It is known that neonatal life (as well as prenatal)
organizes and controls mucosal homeostasis through endogenous and exogenous factors that drive
the development and maturation of the intestinal immune system (for a review, see [67]). Recent
studies have shown the effects of intestinal microbiota in the development of the immune system and
intestinal architecture [68,69]. Gut microbiota could have an impact on HTLV-1 MTCT efficiency, as
reported for HIV-1 [70] or Mouse Mammary Tumor Virus [71], as well as the human milk microbiota,
which participate in the neonate’s gut microbiota constitution [72].
Altogether, these further studies could delineate new preventive strategies to counteract HTLV-1
MTCT, as well as provide new data on the general mechanisms of pathogenic agents in MTCT.
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Abstract: Human T-cell leukemia virus type 1 (HTLV-1), hepatitis C virus (HCV) and human
immunodeficiency virus type 1 (HIV-1) are prevalent worldwide, and share similar means of
transmission. These infections may influence each other in evolution and outcome, including cancer
or immunodeficiency. Many studies have reported the influence of genetic markers on the host
immune response against different persistent viral infections, such as HTLV-1 infection, pointing to
the importance of the individual genetic background on their outcomes. However, despite recent
advances on the knowledge of the pathogenesis of HTLV-1 infection, gaps in the understanding of
the role of the individual genetic background on the progress to disease clinically manifested still
remain. In this scenario, much less is known regarding the influence of genetic factors in the context
of dual or triple infections or their influence on the underlying mechanisms that lead to outcomes
that differ from those observed in monoinfection. This review describes the main factors involved in
the virus–host balance, especially for some particular human leukocyte antigen (HLA) haplotypes,
and other important genetic markers in the development of HTLV-1-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) and other persistent viruses, such as HIV and HCV.
Keywords: HTLV-1; HIV-1; HCV; genetic factors
1. Introduction
Human T-cell leukemia virus type 1 (HTLV-1), hepatitis C virus (HCV) and human
immunodeficiency virus type 1 (HIV-1) have been reviewed, since these viruses are prevalent
worldwide, and share similar means of transmission, and superposition of infected populations,
such as intravenous drug users (IDU) and commercial sex workers, especially in endemic areas for
HTLVs. In addition, these infections may influence each other in evolution and outcome, including
cancer or immunodeficiency.
Many studies have reported the influence of genetic markers on the host immune response
against different persistent viral infections, such as HTLV-1 infection, pointing to the importance of the
individual genetic background on their outcomes. However, despite recent advances on the knowledge
of the pathogenesis of HTLV-1 infection, gaps in the understanding of the role of the individual genetic
background on the progress to clinically manifested disease still remain. In this scenario, much less
is known about the influence of genetic factors in the context of dual or triple infections, or their
influence on the underlying mechanisms that lead to outcomes that differ from those observed in
monoinfection. HTLV-1 is an ancient infection, with better adaptation to its host than HIV or HCV.
HIV often complicates the evolution of HCV and HTLV-1, but the reverse may not be true, with a
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higher spontaneous clearance rate of HCV in those triple co-infected with HCV/HIV/HTLV than in
those with HCV/HIV, or monoinfected with HCV.
This review describes the main factors involved in the virus–host balance, especially for some
particular human leukocyte antigen(HLA) haplotypes, and other important genetic markers in the
development of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and other
persistent viruses, such as HIV and HCV.
2. HLA Risk for HAM/TSP
HAM/TSP occurs in only 1%–2% of those infected by HTLV-1,thus, host genetic factors interacting
with viral factors have been suggested as determinant to the outcome; that is, whether the individual
will develop an effective immune response to HTLV-1 or will progress to clinically manifested
HAM/TSP. Among those genetic factors, the most frequently studied have been the haplotypes
of HLA Class 1 (HLA-A, HLA-B, HLA-C) of the major histocompatibility complex (MHC), molecules
that encode glycoproteins expressed on the surface of almost all nucleated cells, and of which the
major function is the presentation of antigenic peptides to CD8+ T lymphocytes. The effectiveness of a
specific immune response to HTLV-1, especially the cytotoxic CD8+ T lymphocytes’ response (CTL),
has been shown to be the key to control the provirus load (PVL) of HTLV-1 [1]. The most compelling
evidence for a role of host CTLs came from the observation of a population in Southern Japan, where
the presence of two genes of the HLA class 1 (HLA-A*02 or HLA-Cw*08) was associated with a lower
PVL and decreased prevalence of HAM/TSP [2,3].
Some specific HLA alleles have been associated with protection, while others have been associated
with an increased risk of HAM/TSP. However, unlike the expressions of both HLA-A*02 and
HLA-Cw*08, which are associated with a protective effect, HLA-DRB1*0101 and HLA-B*5401 have
been linked with an increased susceptibility to HAM/TSP [2,3]. The association of HLA-DRB1*0101
with disease susceptibility only becomes evident in the absence of the HLA-A*02 protective effect [2],
whereas HLA-B*5401 is independently associated with susceptibility to disease; moreover, among
patients with HAM/TSP, HLA-B*5401 is associated with a significant increase in PVL. HLA-A*02,
HLA-Cw*08 and HLA-DR1 are also found in the population of Southern Japan, where they are associated
with a higher risk for HAM/TSP [4].
There may be differences in the frequency of HLA alleles in different populations, and changes in
the protective effect of certain HLA alleles according to ethnicity (Table 1). The same protective effect
of HLA-A*02 in HAM/TSP, seen in Japanese, has been reported in a small sample of 29 individuals
from London, 27 of whom had a Caribbean origin [2], a finding also observed in Brazil [5,6] but not in
other populations, such as Afro-Caribbean individuals from Martinique [7], Jamaica [8], Spain [9] and
Iran [10,11].
HTLV-1 PVL is controlled by the host immune response, with a dominant role for an effective
CTL response [8]. Long-term studies have shown that CTL is determinant of the outcome; for example,
in Japanese cohorts, HLA-A*02 and HLA-C*08 play a protective role against the development of
HAM/TSP, whereas HLA-B*54 is associated with a higher risk. This outcome is possibly related to
the killing of infected cells with HLA-A2 or -C*08 restricted HTLV-1 epitopes, resulting in decreased
PVLs [9]. In fact, such HLAs have the ability to present peptides derived from viral proteins to CD8+
T cells, which are mostly protective during HTLV-1 infection [10].
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Table 1. Distribution of human leukocyte antigen (HLA) haplotypes according to risk of
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) development.






A*02 ++ + 0 0 0 ++ 0
Cw*08 ++ 0 0 0
A*24 - 0 0
B*07 - ˘ 0 - 0 0
B*5401 -
DRB1*0101 ˘ 0 ˘ - 0 0
DRB1*11 - - - - 0 0
++ protective effect; + tendency to protective effect; - susceptibility; ˘ susceptibility only in negative HLA-A*02;
0 no associated effect; HLA not prevalent.
In Iran, alleles HLA-A*02, HLA-Cw*08 and HLA-A*24 were not associated with a lower risk of
HAM/TSP or lower provirus load [10,12]. In Brazil, HLA-Cw*08 showed no protective effect, and,
among HLA-B*07 individuals, only those negative for HLA-A*02 [6] were susceptible to HAM/TSP [6].
In Spain, no association between the presence of protective alleles (HLA-A*02 and/or HLA-Cw08) and
HAM/TSP could be demonstrated nor were there significant differences in PVLs; however, HAM/TSP
was significantly associated with HLA-B*07 and HLA-DRB1*0101 [9]. The HLA-B*5401 allele was not
found in the populations of Iran, Brazil and Spain (Table 1), and has been described almost exclusively
in East Asian individuals [13].
Alleles associated with a higher risk, such as HLA-DRB1*0101, were also associated with
susceptibility to HAM/TSP in Iran’s population, as well as in Japanese, an effect was observed only
among HLA-A*02-negative individuals, and not occurring in HLA-A*02-positive individuals [10]. The
association of HLA-DR*11 with HAM/TSP, previously described in Japanese patients, was observed
only in Brazilian patients [5]. Among Brazilian individuals, HLA-Cw*07 was associated with HAM/TSP
only in the absence of HLA-A*02 [6].
The protective ability of HLA class 1 allele correlates with the affinity to bind antigenic peptides
derived from the HTLV-1 proteins [14]. However, contrary to what was expected, HTLV-1 antigen,
which is recognized by the protective immune response class 1 immune dominant Tax, was not
associated with this protein, but rather with the regulatory protein encoded hemoglobin subunit zeta
(HBZ) on the negative strand of the provirus. A combination of theoretical methods for the prediction
of epitopes [15] and cellular laboratory experiments demonstrated that the binding to epitopes of the
protective HLA-A*02 and HLA-Cw*08 alleles are stronger than that of the detrimental HLA-B*54 [14].
In that study, HLA class 1 molecules that bind strongly to HBZ epitopes were significantly associated
with the asymptomatic state, an association remaining even after patients with HLA-A*02, HLA-A*08
and HLA-B*54 were excluded from the analysis, demonstrating that the protective effect of binding
HBZ is common to several HLA alleles and not just a feature of particular alleles. Moreover, among
both asymptomatic subjects and HAM/TSP patients who carry protective alleles, epitopes that could
bind HBZ were strongly associated with a significant reduction in HTLV-1 PVL [14].
3. Interferon Lambda 3 (IFN-λ3)
IFN lambda 3 (IFN-λ3) is an important cytokine that is responsible for an unspecific antiviral
response by interacting with the HLA class II receptor, inducing intracellular signaling by janus
kinase/signal transducers and activators of transcription (JAK/STAT) and mitogen-activated
protein kinases (MAPK). Host genetic background in HLA class II, encoded by single nucleotide
polymorphisms (SNPs), can lead to a spatial conformation in the receptor, modifying the attachment
that avoids interaction between IFN-λ3 and its receptor, inducing a genetic by stand interaction [16].
The first reports about the role of IL28B (coding for IFN-λ3) on HAM/TSP outcomes could not
clearly show the connection [17,18]. However, it was noted that HAM/TSP patients presented an
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independent association with the polymorphism in IL28B SNP rs8099917 (GG), when compared to
asymptomatic HTLV-1 carriers [19]; such a finding has not been reported for other infections, such
as HIV and HBV infections [20], except for patients with acute HIV infection, whose response to
antiretrovirals was related to SNP rs12979860 [21].
In recent years, an association between IFN-λ3 polymorphisms and anti-HCV treatment
with pegylated interferon (PEG-IFN) outcome was described [22]. The correlation between the
polymorphism of IFN-λ3 was noted in two positions (rs12979860 and rs8099917) [16,22]. Co-infection
with HIV or HTLV is widely present among HCV subjects, making interaction a possibility, and
potentially changing both the pathogenesis of the disease and/or the response to treatment [23,24].
It is noteworthy that the immune response seems to be a crucial factor in the pathogenesis
of HAM/TSP. For example, a study showed that patients with HAM/TSP had higher levels of
IFN-gamma compared to asymptomatic patients [25]. Furthermore, the polymorphism of rs12979860
SNP profile induces the production of IFN-λ3 and an immune response to HTLV-1, leading to neuronal
injury in the spinal cord [26,27]. As reported, the interferon stimulated genes likely regulate the
expression of cytokines and this regulation may differ in the infected tissue and between cell types
within the liver and spinal cord [28]. It is known that IFN-λ3 attenuates interleukin (IL)-13 production,
leading to a protective effect and decreased inhibition between killer-cell immunoglobulin-like receptor
(KIR) and HLA-C [29]. Thus, it is possible to infer that IFN-λ3 and two other interferons, IL-28A and
IL-29, can activate the JAK-STAT cascade, which is similar and probably synergistic with type 1
interferons (e.g., interferon alpha), although using different receptors, and contributing to the immune
pathogenesis of HAM/TSP.
4. miRNA
The importance of microRNA (miRNA) in the replicative cycle of several other viruses, as well as
to the progression of associated pathologies, was established over the past decade. Furthermore, the
involvement of miRNAs in altering the life cycle of HTLV-1 and progression to neurodegenerative
diseases and related oncogene has been investigated [30]. Various miRNA-derived transcript
proteins can change the features of HTLV-1, either interacting with the restructuring of chromatin or
manipulating components of the RNA interference (RNAi), by providing multiple routes through
which miRNA expression, etc., can be down-regulated in the cell host. Furthermore, the mechanism
of action by which deregulation of host miRNAs can affect cells infected with HTLV-1 can vary
substantially through the silencer, including miRNA-induced silencing complex of RNA (RISC), gene
transcription, inhibition of components RNAi, and chromatin remodeling. These changes induced by
miRNA can lead to increased cell survival, invasiveness, proliferation and differentiation; they can also
allow viral latency. Recent studies have shown the involvement of successful miRNAs in the life cycle
and pathogenesis of HTLV-1, but there are still significant issues to be addressed. In Table 2, a summary
of the already identified miRNAs and their biological effects on HTLV-1 are presented. In HAM/TSP,
the miRNA involved in the pathogenesis is the miR-132, while, in adult T-cell leukemia/lymphoma
(ATL), miR-223 is responsible for promoting oncogenesis, an important biological marker [31].
HTLV-1 can change the miRNA profiles of infected cells, contributing to cell transformation and
leading to the development of ATL and/or HAM/TSP [30]. Moreover, the modification of chromatin
by viral proteins and host cell miRNAs may contribute to the deregulation of cells expressing miRNA
and may possibly serve as a key mechanism by which the virus manipulates the status of miRNA host.
Recent discoveries attempt to validate the importance of variation in the levels of miRNA mediated
by HTLV-1, but there is a gap on this recent field of study. Moreover, a better understanding of
the molecular mechanisms may contribute to a better understanding of viral regulation and cellular
regulatory pathways. Taken together, this knowledge can identify potential therapeutic intervention
points in the future [31].
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Table 2. Identified miRNAs and their biological effects on HTLV-1.
MiRNA Regulation miRNA Target Function
miR-21 Upregulated PTEN Antiapoptotic
miR-93 Upregulated p21 (WAF1/CIP1); MICB Antiapoptotic
miR-132 Downregulated p300 Immune evasion
miR-143-p3 Upregulated AChE; PKA; GRα Increase of viral transcription
miR-146 a Upregulated Unknown Pro-inflammatory
miR-149 Downregulated p300 Proliferation
miR-155 Upregulated TP53INP1; Unknown Proliferation
miR-873 Downregulated p300 Proliferation
PTEN: Phosphatase and tensin homolog; MICB: MHC class I polypeptide-related sequence B; AChE:
Acetylcholinesterase; PKA: Protein kinase A; GRα: glucocorticoid receptor α; TP53INP1: Tumor protein P53
inducible nuclear protein 1.
5. Killer Cell Immunoglobulin-Like Receptors (KIRs)
KIR present a high tendency to suffer genetic mutations, indicating a high polymorphic capacity.
HLA-C molecules present ligands for KIR2DL receptors, with a functionally relevant indistinct
to determine KIR specificity, like HLA-C group 1 (HLA-C1) alleles, where the HLA-C alpha 1
domain is ligand for the inhibitory receptors KIR2DL2 and KIR2DL3 and the activating receptor
KIR2DS2 [32,33]. HLA-C group 2 (HLA-C2) alleles are involved in inhibitory KIR2DL1 and in the
activation of KIR2DS1 [32–35]. KIR2DL3 and its ligand HLA-C1 have been associated with an increased
likelihood of spontaneous [36,37] and treatment-induced HCV clearance [37,38]. This association is
attributed to differential natural killer (NK) cell activation and function in the context of this KIR/HLA
interaction [39]. SNPs from the HLA-C coding regions show weak associations with sustained virologic
response(SVR) [16,40] for chronic hepatitis C.
New evidence has shown that the pathogenic mechanism of disease-associated HTLV-1 infection
is an impairment of the immunity [41]. The KIR genotype influences CTL efficiency, by affecting
HLA class I-mediated HTLV-1 immunity [42], and KIRs influence both innate and adaptive immunity
(Figure 1) [1,42], however KIR2DL2 gene is associated with an enhancement of the effect of known
protective or detrimental HLA class I alleles on PVL and HAM/TSP risk, for multiple HLA-A, -B
and -C molecules. Surprisingly, KIR2DL2 also exhibits the same behavior in HCV infection, another
unrelated virus. In HTLV-1 infection, KIR2DL2 enhanced the protective and detrimental effects of
HLA-C*08 and B*54, respectively, on disease status and enhanced the association between B*54 and
high PVL in HAM/TSP patients [42]. In HCV infection, KIR2DL2 enhanced the protective effect of
B*57 on its spontaneous clearance and the association between B*57 and low viral load in chronic
carriers [42]. These observations suggest that KIR2DL2 enhancement of the HLA class I-restricted
response may be a general mechanism.
Figure 1. Mechanisms explaining inhibitory killer-cell immunoglobulin-like receptor (KIR) enhancement
of human leukocyte antigen (HLA) class I associations.
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6. Genes and Susceptibility to HIV Infection
Susceptibility to HIV infection and the clinical course after infection are both influenced by the
complex interaction of factors related to the human host, the virus and the surrounding environment,
resulting in large epidemiological and clinical heterogeneity among infected individuals. Host genetic
factors play an important role in this variability and pathogenesis. For example, the gene encoding
the CCR5 (chemokine (C-C motif) receptor 5) co-receptor necessary for infection of R5 strains of HIV,
which usually initiate infection, and may influence both the acquisition of infection and the rate of
progression to disease.
The CCR5 gene is located on chromosome 3 and individuals with CCR5 Δ32 deletion acquire
protection against virus to produce a defective protein, which is not expressed on the cell surface,
preventing the virus from binding to the CCR5 co-receptor to penetrate the cell. While homozygous
for CCR5 deletion has Δ32-protection against HIV [43–45], heterozygous for the mutation has a delay
of two to four years of progression to acquired immune deficiency syndrome (AIDS) [46–48]. However,
homozygous for the CCR5Δ32 deletion mutation is the only genotype identified as being capable
of protecting against HIV infection. The CCR5Δ32 allele occurs at a frequency of 4% to 15% in the
Caucasian population, with a higher frequency in the Northern European populations [44,49]. Other
genetic potential protective effects against infection caused by deletions seem to involve more complex
interactions between two or more gene variants. Apparently, Asians and Africans with CCL5-403A/A
genotype (chemotactic chemokine ligand 5), also called RANTES (regulated on activation, normal,
T cell expressed and secreted), could be resistant to HIV-1 but controlled studies are still lacking to
confirm this observation [50]. In China, a genetic variant of SDF-1, the primary ligand of CXCR4
((C-X-C motif) receptor 4), was associated with resistance to HIV infection in intravenous drug
users [51].
ZNRD1 (zinc ribbon domain-containing protein 1) is a DNA-dependent RNA polymerase
catalyzing the transcription of DNA into RNA required to complete the life cycle of HIV, which
was subsequently identified as SNPs associated with depletion of CD4+ T cells. A haplotype in ZNRD1
gene was associated with a 35% reduction in the risk of HIV acquisition in Euro-Americans (Americans
with European ancestry) and ZNRD1 variants also affect the progression of HIV-1 infection to disease
in European, American, and African cohorts [52].
Langerin, also known as CD207, is a transmembrane receptor encoded by the CD207 gene
and expressed in Langerhans cells, scattered throughout the genital mucosal epithelium where the
transmission of HIV occurs. Although Langerhans cells are considered dendritic cells (DC), and
immature DCs are involved in the transmission of HIV to lymphocyte T [53], there is evidence
suggesting that Langerin prevents HIV transmission. The HIV particles captured by Langerin are
internalized and degraded in the Birbeck granules [54]. However, a mutation in the gene of persons
deficient in the Langerin Birbeck granules has been described [55].
Defensins are small cationic proteins rich in cysteine produced by leukocytes and epithelial cells
that are active against bacteria, viruses, and fungi. They play a role in immunity penetration through
the cell membrane and pore formation flue material [56–58]. Mammalian defensins are classified as
alpha, beta, and theta defensins [58]. Alpha-defensin bound to receptor CD4 and gp120 glycoprotein
of the viral envelope may negatively modulate CD4+ T cells and inactivate viral particles through
disruption of membrane [59,60]. Accordingly, they could block HIV entry directly by inactivating it or
by blocking or eliminating viral receptor on the cell surface. Beta-defensins have mechanism of action
similar to that of alpha-defensin, blocking virus entry of both the tropic virus strains macrophage
(R5 viruses), as well as tropic strains for T cells (X4 viruses), achieving its effect by direct inactivation
of viral particles or negative modulation of CXCR420 [61]. Six human beta-defensins were identified in
epithelial cells, although they can be present in up to 28 different human genes [62]. Theta-defensins
in humans and chimpanzees are only found as inactive pseudogenes, which are transcribed into
mRNA, but are home to premature stop codons that prevent expression of functional products [63].
However, by reconstituting the human putative ancestral gene for theta-defensin, the presence of
168
Viruses 2016, 8, 38
potent activity against strains X422 and R5 was observed in vitro. The reconstituted product, called
human retrociclin-1, binds to CD4 molecule and gp120, preventing viral entry into target cells [64].
TREX-1 (three prime repair exonuclease), which degrades cytosolic DNA, preventing unnecessary
immune response against free nucleic acids, is a limiting factor for HIV-1 and polymorphism of a
single nucleotide rs3135945 and was associated with susceptibility to HIV infection, emphasizing the
participation of TREX-1 in anti-HIV response [65].
6.1. Genes that Influence the Dynamic Progression of AIDS
Apart from individuals uninfected by HIV, despite repeated sexual exposure to the virus in high
risk situations, known as exposed uninfected, there is a small proportion of HIV-infected individuals
who remain clinically and immunologically healthy for more than one or two decades after being
seroconverted, while in others infection may be characterized by an extremely rapid progression
to AIDS within one year [66]. Host genetic factors possibly contribute to this heterogeneity, as
demonstrated by many studies in which genetic polymorphisms in human genes are able to influence
the risk of HIV infection and progression to AIDS [66].
The type of HLA is one of the host genetic factors associated with the course of HIV infection.
The HLA-B alleles are considered the primary genetic determinants of disease progression, according
to the categorization in rapid progressors, slow progressors and long-term non-progressors [67]. While
HLA-B35 is associated with rapid progression to AIDS [67–69], HLA-B*5701 and HLA-B27 are more
prevalent among long-term non-progressors (LTNP) [70–75], of which 1% are the elite controllers
(EC), who are mainly characterized by maintaining persistently undetectable viral loads without
antiretroviral treatment.
Associations among the SNPs of MHC class I, MHC class III and LTNP phenotype are
observed [76] is also noted in other factors, such as the co-expression of multiple HLA protectors, SNPs
of HLA-C, and stronger T cell responses against the HIV proteins in elite controllers individuals [77].
These different genetic variant combinations may have addictive, synergistic or inhibitory effects
determining the course of HIV infection. HLA class II also contributes to the immune response in the
control of the viral load of HIV patients and distinct stratifications of HLA-DRB1 effect on HIV viremia
between controllers and progressors are associated with different subsets of HLA-DRB1 alleles, with
DRB1*15:02 significantly associated with low viremia and DRB1*03:01 with high viremia [78,79].
Unlike individuals with two copies of the mutation CCR5Δ32 who are protected from HIV
infection by non-functionality of CCR5 [43–45], heterozygous individuals for this mutation can be
infected by HIV R5 strains but exhibit an altered activity of the chemokine receptor, resulting in delayed
progression to AIDS [46–48]. Occurring at a frequency of up to 15% in the Caucasian population,
especially in the Northern European population, the allele CCR5Δ32 is virtually absent among natives
of Africa and its marginal presence in Asian populations may be due to gene flow from Caucasian
populations [80–82].
Polymorphism in otherwise apparently normal chemokine receptors also has some degree of
influence on disease progression. For example, CCR2 chemokine receptor can function as a HIV
co-receptor in some situations [83]. Person with homozygous or heterozygous for CCR2-64I which
results mutation from valine to isoleucine changed at amino acid position 64, progress more slowly
to AIDS than those homozygous for the wild type variant, although not all studies confirm this
association [84]. There is also controversy as to CX3CR1, fractalkine, a receptor for chemokine, for
which the initial studies showed an association with more rapid progression to AIDS [85–87].
The beta-chemokines MIP-1α (CCL3), MIP-1β (CCL4) and RANTES (CCL5) are natural ligands of
CCR543. Two natural variants have been described and named CCL3L1 and CCL4L147. CCL3L1 (also
known as MIP-1αP) is the most potent CCR5 agonist and is a strong inhibitor of infection by R5 strains
of HIV-1 [88,89]. RANTES (CCL5), through promoters 28G-403A, could also slow progression to AIDS,
whereas RANTES has another variant, named 1.1.C, which accelerates AIDS development [84].
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The LTNP condition probably results from a complex association of various genetic factors rather
than only one variant of a single gene, as confirmed by the later discovery of two new association
between allelic variants of TNF-a-238 genes and PDCD1-7209 and LTNP situation [90].
6.2. Genes Important to Anti-HIV Treatment
Abacavir is a reverse transcriptase inhibitor antiretroviral used in current clinical practice with
other antiretroviral agents with few interactions with other drugs and favorable long-term toxicity
profile. However, it has the most important adverse effect on the immune-mediated hypersensitivity
reaction, affecting 5% to 8% of patients in the first weeks of treatment, requiring the immediate cessation
of treatment [91]. Their subsequent reintroduction is contraindicated due to the risk of recurrence
of the reaction with greater severity, speed and risk of death [91]. A hypersensitivity reaction to
abacavir is strongly related to the presence of the HLA-B*5701 [92–96] and avoiding abacavir in
patients with HLA-B*5701 reduces the incidence of that reaction [97]. The effectiveness of screening
for HLA-B*5701 in preventing hypersensitivity reaction to abacavir has been established, although its
cost-effectiveness depends on factors that vary between populations and health care settings, and the
availability of test [98].
The observation that individuals homozygous for the CCR5-Δ32 deletion show protection against
HIV led to the development of drugs antagonist of the CCR5 chemokine receptor, blocking this receptor
and inhibiting HIV entry that uses CCR5. As the CCR5 antagonists administration carries the risk of
selection of viral variants able to use alternative CXCR4 co-receptor, tropism for co-receptor should
be assessed prior to clinical use of inhibitor [99]. Maraviroc was the first antiretroviral drug with this
mechanism of action; other drugs of this group include vicriviroc, cenicriviroc, adaptavir, INCB-9471
and PRO-140.
In 2007, an HIV-infected adult patient living in Berlin developed acute myelogenous leukemia and
was treated with a transplant from an allogeneic hematopoietic stem cell donor who was homozygous
for the CCR5-Δ32 deletion and, after stopping antiretroviral therapy following transplantation, his
viral load remained undetectable, becoming the first confirmed case of cure of HIV infection [100].
Since then, several efforts are underway in an attempt to reproduce the Berlin patient’s condition
through the engineering of autologous T cells or hematopoietic stem cells resistant to HIV [100].
6.3. Co-Infection HIV–HTLV
HTLV-1 and -2 have the same modes of transmission as HIV, resulting in common risk factors and
overlapping of populations exposed, so that in individuals infected with HIV, HTLV is 100 to 500 times
more frequent than in the general population. In vitro, Tax gene products of HTLV-1 increment the
release of free viral particles of HIV-1 [101] and an accelerated course of HIV-1 infection has been
reported in patients co-infected with HIV-1 and HTLV-1 [24,102,103].
On the other hand, the Tax protein of HTLV-2 may have an immunomodulatory effect,
increasing IFN-y synthesis by cells infected with HIV-1 [104], and HTLV-2 induces the production
of CCL3 chemokine, CCL4 and CCL5, which can have a protective effect on disease progression by
HIV [105,106]. Lymphocytes T CD8+ recovered from patients infected with HTLV-2 spontaneously
produce high levels of chemokines [107] and these chemokine molecules are natural ligands for the
CCR5, the most important co-receptor for input of HIV in cells, suppressing the infection with HIV
strains with tropism for macrophages [108,109]. Thus, an association between increased production of
chemokine and slower disease progression by HIV [110,111], and between increased production of
chemokines and reduction of HIV [112] levels has been reported, and slower depletion of CD4+ T cells
in individuals with co-infection HIV-1/HTLV-2 [105,113–115], as well as lower plasma HIV RNA than
for the mono HIV-infected subjects [116].
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7. HCV and Genetic Susceptibility
Approximately 20%–30% of individuals infected with HCV will clear the virus spontaneously [117],
and around of 185 million are infected with this virus worldwide [118]. Chronic hepatitis C is the
major cause of hepatocellular carcinoma, end-stage liver disease, and liver transplantation in the
USA [117]. Genome-wide association studies (GWAs) identified variants located in the interferon
lambda region, and it is associated with HCV clearance spontaneously in subjects under treatment with
interferon alfa [26], and interferon lambda 4 (IFNL4) plays a fundamental role in these associations [119].
Interferon lambda 4 protein (IFN-λ4) was found in persons who have the ΔG allele of the ss469415590
variant (IFNL4-ΔG), another important variant is rs12979860, which was associated with spontaneous
HCV clearance [120,121] and is a SNP located in IL28B.
Indeed, the linkage disequilibrium is strong among IFNL4-ΔG allele and rs12979860-T allele is
unfavorable in individuals of European or Asian ancestry; nevertheless, this linkage disequilibrium
is moderate in individuals of African ancestry [119]. Among black participants, IFNL4-ΔG genotype
was associated with spontaneous HCV clearance more strongly than rs12979860 genotype [120,121].
On the other hand, the linkage disequilibrium in the SNP of IL28B in rs8099917-T was described as an
important predictor of sustained virologic response in chronic HCV subjects undergoing treatment
with pegylated alfa interferon and ribavirin over 48 weeks [16].
Other mutations in the innate immune response regulator genes have important roles in the
response to treatment in patients with chronic HCV infection, which emphasizes the important role
of KIR and HLA genotypes [40,122]. The variant KIR2DS3 gene was described as the principal gene
associated with chronic HCV infection, whereas the reduction of HLA-Bw4+ KIR3DS1+ was associated
with an increased risk of developing hepatocellular carcinoma. Therefore, they have a role in the
innate system in developing HCV-related disorders, of which KIR2DS3 and KIR2D genes stand out as
related to HCV disease progression, and lymphoproliferative disorders [122]. This was observed in
Brazil, and the most important KIR variants associated with SRV was KIR2DS5, whereas KIR2DL2 was
associated with chronic hepatitis C [123].
8. Concluding Remarks
There are several studies on the immune response against persistent viral infections. In contrast,
only a small number of studies on genetic markers have been published recently. This review
highlights some specific HLA alleles that have been associated with protection or with increased
risk of HAM/TSP development; KIR2DL2 and IFN-λ3 rs8099917 (GG) polymorphism, associated with
HLA class I-restricted, may be involved in the pathogenic mechanism of HIV and HCV infections. All
of these polymorphisms should be studied in the future as potential markers in HTLV-1, as well for
HIV and HCV infected subjects.
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Abstract: Human T-cell leukemia virus type-1 (HTLV-1) is a tumorigenic retrovirus responsible for
development of adult T-cell leukemia/lymphoma (ATLL). This disease manifests after a long clinical
latency period of up to 2–3 decades. Two viral gene products, Tax and HBZ, have transforming
properties and play a role in the pathogenic process. Genetic and epigenetic cellular changes
also occur in HTLV-1-infected cells, which contribute to transformation and disease development.
However, the role of cellular factors in transformation is not completely understood. Herein, we
examined the role of protein arginine methyltransferase 5 (PRMT5) on HTLV-1-mediated cellular
transformation and viral gene expression. We found PRMT5 expression was upregulated during
HTLV-1-mediated T-cell transformation, as well as in established lymphocytic leukemia/lymphoma
cell lines and ATLL patient PBMCs. shRNA-mediated reduction in PRMT5 protein levels or its
inhibition by a small molecule inhibitor (PRMT5i) in HTLV-1-infected lymphocytes resulted in
increased viral gene expression and decreased cellular proliferation. PRMT5i also had selective
toxicity in HTLV-1-transformed T-cells. Finally, we demonstrated that PRMT5 and the HTLV-1 p30
protein had an additive inhibitory effect on HTLV-1 gene expression. Our study provides evidence
for PRMT5 as a host cell factor important in HTLV-1-mediated T-cell transformation, and a potential
target for ATLL treatment.
Keywords: HTLV-1; PRMT5; transformation; ATLL; Tax; HBZ; p30; lymphoma
1. Introduction
Human T-cell leukemia virus type-1 (HTLV-1) is a tumorigenic retrovirus that infects an estimated
15–20 million people worldwide [1]. This blood-borne pathogen is the causative infectious agent of
adult T-cell leukemia/lymphoma (ATLL), a disease of CD4+ T-cells [2–4]. HTLV-1 is also associated
with inflammatory disorders such as HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [5,6]. The likelihood of developing ATLL is between 2%–6% during the lifetime of an
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infected individual [7], with symptoms taking up to 20–30 years to present. Despite the long clinical
latency period, diseases such as ATLL are extremely aggressive and usually fatal. ATLL is highly
chemotherapy-resistant, and while many current therapies (e.g., antivirals AZT/IFN-α, proteasome
inhibitors, anti-CCR4 monoclonal antibody) improve ATLL patient survival (reviewed in [8]), the
patients consistently relapse.
As a complex retrovirus, HTLV-1 has a genome that encodes structural and enzymatic proteins
(Gag, Pro, Pol, Env), regulatory proteins (Tax and Rex), and several accessory proteins (p30, p12/p8,
HBZ). Studies have shown that at least two viral gene products, Tax and HBZ, have transforming
properties and play a role in the pathogenic process [9,10]. Tax acts as a viral transcriptional activator
of HTLV-1 gene expression through activation of the viral long terminal repeat (LTR) and various
cellular signaling pathways such as CREB, NF-κB, and AP-1 [11,12]. Tax also causes deregulation
of the cell cycle by silencing cellular checkpoints that guard against DNA structural damage and
abnormal chromosomal segregation, thus leading to the accumulation of mutations in HTLV-1 infected
cells [13]. However, Tax expression is lost in greater than 70% of ATLL cells due to genetic and/or
epigenetic changes in the HTLV-1 provirus, which include deletion or methylation of the viral 5' LTR.
These changes abolish expression of other viral genes with the exception of HBZ. In fact, HBZ is the
only viral gene that is intact and expressed in all ATLL cases [14,15]. HBZ protein is expressed from a
promoter located in the viral 3' LTR; current data indicates that HBZ promotes proliferation of ATLL
cells through both its mRNA and protein forms [15,16]. HBZ protein has also been shown to interact
with several cellular transcription factors such as CREB and CBP, p300, JunD, JunB, and c-Jun and to
act as a negative regulator of Tax-mediated HTLV-1 transcription [17–22].
Although Tax is indispensable for viral transformation, the mechanisms by which the virus
persists in vivo and transforms CD4+ T-cells are not completely understood. The requirement for Tax
and other viral proteins in vivo suggests that expression of viral proteins early in infection plays a major
role in viral replication, infected cell survival, and disease development. A favored theory within the
field is that the virus is critically dependent on Tax early in infection to initiate transformation, but
then Tax expression is highly regulated and often times silenced to prevent immune detection. HBZ
is hypothesized to provide the maintenance or cell survival signal necessary for the transformation
process. Over time, the combination of genetic and epigenetic changes in an HTLV-1-infected cell
can lead to transformation and potentially, disease development [23]. While we know that the viral
proteins Tax and HBZ are intimately involved in the cell transformation process, neither is sufficient,
which suggests the involvement of cellular factors.
Chromatin remodeling complexes and associated co-repressors such as histone deacetylases
(HDAC), DNA methyltransferases (DNMT), and protein arginine methyltransferase 5 (PRMT5)
participate in silencing tumor suppressor gene expression and contribute to cellular transformation [24–26].
Recent reports have indicated PRMT5 over-expression as relevant to the pathogenesis of many cancers,
including lymphomas, melanomas, and astrocytomas [27–32]. PRMT5 is a type II PRMT enzyme that
silences the transcription of key regulatory genes by symmetric di-methylation (S2Me) of arginine
(R) residues on histone proteins (H4R3 and H3R8) [33]. PRMT5 is also involved in a wide variety
of cellular processes, including RNA processing, transcriptional regulation, and signal transduction
pathway regulation that are highly relevant to the pathogenesis of cancer [34–36]. Recently, PRMT5
was found to play a critical role in Epstein-Barr virus (EBV)—driven B-cell transformation [31].
Our group previously identified PRMT5 as a binding partner of the HTLV-1 accessory protein
p30, using mass spectrometry [37]. p30 is encoded from a doubly spliced mRNA and is dispensable for
viral infection and T-cell transformation in vitro, but is required for establishment of viral persistence
in an in vivo rabbit model of infection [38,39]. p30 negatively regulates viral gene transcription at both
the transcriptional and post-transcriptional levels by competing with Tax for binding to CBP/p300
and retaining the tax/rex mRNA in the nucleus, respectively [40–42].
Currently, there have been no studies investigating the role of PRMT5 in T-cell malignancies,
including HTLV-1-associated disease. Therefore, we sought to determine if PRMT5 plays a role in
184
Viruses 2016, 8, 7
HTLV-1 transformation/malignancy. Indeed, we found PRMT5 levels were upregulated during T-cell
transformation and in established lymphocytic leukemia/lymphoma cell lines. Our data suggested
that PRMT5 negatively regulated HTLV-1 viral gene expression, which indicated that PRMT5 could be
an important cellular regulator of the viral transformation process. Furthermore, selective inhibition
of PRMT5 by a novel small molecule inhibitor (PRMT5i) in HTLV-1-positive cell lines reduced cell
survival; therefore, PRMT5 may represent an important therapeutic target for ATLL.
2. Materials and Methods
2.1. Cell Lines and Culture
HEK293T and pA-18G-BHK-21 cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) (Gemini Bio-Products, Broderick, CA, USA),
2 mM glutamine, penicillin (100 U/mL), and streptomycin (100 μg/mL). PBL-ACH and ACH.2 cells
(early passage HTLV-1-immortalized human T-cells) were maintained in RPMI 1640 supplemented
with 20% FBS, 10 U/mL recombinant human interleukin-2 (rhIL-2; Roche Applied Biosciences,
Indianapolis, IN, USA), 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. SLB-1
cells (HTLV-1-transformed T-cell line) were maintained in Iscove’s medium supplemented with 10%
FBS, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. C8166, MT-1, MT-2, Hut-102
(HTLV-1-transformed T-cell lines), Hut-78 and Jurkat cells (HTLV-1-negative transformed T-cell lines)
were maintained in RPMI 1640 supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin,
and 100 μg/mL streptomycin. TL-Om1, ATL-43T, and ATL-ED cells (ATL-derived T-cell lines) were
maintained in RPMI 1640 supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin, and
100 μg/mL streptomycin. ATL-55T cells (ATL-derived T-cell line) were maintained in RPMI 1640
supplemented with 20% FBS, 20 U/mL rhIL-2, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL
streptomycin. The parental 729.B (uninfected) and derivative 729.ACH (HTLV-1 producing) cell lines
were maintained in Iscove’s medium supplemented with 10% FBS, 2 mM glutamine, 100 U/mL
penicillin, and 100 μg/mL streptomycin. ACH-2 (HIV-1LAV) cells were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. ACH-2 cells (HIV-1LAV)
were maintained in RPMI 1640 supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin,
and 100 μg/mL streptomycin. All cells were grown at 37 ˝C in a humidified atmosphere of 5% CO2
and air. The SeAx cell line was derived from peripheral blood of a patient with Sezary syndrome
(kind gift from Dr. Henry Wong, The Ohio State University). Human PBMCs were isolated using
Ficoll-Paque PLUS (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and naïve T-cells were enriched
using a Pan T-Cell Isolation Kit (Miltenyi Biotec, Inc., Gaithersburg, MD, USA). Whole blood samples
obtained from ATLL patients were a generous gift from Dr. Lee Ratner (Washington University,
St. Louis, MO, USA).
2.2. Plasmids and Cloning
Plasmid DNA was purified on maxi-prep columns according to the manufacturer’s protocol
(Qiagen, Valencia, CA, USA). The flag-tagged PRMT5 expression vector was described previously [37].
p30 cDNA was cloned into the pcDNA3.1 expression vector (Invitrogen, Grand Island, NY, USA) to
create pcDNA3.1-p30. The S-tagged Tax and HBZ expression vectors contained Tax or HBZ cDNA
inserted into a pTriEx™-4 Neo vector (Novagen, Madison, WI, USA) for mammalian cell expression
of S-tagged Tax and HBZ proteins. The plasmid containing the wild-type HTLV-1 infectious proviral
clone, ACHneo, was described previously [43]. The LTR-1-luciferase reporter plasmid and transfection
efficiency control plasmid TK-renilla were described previously [41].
2.3. Immunoblotting
Cell lysates from luciferase assays were harvested in Passive Lysis Buffer (Promega, Madison,
WI, USA) containing protease inhibitor cocktail (Roche) and quantitated using an ND-1000 Nanodrop
185
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spectrophotometer (ThermoFisher, Waltham, MA, USA). All other cell lysates were harvested in NP-40
lysis buffer containing protease inhibitor cocktail, and were quantitated using the PierceTM BCA Protein
Assay Kit (ThermoFisher) and a FilterMax F5 Multi-Mode Microplate Reader (Molecular Devices,
Sunnyvale, CA, USA). Equivalent amounts of protein were separated in Mini-PROTEAN TGX™
Precast 4%–20% Gels (Bio-Rad, Hercules, CA, USA) and transferred to nitrocellulose membranes.
Membranes were blocked in PBS containing 5% milk and 0.1% Tween-20 and incubated with primary
antibody. The following antibodies were used: anti-PRMT5 (ab31751, 1:1000; Abcam, Cambridge,
MA, USA), anti-p19 (patient anti-sera specific for gag proteins), anti-Flag clone M2 (1:1000; Agilent,
Wilmington, DE, USA), anti-p30 (rabbit anti-sera), anti-Tax (rabbit anti-sera), anti-HBZ (rabbit anti-sera),
anti-p27 (1:250; Santa Cruz Biotechnology, Dallas, TX, USA), anti-p21 (1:250; Santa Cruz Biotechnology),
anti-cyclin B1 (1:250; Santa Cruz Biotechnology), and anti-β-actin 1:5000 (Sigma, St. Louis, MO,
USA). The secondary antibodies used were HRP goat-anti-rabbit and goat-anti-mouse (1:5000; Santa
Cruz Biotechnology). Blots were developed using Immunocruz Luminol Reagent (Santa Cruz
Biotechnology). Images were taken using the Amersham Imager 600 (GE Healthcare Life Sciences) and
densitometric data was calculated using the ImageQuantTL program (GE Healthcare Life Sciences).
2.4. Quantitative RT-PCR
Total RNA was isolated from 106 cells per condition using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. Isolated RNA was quantitated and DNase-treated
using recombinant DNase I (Roche). Reverse transcription was performed using the Omniscript RT Kit
(Qiagen) according to the manufacturer’s instructions. The instrumentation and general principles of
the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad) are described in detail in the operator’s
manual. PCR amplification was carried out in 96-well plates with optical caps. The final reaction
volume was 20 μL consisting of 10 μL iQ™ SYBR Green Supermix (Bio-Rad), 300 nM of each specific
primer, and 2 μL of cDNA template. For each run, sample cDNA and a no-template control were
assayed in triplicate. The reaction conditions were 95 ˝C for 5 min, followed by 40 cycles of 94 ˝C for
30 s, 56 ˝C for 30 s, and 72 ˝C for 45 s. Primer pairs to specifically detect viral mRNA species (tax, hbz),
prmt5, st7, and gapdh were described previously [28,44]. Data are presented in histogram form as
means with standard deviations from triplicate experiments.
2.5. Co-Culture Immortalization Assays
Long-term immortalization assays were performed as detailed previously [45]. Briefly, 2 ˆ 106
freshly isolated human PBMCs were co-cultivated at a 2:1 ratio with lethally irradiated cells (729.B
uninfected parental; 729.ACH HTLV-1-producing) in 24-well culture plates (media was supplemented
with 10 U/mL rhIL-2). HTLV-1 gene expression was confirmed by the detection of p19 Gag protein in
the culture supernatant, and was measured weekly by p19 ELISA (Zeptometrix, Buffalo, NY, USA).
Viable cells were counted weekly by Trypan blue dye exclusion.
2.6. Packaging and Infection of Lentivirus Vectors
Lentiviral vectors expressing five different PRMT5-directed shRNAs (target set RHS4533-EG10419),
and the universal negative control, pLKO.1 (RHS4080) were purchased from Open Biosystems
(Dharmacon, Lafayette, CO, USA) and propagated according to the manufacturer’s instructions.
HEK293T cells were transfected with lentiviral vector(s) expressing shRNAs, plus DNA vectors
encoding HIV Gag/Pol and VSV-G in 10-cm dishes with Lipofectamine2000 according to the
manufacturer’s instructions. Media containing lentiviral particles was collected 72 h later and filtered
through 0.45 μm pore size filters. Lentiviral particles were then concentrated using ultracentrifugation
in a Sorvall SW-41 swinging bucket rotor. Lymphoid cell lines were infected with the concentrated
lentivirus in 8 μg/mL polybrene by spinoculation at 2000 xg for 2 h at room temperature. HEK293T
cells were infected with the concentrated lentivirus in 8 μg/mL polybrene. After 72 h, stable cell lines
were selected by treatment with 1–2 μg/mL puromycin for 7 days.
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2.7. PRMT5i Treatment
A selective PRMT5 inhibitor (PRMT5i) drug was recently described by Alinari et al. [31]. Lymphoid
cells were seeded into a 12-well plate at 0.5 ˆ 106 cells/mL. Indicated concentrations of the PRMT5i
were added to duplicate wells. Cells were incubated at 37 ˝C for 48 h. After incubation, cell viability
and proliferation were measured. Cell viability was determined using Trypan blue dye exclusion.
Cellular proliferation was measured in duplicate in each condition using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega). Cells were collected by slow centrifugation (5 min,
800 xg) for downstream qRT-PCR analysis as described above.
2.8. HIV-1 Gene Expression in Chronically Infected Cells
ACH-2 (HIV-1LAV) cells were seeded into a 12-well plate at 1.6 ˆ 106 cells/mL. Indicated
concentrations of PRMT5i were added in triplicate wells. Cells were incubated at 37 ˝C for 48 h.
After incubation, 10 μL of culture supernatant was removed and freeze-thawed once for reverse
transcriptase (RT) assays. Briefly, 10 μL of culture supernatant was incubated overnight at 37 ˝C with
25 μL buffer (50 mM Tris-HCl pH 7.8, 75 mM KCl, 2 mM DTT, 5 mM MgCl2, 5 μg/mL Poly(dA:dT),
and 0.5% NP-40) containing 10 μCi/mL [α32P]-labeled dTTP (Perkin Elmer, Waltham, MA, USA).
A volume of 10 μL was spotted onto a DEAE filtermat (Perkin Elmer), air dried at room temperature,
then washed 5ˆ with 1ˆ saline-sodium citrate buffer (SSC) and 2ˆ with 85% ethanol. Filtermats
were air dried and exposed to a phosphorimaging screen for 2.5 h at room temperature. Density,
counts/mm2, was determined using the Typhoon Scanner (GE Healthcare Life Sciences) and Quantity
One software (Bio-Rad).
2.9. Transient Transfections, Reporter Assays, and p19 Gag ELISA
HEK293T cells were transfected using Lipofectamine2000 Transfection Reagent according to the
manufacturer’s instructions. Each transfection experiment was performed in triplicate and presented
as means plus standard deviations. In general, HEK293T cells in a 6-well dish were transfected
with approximately 1–2 μg total DNA consisting of 20 ng TK-renilla (transfection control), 100 ng
LTR-1-luciferase, 1 μg ACHneo, 500 ng Flag-PRMT5, 500 ng pcDNA3.1-p30, 100 ng S-tag-Tax, or
500 ng S-tag-HBZ, where indicated. HEK293T cells were harvested 48 h post-transfection in Passive
Lysis Buffer (Promega). Relative firefly and Renilla luciferase units were measured in a FilterMax
F5 Multi-Mode Microplate Reader using the Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s instructions. Each condition was performed in duplicate. Extracts
also were subjected to immunoblotting to verify equivalent protein levels. Cell supernatants (48 h)
were used for p19 ELISA (Zeptometrix).
2.10. Annexin V Staining
Lymphoid cells were seeded into a 6-well plate at 1 ˆ 106 cells/mL. Indicated concentrations
of the PRMT5i were added to the appropriate wells. Cells were incubated at 37 ˝C for 24 h. After
incubation, cells were collected by slow centrifugation (5 min, 800 xg) for apoptosis analysis via
flow cytometry. Collected cells were stained using the FITC Annexin V Apoptosis Detection Kit I
(BD Biosciences; San Diego, CA, USA) according to the manufacturer’s instructions.
2.11. ChIP Assays
pA-18G-BHK-21 cells are a Syrian Hamster kidney cell line stably transfected with a plasmid
vector containing the lacZ bacterial gene under the control of a HTLV-1-LTR promoter as previously
described [46]. pA-18G-BHK-21 cells were transfected in 10-cm dishes (1 μg ACHneo and 5 μg
flag-PRMT5) using Lipofectamine2000 according to the manufacturer’s instructions. Cells were
cross-linked in fresh 1% paraformaldehyde for 10 min at room temperature. The cross-linking reaction
was quenched using 125 mM glycine. Following cell lysis and DNA fragmentation by sonication,
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DNA-protein complexes were immunoprecipitated with anti-PRMT5 (Santa Cruz) and control
anti-IgG (Santa Cruz) antibodies. Immunoprecipitated DNA-protein complexes were washed
using sequential low-salt, high-salt, lithium chloride, and Tris-EDTA (TE) buffers. DNA was
purified using the Qiagen Gel Extraction Kit (Qiagen). The presence of specific DNA fragments
in each precipitate was detected using PCR. Primers used for amplifying the HTLV-1 LTR
were 5'-CCACAGGCGGGAGGCGGCAGAA-3' and 5'-TCATAAGCTCAGACCTCCGGGAAG-3'
and LacZ-coding region were 5'-AAAATGGTCTGCTGCTG-3' and 5'-TGGCTTCATCCACCACA-3'.
Quantification of each ChIP experiment was performed using ImageJ software.
3. Results
3.1. PRMT5 Was Upregulated in T-Cell Leukemia/Lymphoma Cells
Recently, PRMT5 over-expression was identified to be involved in the pathogenesis of hematologic
(lymphoma) and solid tumors (melanoma, astrocytomas) [27–32]. To determine whether PRMT5 is
important to HTLV-1 biology and pathogenesis, we first examined the levels of PRMT5 protein
(Figure 1A) and RNA (Figure 1B) in a wide variety of T lymphocytic leukemia/lymphoma cells,
including HTLV-1-transformed T-cell lines (PBL-ACH, ACH.2, SLB-1, Hut-102, MT-1, MT-2, C8166),
ATL-derived T-cell lines (TL-Om1, ATL-43T, ATL-55T, ATL-ED), HTLV-1-negative T-cell lines (SeAx,
Jurkat), and naïve primary T-cells. Both PRMT5 protein and RNA were upregulated in all T-cell
leukemia/lymphoma cell lines compared to naïve T-cells. Interestingly, although protein and
RNA levels were upregulated, PRMT5 RNA was not directly correlated to PRMT5 protein levels,
which suggested a post-transcriptional method of regulation. PRMT5 protein (Figure 1C) and RNA
(Figure 1D) were also upregulated in 3 of 4 and 4 of 4 PBMC samples from ATLL patients, respectively,
relative to HTLV-1-negative naïve T-cells.
Figure 1. Cont.
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Figure 1. PRMT5 was upregulated in T-cell leukemia/lymphoma cells. (A) Total cell lysates of
HTLV-1-transformed cell lines (PBL-ACH, ACH.2, SLB-1, Hut-102, MT-1, MT-2, C8166), ATL-derived
cell lines (TL-Om1, ATL-43T, ATL-55T, ATL-ED), HTLV-1-negative transformed cell lines (SeAx, Jurkat),
and naïve T-cells were subjected to immunoblot analysis to compare the levels of endogenous PRMT5
expression. β-Actin expression was used as a loading control. The amount of PRMT5 in each cell line
was measured relative to β-actin; the level of PRMT5 expression obtained with naïve T-cells was set at 1;
(B) Quantitative RT-PCR for PRMT5 and GAPDH was performed on mRNA isolated from cells in
panel A. Total PRMT5 mRNA level was determined using the ΔΔCt method [47] and normalized to
relative GAPDH levels. Data are presented in histogram form with means and standard deviations
from triplicate experiments; (C) Lysates of ATLL PBMCs from four independent donors and naïve
T-cells were subjected to immunoblot analysis to compare endogenous PRMT5 protein expression
levels. β-Actin expression was used as a loading control. The amount of PRMT5 in each condition
was measured relative to β-actin and depicted in histogram form; the level of expression obtained
with naïve T-cells was set to 1. Each sample was measured in duplicate; (D) Quantitative RT-PCR for
PRMT5 and GAPDH was performed on mRNA isolated from cells in panel C. Total PRMT5 mRNA
level was determined using the ΔΔCt method and normalized to relative GAPDH levels. Data are
presented in histogram form with means and standard deviations from triplicate experiments.
3.2. PRMT5 Levels Were Elevated during HTLV-1-Mediated Cellular Transformation
We next determined whether PRMT5 becomes dysregulated and over-expressed during
HTLV-1-driven T-cell transformation. Freshly isolated human PBMCs co-cultured with lethally
irradiated HTLV-1 producer cells (729.ACHi) in the presence of 10 U/mL of human IL-2 showed
progressive growth consistent with HTLV-1 immortalization (Figure 2A, left panel). As a control,
PBMCs co-cultured with lethally irradiated 729.B (HTLV-1-negative parental line) were unable to
sustain progressive growth. We also detected continuous accumulation of p19 Gag in the culture
supernatants of PBMCs co-cultured with 729.ACHi cells, which indicated viral replication and virion
production; as expected, irradiated HTLV-1 producer cells alone failed to grow or produce p19 over
time (Figure 2A, right panel). We examined PRMT5 protein (Figure 2B) and RNA (Figure 2C) levels
throughout the 10-week in vitro transformation assay. Protein and RNA were isolated from two
independent wells of cells at weekly time points. Our data revealed that PRMT5 protein and RNA
were upregulated at each time point, to varying degrees, throughout the transformation assay.
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Figure 2. PRMT5 levels were elevated during HTLV-1-mediated cellular transformation. Freshly
isolated PBMCs (2 ˆ 106 cells) were co-cultivated with 106 lethally irradiated 729.B uninfected parental
or 729.ACH HTLV-1-producer cells in 24-well plates. (A) A growth curve showing the immortalization
process as measured by T-cell number and ELISA data showing p19 Gag protein production at weekly
intervals are presented. Means and standard deviations of data from each time point were determined
from four random independent wells; Cells were also collected at weekly intervals and analyzed by
immunoblotting for PRMT5 protein expression (B); and qRT-PCR analysis for PRMT5 RNA levels (C).
PRMT5 levels are shown relative to an internal control (β-actin, GAPDH) for each time point. Resting
PBMC PRMT5 levels were set to 1. Means and standard deviations of data from each time point were
determined from two random independent wells.
3.3. Loss of Endogenous PRMT5 Increased HTLV-1 Gene Expression
To determine whether PRMT5 over-expression is a marker for T-cell transformation and/or
contributes to the process of HTLV-1 transformation, we utilized shRNA vectors to knockdown PRMT5
expression in three different HTLV-1-transformed cell lines. As shown in Figure 3A, shRNA-mediated
knockdown of endogenous PRMT5 expression in the early passage HTLV-1 immortalized T-cell line,
PBL-ACH, resulted in a significant increase of viral p19 Gag protein production (left and right panel)
and a significant increase in the levels of Tax and HBZ gene expression (middle panel). Knockdown
of PRMT5 expression likewise significantly increased Tax and HBZ transcript levels in another
HTLV-1-transformed cell line, SLB-1 (Figure 3B). Finally, knockdown of PRMT5 protein expression
in the Tax-negative ATL-derived T-cell line, TL-Om1, significantly increased HBZ transcript levels
(Figure 3C).
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Figure 3. Loss of endogenous PRMT5 increased HTLV-1 gene expression. (A) PBL-ACH cells
(HTLV-1-transformed) were infected with a pool of five different lentiviral vectors directed against
PRMT5, or control shRNAs. The cells were selected for 7 days using puromycin. Immunoblot analysis
was performed to compare the levels of PRMT5, p19 (Gag), and β-actin (loading control) in each
condition (left panel). Quantitative RT-PCR (middle panel) for Tax, HBZ, and GAPDH was performed
on mRNA isolated from shControl and shPRMT5 cells. Transcript levels were determined using the
ΔΔCt method and normalized to relative GAPDH levels. Levels of Tax and HBZ relative to GAPDH in
shControl cells were set to 1. Data are presented in histogram form with means and standard deviations
from triplicate experiments. HTLV-1 gene expression was quantified by the detection of the p19 Gag
protein in the culture supernatant using ELISA (right panel); (B) SLB-1 cells (HTLV-1-transformed)
were infected with a pool of five different lentiviral vectors directed against PRMT5 or control shRNAs.
The cells were selected for 7 days using puromycin. Immunoblot analysis was performed to compare
the levels of PRMT5 and β-actin protein (loading control) in each condition (left panel). Quantitative
RT-PCR for Tax, HBZ, and GAPDH was performed on mRNA isolated from shControl and shPRMT5
cells (right panel). Transcript levels were determined using the ΔΔCt method and normalized to
relative GAPDH levels. Data are presented in histogram form with means and standard deviations
from triplicate experiments. Levels of Tax and HBZ relative to GAPDH in shControl cells were set to 1;
(C) TL-Om1 cells (ATL-derived, Tax-negative) were infected with a pool of five different lentiviral
vectors directed against PRMT5, or control shRNAs. The cells were selected for 7 days using puromycin.
Immunoblot analysis was performed to compare the levels of PRMT5 and β-actin protein (loading
control) in each condition (left panel). Quantitative RT-PCR for HBZ and GAPDH was performed on
mRNA isolated from shControl and shPRMT5 cells (right panel). HBZ transcript level was determined
using the ΔΔCt method and normalized to relative GAPDH levels. Data are presented in histogram
form with means and standard deviations from triplicate experiments. Levels of HBZ relative to
GAPDH in shControl cells were set to 1. Student’s t test was performed to determine significant
differences in viral transcript levels between shControl and shPRMT5 cells; p < 0.05 (*).
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3.4. Selective Inhibition of PRMT5 Enhanced HTLV-1 Gene Expression
Recently, a first-in-class, small-molecule PRMT5 inhibitor (PRMT5i) was developed [31]. This
novel inhibitor selectively blocks S2Me-H4R3 (symmetric di-methylation of H4R3) but is inactive
against other type I and type II PRMT enzymes, which highlights its specificity for PRMT5. To evaluate
whether PRMT5 over-expression is a marker for T-cell transformation or contributes to the process of
HTLV-1 transformation, we treated six different HTLV-1-transformed cell lines with titrating amounts
of PRMT5i ranging from 10 μM to 50 μM. As shown in Figure 4A–D, inhibition of PRMT5 resulted
in a significant increase in Tax and HBZ viral gene expression in the HTLV-1-transformed T-cell lines
PBL-ACH, ACH.2 SLB-1, and Hut-102. ST7 transcript levels were measured as a control to ensure
successful PRMT5 inhibition because PRMT5 was reported to repress the tumor suppressor ST7 in
MCL [28]. Treatment with PRMT5i also resulted in a significant increase in HBZ transcript levels in
the Tax-negative, ATL-derived T-cell lines TL-Om1 and ATL-ED (Figure 4E,F). HTLV-1-negative cell
lines, Jurkat and Hut-78, were also treated with titrating amounts of PRMT5i. ST7 transcript levels
were measured to ensure successful PRMT5 inhibition (Figure 4G). PRMT5 expression levels were
examined and found to be relatively unchanged in all PRMT5i treated cells tested (western blot lower
panels; Figure 4A–G). ACH-2 cells (HIV-1LAV) were also treated with titrating amounts of PRMT5i
(Figure 4H) to examine if PRMT5 might regulate viral gene expression of another human retrovirus.
Treatment with PRMT5i did not significantly alter the expression of HIV-1 as measured by RT activity
in the cell supernatant.
3.5. Selective Inhibition of PRMT5 Decreased Cell Proliferation and Viability
In a recent report, PRMT5 was linked to proliferation in B-cell lines and MCL because knockdown
of PRMT5 expression reduced cell proliferation [28]. Treatment of HTLV-1-positive T-cell lines with
titrating amounts of PRMT5i or shRNA-mediated knockdown of PRMT5 resulted in a significant
decrease in cellular proliferation (Figure 5A,B) and cell viability (Figure 5C). Surprisingly, the
same dose of PRMT5i had minimal effects on proliferation and viability of Jurkat and Hut-78 cells
(HTLV-1-negative). The level of cellular apoptosis (Figure 5D) and senescence (Figure 5E–H) was also
measured in response to titrating amounts of PRMT5i treatment. The number of apoptotic cells was
increased in all cell lines in response to PRMT5i treatment; however, the amount of apoptotic cells in
HTLV-1-transformed lines was higher. We found a slight increase in the level of cellular senescence
(as measured by increased p21 and p27 levels and decreased cyclin B1 levels) in response to PRMT5i in
the HTLV-1-positive cell lines examined.
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Figure 4. Selective inhibition of PRMT5 enhanced HTLV-1 gene expression. (A) PBL-ACH, (B) ACH.2,
(C) SLB-1, (D) Hut-102, (E) TL-Om1, (F) ATL-ED, (G) Jurkat, and Hut-78 cells were treated with titrating
amounts of PRMT5i for 48 h. (PBL-ACH, ACH.2, SLB-1, and Hut-102 cells are HTLV-1-tranformed
lines; TL-Om1 and ATL-ED are ATL-derived Tax-negative lines; Jurkat and Hut-78 are HTLV-1 negative
lines.) Cells were collected by slow centrifugation at 800 xg for 5 min. Quantitative RT-PCR for Tax
(where indicated), HBZ (where indicated), ST7, and GAPDH was performed on mRNA isolated from
cells in each condition. Transcript level was determined using the ΔΔCt method and normalized to
relative GAPDH levels. Data are presented in histogram form with means and standard deviations
from duplicate experiments; vehicle-treated cells were set to 1 (upper panel). Student’s t test was
performed to determine significant differences in viral transcript levels between vehicle and inhibitor
treated cells; p < 0.05 (*). Inhibitor-treated cells were also subjected to immunoblot analysis to compare
the levels of endogenous PRMT5 expression. β-actin expression was used as a loading control (lower
panel); (H) ACH-2 cells were treated with titrating amounts of PRMT5i for 48 h. Average reverse
transcriptase (RT) activity of triplicate experiments is depicted.
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Figure 5. Selective inhibition of PRMT5 decreased cell proliferation and viability. (A) Cellular
proliferation was measured using an MTS cellular proliferation assay in Jurkat, Hut-78, PBL-ACH,
SLB-1, Hut-102, and TL-Om1 cell lines after 48 h of PRMT5i treatment. (Jurkat and Hut-78 are
HTLV-1 negative lines; PBL-ACH, SLB-1, and Hut-102 cells are HTLV-1-tranformed lines; TL-Om1 is
an ATL-derived Tax-negative line.) Data are presented in histogram form with mean and standard
deviations from duplicate experiments. Vehicle treatment for each cell type was set at 1. Student’s
t test was performed to determine significant differences in cellular proliferation between vehicle
and inhibitor-treated cells; p < 0.05 (*); (B) SLB-1 cells were infected with a pool of five different
lentiviral vectors directed against PRMT5 or control shRNAs. The cells were selected for 7 days
using puromycin. Immunoblot analysis was performed to compare the levels of PRMT5 and β-actin
protein (loading control) in each condition (right panel). Cellular proliferation was measured using
an MTS cellular proliferation assay (left panel); (C) Cellular viability was measured using Trypan
blue exclusion method in Jurkat, Hut-78, PBL-ACH, SLB-1, Hut-102, and TL-Om1 after 48 h of
PRMT5i treatment. Data are presented in histogram form with means and standard deviations from
duplicate experiments. Vehicle treatment for each cell type was set at 100% viability. Student’s
t test was performed to determine significant differences in cellular viability between vehicle and
inhibitor treated cells; p < 0.05 (*); (D) Cellular apoptosis was measured using a FITC Annexin V
Apoptosis Detection Kit as described in the Materials and Methods. The percentage of cells undergoing
apoptosis in vehicle (DMSO) treated cells was set at 1. The fold increase in apoptosis was measured in
Hut-78, SLB-1, Hut-102, and ATL-ED cells in response to titrating amounts of PRMT5i after 24 h of
treatment; (ATL-ED is an ATL-derived Tax-negative line.) (E–H) Immunoblot analysis was performed
in Hut-78, SLB-1, Hut-102, and ATL-ED cells after 24 h of PRMT5i treatment to compare the levels of
p21, p27, cyclin B1, and β-actin expression (loading control) in each condition (right panel).
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3.6. PRMT5 Negatively Regulated HTLV-1 Gene Expression
A recent report identified PRMT5 as a binding partner of the HTLV-1 accessory protein p30, a
known negative regulator of HTLV-1 gene expression [37]. To investigate the effect(s) of exogenous
PRMT5 on p30, HEK293T cells were transfected with a LTR-1-luciferase reporter vector (LTR-1-luc),
TK-renilla control, the ACHneo proviral clone, a flag-tagged PRMT5 expression vector, and a p30
expression vector as indicated (Figure 6A). Luciferase activity was measured after 48 h. The luciferase
activity of the empty control reflected the amount of Tax and therefore, was a measure of transcription
from the provirus. In the presence of either exogenous p30 or PRMT5, LTR-1-luciferase reporter was
significantly repressed (left panel). However, in the presence of both p30 and PRMT5, there was
an additive effect on LTR-1-luciferase repression. The amount of viral p19 Gag protein present in
the culture supernatant of each condition also was examined using ELISA, which provided another
method to quantify HTLV-1 gene expression (middle panel). Similar to the luciferase results, p30
and PRMT5 individually repressed viral p19 Gag production, and the presence of both p30 and
PRMT5 repressed viral gene transcription further. We next asked whether PRMT5 was required
for p30 function by transducing HEK293T cells with shRNA vectors directed against PRMT5 or a
scramble control (Figure 6B). Scramble and shPRMT5 HEK293T cell lines were selected for 7 days
using puromycin to ensure sufficient knockdown of endogenous PRMT5. After selection, each cell line
was transfected with LTR-1-luc, TK-renilla control, the ACHneo proviral clone, and a p30 expression
vector as indicated. Luciferase activity was measured after 48 h. Knockdown of endogenous PRMT5
significantly enhanced viral transcription, as measured by LTR-1-luciferase activity (left panel) and
p19 Gag ELISA (middle panel). In addition, reduced levels of PRMT5 did not significantly affect the
ability of p30 to repress viral transcription.
3.7. PRMT5 Did Not Affect Tax Transcriptional Function
We next asked what effect PRMT5 had on Tax and HBZ transcriptional activity. HEK293T cells
were transfected with LTR-1-luc, TK-renilla control, the ACHneo proviral clone, flag-PRMT5 expression
vector, S-tag-Tax expression vector, and S-tag-HBZ expression vector as indicated (Figure 7A). Tax
activated transcription while HBZ repressed Tax-mediated transcriptional activation (left and middle
panels), as expected [17–19]. In the presence of exogenous PRMT5, Tax transcriptional activity and
HBZ-mediated repression of Tax transcriptional activity were decreased. To determine if PRMT5 was
able to specifically repress Tax in the absence of other viral genes, HEK293T cells were transfected
with LTR-1-luc, TK-renilla control, flag-PRMT5 expression vector, and an S-tag-Tax expression vector
(Figure 7B). Tax was able to activate LTR-1-luciferase activity, while PRMT5 had no effect in the presence
or absence of Tax on LTR-1 luciferase activity. Our results suggested that PRMT5 requires the HTLV-1
proviral DNA to suppress Tax-induced LTR activation. To examine if viral factors other than Tax are
implicated in suppression of viral transcription by PRMT5, we examined the effect of HBZ or p30 with
PRMT5 on LTR-1 luciferase activity. HEK293T cells were transfected with LTR-1-luc, TK-renilla control,
flag-PRMT5 expression vector, and an S-tag-HBZ or p30 expression vector (Figure 7C,D). Neither HBZ
nor p30 activated or repressed LTR-1-luciferase activity in the absence of Tax, as expected [17–22,41,42].
Also, PRMT5 had no effect in the presence or absence of HBZ or p30 on LTR-1-luciferase activity. To
determine if PRMT5 associated with the viral LTR promoters in vivo, we performed ChIP assays using
pA-18G-BHK-21 cells. The Syrian Hamster kidney cell line was stably transfected with a plasmid
vector containing the HTLV-1-LTR promoter that drives expression of lacZ [46]. pA-18G-BHK-21 cells
were transfected with ACHneo proviral DNA and flag-PRMT5 expression vector (Figure 7E). PRMT5
was associated with the viral LTR, but not the downstream LacZ-coding region (negative control).
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Figure 6. PRMT5 negatively regulated HTLV-1 gene expression. (A) HEK293T cells were transfected
with 20 ng TK-renilla, 100 ng LTR-1-luciferase reporter, 1 μg ACHneo, 500 ng flag-PRMT5, and 500 ng
p30 expression plasmid as indicated. At 48 h post-transfection, cell lysates were collected and luciferase
levels measured; relative luciferase activity for each condition is shown (left panel). The decreases in
relative LTR-1-luc activity compared to control were significant (p < 0.05 (*)). HTLV-1 gene expression
was quantified by the detection of the p19 Gag protein in the culture supernatant of each condition
using ELISA (middle panel). The decreases in p19 Gag levels compared to control were significant
(p < 0.05 (*)). Immunoblot analysis was performed to compare the levels of PRMT5 (Flag), p30, and
β-actin (loading control) in each condition (right panel); (B) HEK293T cells were infected with a
pool of five different lentiviral vectors directed against PRMT5 or control shRNAs. The cells were
selected for 7 days using puromycin. HEK293T shControl and shPRMT5 cells were then transfected
with 20 ng TK-renilla, 100 ng LTR-1-luciferase reporter, 1 μg ACHneo, and 500 ng p30 expression
plasmid as indicated. Forty-eight hours post-transfection, cell lysates were collected, and luciferase
levels measured; relative luciferase activity for each condition is shown (left panel). The differences in
relative LTR-1-luc activity were significant (p < 0.05 (*)). HTLV-1 gene expression was quantified by
the detection of the p19 Gag protein in the culture supernatant of each condition using ELISA (middle
panel). The differences in p19 Gag levels were significant (p < 0.05 (*)). Immunoblot analysis was
performed to compare the levels of endogenous PRMT5, p30, and β-actin (loading control) in each
condition (right panel).
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Figure 7. PRMT5 did not affect Tax transcriptional function. (A) HEK293T cells were transfected with
20 ng TK-renilla, 100 ng LTR-1-luciferase reporter, 1 μg ACHneo, 100 ng S-tag-Tax, 500 ng S-tag-HBZ,
and 500 ng flag-PRMT5 as indicated. Forty-eight hours post-transfection, cell lysates were collected
and luciferase levels measured; relative luciferase activity for each condition is shown (left panel). The
differences in relative LTR-1-luc activity compared to control were significant (p < 0.05 (*)). HTLV-1
gene expression was quantified by the detection of the p19 Gag protein in the culture supernatant of
each condition using ELISA (middle panel). The differences in p19 Gag levels compared to control were
significant (p < 0.05 (*)). Immunoblot analysis was performed to compare the levels of PRMT5 (Flag),
Tax, HBZ, and β-actin (loading control) in each condition (right panel). All samples were analyzed
on the same nitrocellulose membrane; (B) HEK293T cells were transfected with 20 ng TK-renilla,
100 ng LTR-1-luciferase reporter, 100 ng S-tag-Tax, and titrating amounts of flag-PRMT5 as indicated.
Forty-eight hours post-transfection, cell lysates were collected, and luciferase levels measured; relative
luciferase activity for each condition is shown (upper panel). Immunoblot analysis was performed to
compare the levels of PRMT5 (Flag), Tax, and β-actin (loading control) in each condition (lower panel).
All samples were analyzed on the same nitrocellulose membrane; (C) HEK293T cells were transfected
with 20 ng TK-renilla, 100 ng LTR-1-luciferase reporter, 500 ng flag-PRMT5, and titrating amounts
of HBZ as indicated. Forty-eight hours post-transfection, cell lysates were collected and luciferase
levels measured; relative luciferase activity for each condition is shown (upper panel). Immunoblot
analysis was performed to compare the levels of PRMT5 (Flag), HBZ, and β-actin (loading control)
in each condition (lower panel); (D) HEK293T cells were transfected with 20 ng TK-renilla, 100 ng
LTR-1-luciferase reporter, 500 ng flag-PRMT5, and titrating amounts of p30 as indicated. Forty-eight
hours post-transfection, cell lysates were collected and luciferase levels measured; relative luciferase
activity for each condition is shown (upper panel). Immunoblot analysis was performed to compare
the levels of PRMT5 (Flag), p30, and β-actin (loading control) in each condition (lower panel); (E) ChIP
assays were performed on cross-linked chromatin from pA-18G-BHK-21 cells using either IgG or
PRMT5 antibodies, and the retained DNA was amplified using LTR or LacZ coding region-specific
primers. Fold-enrichment with each antibody was calculated relative to the IgG sample. Each ChIP
experiment was repeated twice in duplicate.
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4. Discussion
HTLV-1 is a tumorigenic retrovirus and the causative infectious agent of ATLL, an extremely
aggressive and fatal disease of CD4+ T-cells [2–4]. In culture, HTLV-1 can effectively immortalize
and eventually transform primary human T-cells. However, in infected individuals, the incidence of
disease is only 2%–6% [7] after an extensive clinical latency period. Evidence suggests both genetic
and epigenetic changes in the cellular environment that accumulate over time contribute to the
development of ATLL [23]. While many aspects of HTLV-1 biology have been revealed, the detailed
mechanisms of ATLL development remain poorly defined. Recently, the cellular protein PRMT5 has
been shown to play a critical role in EBV-driven B-cell transformation as well as the pathogenesis
of many types of hematologic and solid tumors [27–32]. We hypothesized that PRMT5 could be
important in HTLV-1-mediated cellular transformation and in regulation of viral replication. Given the
development of a novel small molecular inhibitor (PRMT5i) [31], identification of PRMT5 as a factor
during HTLV-1 transformation will provide valuable insights into improved strategies to treat patients
with ATLL.
To determine the importance of PRMT5 in HTLV-1-infected cells, we first examined the expression
level of endogenous PRMT5 in a variety of HTLV-1-transformed, ATLL-derived, and HTLV-1-negative
T-cells lines (Figure 1A). PRMT5 proteins levels were upregulated in HTLV-1-positive cells, but
also in all transformed T-cell lines, regardless of origin. This is not surprising given that PRMT5
over-expression has recently been identified in lung carcinoma, glioblastoma, B-cell lymphoma,
mantle cell lymphoma, and melanoma, to name just a few [28,31,48–50]. It appears that PRMT5
over-expression is a hallmark of most transformed cells, not specifically HTLV-1-transformed cells.
Previous work by Pal et al. found decreased PRMT5 mRNA levels in mantle cell lymphoma cell lines
despite abundant PRMT5 protein over-expression [28]. In this instance, the increase in PRMT5 protein
was not due to an increase in mRNA levels, but instead was due to a decrease in the inhibitory miRNAs
miR-92b and miR-96, which allowed for enhanced PRMT5 translation. Conversely, a recent report by
Shilo et al. found both PRMT5 protein and mRNA were upregulated in lung tumors [48]. We examined
the level of PRMT5 mRNA in a variety of HTLV-1-transformed, ATLL-derived, and HTLV-1-negative
T-cell lines and found that the PRMT5 mRNA level was increased in every transformed cell line relative
to naïve T-cells (Figure 1B). However, the increase in PRMT5 mRNA did not directly correlate with the
level of PRMT5 protein expression, which suggested some degree of post-transcriptional regulation.
Because these experiments were conducted in cell lines grown in vitro, we also examined the level of
PRMT5 protein and RNA in total PBMCs isolated from ATLL patients (Figure 1C,D). Both PRMT5
protein and RNA were upregulated in a majority of ATLL patient samples. The increased level of
PRMT5 RNA and protein expression in patient PBMCs was not as prominent as what was found in
transformed cell lines, likely due to the use of total PBMCs, which contain a mixture of normal and
leukemic cells.
HTLV-1 infection of CD4+ T-cells does not always lead to transformation. A delicate balance
must be achieved between viral gene expression and certain genetic and epigenetic events to result in
transformation. Using a long-term immortalization co-culture assay, we found both PRMT5 protein
and RNA were upregulated throughout the immortalization process (Figure 2). It is important to note
the producer cells were lethally irradiated, and although there was some residual p19 Gag detected in
the supernatant, the producer cells were dead by week 1. Since only a portion of the total co-culture
assay was tested, the levels of both protein and RNA fluctuated from week to week; however, the
overall trend showed that PRMT5 was upregulated.
Regulation of viral gene expression early after infection is highly relevant for successful
transformation; for example, too much Tax expression can cause a phenomenon known as Tax-induced
senescence (TIS) [51]. Using shRNA vectors directed against PRMT5, we found that knockdown of
PRMT5 enhanced HTLV-1 viral gene expression and decreased cellular proliferation in HTLV-1-infected
cell lines (Figures 3 and 5B). Given the importance of PRMT5 in cellular proliferation, long-term stable
cell lines were difficult to create. Thus, we transduced cells and selected with drug for less than two
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weeks, which provided the added benefit of less antigenic drift within the cell population over time.
Similar results were obtained using a novel, small molecule inhibitor of PRMT5 (Figure 4A–F). Because
Tax expression is lost in a majority of ATLL-transformed cells and only HBZ is expressed in every
cell, we included the Tax-negative ATLL transformed cell lines, TL-Om1 and ATL-ED, in our studies.
PRMT5 knockdown and inhibition enhanced HBZ expression in ATLL transformed cell lines. Of
interest, PRMT5i did not affect HIV-1 gene expression, which suggested that PRMT5 was not a global
repressor of all retrovirus gene expression (Figure 4G). Because Tax and HBZ are driven from separate
viral promoters (5' LTR and 3' LTR opposite strand, respectively), this finding would suggest that
PRMT5 is a global repressor of HTLV-1 transcription. In support of this hypothesis, we found PRMT5
associated with the viral LTR using ChIP analysis (Figure 7E).
Using reporter gene assays, we found PRMT5 inhibited HTLV-1 gene transcription, but not Tax
protein specifically (Figures 6 and 7A,B). We also found LTR promoter activation was unaffected
by PRMT5 (with or without viral accessory proteins HBZ or p30) in the absence of the proviral
genome (Figure 7B–D). This result was not surprising since one of the functions of HBZ is to repress
Tax-mediated transcriptional activation of the viral LTR and the function of p30 is to retain unspliced
tax/rex mRNA in the nucleus. Taken together, these results suggested that other viral proteins were
required for the repressive effects of PRMT5, and/or PRMT5 affected a cellular transcription factor
responsible for activating viral transcription. Although not required for the repressive effects of p30 on
viral gene expression, we did find PRMT5 and p30 had additive repressive effects on viral transcription,
which adds yet another level of regulation to HTLV-1 gene expression. The roles of additional PRMT5
interacting partners, such as MEP50, in PRMT5-mediated HTLV-1 gene regulation are also a possibility
to explore in the future. MEP50 is a WD-40 repeat protein and a common PRMT5 cofactor, likely
present in most PRMT5-containing complexes in vivo [52]. Phosphorylation of MEP50 by Cdk4 alters
the activity and targeting of the PRMT5 protein in cells [53].
Importantly, we found PRMT5i treatment or shRNA-mediated knockdown of PRMT5 in
HTLV-1-positive cell lines caused a decrease in cell proliferation compared to HTLV-1-negative
cell lines (Figure 5A,B). Furthermore, PRMT5i was selectively toxic to HTLV-1-positive cell lines
(Figure 5C). These results suggested that HTLV-1-positive cells rely strongly on PRMT5 for cellular
growth and survival. Treatment with PRMT5i induced cellular apoptosis to some degree in all cell lines
(Figure 5D). Interestingly, HTLV-1-transformed cell lines underwent noticeably more apoptosis than
either the HTLV-1-negative or the ATL-derived cell lines. Previous reports have found that aberrant
expression of Tax protein can lead to TIS in cells [51]. We did observe a slight increase in cellular
senescence in response to PRMT5i in the HTLV-1-positive cell lines tested, including Tax-expressing
HTLV-1-transformed cells and Tax-negative ATL-derived cells (Figure 5E–H). We would predict an
increase in cellular senescence in the HTLV-1-transformed cell lines, as they are the only Tax-expressing
lines. However, these cell lines also express HBZ, which has been reported to repress TIS. Another
possibility is the level of Tax expression induced in response to PRMT5i in our cell lines was not
substantial enough to elicit a measurable increase in cellular senescence. In summary, our study
highlighted the significance of PRMT5 in HTLV-1-mediated cellular transformation and its importance
as a target for the newly developed PRMT5i, presenting a viable strategy for treatment of ATLL.
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Abstract: Human T-cell leukemia virus type-1 (HTLV-1) Rex is a viral RNA binding protein. The most
important and well-known function of Rex is stabilizing and exporting viral mRNAs from the nucleus,
particularly for unspliced/partially-spliced mRNAs encoding the structural proteins essential for
viral replication. Without Rex, these unspliced viral mRNAs would otherwise be completely spliced.
Therefore, Rex is vital for the translation of structural proteins and the stabilization of viral genomic
RNA and, thus, for viral replication. Rex schedules the period of extensive viral replication and
suppression to enter latency. Although the importance of Rex in the viral life-cycle is well understood,
the underlying molecular mechanism of how Rex achieves its function has not been clarified.
For example, how does Rex protect unspliced/partially-spliced viral mRNAs from the host cellular
splicing machinery? How does Rex protect viral mRNAs, antigenic to eukaryotic cells, from cellular
mRNA surveillance mechanisms? Here we will discuss these mechanisms, which explain the function
of Rex as an organizer of HTLV-1 expression based on previously and recently discovered aspects of
Rex. We also focus on the potential influence of Rex on the homeostasis of the infected cell and how
it can exert its function.
Keywords: HTLV-1 Rex; pro-viral expression; unspliced RNA; NMD; alternative splicing; cell
cycle regulation
1. Molecular Events in the Host Cell Caused by HTLV-1 Infection
Infection of T-cells with human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia
(ATL), HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) and HTLV-1 uveitis
(HU) [1,2], although the molecular basis of such variations in the pathogenesis of HTLV-1 has not
been fully elucidated. The structure of the genomic HTLV-1 RNA and the molecular events triggered
by HTLV-1 infection have been thoroughly investigated [3–7]. Briefly, the genomic RNA of HTLV-1
is composed of 8685 nucleotides with two long terminal repeats (LTRs), which function as the viral
promoter, at the both 51 and 31 ends. Although the genomic RNA is compact, HTLV-1 has various RNA
signals to obtain the most out of its coding potential. By utilizing (1) three overlapped reading frames
with two -1 programmed ribosomal frameshift signal (-1PRF), (2) two alternative splicing sites, (3) and
multiple start and stop codons, HTLV-1 genomic RNA encodes more than 10 viral proteins [8]. HTLV-1
has three alternatively-spliced forms of viral mRNAs, which are unspliced, singly (partially)-spliced
and doubly (fully)-spliced. The unspliced HTLV-1 mRNA encodes Gag, Pro, and Pol proteins, while
singly-spliced RNA encodes Env. The doubly-spliced HTLV-1 mRNA encodes functional accessory
proteins, such as Tax, Rex, P30II, p12, p13 in sense open reading frames (ORFs) and HBZ (HTLV-1
basic leucine zipper factor protein) in an anti-sense ORF.
After integration to the human genome, transcription and translation from the HTLV-1 provirus
rely entirely on the host cell machinery. The translated viral accessory proteins then function in
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a precise schedule for effective viral replication [9,10] (Figure 1). The viral mRNA from the provirus
for the first round of transcription is completely spliced to tax/rex mRNA by the cellular splicing
machinery. Tax is more effectively translated from tax/rex mRNA because of its stronger Kozak
sequence compared with that of Rex [11]. Then, Tax stimulates the transactivation of LTRs for
enhanced tax/rex mRNA transcription. Such feed-forward activation of the HTLV-1 provirus results
in the gradual accumulation of Rex in the infected cell. Subsequently, accumulation of sufficient
Rex permits Rex-mediated nuclear export of unspliced and partially spliced viral RNA. The active
export of these viral mRNAs to the cytoplasm by Rex results in enhanced translation of the viral
structural proteins, Gag, Pro, Pol, and Env and, thereby, enhances viral replication. Inversely with the
active nuclear-export of unspliced and partially-spliced viral mRNA by Rex, that of tax/rex mRNA is
reduced; thus, cellular concentrations of Tax and Rex proteins are also decreased. Moreover, p30II
from the minor doubly-spliced viral mRNA binds and retains tax/rex mRNA in the nucleoli by its
strong nucleolar localization signal (NoLS). In combination, the cellular levels and activities of Tax
and Rex proteins are gradually reduced, and both viral expression and replication are diminished
to enter the latency. Rende et al. [12] mathematically analyzed the molecular events in early-phase
HTLV-1 infection and confirmed that viral expression was indeed divided into two phases. The first
phase was Tax/Rex expression, and the second phase was structural protein expression, which were
both controlled by the functions of Tax and Rex. Furthermore, they concluded that the two-phase
kinetics of HTLV-1 expression was strictly regulated by Rex, indicating that Rex is the major conductor
of HTLV-1 expression.
Figure 1. After HTLV-1 entry, the viral genomic RNA is reverse-transcribed and integrated into the host
human genome (1). The viral mRNA from the provirus for the first-round of transcription is completely
spliced to tax/rex mRNA by the cellular splicing machinery (2). Tax stimulates the transactivation of
LTRs for further viral transcription, resulting in the gradual accumulation of Rex in the infected cell (3).
Rex then starts exporting the unspliced and partially spliced viral mRNAs, encoding Gag, Pro, Pol,
and Env, to the cytoplasm by binding to RxRE of viral mRNA (4),resulting in active viral replication (5).
Due to active nuclear export of unspliced and partially spliced viral mRNA by Rex, that of tax/rex
mRNA is eventually reduced to enter the latency.
204
Viruses 2016, 8, 58
2. Canonical Rex Function as a Post-Transcriptional Regulator of Viral Expression
2.1. Rex-Dependent Nuclear Export of Viral mRNAs
Rex binds to the Rex Responsive Element (RxRE) of the HTLV-1 mRNAs to form Rex-viral
mRNA complex for selective nuclear-export. Unlike the Rev Responsive Element (RRE) in human
immunodeficiency virus type-1 (HIV-1) mRNAs, RxRE is in all HTLV-1 mRNAs [5,13]. The RxRE
of HTLV-1 mRNA maps to the region of 255 nucleotides (nt) from the U3 to the R region of the
31-LTR and forms a stable secondary structure with four stem loops. Such a unique structure of RxRE
is considered to function as the landmark for Rex to selectively bind to the viral mRNAs [14,15].
Although, all HTLV-1 derived mRNAs have RxRE, the nuclear export efficiency by Rex is different
among HTLV-1 mRNAs. It has been widely accepted that cytoplasmic accumulations of unspliced
and partially-spliced HTLV-1 mRNAs are Rex dependent, while that of fully spliced tax/rex mRNA
is suppressed by Rex [12,16]. Subsequently, Bai et al. demonstrated that Rex also stimulated the
nuclear-export of tax/rex mRNA and Tax expression, at least partially [17]. Most recently, Cavallari et al.
elegantly demonstrated that not only unspliced gag/pol mRNA and singly spliced env mRNA, but also
some of singly- and fully-spliced mRNAs encoding viral accessory proteins were also nuclear-exported
in Rex-dependent manner. They showed that p30II, p12/p8, and p13 mRNAs were Rex-dependent,
while tax/rex and p21rex mRNAs were Rex-independent. Interestingly, all Rex-dependent viral mRNAs
contain 75 nt intronic regions, which control Rex-dependency as a cis-acting sequence [18]. Another
study group demonstrated that HBZ, the antisense protein of HTLV-1, inhibited the nuclear-export
of intron-containing mRNA by Rex, thus inhibited active viral replication and induced latency [19].
These reports suggest that Rex-mediated nuclear exports of HTLV-1 mRNAs are finely-tuned by RxRE,
inherent cis-acting viral sequence, and viral proteins.
Rex binds to Chromosomal Maintenance 1 (CRM1), also known as Exportin 1 (XPO1), via
its nuclear export signal (NES) for nuclear export. CRM1 is a cellular nuclear export protein
which is responsible for the translocation of various cellular proteins with NES. Thus, the export
of HTLV-1 mRNAs to the cytoplasm is dependent on CRM1, which is separated from the bulk cellular
mRNAs exported in an Aly/Ref export-factor-dependent manner. The molecular mechanism of the
RxRE-Rex-CRM1 complex formation has been extensively studied by Hakata et al. [20,21]. The authors
revealed that the Rex has to be multimerized to bind to RxRE. They also propose a possibility that
CRM1 is involved not only in the translocation of Rex but also in its multimerization. Therefore,
one may speculate that Rex initially forms a complex with CRM1, which assists oligomerization of Rex
on CRM1 before binding to RxRE. Nevertheless, the detailed order of the complex formation has never
been investigated.
2.2. Primary Structure of Rex and Its Function
HTLV-1 Rex protein consists of 189 amino acids with its molecular weight of approximately 27 kDa.
The HTLV-1 Rex protein contains several functional domains essential for its function. The primary
structure of Rex has been well-described [22,23]. The N-terminal arginine-rich RNA-binding domain
(aa 1–19) is required for binding to RxRE. Additionally, this domain overlaps with the nuclear
localization signal (NLS), which is essential for Rex to shuttle-back to nucleus with importin-β,
and with the p30II-binding domain. Rex interacts with CRM1 through the NES (aa 66–118) for nuclear
export. Rex has two multimerization domains (aa 57–66 and 106–124) with NES in between and both of
them are considered to be necessary for stable oligomerization of Rex. Most recently, a stability domain
was identified at the C-terminal region of Rex (aa 170–189) [24–26]. The authors demonstrated that
deletion of the stability domain destabilized Rex significantly but did not influence the function of Rex.
2.3. Rex Activity and Phosphorylation
It has been described that the activity Rex is finely regulated through its phosphorylation [27]
at several serine(Ser)/threonine(Thr) residues [24]. The treatment of HUT102 (an HTLV-1-infected
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cell line) with a protein kinase C inhibitor, H-7 [1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine]
destabilized unspliced viral mRNA and reduced the expression level of Gag-p19 protein [27]. To date,
seven phosphorylation sites of Rex have been identified at Thr-22, Ser-36, Thr-37, Ser-70, Ser-97,
Ser-106, and Thr-174 [24,28]. Kesic et al. [24] evaluated the importance of phosphorylation sites and
demonstrated that Rex phosphorylation at Ser-97 and Thr-174 was the most critical for the efficiency of
RxRE-dependent nuclear export by Rex.
2.4. Regulation of Rex by Other HTLV-1 Viral Proteins
As described above, Rex plays a central role in selective expression of HTLV-1 viral structural
proteins and is, thus, in active viral reproduction. The Rex activity is critical to switch from the
early productive period to late latent period. Therefore Rex activity has to be finely tuned during
HTLV-1 infection. HTLV-1 has an elegant auto-regulatory mechanism to regulate the activity of Rex,
i.e., by two-phased HTLV-1 expression kinetics, which is described above (see Section 1), and by the
function of other viral proteins.
The suppressive function of p30II for the Rex has been well investigated, following extensive
reproduction of HTLV-1 virus by Tax and Rex, p30II is expressed from the minor doubly-spliced HTLV-1
mRNA. P30II selectively binds to tax/rex mRNA. Then, p30II, with a strong nucleolar localization signal
(NoLS), localizes and retained tax/rex mRNA in nucleoli, thus preventing their expression and functions.
Such time-lagged operations of the positive (Tax and Rex) and negative (p30II) regulators of HTLV-1
promotes the early infectious phase followed by the late infectious phase with a rapid shutdown to
escape from the host immune surveillance against pathogens [29–32]. On the other hand, Rex binds
to p30II and rescues tax/rex mRNA [32]. The timing of Rex-p30II interaction is considered to regulate
switching from the early active-viral-reproduction phase to the late rapid-shutdown phase to escape
from the host immune system. Most recently, HBZ, the antisense protein of HTLV-1, was demonstrated
to inhibit the nuclear-export of intron-containing mRNA by Rex, thus inhibiting active viral replication
and induced latency [19].
Since p21Rex is constitutively expressed in primary peripheral blood mononuclear cells from
HTLV-1 carriers and ATL patients [33–35], it has been expected that p21Rex plays a role in the
HTLV-1 life cycle, such as p27Rex suppressor as a dominant-negative isoform, although, a clear
biological function of p21Rex has not been elucidated, yet. P21Rex is expressed from a defective
HTLV-1 mRNA without the exon 2, and lacks the N-terminus 78 amino acids of p27Rex, ranging
from NLS to the N1-multimerization domain [36,37]. Without NLS, p21Rex localizes to the cytoplasm;
thus, the functional importance of this isoform has not yet been elucidated. More recently, Bai et al.
demonstrated that p21Rex neither nuclear-exported the viral mRNA, nor influenced the p27Rex
function [17]. Therefore, p21Rex seems not to be involved in HTLV-1 lifecycle as an isoform of Rex,
although possible roles of this short Rex isoform in the cellular biological pathways are required to be
elucidated in the future.
3. Non-Canonical Functions of Rex: Exploring New Aspects of Rex
3.1. NMD Inhibition by Rex
3.1.1. Rex Stabilizes HTLV-1 Genomic RNA by Inhibition of NMD
For viruses, stabilization of viral mRNAs in the host cells is a major issue to overcome for
self-replication [38]. Recently, a lot of attention has been directed towards one of the host mRNA
decay mechanisms in the host´pathogen interaction, Nonsense-mediated mRNA decay (NMD), and
has revealed how viruses evade NMD and protect viral mRNAs [39–42]. These reports have shown
that each virus has its own strategy to stabilize viral mRNAs; for example, by an inherent viral RNA
stabilization mechanism, utilizing host RNA stability factors, inhibition of the host mRNA decay
machinery, or hijacking the host cell RNA metabolism with viral nucleases [38,43].
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NMD is an essential and evolutionarily-conserved cellular mRNA quality control mechanism.
The principal function of NMD is to prevent the expression of harmful truncated proteins by selective
elimination of aberrant mRNAs containing premature termination codons (PTCs) (see reviews [43,44])
(Figure 2A). As indicated above, the major Rex function is the stabilization and export of the viral
unspliced and partially-spliced mRNAs to cytoplasm. However, unspliced HTLV-1 mRNA (i.e., viral
genomic RNA) contains various RNA signals, such as multiple start and stop codons, overlapping
ORFs, programmed ribosomal frameshift signals, and a long 31-untranslated region (>1000 nt). These
RNA signals are unusual for eukaryotic cells and have the potential to initiate NMD (Figure 2B).
However, it is not clear how HTLV-1 evades NMD to protect its genomic RNA. Our laboratory has
demonstrated that full-length HTLV-1 transcripts exhibit enhanced turnover in NMD-activated cells
that overexpress UPF1, while knockdown of UPF1 by small interfering (si) RNA promotes enhanced
stability of HTLV-1 genomic mRNA [45]. By confirming that the genomic and full-length mRNAs of
HTLV-1 are sensitive to NMD, we further demonstrated that Rex inhibited NMD. We suggest that
through the inhibition of NMD, Rex stabilizes viral transcripts in the cytoplasm to secure translation
of viral structural proteins. In contrast, it is highly probable that Rex also perturbs cellular mRNA
metabolism and host cell homeostasis by inhibition of the global NMD activity. It is noteworthy that
Rex-mediated inhibition of NMD is not RNA- or sequence-specific, but Rex establishes a general
blockage of NMD. Thus, not only the viral transcripts, but also natural host-encoded NMD substrates
are stabilized in the presence of Rex. We demonstrated that Rex stabilized well-known NMD target
mRNAs, such as IL-6, MAP3K14, and FYN mRNAs.
It has been reported that IL-2Rα mRNA was stabilized up to a five-fold level in Rex-overexpressing
cells compared with the control cells without Rex [46,47], although the underlying mechanism has not
been clarified. Since IL-2Rα mRNA can be a NMD target because of its upstream (u)-ORF structure, we
speculate that this mRNA is stabilized by Rex through NMD inhibition. Indeed, UPF1 knockdown
by siRNA in HeLa cells resulted in a significant increase in the IL-2Rα mRNA expression (Nakano
unpublished data).
3.1.2. How Does Rex Protect Viral mRNAs from NMD in the Cytoplasm?
NMD is a complex mechanism coupled with splicing and translation. Briefly, the core components
of NMD are UPF1, UPF2, and UPF3, which detect the PTC-containing mRNA to be degraded via
NMD, and SMG1, SMG5, SMG6, and SMG7, which phosphorylate/dephosphorylate UPF1 (Figure 2B).
This results in the regulation of the activity of UPF1, the key molecule of NMD. UPF1 is a component
of the termination complex, assembled when the ribosome reaches the termination codon of mRNA,
while UPF2 and UPF3 are components of the exon junction complex (EJC) formed at the exon-exon
boundary and are removed by the ribosome while it moves through. In normal mRNA, the termination
codon is in the last exon, thus EJC does not remain at the end of translation. In contrast, PTC is located
upstream of EJC, thus UPF1 on PTC comes into contact with UPF2 and UPF3, which triggers the
phosphorylation of UPF1 by SMG1, and the onset of NMD. Phosphorylated UPF1 is dephosphorylated
by the SMG5/SMG7 complex and recycled, while SMG7 completes the NMD process in mRNA
processing bodies (p-bodies) of the cytoplasm. Recently, it was reported that SMG6 functioned as
an endonuclease in the degradation of PTC-containing mRNA (see review [43]).
Since NMD machinery is coupled with splicing and translation apparatus, we speculate that Rex
may influence the overall NMD activity directly via interaction with NMD core-components, and
indirectly via interaction with splicing and translational machinery. Comprehensive protein-protein
interactome analysis between Rex and the host-cellular proteins by a high-resolution mass spectrometry
(MS) will be fruitful to understand the overall molecular landscape of NMD inhibition by Rex.
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Figure 2. (A) NMD is an essential and evolutionarily-conserved cellular mRNA quality control
mechanism. The principal function of NMD is to prevent the expression of harmful truncated proteins
by selective elimination of aberrant mRNAs containing premature termination codons (PTCs). It has
been reported that NMD also regulates the expression levels of normal mRNAs, which inherently
contain RNA signals to generate PTC: 1. Upstream (U)-ORF, 2. alternative splicing producing PTC,
3. intron in 31-UTR, 4. -1 programmed ribosomal frameshift signal (-1PRF) and 5. long 31-UTR more
than 1000 nt; (B) The genomic RNA of HTLV-1 contains various RNA signals potentially initiate NMD,
i.e., 1. multiple start and stop codons, 2. two alternative splicing sites, 3. intron in the 31-UTR region
of gag/pro/pol mRNA, 4. overlapping ORFs, and -1 PRF and 5. a long 31-UTR (>1000 nt). We reported
that HTLV-1 genomic RNA was indeed destabilized by NMD, and HTLV-1 Rex had a new function to
inhibit NMD [32].
3.2. Regulation of mRNA Splicing Machinery by Rex
It is well known that mRNA splicing is coupled with transcription, and virtually all primary
(unspliced) mRNAs are spliced at the site of transcription (see review [48]). Thus, HTLV-1 unspliced
and partially-spliced mRNAs cannot evade splicing only through selective nuclear export by Rex.
Consequently, we may speculate that Rex has a function to inhibit cellular splicing activity against the
viral mRNAs, which is independent of the well-known CRM1-dependent nuclear export mechanism of
Rex. Gröne et al. [49] demonstrated that Rex increased the nuclear quantity of unspliced viral mRNAs
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and reduced the number of spliced viral mRNAs. Since Rex did not influence the total quantity of
viral transcripts, the authors conclude that Rex has a function by which it reduces splicing activity.
SF2/ASF regulates splicing activity and plays an important role in the splice-site selection [48,50].
Splicing patterns of HTLV-1 mRNA are governed by SF2/ASF i.e., the differential pX splice site
utilization of HTLV-1 mRNA is dependent on the expression level of SF2/ASF [51], although the
viral mechanism to regulate the splicing activity through SF2/ASF has not been fully investigated.
Interestingly, Powell et al. [52] demonstrated that HIV-1 Rev suppressed cellular splicing activity
by recruiting SF2/ASF to the Rev-RRE RNP complex. Tange et al. [53] also showed the interaction
between Rev and p32, the ASF/SF2-associated protein. The authors speculated that the interaction
might function as a bridge between Rev and the host cellular splicing machinery. Considering the
homologous function and molecular mechanism of HTLV-1 Rex and HIV-Rev, it is possible that Rex
has a similar mechanism to suppress splicing machinery by binding and inhibiting the function
of SF2/ASF.
Heterogeneous Nuclear Ribonucleoprotein A1 (hnRNPA1) is another cellular protein which is
known to interact with Rex. hnRNPA1 associates with mRNA as a component of the RNP complex
in the nucleus and influences the transcription, maturation and transport of mRNA [54]. HnRNPA1
also plays a crucial role in the regulation of alternative splicing, mainly as a splicing suppressor [48].
A recent study clearly showed that the expression level of hnRNPA1 had strong implications for the
determination of exon-inclusion/skipping [55]. Hamaia et al. [56] first demonstrated that Rex function
was impaired in a T cell line not infected by HTLV-1, Jurkat, and speculated that Rex was unable to bind
to RxRE in the cell line. Later, the same study group found that hnRNPA1 bound to RxRE in competition
with Rex, thus influencing the function of Rex [57]. Subsequently, Kress et al. [58] demonstrated that
hnRNPA1 suppressed the Rex activity in a dose-dependent manner, while the suppression of hnRNPA1
in C91/PL, a HTLV-1-infected cell line, increased the Rex-dependent nuclear export of unspliced and
partially-spliced mRNA. The authors proposed the possibility that hnRNPA1 enhances the splicing
processes of viral mRNA. Indeed, hnRNPA1 caused enhanced exon 2 skipping in HTLV-1 mRNA [51].
On the other hand, the basal hnRNPA1 level was lower in HTLV-1-infected T cell lines (C91/PL,
MT2, and HUT102) compared with other T cell lines without HTLV-1 infection (CBL and Jurkat) [57].
The authors concluded that HTLV-1 may have a mechanism to downregulate hnRNPA1, which is not
advantageous for viral replication. Glutathione S-transferase (GST)-Rex pulldown assays conducted in
our laboratory showed that Rex physically interacted with hnRNPA1 (Nakano, unpublished data).
The underlying mechanism of how Rex is involved in the downregulation/inhibition of hnRNPA1
requires further investigation.
It has been shown that Rex changes the preference for exon usage during FYN mRNA
splicing/maturation from exon7B to exon7A, resulting in enhanced production of the brain-type Fyn-B
instead of the T cell-type Fyn-T [59]. Fyn is a proto-oncogene, belonging to the membrane-associated
tyrosine kinase family. Its overexpression/disorder has been implicated to the tumorigenesis of several
malignancies. Fyn has two major isoforms of distinct functions, Fyn-B expressed in the brain and
Fyn-T expressed exclusively in hematopoietic cells, which are derived from exon7A and exon7B,
respectively. Picard et al. [60] reported that the expression level of FYN-B mRNA was significantly
increased in acute lymphoblastic leukemia or chronic lymphocytic leukemia. As indicated above,
hnRNPA1, the regulator of exon usage, is downregulated in HTLV-1-infected cells. Moreover, we found
that Rex interacts with hnRNPA1. If Rex itself is involved in the downregulation and/or suppression
of hnRNPA1, such deregulation of hnRNPA1 function by Rex may have implications to alterations in
the exon usage during mRNA maturation, such as observed in FYN mRNA. Aberrant overexpression
of various splicing variants caused by genetic lesions in the splicing machinery may have implication
to the HTLV-1 pathogenesis.
Taken together, the biological significance of the molecular interactions between Rex and the
splicing-regulatory proteins in the regulation of splicing activity and splicing patterns requires
elucidation in the future.
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3.3. Cell-Cycle Regulation: Does Rex Interfere the Host Cell-Cycle Regulation?
A wealth of evidence has indicated that a number of viruses have mechanisms to modify cellular
cell-cycle regulation for the promotion of viral replication. It has been well documented and reviewed
that HIV-1 Vpr induces G2 arrest of the host cell-cycle [61–63]. The G2/M check point or DNA
damage checkpoint is regulated by the activity of the Cdc2 (Cdk1) and CyclynB complexes, which are
finely tuned by various kinases and phosphatases. Cdc2 undergoes inhibitory phosphorylation by
Wee1 and Myt1, or Chk1/2, which are activated by the ATM/ATR DNA damage response pathway.
Cdc25s are phosphatases and activate Cdc2 by dephosphorylation. When the cell senses DNA damage,
Cdc2 is inhibited by the ATM/ATR pathway, and the cell cycle is arrested at G2. At the G2/M
transition, PLK1 phosphorylates Cdc25s and Wee1 for activation and inhibition, respectively. Thus,
Cdc2 is activated to enter the M phase (see review [64]). Furthermore, PLK1 is phosphorylated and
activated by Aurora kinase A (AURKA) and its co-factor, Bora [65]. For the molecular mechanism of
G2 arrest by Vpr, Zhao and Elder [61] indicated the importance of the interaction between Vpr and
IκB kinase-associated serine/threonine protein phosphatase 2A (PP2A) in the induction of G2 arrest,
although the detailed mechanism has yet to be clarified. Goh et al. [66] demonstrated that Vpr interacts
with and inhibits Cdc25C. However, because Vpr is also known to activate ATR and Chk1 [67], it has
not been fully elucidated whether Vpr directly inhibits Cdc25C or does so through the ATR pathway.
Noronha et al. [68] investigated the influence of Vpr using a different methodology and showed that
Vpr altered the subcellular localization of CyclinB1, Wee1, and Cdc25C. These authors also found
that Vpr-induced herniations of the nuclear envelope and speculated that such disrupted nuclear
architecture might interrupt normal cell-cycle progression.
Why does HIV-1 Vpr induce G2 arrest? For viral replication, transcription from the provirus
and translation of viral proteins are dependent on the host machinery. It is thought that G2 arrest by
Vpr is beneficial for the selective translation of viral proteins (Figure 3). The m7G-Cap structure of
transcribed mRNA is first recognized by the Cap binding complex (CBC) and subjected to the pioneer
round of translation for the quality check of mRNA. Then, CBC is replaced by the eIF4F complex
for the steady-state translational procedure, which is regulated by eIF4E within the eIF4F complex.
It is thought that the translation of a viral protein from HIV-1 mRNA relies on CBC-dependent
pioneer-round translation, which is cell-cycle independent. In contrast, the major eIF4E-dependent
translation is inhibited during G2 phase. Therefore, G2-arrest by Vpr can enhance the translation
of viral proteins (see review [69]). Furthermore, Sharma et al. [70] elegantly demonstrated that Vpr
abrogates activated (phosphorylated) eIF4E levels. They also showed that CBC was retained at the
Cap structure of unspliced and partially-spliced HIV-1 mRNAs in the cytoplasm. Taken together, these
findings indicate that Vpr suppresses eIF4E activity by the reduction of its active form, as well as
by the induction of G2-arrest. Thus, only CBC-bound HIV-1 mRNAs can be effectively subjected to
cellular translational machinery (Figure 3). Most recently, it has been demonstrated that Vpr interacts
with and activates the SLX4 endonuclease complex, which activates the DNA damage/repair response
through the ATR/Chk1 pathway, resulting in G2 arrest [71].
HTLV-1, with a similar life-cycle to HIV-1, may have a similar strategy to enhance self-reproduction.
However, the HIV-1 Vpr homologue has not been identified among the HTLV-1-encoded proteins.
In the review by Zhao and Elder [61], they mention that HTLV-1 Tax showed similar characteristics to
HIV-1 Vpr, such as binding to PP2A and the induction G2 arrest. Haoudi et al. [72] first indicated that
Tax bound to and activated Chk2 in the DNA damage response, resulting in G2 arrest. Moreover, the
interaction between Tax and Chk2 was further investigated by the same group, and they subsequently
concluded that Tax inhibits the Chk2-induced DNA damage response through its retention in chromatin
in order to evade the cellular DNA damage response to Tax-induced DNA instability [73]. Another
study group also demonstrated that Tax bound to and inhibited the activity of Chk1, which is
also involved in the ATM/ATR-mediated DNA damage response [74]. Fu et al. [75] showed that
Tax interacted with PP2A to activate I kappa B kinase (IKK), thus influencing the nuclear factor
(NF)-κB pathway. Together, these previous reports indicate that Tax inhibits the ATM/ATR-dependent
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DNA damage response and, thus, is not likely to induce G2 arrest. Anupam et al. [76] conducted
a protein-interactome analysis for p30II and demonstrated that p30II interacted with ATM and
modulated the activity of the G2/M checkpoint. There have been no reports implicating Rex to
the cell-cycle regulation. Yet, we observed G2 arrest in CEM (ALL patient-derived human T cell
line) overexpressing Rex (Nakano, unpublished data). Rex has arginine-rich NLS at the N-terminus
similar to Vpr-NLS2, which is essential for G2 arrest. It has been demonstrated that eIF4E specifically
binds to the mRNAs of cell-cycle promoting proteins in nucleus and is exported by CRM1. This
mechanism is separated from TAP/NXF1 and REF/Aly-dependent export of bulk mRNAs [77–80].
Since Rex is also nuclear-exported by CRM1, we speculate that Rex may compete for CRM1 with eIF4E.
Consequently, Rex may suppress the eIF4E-CRM1-dependent nuclear export of mRNAs encoding
cell-cycle promoting proteins and, therefore, may induce cell-cycle arrest. The interaction between Rex
and eIF4E and other cell-cycle regulating proteins should be investigated in the future.
Figure 3. The G2-arrest by Vpr is beneficial for the selective translation of viral proteins. In the
regular mRNA translation, the m7G-Cap structure of transcribed mRNA is first recognized by the
Cap binding complex (CBC) and subjected to the pioneer round of translation for the quality check
of mRNA. Then, CBC is replaced by the eIF4F complex for the steady-state translational procedure,
which is regulated by eIF4E within the eIF4F complex. The majority of eIF4E-dependent translation is
inhibited during G2 phase. On the other hand, CBC-dependent pioneer-round translation is cell-cycle
independent. Since the translation of a viral protein from HIV-1 mRNA relies on CBC-dependent
pioneer-round translation, G2-arrest by Vpr can enhance the translation of viral proteins by suppressing
the eIF4E-dependent translation. Additionally, Vpr reduces the activated (phosphorylated) eIF4E level.
Taken together, Vpr assists selective translation of HIV-1 mRNAs by induction of G2-arrest, as well as
by suppression of eIF4E activity.
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4. Function of Rex and the Viral Pathogenesis
4.1. Do Rex-1/Rex-2 Functions Relate to the Pathogenesities of HTLV-1/HTLV-2?
Comparative analysis between Rex-1 (Rex) from HTLV-1 and Rex-2 from HTLV-2 can be helpful to
understand the relationship between the function of Rex and the viral pathogenesity [13]. Both HTLV-1
and HTLV-2 belong to the same genus [81] and infect human T cells. Both viruses encode a similar set
of viral proteins, including Tax and Rex and, thus, reproduce through a similar pathway. Yet, only
HTLV-1 causes ATL and HAM/TSP in infected T cells, but not HTLV-2. The primary structures
of Rex-1 and Rex-2 show 60% homology with common functional domains, such as RNA binding
domain (RBD)/NLS, two multimerization domains, nuclear export signal (NES), and stability domain
(SD) [24–26] and, thus, function as the viral RNA binding/transporting proteins through the common
cellular pathways. On the other hand, the position of RxRE in the viral mRNA is different between
HTLV-1 and HTLV-2, which may modulate impacts of Rex-1 and Rex-2 functions in their respective
viral life cycles [13]. It has been clarified that all HTLV-1 mRNAs have RxRE , which is located in the
U3/R region, while only unspliced HTLV-2 mRNA has RxRE, which is located in the R/U5 region [82].
Thus, it can be speculated that Rex-1 nuclear-exports all HTLV-1 mRNAs, including tax/rex mRNA,
which enhances Tax/Rex expression and, thus, viral reproduction, whereas Rex-2 does not, resulting
in a low viral production. Indeed, Bai et al. demonstrated that the nuclear export of the doubly spliced
tax/rex mRNA of HTLV-1 was also enhanced by Rex-1 in a RxRE-1/CRM1-dependent manner [17].
Differences in nuclear export efficiencies of viral mRNA/Rex/CRM1 complex between HTLV-1 and
HTLV-2 may influence viral replications and activities and, thus on pathogenesities of these viruses in
infected T cells.
4.2. HTLV-1 Rex and HIV-1 Rev: Are They Similar or Different?
4.2.1. HIV-1 Rev, the Molecular Counterpart of HTLV-1 Rex
Rev protein of HIV-1 (Human Immunodeficiency Virus type-I) is the molecular counterpart of
HTLV-1 Rex. HTLV-1 and HIV-1 both belong to the family of Retroviridae, and are further specified to
the genuses of Deltaretrovirus and Lentivirus, respectively. In addition, the major tropism of both viruses
is human CD4+ T cells. HTLV-1 and HIV-1 have genomic RNA of a similar size, i.e., about 8.5 knt
and 9.75 knt, respectively, which encodes viral proteins with considerably homologous functions.
HTLV-1 Rex and HIV-1 Rev bind viral mRNAs and shuttle between the nucleus and cytoplasm for
nuclear export of viral transcripts, through quite similar mechanisms yet, interestingly, the homology
between their amino acid sequences is very low [22,83]. Messenger-RNAs of HTLV-1 and HIV-1
have regions to form complex secondary structures called RxRE and RRE. Rex and Rev bind to viral
mRNAs thorough RxRE and RRE as highly-specific landmarks, respectively. In terms of primary
functional domains, both Rex and Rev have arginine-rich RNA binding domains for selective binding
to their respective responsive elements (Figure 4A). It has been well documented that Rex and Rev
stabilize unspliced and partially-spliced viral mRNAs, encoding viral structural proteins, and actively
transport them to the cytoplasm for selective translation (Figure 4B). For shuttling between nucleus and
cytoplasm, both proteins have NLSs for binding to importin-β and NESs for binding to CRM1 [23,83].
Furthermore, they bind to B-23 via NLSs to be translocated to the nucleolus [84–87] (Figure 4B).
While the uniform role and mechanism of Rex and Rev are extensively discussed, some differences in
the detailed molecular mechanism between Rex and Rev have been also described. It is now accepted
that multimerization is essential for Rex to interact with RxRE, yet the monomer Rex is still able to
bind to CRM1 for translocation to the cytoplasm [20–22]. Quite the opposite, the monomer Rev is
known to bind to RRE, however multimerization of Rev up to 12 molecules is necessary for stable
binding to CRM1 and for effective cytoplasmic-translocation [88,89]. These differences between these
two viral RNA binding proteins may be closely related to the nuclear export efficiency of viral mRNAs,
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thus, viral replication and, consequently, to different disease associations, i.e., ATL and HAM/TSP
with HTLV-1, and AIDS with HIV-1.
Figure 4. (A) The primary structures of HTLV-1 Rex and HIV-1 Rev. The homology in the primary
sequences of HTLV-1 Rex and HIV-1 Rev is low, but they share most of the functional domains critical
for their function, i.e., arginine-rich RNA binding domain, NLS, NES, and two multimerization domains;
(B) HTLV-1 Rex and HIV-1 Rev play similar functions through similar mechanisms. In the nucleolus,
Rex and Rev specifically bind to the respective viral mRNAs through Rex responsive element (RxRE)
for Rex and the Rev responsive element (RRE) for Rev. They stabilize unspliced or partially-spliced viral
mRNA and actively transport these to the cytoplasm for selective translation of viral structural proteins
by CRM1 binding through their NES. Rex and Rev return to the nucleus by binding to Importin-β, and
further translocated to the nucleolus (No) by binding to B-23 via NLS.
4.2.2. The Structural Biology of HTLV-1 Rex; Learning from that of HIV-1 Rev
Along with accumulation of knowledge in the molecular characteristics and functions, both Rex
and Rev propose a common question; how these small viral proteins bind to RxRE/RRE of viral
mRNAs and CRM1 simultaneously, and how they form a large, but stable, RNP complex for the
nuclear export of viral mRNAs. To answer these questions, information from the structural biology
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may contribute significantly. In terms of structural biology, investigations into Rev have progressed far
more than those of Rex. In contrast, our knowledge of the structure of Rex has not been updated from
that of the N-terminal arginine-rich domain (aa 1–16) of the Rex peptide solved by nuclear magnetic
resonance [90]. On the contrary, great efforts have been made to obtain the structural information on
the Rev´Rev dimer interface or the Rev´RRE interaction since the early 2000’s. Daugherty et al. [91]
clarified for the first time that Rev formed a homo-oligomer on the RRE via an oligomerization
domain. In 2010, two different groups reported the partial structure of Rev in a dimer form [92,93].
Daugherty et al. [93] proposed the “jellyfish model” in which a rigid Rev dimer(s) forms an oligomeric
structure, similar to the head of a jelly fish, while an unstructured NES region extended from each
Rev molecule to form a tentacle-like alignment in binding to CRM1. They also mentioned that at the
RNA-binding surfaces, “the two ARMs are arranged to reach out from the body of the Rev dimer to
grasp RNA, much as two human arms are positioned to grip objects”.
Based on the Rev structure, the detailed molecular mechanism of HIV-1 viral mRNA nuclear
export by Rev has since been clarified greatly. Fang et al. [94] investigated the structure of RRE
thoroughly and demonstrated that RRE functioned as the topological landmark for Rev by forming an
unusual structure, to which only Rev was able to specifically bind with high affinity. Finally, it was
demonstrated that the RRE-Rev-CRM1 “HIV-1 export complex” was assembled co-transcriptionally
at the transcription site, thus unspliced HIV-1 mRNAs were stably exported from the nucleus [95].
Moreover, it has been demonstrated that RRE-Rev assembly starts with changes in the RRE structure
so that binding to the first two dimer complexes of Rev leads to further conformational changes of
RRE, triggering oligomerization of Rev [96]. This enables stable binding to the CRM1 dimer [97].
Structural analysis of the Rev-dimer and RRE complex revealed that the Rev-dimer architecture can be
flexibly altered depending on the structure of RRE [98]. The authors speculated that such changes in
RRE structure and in the Rev-dimer architecture might alter the whole architecture of the “jellyfish
complex” i.e., the RRE-Rev-CRM1 complex. Overall, the structural biology of Rev indeed provided
tremendous information to clarify the regulatory mechanism of the nuclear export efficiency of the
HIV-1 export complex, thus resulting in pathogenesis of HIV-1. At present, the same questions still
remain for HTLV-1 Rex. The structural biology of Rex is promising to provide significant information
to answer these questions in the future.
5. Conclusions
Accumulating data on the analysis of the Rex interactome shows that Rex has a significantly
high potential to interact with a wide variety of cellular proteins. These cellular proteins are crucial
for the maintenance of the cellular homeostasis by playing essential roles in mRNA surveillance
and metabolism, nucleo-cytoplasmic shuttling, tumor growth regulation and in post-translational
modification of proteins, such as SUMOylation [13,99,100]. These data strongly suggest that Rex
modifies a wide range of cellular pathways in order to organize the host cellular environment suitable
for the stabilization and translocation of viral mRNAs, as well as for selective translation of viral
proteins for effective self-replication (Figure 5A). Such Rex-oriented tuning of the host cell environment
can alter cellular homeostasis, and thus may provide a basis for the pathogenesis of HTLV-1 (Figure 5B).
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Figure 5. In this review, we focused on three cellular pathways, NMD, splicing machinery, and
cell-cycle regulation, since we may expect that Rex interacts with these pathways to adjust the
cellular environment suitable for the viral replication. (A) In the normal cells, the activities of NMD,
splicing, and cell-cycle regulation are optimized to maintain the cellular homeostasis by eliminating
PTC-containing harmful mRNAs, production of correctly spliced mRNAs encoding functional proteins,
and adjusting the cell-cycle for n optimal cell proliferation rate and for effective eIF4E-dependent
RNA translations, respectively; (B) In HTLV-1 infected cells, Rex inhibits NMD for stabilization of
the viral genomic mRNA [32]. Additionally, based on previous reports and newly discovered aspects
of Rex in our laboratory, we assume that Rex may suppress the activity of splicing machinery and
may induce G2 arrest. These adjustments of host-cell mechanisms are favorable for the stabilization
and translocation of viral mRNAs, as well as for selective translation of viral proteins for effective
self-replication. On the other hand, suppression/alteration in these pathways may cause accumulation
of abnormal PTC-containing mRNAs, thus harmful proteins; abnormal splicing patterns; deregulated
cell proliferation; and suppression of eIF4E-dependent translation. Therefore, Rex-oriented tuning of
the host cell environment may alter cellular homeostasis, and provide a basis for the pathogenesis
of HTLV-1.
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Abstract: The Gag polyprotein is the main retroviral structural protein and is essential for the
assembly and release of virus particles. In this study, we have analyzed the morphology and
Gag stoichiometry of human T-cell leukemia virus type 1 (HTLV-1)-like particles and authentic,
mature HTLV-1 particles by using cryogenic transmission electron microscopy (cryo-TEM) and
scanning transmission electron microscopy (STEM). HTLV-1-like particles mimicked the morphology
of immature authentic HTLV-1 virions. Importantly, we have observed for the first time that the
morphology of these virus-like particles (VLPs) has the unique local feature of a flat Gag lattice that
does not follow the curvature of the viral membrane, resulting in an enlarged distance between the
Gag lattice and the viral membrane. Other morphological features that have been previously observed
with other retroviruses include: (1) a Gag lattice with multiple discontinuities; (2) membrane regions
associated with the Gag lattice that exhibited a string of bead-like densities at the inner leaflet; and
(3) an arrangement of the Gag lattice resembling a railroad track. Measurement of the average size
and mass of VLPs and authentic HTLV-1 particles suggested a consistent range of size and Gag copy
numbers in these two groups of particles. The unique local flat Gag lattice morphological feature
observed suggests that HTLV-1 Gag could be arranged in a lattice structure that is distinct from that
of other retroviruses characterized to date.
Keywords: deltaretrovirus; lentivirus; virus assembly
1. Introduction
Approximately 10–20 million people are infected with human T-cell leukemia virus type 1
(HTLV-1) worldwide [1,2]. HTLV-1 is a deltaretrovirus and is associated with adult T-cell leukemia/
lymphoma, tropical spastic paraparesis, as well as HTLV-1-associated myelopathy [3,4]. These diseases
are prevalent in places highly endemic for HTLV-1 infection such as southwestern Japan, central Africa,
South America and the Caribbean. Despite the association of HTLV-1 with cancer and its significant
impact on human health and well-being, the molecular mechanisms of viral replication, virus particle
assembly and morphology remain poorly understood due to difficulties in propagating the virus in
tissue culture.
Like other retroviruses, the assembly and budding of HTLV-1 particles is directed by the viral Gag
polyprotein (recently reviewed by Maldonado et al. [5]). Briefly, HTLV-1 Gag molecules translocate to
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the plasma membrane (PM) soon after the protein is synthesized [6]. A previous study with human
immunodeficiency virus type 1 (HIV-1) suggested that the viral RNA is recruited to the PM by Gag and
serves as a platform to promote Gag-Gag interactions, allowing Gag to form higher order oligomers
in immature particles [7]. Infectious virions are produced via a maturation process that occurs either
concomitantly with or after budding of the immature virus. During virus maturation, the viral protease
(PR) cleaves the Gag polyprotein into three structural proteins: matrix (MA), which remains associated
with the inner leaflet of the viral membrane; capsid (CA), which organizes into a closed protein shell
to package the genomic RNA; and nucleocapsid (NC) which is in complex with the viral genome.
The diameters of retrovirus particles are typically variable and commonly appear to form a normal
distribution [8–16]. Calculations of the average Gag copy number per virus particle vary somewhat
depending on the methods used for the measurement as well as on the type of retrovirus being
analyzed. Scanning transmission electron microscopy (STEM) has previously been used successfully to
determine the average Gag copy number per particle [9,10,15–18]. This method estimates the mass of
the whole virus particle. Since the majority of the virus particle mass is contributed by Gag, the mass
of the entire particle has been used for calculating the Gag stoichiometry. Multiple studies have
reported varying Gag copy numbers, ranging from approximately 750 to 5000, which coincide with
varying virus particle size distributions [10,12,13,15–19]. To date, there are no reported studies on
Gag stoichiometry that would be present in the immature precursors of authentic, mature HTLV-1
particles. Determination of Gag stoichiometry is critical to understanding the mechanisms of HTLV-1
replication, for this information assists in the interpretation of HTLV-1 particle structures, and helps in
determining the copy number of other viral proteins in the virus particle (e.g., Pol).
In this study, a comparative analysis of HTLV-1-like particles and authentic, mature HTLV-1
particles was performed by cryogenic transmission electron microscopy (cryo-TEM) and scanning
transmission electron microscopy (STEM). These findings provide the first demonstration of the
morphology of these virus-like particles (VLPs) having the unique feature of local flat Gag lattice
regions that did not follow the curvature of the viral membrane and had an enlarged distance toward
the membrane. Morphological features similar to that observed with other retroviruses [20] include
(1) a Gag lattice with multiple discontinuities; (2) a string of bead-like densities at the inner leaflet
that is associated with the Gag lattice; and (3) a Gag lattice resembling a railroad track. We also
demonstrate that HTLV-1-like particles and authentic mature HTLV-1 particles possess a consistent
size and Gag stoichiometry.
2. Materials and Methods
2.1. Transfection and HTLV-1-Like Particle Production
A codon-optimized HTLV-1 gag gene expression construct (pN3 HTLV-1 Gag, Figure 1A) was
created in a similar manner to that of a previously described construct in which the yellow fluorescence
protein (YFP) was fused to the carboxy-terminus of Gag (pEYFP-N3 HTLV-1 Gag) [21]. The new gag
gene which does not have a YFP tag was synthesized with an optimal Kozak consensus sequence at
the 51 end of the gene: GCCACCATGG (start codon in bold and underlined) (Figure 1A). In order to
produce VLPs, six 10 cm tissue culture dishes each containing 2.2 ˆ 106 human embryonic kidney
293T cells in 6 mL of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Fetal
Clone III were co-transfected with the pN3-HTLV-1 Gag expression construct along with an HTLV-1
envelope protein expression construct (ratio of 10:1) using GeneJet (SignaGen, Gaithersburg, MD,
USA) following the manufacturer’s instructions. Twenty-four hours post-transfection, 2 mL of fresh
media were added to each plate and incubated for additional 24 h at 37 ˝C in 5% CO2. To harvest
VLPs, cell culture supernatants from transfected cells were centrifuged at 3000ˆ g for 5 min to remove
large cellular debris and then filtered through a 0.2 μm filter. The samples were then concentrated and
purified in the same manner as with authentic particles.
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Figure 1. Analysis of the diameter and morphology of human T-cell leukemia virus type 1 (HTLV-1)
virus-like particles (VLPs) by transmission electron microscopy (TEM). (A) HTLV-1-like particle
expression construct. A codon-optimized Gag expression construct (pN3 HTLV-1 Gag) with a Kozak
sequence was used to produce HTLV-1 VLPs; (B) Representative micrograph of HTLV-1-like particles
of different sizes and morphology; (C) Size distribution of HTLV-1-like VLPs.
2.2. Gradient Purification of Authentic Virus Particles and VLPs
Authentic HTLV-1 particles were produced from MT-2 cells, a T-cell line chronically infected with
HTLV-1, which was obtained from Dr. Douglas Richman through the NIH AIDS Reagent Program,
Division of Acquired Immune Deficiency Syndrome (AIDS), National Institute of Allergy and Infectious
Diseases (NIAID), National Institutes of Health (NIH) [22,23]. MT-2 cells were grown in two T-75
flasks with up to 60 mL of Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with
10% Fetal Clone III, for ~10 days. After the cells reached about 90% confluency, which was indicative
by the formation of large cell clumps, virus particles were harvested and centrifuged at 3000ˆ g for
5 min to remove large cellular debris and then filtered through a 0.2 μm filter.
The concentrated particles (i.e., authentic virus particles or VLPs) were then ultracentrifuged
through an 8% OptiPrep (60% iodixanol in water with a density of 1.32 g/mL, (Sigma-Aldrich,
St. Louis, MO, USA) cushion at 109,000ˆ g for 1.5 h in a 50.1 Ti rotor (Beckman, Brea, CA, USA) at
4 ˝C. The particle pellet was resuspended in 0.5 mL of 1ˆ STE buffer (100 mM NaCl , 10 mM Tris-Cl,
pH 7.4, 1 mM sodium chloride-Tris-ethylenediaminetetraacetic acid (EDTA), and overlaid onto a 4 mL
10%–40% OptiPrep gradient and centrifuged to equilibrium in a SW55 Ti rotor (Beckman) at 250,000ˆ g
for 3 h at 4 ˝C. The virus- or VLP-containing fraction, at about 20% OptiPrep, was removed from the
gradient using a hypodermic needle. The collected virus particles were diluted 10 fold in 1 ˆ STE
and pelleted at 195,000ˆ g for 1 h in a SW55 Ti rotor at 4 ˝C. Following centrifugation, the pellet
was re-suspended in ~15 μL of 1 ˆ STE at 4 ˝C overnight and then analyzed by cryo-TEM or STEM.
The compound 2, 21-dithiodipyridine (aldrithiol-2; AT-2) was used to inactivate authentic HTLV-1
infectivity prior to cryo-TEM or STEM analysis as previously described [24].
2.3. Cryo-TEM of HTLV-1-Like Particles and Authentic Virus Particles
Virus and VLP samples were prepared for cryo-TEM as previously described [21]. Briefly, 3 μL
concentrated virus or VLP sample was applied to a glow-discharged c-flat holey carbon grid (Ted Pella,
Redding, CA, USA) and then blotted with filter paper to remove the sample excess. The grid was then
plunged frozen into liquid ethane [25] with a FEI MarkIII Vitrobot system (FEI Company, Hillsboro,
OR, USA). The frozen grids were then transferred to a FEI TF30 field emission gun transmission
electron microscope at liquid nitrogen temperature (FEI Company). Images were then recorded at a
nominal magnification of 39,000_x and 59,000_x at low-dose (~30 electrons/Å2) and 1 to 5 μm under
focus conditions using a Gatan 4 k by 4 k CCD camera (Gatan Inc., Pleasanton, CA, USA).
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2.4. Determination of Particle Size
Cryo-TEM images were analyzed by using ImageJ software (Version 1.49c, NIH, Bethesda, MD,
USA). For each virus particle or VLP analyzed, two perpendicular diameters were used to calculate
the average diameter [21]. Histograms of particle diameters were generated by using GraphPad Prism
6 software (Version 6.0c, GraphPad, La Jolla, CA, USA).
2.5. Determination of Particle Mass by STEM
The mass of virus particles or VLPs was determined by quantitative dark-field STEM, which
was developed at the Brookhaven National Laboratory (BNL, Upton, NY, USA) [26]. This method
allows for the study of individual unstained virus particles with minimal radiation damage. The
particle sample was first mixed with tobacco mosaic virus (TMV) particles that were used as an internal
control. Then the mixture was applied onto a thin-carbon transmission electronic microscopy (TEM)
grid, extensively washed, blotted and freeze-dried overnight. The TEM grid was imaged under a
40 keV electron beam at ´150 ˝C. The grid was first scanned with a low dose electron beam and areas
with clean background were used for the final scan. Prior to the final scanning, the electron beam
was focused in a nearby area to minimize radiation damage to the specimen. The low temperature
and low dose imaging technique (<500 electrons/nm2) was used to help to reduce mass loss (less
than 1%) caused by electron radiation as well as to eliminate contamination from mobile hydrocarbons.
Each point in the STEM image corresponds to an area of 0.625 nm2 over the specimen. The whole
image corresponds to 512 by 512 nm in the specimen with the center of the points separated by 1 nm.
A large- and a small-angle annular dark-field detector were used to digitally record the number of
scattered electrons in each scanning point. The number of scattered electrons at any scanning point is
proportional to the sample mass in that local region.
STEM images were analyzed by using the PCMass software developed by the BNL STEM facility
(Version 32, Brookhaven National Laboratory, Upton, New York, USA). Each virus particle or VLP in
the STEM micrograph was first masked by a density profile model (i.e., a sphere) in order to mimic
the virus density profile. The diameter of the sphere was based on the dimension of the measured
particle. The mass of each virus particle was then calculated using the sum of the electron densities
within the mask and a scale factor, which was determined using the image of TMV and its mass per
unit length (i.e., 13.1 kDa/Å) [26,27]. The resulting histograms and graphs of particle mass distribution
were generated by using GraphPad Prism 6 software (Version 6.0c, GraphPad, La Jolla, CA, USA).
3. Results
3.1. Analysis of the Morphology of HTLV-1-Like Particles
HTLV-1-like particles produced using the HTLV-1 Gag-only expression construct (Figure 1A) were
observed to be spherical in shape with a mean diameter of 110 ˘ 32 nm measured from 1172 particles
(Figure 1B,C). This is in contrast to a previous study using a Gag-YFP expression construct in which a
mean particle diameter of 71 ˘ 20 nm was determined by cryo-TEM [21]. The electron density adjacent
to the inner viral membrane was interpreted as being the immature Gag lattice. All particles with this
electron density pattern were counted as Gag-containing particles. Intriguingly, many local regions of
Gag assembly were observed to exhibit flat electron density features that did not strictly follow the
curvature of the membrane and showed enlarged distance toward the viral membrane (4 vs. 8 nm)
(Figure 2A,B). About 20% of particles had this morphological feature. This unique structural feature
has not been reported for other retrovirus immature particles. The flat Gag density feature observed
with HTLV-1-like particles suggests that HTLV-1 Gag could be arranged in a lattice structure that is
distinct from that of other retroviruses characterized to date (i.e., HIV-1, Mason-Pfizer monkey virus
(MPMV) and Rous sarcoma virus (RSV)) [13,28,29].
Other morphological features have commonalities with other retroviruses. First, the Gag densities
in the cryo-TEM images were not always continuous. In particular, smaller VLPs were observed to
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have multiple discontinuities in the immature Gag lattice (Figure 2A,B). The membrane regions that
associate with organized Gag lattices appear to be wider and more pronounced. Between the Gag
lattice and the viral membrane, a string of bead-like densities is sometimes observed (i.e., in ~10% of
particles analyzed) lining along the inner leaflet of the viral membrane (Figure 2E,G). These density
features are likely due to the association of MA with the inner membrane of the virus particle. The MA
lattice has been observed in a large membrane-enclosed multi-core structure in supernatants of
HIV-1-infected cells [30]. In the cryo-TEM images (Figure 2A-G), the arrangement of the Gag molecules
within the lattice is similar but not identical to that in other retrovirus immature particles such as
HIV-1. The cryo-TEM image (Figure 2H) and cut-away view of the HIV-1 Gag lattice assembly in a
three-dimensional (3D) reconstruction map [31,32] has two density layers: closer to the viral membrane
is the CA protein layer showing an array of rod-like densities, while towards the center of the particle
is the NC layer that has a continuous density. In contrast, the HTLV-1-like particles consistently display
a continuous density at the region closer to the membrane inner leaflet. Underneath the continuous
density layer, closer to the center of the virus particle, is an array of densities that resembled a railroad
track (Figure 2H).
Figure 2. Cryogenic transmission electron microscopy (Cryo-TEM) images of HTLV-1-like particles
and comparison of Gag lattice between HTLV-1 and human immunodeficiency virus type 1 (HIV-1).
(A–G) Cryo-TEM images of HTLV-1-like particles. The white arrows indicate regions of the Gag lattice
that appear flat in contrast to the curvature observed with the viral membrane. The black arrows show
the membrane regions that are associated with Gag lattice and exhibit a string of bead-like densities in
the inner membrane leaflet. The black arrowheads demark discontinuity of the Gag lattice. The black
dash-lined box in D shows a region displayed in the top panel of H. The scale bar in G is applicable
to the panels C–G; (H) Comparison of Gag lattice morphology between HTLV-1-like and HIV-1-like
particles. The electron densities representing the Gag lattice structure are indicated by the left and right
bracket, respectively.
3.2. Morphology of Authentic HTLV-1 Mature Particles Produced from MT-2 Cells
As a control and to confirm our previous studies with authentic HTLV-1 particles by cryo-electron
tomography [33], the morphology of authentic HTLV-1 particles, harvested and purified from MT-2
cells [22,23], was also studied by cryo-TEM (Figure 3A). Mature virus particles were identified by
either the presence of readily observable electron-dense cores, or by the presence of significant electron
density within the particle. The lack of HTLV-1 protease inhibitors prevented the production of large
numbers of authentic immature particles. Vesicles were identified by the absence of core structures or
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significant internal electron density. The particles were primarily spherical and heterogeneous in size.
The particle diameter was determined by averaging the longest and shortest measurements of each
particle. A total of 1074 authentic particles were measured and had a mean diameter of 113 ˘ 23 nm
(Figure 3A,B). This measurement based on two-dimensional (2D) cryo-TEM images was in good
agreement with our previous analyses using the cryo-electron tomography method [33].
A.# B.# C.#
Figure 3. Analysis of the diameter of authentic mature HTLV-1 virus particles. (A) Authentic mature
HTLV-1 particles produced from MT-2 cells; (B) Size distribution of authentic mature HTLV-1 particles;
(C) Magnified images of authentic mature HTLV-1 particles showing irregular polyhedral-like core
structures. The scale bars in A and C are 100 nm.
A gallery of cryo-TEM images of authentic HTLV-1 particles (Figure 3C) revealed that the particles
contained an unordered polyhedral-like capsid core structure, which is different in each particle
regardless of particle size. The core size varied by particle, with some regions of the protein capsid of
the cores following the curvature of the inner leaflet of the viral lipid bilayer, while other parts of the
capsid appeared completely separated from the viral membrane.
3.3. STEM Analyses of HTLV-1-Like Particles and Authentic Mature HTLV-1 Particles
STEM analysis was used to determine the total molecular mass of HTLV-1 particles as previously
described [26]. Representative dark-field electron micrographs of HTLV-1-like particles and authentic
mature HTLV-1 particles are shown in Figures 4A and 5A. Only isolated intact particles that were
of the expected particle diameter range, as determined by cryo-TEM imaging, were used for mass
measurements. Some smaller randomly distributed contaminants are visible in the background. Using
the known mass of TMV as an internal control, we are able to obtain the average masses of HTLV-1
VLPs and authentic particles.
Both HTLV-1-like particles and authentic particles showed a wide distribution of mass diversity,
which correlates with the wide particle size distribution (Figures 4B and 5B). The TMV-corrected masses
of HTLV-1-like particles (Figure 4B) and HTLV-1 authentic particles (Figure 5B) were determined to be
174 ˘ 96 MDa and 204 ˘ 67 MDa, respectively (Table 1). The average masses were used for estimating
the Gag copy numbers in HTLV-1-like particles and inferred immature precursors of the authentic
HTLV-1 particles. AT-2 was used to inactivate the particles. It is formally possible that AT-2 treatment
could affect particle morphology.
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Figure 4. Scanning transmission electron microscopy (STEM) analysis of HTLV-1-like particles. (A) A
STEM micrograph of HTLV-1-like particles mixed with tobacco mosaic virus (TMV); (B) TMV-corrected
mass measurement distribution in MDa of purified HTLV-1-like particles, which was determined based
on the known TMV mass per unit length of 13.1 kDa/Å.
A.# B.#
Figure 5. STEM analysis of authentic mature HTLV-1 virus particles. (A) A STEM micrograph of
authentic HTLV-1 particles mixed with TMV. The region labeled as “clusters” represents closely
associated viral particles and is excluded from the calculation; (B) The TMV-corrected measurement
of mass distribution in MDa of purified authentic mature HTLV-1 particles was determined.
The TMV-corrected particle mass determination was based on the known TMV mass per unit length of
13.1 kDa/Å.
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Table 1. Summary of the mass determinations and the calculated Gag copy number per particle in
human T-cell leukemia virus type 1 (HTLV-1)-like particles and authentic HTLV-1 particles.
HTLV-1 Particle Sample
Measurement Virus-Like Particle Authentic Particle
Average Diameter (nm) a 110 113
Average Particle Mass (MDa) b 174 204
Mass of RNA, Lipid
and Protein (MDa)
RNA c 7 7
Lipid d 70 80
Total protein e 97 118
Mass of Gag
Molecules (MDa)




Gag polyprotein copy number g 1300–1600 1500–1900
a As determined by cryogenic transmission electron microscopy (Cryo-TEM); b As determined by scanning
transmission electron microscopy (STEM); c Mass contributed by RNA in virus-like particles was estimated
experimentally as described in the Materials and Methods. The RNA mass contribution for authentic HTLV-1
particles was estimated based upon the genome size; d Mass contributed by lipids was estimated from average
particle size and membrane thickness; e Mass of total protein was determined by subtraction of the RNA and
lipid mass from the total particle mass as determined by STEM; f Total Gag polyprotein was estimated based
upon the assumption that Gag contributes ~70%–90% of the total protein mass; g The Gag polyprotein copy
number represents the range of Gag copy number in a particle that has both average mass and dimensions.
3.4. Calculation of Gag Stoichiometry in HTLV-1-Like Particles
The average mass of HTLV-1-like particles determined by STEM was used to estimate the average
Gag copy number per virus particle. The viral RNA mass contribution from total particle mass was
determined by extracting the RNA from particle lysates with RNA columns, using Roche’s High Pure
Viral RNA Kit (Roche Diagnostics, Indianapolis, IN, USA). The extracted viral RNA was quantified by
determining the ultraviolet (UV) absorption at 260 nm and a conversion factor of 40 μg/mL ˆ A260
optical density unit x dilution factor using a Beckman DU-65 spectrophotometer (Beckman Coulter,
Brea, CA, USA). The Thermo Scientific Pierce BCA Protein Assay Kit (Thermo Fisher Scientific,
Waltham, MA, USA) was used to estimate the protein content of the same sample used to determine
the VLPs’ RNA content. The VLPs’ Gag/RNA mass ratio was determined to be 14.4:1, equivalent to
about 4% of the averaged molecular mass of the VLPs measured by STEM (Table 1). Based upon the
average size of the VLPs, which is 110 nm, and estimating the average thickness of the viral membrane
to be 5 nm, an estimate of the number of lipid molecules in the virus envelope was made. Assuming
that the distance between lipid molecules in the same leaflet was 0.85 nm [34], and the average
molecular weight of lipids was 750, the mass of lipids in an averaged size particle was determined to
be approximately 70 MDa (i.e., ~40% of the total mass of an averaged sized particle) (Table 1).
Assuming that the mass of the Gag protein in HTLV-1-like particles is similar to that of other
retroviruses, approximately 70%–90% of the total protein mass [17,35], the mass contribution of
Gag in an HTLV-1-like particle with an average size of 110 nm would be 70–87 MDa. Given the
molecular weight for HTLV-1 Gag is ~53 kDa [36,37], it was estimated that HTLV-1-like particles
contain approximately 1300–1600 Gag polyproteins per VLP with a mass and diameter of 174 MDa
and 110 nm, respectively (Table 1).
3.5. Estimating Gag Stoichiometry in Authentic Immature HTLV-1 Particles by Calculating Gag Copy Number
in Authentic Mature HTLV-1 Particles
The same methodology used to calculate the Gag copy number in HTLV-1-like particles was used
to estimate the Gag stoichiometry in authentic immature HTLV-1 particles by calculating the Gag
copy number in authentic mature HTLV-1 particles. Based upon the average size of the authentic
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mature HTLV-1 particles, which is 113 nm, we estimated the lipid mass to be approximately 80 MDa
(Table 1). The viral RNA in authentic HTLV-1 particles was calculated by assuming that each authentic
particle contains two copies of the 8.5 kb genomic RNA, plus tRNA and other small RNAs comprising
approximately 30% of the genomic RNA by mass. The molecular weight of RNA was estimated to be
7 MDa, equivalent to about 3.5% of the averaged molecular mass of the particle measured by STEM.
Assuming that the mass of the Gag protein in retroviruses is about 70%–90% of the total protein,
the Gag protein of authentic HTLV-1 particles would contribute 82–106 MDa to the total particle mass
for a particle of an average size of 113 nm (Table 1). An authentic HTLV-1 particle contains three
forms of the Gag polyprotein: Gag, Gag-Pro and Gag-Pro-Pol, with molecular weights of 53 kDa,
76 kDa and 180 kDa, respectively [36,37]. Given that the estimated molar ratio of the Gag, Gag-Pro,
and Gag-Pro-Pol is 100:10:1 based on in vitro translation of viral RNA [38], it was calculated that the
immature precursor of authentic HTLV-1 particles contains approximately 1500 to 1900 copies of Gag,
which would result in a particle with a mass of 204 MDa and a size of 113 nm (Table 1) [34,38].
4. Discussion
Although HTLV-1 was the first human retrovirus to be discovered [39,40], the morphological
details of HTLV-1 particles have been poorly characterized, including that of Gag stoichiometry.
To combat the technical difficulties in working with HTLV-1 in cell culture, a HTLV-1 Gag-only
expression model system was used to produce and purify HTLV-1-like particles. A key technical
advantage of this HTLV-1 Gag model system is that it is a highly robust system that results in highly
efficient production of VLPs from mammalian cells. In the absence of methodologies to efficiently
produce authentic immature HTLV-1 particles, and given the absence of HTLV-1 PR inhibitors [41–44],
this construct was used as a surrogate to study immature particle morphology.
The electron density of the HTLV-1 Gag lattice appears more compact than what has been
previously observed for Gag lattices from HIV-1, MPMV or RSV [9,28,45]. The most intriguing
morphological feature of the HTLV-1 immature Gag lattice is that about 20% of the HTLV-1-like
particles had regions that appeared to be flat and did not follow the curvature of the viral membrane
in multiple regions. The maximum separation between these ‘flat’ regions and the viral membrane
was approximately 8 nm. This is the first time this observation has been made regarding the structure
of an immature retroviral Gag lattice. One intriguing possibility is that this morphological feature
is indicative of a more rigid lattice structure compared to that of other previously reported HIV-1
immature Gag lattice structures. The addition of a fluorophore tag on the carboxy terminus of the
HTLV-1 Gag protein did affect the diameter of the VLPs (i.e., average diameter of 110 nm without tag
versus 75 nm with tag) as well as the Gag-Gag interactions, given the distinct morphological differences
in the presence and absence of the fluorophore tag [21]. This is in contrast to that observed with HIV-1
Gag, where particles produced from a Gag-YFP expression construct did not influence particle size [19].
Taken together, these results imply distinct differences in the Gag assemblies in HTLV-1 immature
particles compared to that of other retroviruses, particularly HIV-1.
STEM analysis led to the observation that the HTLV-1 Gag copy number distribution per particle
spanned a wide range for both HTLV-1-like particles and HTLV-1 authentic particles (Figures 4B
and 5B), which corresponded to the diverse particle size population (Figures 1C and 3B). HTLV-1-like
particles and mature particles were found to have Gag copy numbers of 1300–1600 and 1500–1900 Gag
molecules/particle, respectively, which is in the general range of Gag copy numbers observed for other
retroviruses including MPMV and RSV [17,18].
The observations made by this study emphasize both unique and common morphological features
of the HTLV-1-like particles in comparison to other retrovirus immature VLPs. Future studies will
include a detailed determination of the immature Gag lattice, which should provide important new
insights into the unique aspects of HTLV-1 particle assembly, in particular, and new insights into
retroviral assembly, in general.
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Abstract: Although the number of human T-cell leukemia virus type-I (HTLV-I)-infected individuals
in the world has been estimated at over 10 million, no prophylaxis vaccines against HTLV-I infection
are available. In this study, we took a new approach for establishing the basis of protective vaccines
against HTLV-I. We show here the potential of a passively administered HTLV-I neutralizing
monoclonal antibody of rat origin (LAT-27) that recognizes epitopes consisting of the HTLV-I
gp46 amino acids 191–196. LAT-27 completely blocked HTLV-I infection in vitro at a minimum
concentration of 5 μg/mL. Neonatal rats born to mother rats pre-infused with LAT-27 were shown
to have acquired a large quantity of LAT-27, and these newborns showed complete resistance
against intraperitoneal infection with HTLV-I. On the other hand, when humanized immunodeficient
mice were pre-infused intravenously with humanized LAT-27 (hu-LAT-27), all the mice completely
resisted HTLV-I infection. These results indicate that hu-LAT-27 may have a potential for passive
immunization against both horizontal and mother-to-child vertical infection with HTLV-I.
Keywords: HTLV-I; NOG mice; neutralizing monoclonal antibody; envelope gp46; passive immunity
1. Introduction
Human T-cell leukemia virus type I (HTLV-I) [1,2] causes both neoplastic and inflammatory
diseases, including adult T-cell leukemia (ATL) [3,4] and HTLV-I-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) [5,6]. The number of HTLV-I-infected individuals in the world has
been estimated at over 10 million [7]. However, no prophylaxis vaccines or drugs against HTLV-I
infection are available. HTLV-I is transmitted through contact with bodily fluids containing infected
cells, most often from mother to child through breast milk or via blood transfusion. It was demonstrated
that HTLV-I efficiently spreads from cell-to-cell via virological synapses [8]. The HTLV-I envelope
spike consists of two glycoproteins, cell surface gp46 and trans-membrane gp21 [9], both of which are
essential for HTLV-I entry into cells [10].
Since there are little or no genetic mutations in these envelope antigens among HTLV-I strains [11],
it is clear that these antigens are the right targets for prophylactic vaccines. Accordingly, a line of
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evidence showed that a recombinant vaccinia virus (RVV) expressing gp46 and synthetic peptides
corresponding to several regions of gp46 conferred immunity against HTLV-I challenge, showing a
possibility of active vaccination [12–15]. However, there are a lot of hurdles before the invention of safe
and effective active vaccines. As it has been demonstrated that humanized or human antibodies
are safe and effective in various areas of medicine, passive immunization of anti-HTLV-I gp46
neutralizing antibodies may provide a choice for prevention of the spread of HTLV-I. Although
antibodies against gp46 antigen and their neutralizing capacity are commonly demonstrated in the
sera of HTLV-I-infected individuals, little is known about whether these polyclonal anti-gp46 antibodies
can control human-to-human infection of HTLV-I [16]. On the way to establishing a basis for vaccine
development against HTLV-I, we previously reported that our anti-gp46 neutralizing mAb (LAT-27)
was capable of blocking of HTLV-I infection by direct neutralization and eradicating HTLV-I-infected
cells via antibody-dependent-cellular-cytotoxicity (ADCC) in vitro [17]. Recently, we showed that
LAT-27 is also capable of blocking primary HTLV-I infection in a humanized mouse model [18].
Here, we show that maternally transferred LAT-27 is capable of protecting newborn rats against
HTLV-I infection, and suggest that humanized LAT-27 is able to block horizontal infection of
humanized mice with HTLV-I. Therefore, humanized LAT-27 may be one of the candidates for passive
vaccines against HTLV-I.
2. Materials and Methods
2.1. Reagents
The medium used throughout was RPMI 1640 medium (Sigma-Aldrich Inc., St. Louis, MO, USA)
supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin and 100 μg/mL streptomycin
(hereafter called RPMI medium). Rat and mouse monoclonal antibodies (mAbs) were purified in our
laboratory from ascites fluids of CB.17-SCID mice carrying the appropriate hybridomas as described
previously [17]. These antibodies were rat IgG2b mAbs anti-gp46 (clones LAT-27), rat IgG2b anti-HIV-1
p24 (clone WAP-24), mouse IgG3 anti-HTLV-I Tax (clone Lt-4). mAbs were labeled with HiLyte Fluor™
647 using commercial labeling kits (Dojindo, Kumamoto, Japan) according to the manufacturer’s
instructions. PE-labeled mouse mAbs against human CD4 were purchased from BioLegend (Tokyo,
Japan). Humanized-LAT-27 (hu-LAT-27) and human-mouse chimeric antibody consisting of human
IgG1 Fc and a part of mouse anti-CEA were generated in collaboration with IBL (Gunma, Japan) and
the information of hu-LAT-27 will be reported elsewhere.
2.2. Cell Culture and Syncytium Inhibition Assay
The IL-2-dependent CD4´CD8+ ILT-M1 cell line derived from a HAM patient was used as a
source of HTLV-I (kindly provided by Kannagi of Tokyo medical and dental university) [17]. These cells
were maintained in culture using RPMI medium containing 20 U/mL IL-2. Syncytium inhibition assay
was carried out using a combination of ILT-M1 and HTLV-I negative Jurkat T-cell lines as reported
previously [17]. ILT-M1 cell line was used because of its superiority in inducing syncytia. Briefly,
a volume of 25 μL ILT-M1 cell suspension at 2 ˆ 106 cells/mL in 20 U/mL IL-2 containing RPMI
media was mixed with 50 μL of serially diluted antibody in a flat-bottom 96-well micro-titer plate
for 5 min followed by the addition of a volume of 25 μL Jurkat cell suspension at 2 ˆ 106 cells/mL.
After cultivation for 16 h at 37 ˝C in a 5% CO2 humidified incubator, syncytium formation was
microscopically observed using an inverted microscope and the concentration of antibody that showed
complete blocking of syncytium formation was determined.
2.3. ELISA
ELISA was used to quantitate rat and humanized LAT-27 in sera of rats and NOD-SCID/γc
null (NOG) mice, respectively. Briefly, HTLV-I gp46 synthetic peptide [19] was coated onto 96-well
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ELISA plates (Nunc) as an antigen, and the bindings of rat and humanized LAT-27 were detected with
HRP-labeled anti-rat and human IgG, respectively.
2.4. Animal Experiments
This research was approved by the institutional review boards of the authors’ institutions
and written informed consent was obtained from all individuals for the collection of samples and
subsequent analysis. The protocols for the use of human PBMCs and animals were approved by the
Institutional Review Board and the Institutional Animal Care and Use Committee on clinical and
animal research of the University of the Ryukyus prior to initiation of the study. Strains of WKA/H,
F344, SD rats were purchased from SLC (Shizuoka, Japan). NOG mice were purchased from the Central
Institute of Experimental Animals (Kanagawa, Japan) and were kept in the specific-pathogen-free
animal facilities of the Laboratory Animal Center, University of the Ryukyus. Mice were six to
seven weeks old at the time of the intra-splenic transplantation of human PBMCs [20]. Fresh
PBMCs were isolated from HTLV-I-negative normal donors by a Histopaque-1077 (Sigma) density
gradient centrifugation.
2.5. Isolation of Human T-Cells from Mouse Spleen
Human CD4+ T-cells were isolated from mouse spleen cells by positive immunoselection with
the Dynal® CD4-positive isolation kit (Invitrogen), according to the manufacturer’s protocol. In brief,
mouse spleen cells were incubated with anti-CD4-coated beads for 30 min at 4 ˝C under gentle tilt
rotation. Captured CD4+ T-cells were collected with a magnet (Dynal MPC-S) and detached from
beads with DETACHaBEAD CD4/CD8® (Invitrogen). Purity was >99% CD4+ T-cells as determined
by flow cytometry.
2.6. Genomic DNA Extraction and Quantification of HTLV-I Proviral Load
Genomic DNA was extracted by QIAamp kit (QIAGEN, Tokyo, Japan) according to the
manufacturer’s instructions. To examine the HTLV-I PVL, we carried out a quantitative PCR method
using StepOnePlus (Applied Biosystems) with 100 ng of genomic DNA (roughly equivalent to 104 cells)
from PBMC samples as reported previously [21]. Based on the standard curve created by four known
concentrations of template, the concentration of unknown samples was determined. Using β-actin as
an internal control, the amount of HTLV-I proviral DNA was calculated by the following formula:
copy number of HTLV-I tax per 1 ˆ 104 PBMCs = [(copy number of tax) / (copy number of β-actin / 2)] ˆ 104.
All samples were performed in triplicate.
2.7. Flow Cytometry
Before staining, live cells were Fc-blocked with 2 mg/mL pooled normal human IgG in FACS
buffer (PBS containing 0.2% bovine serum albumin and 0.1% sodium azide) for 10 min on ice, and
then incubated for 15 min at room temperature. After washing with FACS buffer, the cells were
fixed in PBS containing 4% paraformaldehyde (Sigma) for 20 min at room temperature followed by
permeabilization and washing in 0.5% saponin + 1% BSA (Sigma) containing FACS buffer. The cells
were incubated with 0.1 μg/mL of HiLyte Fluor® 647-labeled anti-Tax mAb (clone Lt-4) for 20 min.
Negative control cells were stained with HiLyte Fluor® 647 Lt-4 in the presence of 50 μg/mL of
unlabelled Lt-4. Finally, the cells were washed twice and analyzed by standard flow cytometry using
a FACSCalibur™ flow cytometer (BD) and FlowJo software (Tree Star).
3. Results
3.1. Mother-to-Child Transfer of Passively Immunized LAT-27
It has been demonstrated that rats are relatively permissive for in vivo infection with HTLV-I.
Although rat T-cells transformed with HTLV-I produce no or little infectious HTLV-I virion, rats can be
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used to evaluate the efficacy of prophylactic vaccines. Thus, we examined whether LAT-27 could be
transferred from mother to neonates without loss of protecting capacity against HTLV-I infection. Our
preliminary studies showed that spleen cells of SD strain rats were more sensitive to HTLV-I infection
in vitro than those of WKA/H and F344 strain rats. Thus, we chose SD rats for this in vivo study.
At first, pregnant SD rats were infused i.p. with 25 mg/head of either LAT-27 or isotype control
mAb two times on –7 d and –2 d of delivery (n = 2). Two days after the birth, blood samples were
collected from both mothers and newborns, and LAT-27 concentrations of their sera were quantitated
using ELISA (Table 1).
Table 1. Mother-to-offspring transfer of LAT-27 in rats. Two pregnant SD rats were infused i.p.
with 25 mg/head LAT-27 two times on ´7 d and ´2 d delivery. Two days after delivery, LAT-27







Mother 102 Mother 51
Offspring-1 204 Offspring-1 102
Offspring-2 204 Offspring-2 51
Offspring-3 102 Offspring-3 102
Offspring-4 102 Offspring-4 102
Offspring-5 204 Offspring-5 51
Offspring-6 102 Offspring-6 51
Offspring-7 204 Offspring-7 51
Offspring-8 204 Offspring-8 102
Offspring-9 102 Offspring-9 102
Offspring-10 51
Figure 1. Neutralization of HTLV-I by mother-to-offspring-transferred LAT-27. Syncytium inhibition
assay was carried out as described in Materials and Methods. ILT-M1 cells were treated with diluted
serum or purified antibody in a flat-bottom 96-well micro-titer plate for 5 min, and then co-cultured
with Jurkat cells. After cultivation for 16 h, syncytium formation was microscopically observed using
an inverted microscope at magnification of 200ˆ.
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The data showed that a substantial dose of LAT-27 was transferred to the neonates from the
mothers. It is of interest that the LAT-27 concentrations in newborn rat sera were equivalent to those in
mother sera, suggesting an efficient transfer of LAT-27.
In order to confirm that the transferred LAT-27 in neonates retained neutralizing activity, we
performed the syncytium inhibition assay (Figure 1).
Overnight co-culture of the HTLV-I-producing ILT-M1 cells and HTLV-I-negative Jurkat T-cells in
media alone gave rise to the generation of a number of syncytia (Figure 1 upper left panel), which was
completely inhibited by the addition of LAT-27 (5 μg/mL) (Figure 1 upper left panel). In contrast to
that, the control serum obtained from a neonate born to an untreated normal mother did not inhibit
the syncytium formation even at 1:3 dilution, thus the serum from a LAT-27-adminstered mother did
neutralize HTLV-I infection at 1:12 dilutions. Taken together, these data indicated that LAT-27 could be
transferred from mother to offspring without any loss of its neutralization property.
3.2. LAT-27 from Mothers Protects Newborns against HTLV-I Infection
Then, we addressed whether mother-to-child-transferred LAT-27 could protect newborn rats
against HTLV-I infection. Pregnant SD rats received 25 mg/head LAT-27 two days before delivery, and
their newborns were challenged i.p. with the mitomycin C-treated HTLV-I-producing cells on day 1
after birth. As controls, two newborn littermates of non-antibody-administered mothers were infected
with HTLV-I before or after administration with 2 mg/head LAT-27. Three weeks after infection,
rats were sacrificed and spleen cells were subjected to quantitative real-time PCR analysis for testing
HTLV-I infection. Figure 2 showed that the rats born to the LAT-27-treated mother rat as well as the
newborn rats directly administered LAT-27 after birth were negative for proviral DNA, suggesting
that mother-to-child-transferred LAT-27 could work in vivo.
Figure 2. Protection of newborns from HTLV-I infection by mother-to-child-transferred LAT-27.
Nine littermates from LAT-27 passively immunized mother rat (left), 11 littermates directly injected
with LAT-27 (center) before infection, and seven naïve littermates (right) were i.p. injected with
MMC-treated ILT-M1 cells. After three weeks, rats were tested for HTLV-I infection.
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3.3. Retention of Humanized LAT-27 in NOG Mice
For future prophylactic and clinical utilization, we have succeeded in generating humanized
LAT-27 (hu-LAT-27) as shown in Figure 3. hu-LAT-27 consists of a complementarity-determining
region (CDR) of the original rat LAT-27 and human IgG1 backbone as illustrated in Figure 3A.
Figure 3. Schematic illustration of humanized LAT-27 and its neutralizing activity. Syncytium inhibition
assay was carried out with either 200 μg/mL of normal human IgG (left of B) and 5 μg/mL of
humanized LAT-27. After cultivation for 24 h, syncytium formation was microscopically observed
using an inverted microscope at magnification of 100ˆ (right of B).
hu-LAT-27 was produced in CHO cells. Due to a patent matter, the gene sequence of hu-LAT-27
will be reported elsewhere. The in vitro neutralization test showed that the minimum concentration of
hu-LAT-27 for complete inhibition of syncytium formation was 5 μg/mL, which was comparable to
the original rat LAT-27 (Figure 3B), demonstrating no decay in neutralizing ability after humanization.
In order to examine whether hu-LAT-27 could work in vivo, we firstly tested the retention time
of hu-LAT-27 in NOG mice. Mice were injected i.v. with 1 mg/head hu-LAT-27 (n = 3). Sera
were collected daily for five days and the concentration of hu-LAT-27 was quantitated by ELISA
as described in the Materials and Methods. The data presented in Table 2 indicated that serum levels
of hu-LAT-27 gradually decreased day by day. The half-life of administrated LAT-27 was estimated to
be approximately two days.
Table 2. Retention of humanized LAT-27 in NOG mice. Each of three NOG mice was infused i.v.
with 1 mg/head hu-LAT-27, and the LAT-27 concentrations in their sera were measured daily by
ELISA using gp46 peptide (180–204) as antigen and secondary anti-human IgG-HRP, in which purified
hu-LAT-27 was used to draw a standard curve.
Days after Injection
hu-LAT-27 Concentration in Serum (μg/mL)
NOG#1 NOG#2 NOG#3
1 268 249 277
2 114 155 124
3 79 88 80
4 57 86 61
5 49 47 48
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3.4. Protection of hu-PBL-NOG Mice against HTLV-I Infection by hu-LAT-27
Then, we tested the protective efficacy of hu-LAT-27 mAbs against in vivo infection with HTLV-I
using our humanized mouse model as reported previously [18]. PBMCs from HTLV-I-negative
donors were transplanted directly into the spleen of NOG mice together with the mitomycin-C-treated
HTLV-I-producing cells. They were intra-peritoneally infused with either hu-LAT-27 or control human
chimeric anti-CEA mAb before HTLV-I infection. Fourteen days after infection, these mice were
sacrificed and fresh spleen cells were isolated, cultured for 24 h and tested for HTLV-I infection by flow
cytometry. As shown in Figure 4A, human CD4+ T-cells from all mice immunized with the hu-LAT-27
before HTLV-I infection were negative for Tax antigen, suggesting complete protection against HTLV-I
infection (lower panels). PCR testing of HTLV-I proviral loads supported this conclusion. The
protective effect was hu-LAT-27-specific since the control anti-CEA did not confer protection against
the infection (upper panels). When hu-LAT-27 was administered one day after HTLV-I infection, it did
not protect mice against HTLV-I infection. These results suggested that hu-LAT-27 could be used
for prophylaxis against HTLV-I infection in vivo when a sufficient amount of it was infused before
infection with HTLV-I.
Figure 4. Protection of hu-PBL-NOG mice against HTLV-I by hu-LAT-27. The Mitomycin C
(MMC)-treated HTLV-I-infected ILT-M1 (1 ˆ 106 cells) was mixed with freshly isolated PBMCs
(2 ˆ 106 cells) from healthy donor in a final volume of 50 μL and then were directly injected into
the spleens of NOG mice. MAbs (0.5 mg each: lower panels) or control IgG (0.5 mg each: upper panels)
was inoculated i.v. one hour before cell transplantation. Fourteen days after cell transplantation, mice
were sacrificed, blood was collected by cardiocentesis, and human lymphocytes were recovered from
the spleen. The bisector indicated in all panels showed tax negative edge of histogram.
4. Discussion
The present study suggested a potential of monoclonal anti-gp46 neutralizing LAT-27 for passive
immunization for prophylaxis against HTLV-I infection. The main mechanism for LAT-27-mediated
protection of animals against HTLV-I in vivo is most likely neutralization via inducing conformational
changes in the gp46 structure. In addition, as we have previously reported, LAT-27 may also inhibit
HTLV-I infection by eliminating HTLV-I-producing cells via HTLV-1-specific ADCC in the presence of
NK cells [17]. In the present study, we have chosen an excess dose of LAT-27 for infusion. Since the
minimum HTLV-I neutralizing antibody concentration of LAT-27 in vitro is as low as 5 μg/mL, further
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studies are required to determine the minimum dose of LAT-27 for perfect in vivo protection against
HTLV-I in each animal system.
Using a rat model, the present study first showed that LAT-27 could be transferred from dams to
infant rats, and that the transferred LAT-27 was active for HTLV-I neutralization and protected the
infants against intraperitoneal HTLV-I infection. It remains to be determined how long the antibodies
were sustained in the littermates born to pregnant rats infused with LAT-27. In rats, it is known that
maternal antibodies are transferred equally effectively to infants either via placenta or from the gut by
breastfeeding [22]. It should be emphasized that administration of LAT-27 to pregnant rats did not
show any obvious effects on delivery and growth of infants, showing the safety of this mAb in rats at
least. It remains to be tested whether the transferred LAT-27 is protective against oral HTLV-I infection.
Although it has been shown that rats are relatively susceptible to oral infection with HTLV-I [23], our
preliminary studies failed to infect newborn (two-day-old) rats with HTLV-I by feeding cow milk
serum containing live HTLV-I at least producing cells. In order to establish a good model for oral
HTLV-I infection, choices of better rat strain, HTLV-I at least producing cells and timing of infection
may be a key. Further studies are in progress.
For future clinical studies in humans, it is necessary to humanize the original LAT-27 (rat origin).
In collaborative investigation with IBL Co., Ltd., we have succeeded in the generation of hu-LAT-27,
and examined its function in vitro and in vivo. Similar to rat LAT-27, hu-LAT27 neutralized HTLV-I
in vitro at a minimum concentration of 5 μg/mL (Figure 1), showing that there is no loss of
neutralizing activity after humanization. Furthermore, hu-LAT-27 was capable of protecting NOG
mice reconstituted with human PBMCs from intraperitoneal infection with HTLV-I (Figure 4). The
half-life of hu-LAT-27 in NOG mice was roughly estimated two days. Since half-life of IgG in vivo is
dependent on its affinity to neonatal FcR, such a short lifetime of hu-LAT-27 in NOG mice (Table 2)
will be prolonged up to three weeks in humans, as in the cases of other humanized mAbs [24].
The present data suggest that hu-LAT-27 mAb will be useful in passive immunization against
HTLV-I infection. The rationale of using these monoclonal antibodies instead of polyclonal antibodies
obtained from healthy HTLV-I carriers for the prevention of HTLV-I infection is that, in contrast
to HIV-1, the genome of HTLV-I is stable [11], and thus the LAT-27 reactive-neutralizing epitope
(gp46 amino acid 191–196 of MT-2 virus) is broadly conserved among wild HTLV-I strains. Indeed,
LAT-27 reacted all HTLV-I-producing cell lines tested, including naturally infected cell lines from ATL
and HAM/TSP patients and asymptomatic carriers. So far, the potential of passive immunization
with IgG from HTLV-I carriers has been show in rabbit [25,26], monkey [27] and humanized NOG
mouse models [18]. Since polyclonal antibodies contain non-neutralizing antibodies, the efficacy of
neutralization by neutralizing antibody could be interfered with by those non-neutralizing anti-gp46
antibodies. More importantly, since the total availability of anti-HTLV-I serum is limited, production
capability in a large quantity of Good Manufacturing Practice-grade of HTLV-I neutralizing mAb
may be a prerequisite for antibody-based prophylaxis against HTLV-I. Another choice, instead of
hu-LAT-27, will be human mAbs with HTLV-I neutralizing capacity, as several human mAbs have
been reported [28].
We anticipate that hu-LAT-27 mAb will be used as a safe passive vaccine against both horizontal
and vertical infection with HTLV-I for people at high risk of HTLV-I infection, including adults
and babies born to HTLV-I carriers. In addition, since organ transplantation to HTLV-I-negative
recipients from HTLV-I-positive donors is another risk factor of HTLV-I infection and the development
of HAM/TSP [29], pretreatment of recipients with hu-LAT-27 may be useful for the prevention of
HTLV-I infection. It may be also possible that, for HTLV-I carriers whose anti-HTLV-I neutralizing
antibody titers are low, administration of LAT-27 may function to inhibit further spreading of HTLV-I
in vivo. Thus, it will be worthy to validate hu-LAT-27 in an animal model in more detail before starting
a clinical study. In addition to this passive vaccine, in order to control HTLV-I infection all over the
world, it is clear that an active vaccine which can elicit or boost anti-HTLV-I gp46 neutralizing antibody
titer should be developed.
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5. Conclusions
This study describes experimental results indicating a possible concept that passive immunization
with our humanized anti-gp46 neutralizing mAb (hu-LAT-27) reduces the chance of HTLV-I infection
of adults and babies at high risk. A combination of hu-LAT-27-based passive vaccination and
yet-to-be-developed active vaccine might be potent in preventing the spread of HTLV-I infection
around the world.
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Abstract: The environmental factors that lead to the reactivation of human T cell leukemia virus
type-1 (HTLV-I) in latently infected T cells in vivo remain unknown. It has been previously shown
that heat shock (HS) is a potent inducer of HTLV-I viral protein expression in long-term cultured cell
lines. However, the precise HTLV-I protein(s) and mechanisms by which HS induces its effect remain
ill-defined. We initiated these studies by first monitoring the levels of the trans-activator (Tax) protein
induced by exposure of the HTLV-I infected cell line to HS. HS treatment at 43 ˝C for 30 min for
24 h led to marked increases in the level of Tax antigen expression in all HTLV-I-infected T cell lines
tested including a number of HTLV-I-naturally infected T cell lines. HS also increased the expression
of functional HTLV-I envelope gp46 antigen, as shown by increased syncytium formation activity.
Interestingly, the enhancing effect of HS was partially inhibited by the addition of the heat shock
protein 70 (HSP70)-inhibitor pifithlin-μ (PFT). In contrast, the HSP 70-inducer zerumbone (ZER)
enhanced Tax expression in the absence of HS. These data suggest that HSP 70 is at least partially
involved in HS-mediated stimulation of Tax expression. As expected, HS resulted in enhanced
expression of the Tax-inducible host antigens, such as CD83 and OX40. Finally, we confirmed that HS
enhanced the levels of Tax and gp46 antigen expression in primary human CD4+ T cells isolated from
HTLV-I-infected humanized NOD/SCID/γc null (NOG) mice and HTLV-I carriers. In summary, the
data presented herein indicate that HS is one of the environmental factors involved in the reactivation
of HTLV-I in vivo via enhanced Tax expression, which may favor HTLV-I expansion in vivo.
Keywords: HTLV-I; Tax; heat shock; adult T cell leukemia (ATL)
1. Introduction
The Human T cell leukemia virus type-I (HTLV-I) is the first human retrovirus that is etiologically
associated with adult T cell leukemia (ATL) and HTLV-I associated myelopathy/tropical spastic
paraparesis (HAM/TSP) [1–3]. HTLV-I is prevalent worldwide with foci of high prevalence in
southwest Japan, the Caribbean islands, South America and parts of Central Africa, most of which
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are located in subtropical and tropical regions [4]. HTLV-I is transmitted through contact with bodily
fluids containing infected cells most often either vertically from mother to child via breastfeeding or
horizontally in adults [5]. The total rate of developing ATL or HAM/TSP is roughly estimated to be 5%
among HTLV-I carriers [6]. Although the molecular basis for the development of these HTLV-I-related
disorders is still unclear, high levels of HTLV-I proviral load (PVL), as shown by the number of proviral
DNA copies per 100 cells, is suggested to be one of the risk factors for the diseases [7].
HTLV-I is dormant in vivo at least in peripheral blood or lymph nodes, so that freshly isolated
lymphoid cells from HTLV-I infected individuals do not express detectable levels of mRNA or proteins
of HTLV-I [8]. However, the continued presence of strong CD8+ cytotoxic T lymphocyte (CTL)
responses and readily detectable levels of antibodies specific for HTLV-I antigens in not only ATL and
HAM/TSP patients but also asymptomatic HTLV-I carriers clearly indicate that repeated production
of HTLV-I must occur in vivo. In accordance, once fresh peripheral blood mononuclear cells (PBMCs)
of HTLV-I infected individuals are cultured in vitro for a short time, they begin to produce HTLV-I
antigens. Little is known, however, about the mechanism(s) for HTLV-I activation in vivo. So far,
several lines of in vitro studies have shown that HTLV-I is activated upon host cell activation by a
variety of stimuli. These include lactoferrin [9], prostaglandin E2 (PGE2) [10], T cell activation agents
such as anti-CD3 plus anti-CD28, anti-CD2 antibodies, mitogens including phytohaemagglutinin
(PHA) and phorbol myristate acetate (PMA) [11–13], and agents that induce cellular stress-including
HS and oxidation [14,15].
It is well established that heat shock proteins (HSPs) play roles not only in housekeeping functions
by serving as molecular chaperones for cell survival but also in supporting gene expression of various
DNA and RNA viruses [16]. According to the geographic bias of HTLV-I prevalence towards regions
in subtropical and tropical areas and the finding that HS up-regulates HTLV-I synthesis in infected
T cell lines in vitro [14,15], we hypothesized that prolonged exposure to strong sunlight may be one
of the environmental factors for HTLV-I reactivation in vivo. This view is supported by the fact that
infrared radiation that accounts for approximately 40% of the solar radiation energy that reaches the
ground leads to the generation of heat and increases skin temperature at a level that induces HS [17].
Because HTLV-I production is dependent on its enhancer onco-protein, trans-activator (Tax), it may be
possible that a thermal shock stimulates Tax expression at first followed by trans-activation of HTLV-I
structural proteins and activation of Tax-inducible cellular proteins including OX40 and CD83 [18]. In
accordance, it has been shown that HTLV-I Tax protein does associate with a number of HS proteins,
such as HSP90 and HSP70 [19,20].
Using our library of anti-HTLV-I monoclonal antibodies (mAbs), and ATL patients’ and HTLV-I
carriers’ blood samples, we determined the effect of HS in more detail by studying the expression of
HTLV-I antigens in various HTLV-I-infected T cell lines and primary human CD4+ T cells. We report
herein that HS significantly enhanced the expression of Tax followed by enhanced expression of gp46
along with Tax-inducible host proteins. These results reported herein suggest a role for environmental
heat stress on HTLV-I reactivation in vivo.
2. Materials and Methods
2.1. Reagents
The medium used throughout the studies consisted of RPMI 1640 medium (Sigma-Aldrich Inc.,
St. Louis, MO, USA), supplemented with 10% fetal calf serum, 100 U/mL penicillin and 100 μg/mL
streptomycin (hereinafter called RPMI medium). The IL-2-dependent T cell lines utilized herein
were maintained in vitro in RPMI medium containing 20 U/mL of recombinant human IL-2. Our
mouse and rat monoclonal antibodies (mAbs) utilized in this study included mouse IgG3 anti-HTLV-I
Tax (clone Lt-4) [21], rat IgG2a anti-HTLV-I gp46 (clone LAT-27) [22], and mouse anti-OX40 (clone
B-7B5) [23]. These in-house mAbs were purified from the ascites fluids of CB.17-SCID mice by
ammonium sulfate precipitation followed by gel filtration using Superdex G-200 (GE Healthcare,
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Tokyo, Japan). Aliquots of these mAbs were labeled with fluorescein isothiocyanate (FITC), HyLite
Fluor™ 488, HyLite Fluor™ 647 or HRP (Dojindo, Kumamoto, Japan) according to the manufacturer’s
instructions. Anti-human CD4 and CD83 mAb were purchased from Beckman Coulter, Inc. (Brea, CA,
USA) and BioLegend (SanDiego, CA, USA), respectively. Anti- HSP70 antibody (clone: C92F3A-5)
was purchased from StressMarq Biosciences Inc (Victoria, BC, Canada). Zerumbone (ZER) [24] and
pifithlin-μ (PFT) [25] were purchased from Focus Biomolecules LLC (Plymouth Meeting, PA, USA)
and Sigma-Aldrich. Inc, respectively. ZER and PFT were dissolved in DMSO and stored at ´20 ˝C
until used. Mitomycin-C (MMC) was purchased from Kyowa Kirin (Tokyo, Japan) and used for the
inactivation of live cells by incubation of cells at 50 μg/mL in RPMI medium at 37 ˝C for 30 min.
Arsenite (As2O3) and N-acetylcysteine (NAC) were purchased from Sigma-Aldrich, Inc. (St. Louis, MO,
USA). Cell proliferation was evaluated using the Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories,
Kumamoto, Japan).
2.2. Cell Culture and Heat Shock (HS)
The IL-2-dependent T cell lines utilized herein included an ATL patient-derived CD4+ ILT-H2 and
the HAM/TSP patient-derived CD8+ ILT-M1 [26]. Other CD4+ T cell lines utilized were established
in our laboratory from ATL patients and included ATL-026i, ATL-056i, ATL-083i, and the cell line
YT/cM1 that was established from CD4+ T cells isolated from a normal donor. The HTLV-I-unrelated T
cell line that was used for the syncytium formation assay was the Jurkat cell line (ATCC, Rockville, MD,
USA) [26]. An ATL-derived IL-2-independent and HTLV-I-producing B cell line, ATL-040 established
in our laboratory was used for in vivo infection of NOD/SCID/γc null mice (NOG mice) with HTLV-I.
The JPX-9 cell line in which HTLV-I Tax antigen can be induced by cultivation in the presence of
10 μM cadmium (Cd) was used to determine the effect of HS on the expressions of Tax-inducible CD83
and OX40 [18].
For HS treatment, cells in growth media in a volume of 1 mL in 15 mL plastic conical tubes
(BD Biosciences, San Diego, CA, USA) were heated in a water bath at various temperatures for various
times as indicated in the text. After heating, these cells were dispensed into 24-well culture plates
(BD Biosciences, San Diego, CA, USA) and cultured at 37 ˝C for 12~72 h. The protocol for the use
of human PBMCs and animals were approved by the Human Institutional Review Board and the
Institutional Animal Care and Use Committee on clinical and animal research of the University of the
Ryukyus, prior to initiation of the present study.
2.3. Flow Cytometry (FCM) Analysis
The polychromatic phenotypic analysis of cells was performed as described previously [18,26].
Briefly, live cells were first Fc receptor-blocked with 1 mg/mL normal human IgG in FACS buffer
(phosphate-buffered saline (PBS) containing 0.2% bovine serum albumin (BSA) and 0.1% sodium
azide) for 15 min on ice. For cell surface staining, aliquots of these cells in a 96-well U-bottom plate
were incubated with a panel of mAbs for 30 min on ice. For intra-cellular Tax staining, cells were fixed
in 4% paraformaldehyde (PFA) for 5 min and washed in FACS buffer containing 1% BSA and 0.5%
saponin, and then aliquots of these cells were stained with HyLite Fluor™ (AnaSpec Inc., Fremont,
CA, USA) 647-labeled anti-Tax mAb (Lt-4) for 30 min on ice. Negative control cells were stained with
fluorochrome-labeled Lt-4 in the presence of 100 μg/mL of unlabeled Lt-4 as shown previously [18].
Cells were washed and re-suspended in 1% PFA-FACS buffer, and analyzed using FACS Calibur (BD
Biosciences, San Diego, CA, USA). Data was collected on a minimum of 100,000 events and analyzed
using either the FlowJo (TreeStar, Inc., Ashland, OR, USA) or CellQuest software (BD Biosciences,
Version 6.0).
2.4. Syncytium Formation Assay
The syncytium formation assay was performed as reported previously [26]. Briefly, YT/cM1 cells
with or without HS treatment followed by in vitro culture for 24 h were co-cultured with an equal
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number of Jurkat cells in 96-well U-bottom plate at 37 ˝C. After 15 h, the cell cultures were transferred
into a 96-well flat-bottomed well plate and syncytia were counted in 5 randomly selected fields of each
well at a magnification of 100ˆ and the mean values calculated.
2.5. Enzyme-Linked Immunosorbent Assay (ELISA)
Tax antigen concentration in whole cell lysates were determined using our in-house formulated
and standardized enzyme-linked immunosorbent assay (ELISA) kit using a pair of anti-Tax mAbs that
included the capture TAXY-7 mAb [27] and the detector HRP-labeled WATM-1 mAb [28]. Recombinant
Tax protein (Proteintech, Rosemont, IL, USA) was used as a standard. The sensitivity of the assay was
determined to be 0.5 ng/mL. Cell lysates were prepared by lysis of cells with a low-salt extraction
buffer on ice for 30 min [29]. Protein concentration of each cell lysate sample was determined using
Quick Start protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
2.6. Primary human CD4+ T Cells Infected with Human T Cell Leukemia Virus Type-I (HTLV-I)
The protocol for infection of humanized mice with HTLV-I has been described previously [30].
Briefly, purified PBMCs (4 ˆ 107 cells/mouse) from HTLV-I-negative donors were transplanted into
the peritoneal cavity of NOG mice together with MMC-treated HTLV-I producing ATL-040 cell line
(1 ˆ 107 cells/mouse). Two weeks later, cells in the peritoneal lavage were collected, either untreated
or heat-treated, and cultured for 1~2 days. The expression of Tax antigen in CD4+ human T cells was
analyzed using flow cytometry (FCM) on day 1 and 2. In addition, whole heparinized peripheral
blood of HTLV-I carriers was diluted 1:4 in RPMI medium, aliquoted, and an aliquot heat treated and
another sham treated, and both cultured. The cells in the cultures were stained with anti-CD4, anti-Tax
and anti-gp46 mAbs, and analyzed using FCM after hypotonic lysis of the red blood cells.
2.7. Statistical Analysis
Data were tested for statistical significance by either paired or unpaired Student’s t test using
Prism software (GraphPad Software, Version 4.03). Data from more than three-armed experiments
were analyzed by one-way analysis of variance (ANOVA) with post hoc Holm test and Tukey test.
3. Results
3.1. HS Up-Regulates the Expression of the HTLV-I Trans-Activator (Tax) Antigen
At first, in order to determine whether HS affects the expression of Tax antigen in HTLV-I-infected
T cells, we examined two IL-2-dependent CD4+ T cell lines generated from acute ATL patients,
ATL-026i and ATL-056i. Aliquots of these cell lines were heated at various temperatures, 37, 39, 41, 43
and 45 ˝C for 30 min and cultured for 24 h. The intra-cellular expression of Tax and HSP70 antigens
was analyzed by FCM. Figure 1a shows that while the frequencies of Tax-expressing cells increased by
HS at 43 and 45 ˝C in the ATL-026i cell line, the ATL-056i cell line had a broader range from 39~45 ˝C
for Tax expression. The enhanced expression of HSP70, a direct indicator of HS, was also observed by
HS at 43 and 45 ˝C in the two cell lines. HS at 45 ˝C resulted in decreased cell viability as determined
using a sensitive CCK-8 cell counting assay. Because the enhanced Tax expression reached a plateau
by heating at 43 ˝C for 30 min, and that HSP70 expression was apparently enhanced at 43 ˝C, all
subsequent studies were carried out with HS treatment at 43 ˝C.
Next, we determined the optimum exposure time for enhanced Tax expression. As shown in
Figure 1b, incubation for 30 min was sufficient for the enhanced expression of both Tax and HSP70
with minimum cytotoxic effect. On the basis of these results, all subsequent studies were carried out
using HS at 43 ˝C for 30 min. It is noteworthy that the MFI for Tax+ cells also slightly increased under
HS at both bulk and single cell levels as shown in Supplemental Figures S1 and S2.
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Figure 1. Effects of heat shock (HS) exposure on human T cell leukemia virus type-I (HTLV-I)-infected
cell lines derived from acute adult T cell leukemia (ATL) patients: (a) Aliquots of ATL-026i and
ATL-056i cells were incubated at various temperatures for 30 min and cultured for 24 h. The cells were
then analyzed for the frequencies of trans-activator (Tax)+ cells (left bar graphs) by flow cytometry
(FCM) and the relative density (Mean Fluorescent Intensity, MFI) of heat shock protein 70 (HSP70)
expression (middle bar graphs) and for cell viability using the CCK-8 cell counting kit (right bar graphs).
(b) The kinetics of the up-regulation of Tax and HSP70 expression by the same two cell lines following
exposure to 43 ˝C for various times is shown. The values denote the means ˘ SD. * p < 0.05, ** p < 0.01,
*** p < 0.001.
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3.2. HS Increases the Total Amount of Tax Protein
The intra-cellular localization of Tax has been shown to be altered in response to various forms
of cellular stress, such as HS and ultra violet (UV) light, resulting in an increase in cytoplasmic Tax
about 1~2 h after treatment and a decrease in Tax speckled structures [15], which might affect Tax
detection by FCM. In order to confirm the enhancing effect of HS on Tax expression, we quantified the
levels of total Tax protein in whole cell lysates by using our in-house Tax-specific ELISA. As shown
in Figure 2, the levels of Tax protein increased significantly by exposure to HS in three distinct T cell
lines including two ATL-derived CD4+ T cell lines and an in vitro- HTLV-I-immortalized CD4+ T cell
line prepared from a normal donor (YT/cM1). These data thus confirm the fact that exposure to HS
treatment increases the total amount of Tax antigen per culture during the 24 h culture period.
Figure 2. Effect of HS on total Tax protein expression: Aliquots of the ATL-derived cell lines (ATL-026i
and ATL-056i) and the HTLV-I-immortalized CD4+ T cell line (YT/cM1) were incubated at either 37 ˝C
or 43 ˝C for 30 min followed by incubation for 24 h in triplicates wells. The cells were then collected,
washed, lysed in lysis buffer and the total protein concentrations were determined. Then amounts
of total Tax concentration/mg total protein were quantitated using our Tax specific enzyme-linked
immunosorbent assay ELISA. The values denote the means ˘ SD. * p < 0.05, *** p < 0.001.
3.3. HS Up-Regulates a Functional Form of Envelope gp46.
Next, we examined whether exposure to HS influences the expression of the HTLV-I structural
envelope protein gp46 whose expression is known to be enhanced by Tax-mediated transactivation.
As shown in Figure 3a,b, the up-regulation of gp46 antigen expression was apparent in three
HTLV-I-infected T cell lines including the CD4+ and CD8+ T cell line (ILT-M1). In Figure 3a, it
was obvious that gp46+ Tax´ cells also increased after HS. We speculate that the gp46 on Tax-negative
cells may represent biofilm of HTLV-I particles produced from Tax-positive cells, or alternatively,
gp46+ Tax´ cells may be at a resting phase after a productive infection phase. It is noteworthy that
syncytium-forming capacity which is an indicator of HTLV-I infectivity, was enhanced significantly
by the exposure of YT/cM1 cells to HS (Figure 3c,d), indicating that HS also enhanced the functional
form of gp46 expression. In addition, production of gag p24 in the culture supernatant of YT/cM1
cells was also enhanced by HS (Supplemental Figure S3).
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Figure 3. Enhancement of HTLV-I envelope gp46 expression by HS: Three HTLV-I-producing T cell lines
CD4+ YT/cM1, an HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP)-derived
CD8+ ILT-M1 and an ATL-derived CD4+ ILT-H2, were either exposed to HS or mock treated and
cultured for 24 h. (a,b) The levels of gp46 along with Tax antigen expression were determined by FCM.
Data shown are representative of three independent experiments. (c) Syncytium formation capacity
was compared between untreated and heat shocked YT/cM1 cells by a co-culture method using Jurkat
cells as the indicator cell line. The numbers of syncytia were counted in triplicate cultures and the
means ˘ SD are shown. ** p < 0.01. (d) Syncytia formed in each culture were microscopically observed
using an inverted microscope at magnification of 100ˆ.
3.4. Time Course Effects of HS
We examined the kinetics by which exposure to HS leads to optimal expression of HSP70, Tax and
gp46 using two HTLV-I+ T cell lines (ATL-026i and YT/cM1). As shown in Figure 4, there appeared to
be a sequential increase in HSP70 expression peaking at during 12~24 h, followed by Tax and then
finally gp46 antigen expression. The expression levels of these three antigens returned to control
levels by ~72 h (unpublished data, [31]). The delay in enhanced gp46 expression in comparison to Tax
antigen suggests that gp46 expression was dependent on Tax antigen expression.
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Figure 4. A comparison of time course of the expression among HSP70, Tax and gp46 antigens followed
by exposure to HS: The ATL-026i (upper panel) and YT/cM1 (lower panel) cells were either exposed to
HS (black square) or mock treated (open square), cultured for 12, 24 and 48 h, and then their phenotypes
were analyzed by FCM. Data shown are representative of three independent experiments.
3.5. A Possible Involvement of Heat Shock Protein 70 (HSP70)
In attempts to test a possible involvement of HSP70 in the enhanced expression of Tax and gp46,
we tested the effects of the HSP70-inducing chemical ZER and the HSP70 functional inhibitor PFT.
The results of preliminary studies indicated that the optimal concentrations to be utilized for ZER
was noted at 10 μM and PFT at 1 μM without any detectable effect on cell viability and cell growth.
As shown in Figure 5a, incubation of cultures with ZER for 24 h significantly up-regulated both
the frequencies of Tax+ and HSP70+ cells in the absence of HS. On the other hand, PFT treatment
inhibited the increase in the frequencies of Tax+ cells by HS (Figure 5b). HSP70 expression itself
was not altered by incubation with PFT since PFT is only a functional inhibitor of HSP70. These
results indicate that HSP70 might be involved at least in part in the HS-induced enhancement of Tax
antigen expression.
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Figure 5. The effects of the HSP70 inducing and inhibiting agents on the expression of Tax antigen:
Triplicate cultures of YT/cM1 cells were either exposed to HS or mock treated, and then cultured in the
presence or absence of either (a) 10 μM zerumbone (ZER, HSP70 inducer) or (b) 1 μM pifithlin-μ (PFT,
HSP70 functional inhibitor) for 24 h. The Tax and HSP70 expression was analyzed by FCM. The values
denote the means ˘ SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
3.6. Effect of HS on Tax-Inducible Host Antigens CD83 and OX40
Because Tax is known to up-regulate a variety of host antigens, some of which are associated
with immortalization or transformation of HTLV-I-infected T cells, we examined the effect of HS on
the expression of some of the Tax-inducible host antigens, including CD83 and OX40. As shown in
Figure 6a, the levels of CD83 and OX40 expression were significantly up-regulated by exposure to HS in
three HTLV-I-infected CD4+ T cell lines. Representative dot blots are shown in Supplemental Figure S4.
To demonstrate the involvement of Tax in these enhanced CD83 and OX40 antigen expressions, we
examined the effect of HS exposure on JPX-9 cells which carry the Cd inducible Tax gene. Figure 6b
showed that incubation of the JPX-9 cells in media containing Cd and HS exposure induced not only
increased levels of Tax but also CD83 and OX40 on the cell surface. Thus, it was apparent that HS
enhanced the expression of not only Tax antigen but also Tax-inducible host antigens.
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Figure 6. The up-regulation of the expression of Tax-inducible host antigens by exposure to HS: The
ATL-derived CD4+ T cell lines (a) and JPX-9 cell line (b) were either exposed to HS or mock treated,
and then cultured for 24 h in the presence or absence 1 μM Cd (Tax inducing agent in JPX-9 cells). The
frequencies (%) of Tax antigen and Tax-inducible host antigens including CD83 and OX40 expressing
cells were analyzed by FCM. Data shown are representative of three independent experiments. In (b),
experiments were performed in triplicates, with incubation in media alone (Cd-) or media containing
Cd (Cd+) and the frequencies of Tax, CD83 and OX40 cells determined. The means ˘ SD values are
shown. *** p < 0.001.
3.7. Effect of HS Exposure on Primary Human CD4+ T Cells Infected with HTLV-I
Finally, we examined the effect of HS exposure on HTLV-I-infected primary human CD4+ T cells,
including those obtained from HTLV-I-infected humanized NOG mice and HTLV-I carriers. As shown
in Figure 7a, exposure to HS resulted in significant increase in the frequencies of Tax+ CD4+ T cells
after in vitro culture for 24 h ( p < 0.05), that returned to control levels by 48 h. Figure 7b shows
that exposure to HS resulted in increase in the expression of Tax antigen in primary CD4+ T cells
from three HTLV-I carriers ( p < 0.05). Representative dot blots are shown in Supplemental Figure
S5. Taken together, these data support the view that HTLV-I activation by exposure to HS is a general
phenomenon rather than restricted to having effects on long-term cultured cell lines.
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Figure 7. Effect of HS exposure on primary human CD4+ T cells infected with HTLV-I:
(a) NOD/SCID/γc null mice (NOG mice, n = 3) were humanized by transplantation with normal human
peripheral blood mononuclear cells (PBMCs) and infected with HTLV-I (as described in Materials and
Methods). After 2 weeks, cells within the peritoneal lavage were collected and either exposed to HS
(black circle) or mock treated (open circle). These cells were cultured in triplicates and examined for
the frequencies of Tax antigen expressing cells on day 0, 1 and 2. The values denote the means ˘ SE.
* p < 0.05; (b) Aliquots of diluted whole blood from three different HTLV-I carriers were either exposed
to HS (43 ˝C) or mock treated, and then cultured for 24 h. The gated population of CD4+ T cells was
analyzed for the expression of Tax and gp46 antigens by FCM.
4. Discussion
In the present study, we demonstrated that exposure to HS up-regulates the expression of HTLV-I
Tax antigen during in vitro culture for 12~48 h along with induction of functional HTLV-I gp46 and the
Tax-inducible host antigens CD83 and OX40 in not only human HTLV-I-infected T cell lines but also in
primary human CD4+ T cells. We conclude from these observations that HS is one of the environmental
factors that can potentially activate integrated HTLV-I provirus in vitro in latently infected T cells,
although in vivo studies are yet to be performed.
In the literature, Andrew et al. reported that heat stress enhances the expression of HTLV-I
envelope and gag antigens in long-term cultured HTLV-I-transformed T cells lines, such as HUT-102
and MT-2 cells [14,32,33], and suggested that the enhancement is due to increased translation of
HTLV-I structural proteins, but not changes in protein turnover. Since the synthesis of viral structural
proteins of HTLV-I is dependent on its Tax protein, our present study suggested that Tax antigen
synthesis precedes that of HTLV-I structural proteins. Indeed, results of the kinetic studies showed
that the enhanced gp46 antigen expression came after enhanced Tax antigen expression (Figure 4).
As expected, enhanced Tax antigen expression was accompanied by enhanced expression of some of
Tax-inducible host antigens (Figure 6), indicating that enhanced Tax antigen molecules are functional.
In addition, in line with the fact that HS is able to enhance HIV-1 Tat-mediated transactivation of the
LTR independently of Tat expression levels, there might be an alternative mechanism for Tax-mediated
enhancement of HTLV-I production upon HS.
The precise mechanism by which Tax antigen synthesis is up-regulated by exposure to HS is yet
to be defined. On the basis of our preliminary data (data not shown) indicating that HS up-regulated
total levels of Tax mRNA, it is possible that HS directly controls transcription. Thus, further studies are
in progress to determine this possibility by measuring nuclear RNA levels for Tax RNA and genomic
RNA in the cytoplasm. Since Tax operates by the activation of transcriptional factors such as the
cAMP-response element-binding protein (CREB) for activation of not only viral but also host cellular
genes, it can be speculated that CREB is also activated by exposure to HS in HTLV-I-infected cells.
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The finding that ER stress is induced by exposure to HS [34] and in turn CREB is activated by ER
stress in HeLa cells supports this view [35]. However, our preliminary FCM experiments showed that
HS did not affect the levels of expression of phosphorylated forms of NF-kB and CREB molecules
(Supplemental Figure S6).
As it is the case that the cellular onco-protein c-Myc protein is up-regulated following HS [36],
rapid induction of Tax antigen after heat-stress may be an advantage of HTLV-I-infected cells for
induction of the recovery process. In addition, enhanced Tax expression resulting in enhanced
infectious HTLV-I viral production may also be an advantage for the spread of HTLV-I from
heat-stressed cells. It is likely that HTLV-I infected cells after HS may become good targets for
HTLV-I Tax-specific CTL [37,38] or ADCC by anti-gp46 antibodies plus NK cells [26]. However,
CTL and NK cell activities are suppressed when exposed to temperatures >41 ˝C and 42 ˝C,
respectively, [39,40]. We have confirmed that exposure to HS inactivates ADCC activity of PBMCs
against HTLV-I-infected cells (unpublished data, [41]). Therefore, heat-stress may favor HTLV-I
infection rather than immune-surveillance against HTLV-I at a local site of exposure to HS. Further
studies to reveal molecular mechanisms underlying this HS-mediated HTLV-I activation are yet to
be performed.
Another representative cellular stress that is critical for Tax expression is oxidative stress, such as
As2O3. It has been utilized for ATL therapy as it induces the apoptosis of HTLV-I-infected cells [42].
The specificity of the effect of As2O3 on HTLV-I synthesis has been a subject of controversy. Thus, while
Andrew et al. reported an enhancing effect [14,32,33], Nabeshi et al. in contrast showed a suppressing
effect [43]. These discrepancies seem to be due to different experimental conditions. In our preliminary
studies, we could not observe As2O3 mediated enhancement of Tax and gp46 expression in various
conditions and various types of cell lines (Supplemental Figure S7). Thus, it is likely that HS stress
and As2O3-mediated oxidative stress may utilize distinct pathways on Tax expression by HTLV-I
infected cells.
The involvement of HSPs in viral infection has been reported for several viruses [44–46] including
HTLV-I [19,47–50]. Our present data indicates that among the HSP family, HSP70 might be associated at
least in part with HS-mediated enhancement of Tax antigen expression based on the data obtained with
the use of the HSP70-inducer, ZER, and the HSP70 functional inhibitor PFT (Figure 5). The increased
numbers of HSP70 molecules after exposure to HS may serve to function as molecular chaperon for
Tax and the other HTLV-I antigen molecules together with the other constitutively expressed HSPs
including HSP90 [49]. Further studies are in progress to determine what types of HSP are involved in
the HS-mediated enhanced Tax expression.
Infrared sunlight is known to generate heat and for their ability to increase skin temperature
depending on exposure dose and time. It has been reported that intra-dermal-temperature reaches up
to 44 ˝C when irradiated with IR at 970 nm at 80 mW/cm2 within 15 min [51]. Thus, it can be speculated
that exposure to direct sunlight in subtropical or tropical areas might raise the skin temperature to
above 43 ˝C resulting in HS of HTLV-I-infected cells. In addition, skin inflammation generated by
exposure to strong solar UV radiation (sunburn) may cause the recruitment of HTLV-I-infected cells
to the sites of inflammation. Furthermore, systemic physiological hyperthermia induced by either
direct exposure to sunlight or an opportunistic infection (for example, infection with Strongyloides
stercoralis) might also stimulate HTLV-I expression in vivo, as is the case for HIV-1 [52]. Although we
failed to demonstrate that activation of HTLV-I-infected CD4+ T cell lines via CD3 molecule further
enhanced the effect of HS on Tax expression (Supplemental Figure S8), it is also possible that immune
activation of fresh HTLV-I-infected T cells in vivo might synergize HS.
In this way, it is likely that, in subtropical and tropical areas, repeated skin exposure to strong
sunlight for a prolonged time can cause HTLV-I reactivation in vivo.
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5. Conclusions
In conclusion, results of the present study indicate that a mild exposure to heat shock may be
one of the natural environmental factors that stimulate Tax antigen expression leading to not only
reactivation of HTLV-I in latently infected T cells but also induction of expression of Tax-inducible host
antigens, which may favor expansion of HTLV-I infection in vivo. It can be speculated that exposure to
strong sunlight in subtropical and tropical areas is involved in the geographic bias of increased HTLV-I
prevalence within these regions, and that, for HTLV-I carriers, precaution against exposure to strong
sunlight for prolonged periods of time might be beneficial to prevent reactivation of HTLV-I.
Supplementary Materials: The following figures are available online at www.mdpi.com/1999-4915/8/7/191/s1.
Figure S1. HS increased the MFI of Tax+ cells. Figure S2. Correlation of Tax and HSP70 expression; Figure S3.
HS increased p24 concentration; Figure S4. Correlation between intra-cellular Tax and cell surface expression of
OX40 and CD83; Figure S5. HS upregulated expression of Tax and gp46 in fresh PBMC from careers; Figure S6.
Effect of HS on the expression of NF-kB and CREB molecules; Figure S7. The failure of exposure to oxidative
stress, As2O3, to induce increased expression of Tax and gp46; Figure S8. Failure to stimulate HTLV-I-infected cell
lines with anti-CD3 mAb (OKT-3).
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Abstract: The oncogenic retrovirus human T-cell lymphotropic virus type 1 (HTLV-1) is endemic in
some countries although its prevalence and relationship with other sexually transmitted infections
in Sub-Saharan Africa is largely unknown. A novel endpoint PCR method was used to analyse the
prevalence of HTLV-1 proviral DNA in genomic DNA extracted from liquid based cytology (LBC)
cervical smears and invasive cervical carcinomas (ICCs) obtained from human immunodeficiency
virus-positive (HIV+ve) and HIV-negative (HIV−ve) Kenyan women. Patient sociodemographic
details were recorded by structured questionnaire and these data analysed with respect to HIV status,
human papillomavirus (HPV) type (Papilocheck®) and cytology. This showed 22/113 (19.5%) of
LBC’s from HIV+ve patients were positive for HTLV-1 compared to 4/111 (3.6%) of those from
HIV−ve women (p = 0.0002; odds ratio (OR) = 6.42 (2.07–26.56)). Only 1/37 (2.7%) of HIV+ve and
none of the 44 HIV−ve ICC samples were positive for HTLV-1. There was also a significant correlation
between HTLV-1 infection, numbers of sexual partners (p < 0.05) and smoking (p < 0.01). Using this
unique method, these data suggest an unexpectedly high prevalence of HTLV-1 DNA in HIV+ve
women in this geographical location. However, the low level of HTLV-1 detected in HIV+ve ICC
samples was unexpected and the reasons for this are unclear.
Keywords: human immunodeficiency virus (HIV); human T-cell lymphotropic virus type 1 (HTLV-1);
human papilloma virus (HPV); retrovirus; liquid based cytology (LBC); invasive cervical cancer (ICC);
proviral DNA; PCR
1. Introduction
Human T-cell lymphotropic virus type 1 (HTLV-1) was the first pathogenic human retrovirus
to be discovered and is known to be associated with various mild to severe pathologies resulting
from chronic lifelong infection [1–4]. It is the aetiological agent for adult-T-cell leukaemia (ATL) and
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) with the former often proving
fatal whilst the latter causes significant debilitating morbidity. Other associated diseases include
arthropathy, HTLV-1 associated infective dermatitis, uveitis and polymyositis [5–7]. The cumulative
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risk of a HTLV-1 carrier developing ATL has been estimated at between 2.5% and 5% although a
latency period of 50–70 years is typical [8,9].
Although HTLV-1 is reported to currently infect between 10 and 25 million people globally,
the true prevalence in different geographical regions of the world is largely unknown [4,7,10,11].
The 2012 review of global HTLV-1 prevalence by Gessain and Cassar [11] summarises the most
recent data and contains comprehensive details of patient numbers, subgroups studied and outcomes.
Current estimates rely on serological screening of blood donors and pregnant women which often
excludes high-risk groups such as human immunodeficiency virus (HIV) positive individuals and
ethnic minorities [4,7]. HTLV-1 infection is endemic in many parts of the world including southern
Japan, Equatorial Africa, Central and South America and in immigrant descendants of people from
these regions [12]. In a recent review of global HTLV-1 prevalence, the highest prevalence was found
in the Japanese islands with 36.4%. Other reports in Africa are between 6.6% and 8.5% in Gabon and
1.05% in Guinea whereas elsewhere, such as in the Caribbean islands, it is 6% [4,7,13]. The prevalence
in female sex workers has ranged from 3.2% in Congo, to 5.7% in Fukuoka (Japan) and from 8.7% to
21.8% in Callao (Peru) [14]. A study done in São Paulo (Brazil) on HIV positive intravenous drug
addicts (IVDAs) showed a HTLV-1 prevalence of 15.3% [15].
Both HIV and HTLV-1 share similar risk factors since they are both transmitted through sexual
contact, blood transfusion, sharing of needles among intravenous drug users and vertical transmission
from mother to child via breast-feeding, [8,10,16,17]. With regard to breast-feeding, transmission
of HTLV-1 via this modality is known to be related to duration, proviral load and antibody titre in
addition to other less well defined factors [18]. The development of neoplasia in patients with HIV
and acquired immune deficiency syndrome (HIV/AIDS) is generally attributed to failure of immune
surveillance and associated co-infections with oncogenic viruses such as human herpes virus 8 (HHV8)
and Kaposi sarcoma, Epstein–Barr virus (EBV) with non-Hodgkins lymphoma (NHL), and human
papilloma virus (HPV) with invasive cervical carcinomas (ICC) [19–22].
During the past 20 years, HIV type 1 (HIV-1)/HTLV-1 co-infection has emerged as a global
health problem with increasing numbers of cases in South America and Africa [8]. Although both
viruses have a tropism for CD4+ T helper cells, the overall effect of virus-virus interactions on their
related pathologies is still controversial [8]. Although Africa is considered to be a large reservoir for
HTLV-1 infection, there is a paucity of prevalence data from Sub-Saharan Africa and especially East
Africa [7,11]. Based on screening pregnant women, in Western Africa Nigeria has been reported to
have the highest prevalence of 5.5% followed by Zaire in Central Africa at 4.6% where subtype B is the
most common [11]. It is thus significant that screening for HTLV-1 during pregnancy and before blood
transfusion is not routine in most Sub-Saharan African countries [10,23]. Furthermore, it is also very
likely that other higher-risk groups, such as intravenous drug addicts (IVDA) and sex workers, will
have a much higher prevalence of the virus. As mentioned the study of IVDA’s in São Paulo found
15.3% prevalence [15] which is much higher than the 0.1% prevalence observed in pregnant women in
the same location [11]. Since there is, as yet, neither an effective vaccine against HTLV-1 nor a cure
for its associated pathologies, the virus has the potential to impose a significant social and financial
burden [10,24] in this area of the world. Moreover, given that Sub-Saharan Africa is also home to two
thirds of the global HIV pandemic, it is important to assess how these two retroviruses associate in
this population and how this may contribute to the pathology of different diseases.
Several previous studies have attempted to link HTLV-1 infection with the aetiology of ICC and
have produced inconsistent findings. For example, a study carried out in Yucatan (Mexico) where
HTLV-1 prevalence is low but the incidence of ICC is high, found no statistical difference between
these two groups [25]. However, a larger study carried out in Japan found the prevalence to be higher
in ICC patients younger than 59 years. Furthermore, increased numbers of HTLV-1 infections were
also found in women from all age groups who developed vaginal carcinomas (VC) when compared
to age-matched healthy controls [26]. The conclusion from this study was that HTLV-1 infection
may promote cervical carcinogenesis and may also affect the prognosis of ICC or VC. These results
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were consistent with a study carried out on Jamaican women where a higher prevalence of HTLV-1
was found in cervical intraepithelial neoplasia 3/invasive cervical cancer (CIN3/ICC) patients when
compared to controls [27]. However, these data were not supported in a more recent report [28].
In light of these previous observations, the objective of the current study was to evaluate the
prevalence of HTLV-1 proviral DNA extracted from liquid based cytology (LBC) specimens from HIV
positive and negative patients attending specialist referral clinics in Kenyatta National Hospital in
Nairobi, Kenya. The same analysis was carried out on DNA extracted from biopsies obtained from
patients with ICC in the same hospital.
2. Materials and Methods
2.1. Study Population and Sample Collection
A cross-sectional study was carried out among women attending Kenyatta National Hospital
(KNH), Nairobi, Kenya. Consecutive female patients attending a Specialist HIV Clinic and Family
Planning Clinic were recruited between April 2008 and February 2009. Women aged between 21 and
52 years were included, while those who had prior destructive procedures for cervical disease and/or
hysterectomy were excluded. A total of 224 patients were recruited, including 111 HIV negative
(median age = 35 years, range = 21–52) and 113 HIV positive (median age = 35 years, range = 21–52)
with 56 of these in receipt of highly active antiretroviral therapy (HAART). After undergoing voluntary
counselling and testing for HIV, a structured questionnaire was administered and a blood sample was
collected. During the same period, 37 HIV positive and 40 HIV negative women newly diagnosed with
ICC at KNH were also randomly recruited. They underwent examination under anaesthesia (EUA),
a biopsy was taken which was then formalin-fixed and paraffin-embedded (FFPE). FFPE samples were
used for histopathology and DNA extractions.
This study was approved by the Kenyatta National Hospital’s Ethics and Research Board (ERB),
the University of Nairobi (No KNH-ERC/01/4988) and the University of Manchester, Oldham Research
Ethics Committee amendment 5 project 07/Q1405/14. All patients gave written informed consent.
2.2. LBC Samples
All patients were examined with a speculum and cervical samples collected using a cervex
brush, which was stirred into a vial of PreservCyt®transport solution (ThinPrep®Pap test, Hologic
Inc., Bedford, MA, USA). Cytology slides were prepared using a Cellspin Cytocentrifuge, (Tharmac,
Waldsolms, Germany) and were stained with Papanicolaou (pap) stain. All pap stained slides were
independently examined by two different pathologists and the Bethesda 2001 criteria were used for
slide interpretation [29].
2.3. HIV Testing
HIV testing was done using Determine® test kit (Abbot Pharmaceuticals, Chicago, IL, USA), and,
if positive, this was confirmed by Uni-Gold® (Trinity Biotech Plc, Bray, Ireland).
2.4. Extraction of Genomic DNA
All residual PreserveCyt®material was used for automated DNA extraction using BioRobot®
M48 (Qiagen, Hilden, Germany) as described by the manufacturer. Approximately 4 × 10 μm FFPE
ICC sections were used for DNA extraction using the Qiagen Qiacube®(Qiagen, Crawley, West Sussex,
UK) according to the manufacturer’s instructions.
2.5. Papillocheck® HPV Genotyping
DNA was quantified using a Nanodrop UV spectrophotometer (Thermo Fisher, Altrincham,
Cheshire, UK) and used for HPV genotyping with the PapilloCheck® test (Greiner Bio-One, Stonehouse,
Gloucestershire, UK) as per the manufacturer’s instructions. This identifies 24 different HPV genotypes:
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six low-risk HPV types (LR: 6, 11, 40, 42, 43, and 44/55) and 18 high-risk HPV types (HR: 16, 18, 31, 33,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82).
2.6. PCR
GAPDH PCR was performed to assess the quality of input DNA using a 50 μL reaction mixture
containing 2 μL of each DNA sample (50 ng), 2.5 units of BioTaq DNA polymerase (Bioline Ltd., London,
UK), 0.2 mM dNTPs, and 0.2 μM of each primer in 10 mM Tris-HCl pH 8.3, 50 mM KCl and 2.5 mM
MgCl2. HTLV-1 Tax PCRs were optimized using a multiplex PCR kit (Qiagen) as recommended by the
manufacturer. All reactions were carried out in duplicate, using a Veriti™ Thermal Cycler (Applied
Biosystems, Paisley, UK) with the conditions and primers indicated in Table 1. The sensitivity of the
method was tested by adding a dilution series of genomic DNA extracted from Tax transduced JPX-9
cells [30] to 50 ng of genomic DNA from a HTLV-1 negative patient per reaction. PCR products were
separated by 1.5%–2.5% agarose gel electrophoresis, stained with ethidium bromide and examined
under UV.








94 ◦C × 5 min; 33 cycles:
94◦C × 25 s; 53 ◦C × 25 s;






95 ◦C × 15 min; 45 cycles:
94◦C × 30 s; 57 ◦C × 30s;
75 ◦C × 30 s; 75◦C × 7 min
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2.7. DNA Sequencing
The gel-separated DNA bands were excised, isolated, purified and sequenced using an ABI
BigDye Cycle sequencing kit (Applied Biosystems, Warrington, UK) as indicated by the manufacturer
and a 3100 ABI sequencer (Applied Biosystems, Warrington, UK).
2.8. Statistical Analysis
The data were captured in an Access database and exported to SPSS version 16.0 for analysis
after cleaning and validation. Statistical tests of significance were done using Pearson’s chi-square
with Yates correction or with Fisher’s test if the expected frequencies were less than five. Odds ratio
(OR), adjusted OR (AOR) and the 95% confidence intervals (CI) were used to measure strengths of
associations. Further, cross-tabulations were also used to assess the distribution between HTLV-1
and HIV status of the participants, and the 95% CI around the prevalence of virus infection was




As indicated, PCR of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with GAPDH specific
primers was used to assess the quality and integrity of all DNA samples prior to these being used for
unknown test PCR’s with Tax specific primers as illustrated in Figures S1 and S2.
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3.2. PCR Detection of Proviral HTLV-1 Tax DNA
As illustrated in Figure 1, this simple hot-start, end-point PCR method specifically detected a
single 264 bp HTLV-1 Tax DNA amplimer from as little as 0.1 fg of input genomic DNA from the JPX-9
cell line.
Figure 1. Sensitivity of human T-cell lymphotropic virus type 1 (HTLV-1) Tax PCR detection.
End-point PCR method able to specifically detect a single HTLV-1 Tax DNA amplimer from 0.1 fg
of input genomic DNA (DNA from the human JPX9 cell line was used as a positive control for Tax).
GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
The specificity of the single Tax amplimer product was confirmed by excision and DNA
sequencing of the 264-bp PCR product and the identity verified by the use of National Center for
Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (See Supplementary
Data S1, Figure S4 and Supplementary Data S2 (BLAST)).
3.3. Analysis of the Association between HTLV-1 Infection and HIV Infection in LBC DNA
Genomic DNA extracted from 113 HIV positive and 111 HIV negative LBC samples was analysed
for the presence of HTLV-1 Tax proviral DNA. As shown in Figure S1, a single HTLV-1 Tax amplimer
was successfully amplified from 26 out of 224 of the LBC samples giving a total infection rate of 11.6%
(95% confidence interval (CI): 7.7%–16.5%). Most significantly, it was found that 22 of the HTLV-1
positive samples were also HIV positive producing an infection rate of 19.5% (95% CI: 12.6%–27.9%) in
the 113 HIV positive patients.
The HTLV-1 prevalence was four out of 111 (3.6%) (95% CI: 0.9%–8.9%) in HIV negative women,
which indicates that the frequency of HTLV-1 infection is >5 times higher in HIV positive than
negative patients, indicating that HTLV-1 infection is significantly associated with a HIV positive
status (p < 0.01).
3.4. Analysis of the Association of HTLV-1 Infection with Abnormal Cervical Cytology
Using the same LBC samples, we have previously shown that HIV infection was associated
with abnormal cervical cytology [31]. In light of this, HTLV-1 infection was assessed in relation to
our previous cervical cytology findings where low-grade and high-grade squamous intraepithelial
lesion (LSIL and HSIL) and abnormal squamous cells of undetermined significance (ASCUS) were
analysed independently. In contrast to HIV infection, there was no statistically significant evidence for
an association between HTLV-1 and abnormal cervical cytology (p = 0.231 using Pearson’s chi-square
with Yates correction). Nevertheless, it was noted that all the HTLV-1 infections were in normal/LSIL
and none were found in HSIL/ASCUS (See Figure S4).
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3.5. Analysis of the Association between HTLV-1 Infection, Stage of HIV and Use of Highly Active
Antiretroviral Therapy (HAART)
According to World Health Organization (WHO) clinical staging system, the 113 HIV positives
were classified as stage I–IV, consisting of stage I in 24, II in 16, III in 38 and IV in 35 patients. There was
no statistical significance between HTLV-1 positive and HIV clinical stages. Additionally, HTLV-1
positivity was not associated with increasing advancement of HIV disease or use of HAART (p > 0.05)
(See Table S3). WHO guidelines for HIV staging can be found on the AIDS Education and Training
Center (AETC) website [32].
3.6. Analysis of the Association between HTLV-1 Infection and HPV in LBC DNAs
As described above, 24 subtypes of HPV, including six low-risk (LR) and 18 high-risk (HR) were
identified in LBC specimens using the Papillocheck® system. Of the samples analysed, one sample had
an invalid result, while 121 (55%, 95%CI: 48.2%–61.7%) had at least one HPV subtype with the highest
number of genotypes detected in any one individual being seven, covering 107 HR (88.4%, 95% CI:
81.3%–93.5%) and 14 LR (11.6%, 95% CI: 6.5%–18.7%) HPV subtypes. None of the HPV subtypes
covered showed any association with HTLV-1 apart from HPV type 53 where there was a significant
positive association (p < 0.05) (Figure 2 and Table 2).
Figure 2. Association of HTLV-1 and human papillomavirus (HPV) type 53 infections. HPV type 53
showed a statistically significant association with HTLV-1 infection (p <0.05). None of the other HPV
sub-types showed a positive association.
Table 2. Analysis of the association between HTLV-1 and HPV infections.
HPV (+) HPV (–)
HTLV-1 (+) 13 13
HTLV-1 (–) 108 89
p-value > 0.05
3.7. Analysis of the Relationship between HTLV-1 Infection and Patient Age
LBC material for this study was obtained from women with an age range of 21 to 52 years and
median or mean ages of 35 or 35.2 years, respectively. The median age of HTLV-1 negatives was 35 and
HTLV-1 positives 31 years with no significant difference observed between the median age of HTLV-1
positives with respect to either HPV or HIV status (Figure 3). Within HTLV-1 positives, no significant
difference was found between infection and any of the age groups.
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Figure 3. Relationship between HTLV-1, HPV, human immunodeficiency virus (HIV) infections and
age. There was no significant difference observed between the median age of HTLV-1 positives with
respect to either HPV or HIV status. However, there was a trend towards a lower HTLV-1 prevalence
among women >45 years old when compared to women positive for HPV and HIV.
Among the 77 ICC study subjects, the median and mean ages were 42 and 44 years, respectively,
with a range of 27–68 years. Any association between HTLV-1 infection and age could not be calculated
since only one ICC sample was positive.
3.8. Analysis of the Relationship between HTLV-1 Infection and Patient Sociodemographics
Analysis of the relationship between HTLV-1 infection and patient’s life style shown in Figure 4
indicated that the rate of HTLV-1 infection in the smoking group was five times higher than that in
the non-smoking group. Women with increased numbers of marriages and sex partners were also
significantly more likely to have HTLV-1 infections confirming that sexual transmission is an important
means of HTLV-1 infection. No significant associations between HTLV-1 infections were found with
religion, educational level, occupation, socio-economic status, contraceptive use, intravenous drug use,
blood transfusion, genital herpes and either rural or urban residency (see Figure S5).
Figure 4. Analysis of the relationship between HTLV-1 infection and life styles factors. The rate of
HTLV-1 infection in the smoking group was five times higher than that in non-smoking group. Women
with increased numbers of marriages and sexual partners were significantly more likely to have HTLV-1
infections confirming that sexual contact is an important means of HTLV-1 transmission.
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3.9. Analysis of HTLV-1 DNA in ICC DNA’s
HTLV-1 DNA was only detected in one out of 77 ICC biopsies, of which 37 were HIV positive
(see Figure S2). This equates to an overall infection rate of 1.3% (95% CI: 0.033%–7%), which is
significantly lower than the 12.1% (95% CI: 8.1%–17%) found in DNA from LBC material. However,
if the HTLV-1 infections found in LBC and ICC material from just HIV positive women are compared,
this equates to 19.5% (95% CI: 12.6%–27.9%) versus 2.7% (95% CI: 0.068%–14%), respectively. Thus,
HIV positive women with ICCs have approximately seven-fold less numbers of HTLV-1 infections
than would be predicted from the rate observed in LBC material from HIV positive women.
4. Discussion
Although HTLV-1 was discovered 35 years ago, information on its prevalence and associated
risk factors in Sub-Saharan Africa countries have remained poorly defined. HIV, HTLV-1 and HPV
can share the same sexual route of transmission and, to our knowledge, this is the first study carried
out in Kenya to analyse the prevalence of HTLV-1 in LBC cervical specimens and formalin fixed and
paraffin-embedded (FFPE) ICC biopsies from HIV positive and negative women. The most significant
observation was the high prevalence of HTLV-1 proviral DNA found in LBC samples from HIV positive
women, consistent with previous work carried out in Guinea-Bissau, showing that HIV infection is a
potential risk factor for acquiring HTLV-1 [33]. Moreover, the seven-fold lower incidence of HTLV-1
DNA found in ICCs from HIV positive women begs the question, what is the explanation for this?
Clearly, it could be related to differences in the type of sample and extraction procedures used for
LBC’s and ICCs although there are other possibilities. For example, women who are positive for both
HTLV-1 and HIV have increased AIDS related mortality, which could prevent them from living long
enough to develop ICC. However, it is still not established that concomitant HTLV-1/HIV infection
does promote progression to AIDS [8,34].
A limitation of the current study is the lack of corroborating serological data on HTLV-1 prevalence.
Although the PCR method is sensitive, it is very clear this may underestimate the true prevalence
since it depends on the inclusion of sufficient numbers of infected cells in extracted material. Indeed,
this could also provide an alternative explanation for the lower detection of HTLV-1 DNA found in
ICC samples. However, another possibility is that HTLV-1 could suppress HPV mediated cervical
carcinogenesis in HIV positive women, which raises the question: is there a potential mechanism for
such an effect? Both HIV and HTLV-1 infect CD4+ cells and it has been previously shown that elevated
numbers of CD4+ cells are associated with HPV-related dysplasia [35–37]. Moreover, persistent HPV
infections are known to suppress T-helper type 1 (Th-1) and promote a T-helper type 2 (Th-2) responses,
which results in defective interferon (IFN) production. This, in turn promotes the development of
HPV related neoplasia [38]. Thus, if co-infection with HTLV-1 and HIV produced a shift from Th-2
to a Th-1 response, this could potentially inhibit cervical carcinogenesis and explain the reduced
prevalence of HTLV-1 in ICCs from HIV positive women. Indeed, it is highly significant that the work
of Abrahäo et al. has shown that concomitant HTLV-1/HIV infection augments production of the Th-1
cytokines interleukin-2 (IL-2) and IFN above that of single HTLV-1 or HIV infected individuals which
is entirely consistent with this hypothesis [39]. It is also curious that none of the 22 HPV subtypes
tested, apart from HPV 53, showed any association with HTLV-1. The importance of this is that, in
an earlier report, we demonstrated that type 53 was significantly more common in LBC’s from HIV
positive than HIV negative women although it was never detected in any of the ICCs examined [31].
With regard to other cancers, a protective role for HTLV-1 is not without precedent. Hirata et al.
evaluated the relationship between HTLV-1 infection and the occurrence of several types of cancers
namely biliary tract, pancreatic, esophageal, gastric, colorectal, liver, and lung cancers using logistic
regression analysis adjusted for age and sex [40]. Curiously, the HTLV-1 infection rate found in gastric
cancer patients was significantly lower than in controls (p = 0.01) but no associations were observed
with any of the other cancers studied.
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Another important question raised by the current study is that, given the high prevalence of
HTLV-1 in HIV positive Kenyan women, is there a correspondingly higher incidence of HTLV-1 related
pathologies in these women as observed in Japan [41]? However, this may not be apparent as the
average 59 years life expectancy in Kenya is much shorter than the 83 years in Japan. Since HTLV-1
related adult-T-cell leukaemia occurs after a long latency period, typically spanning 5–7 decades, it is
thus highly likely that infected individuals in Sub-Saharan Africa will succumb to other illnesses prior
to the development of HTLV-1 related pathologies. Indeed the median age for LBC and ICC subjects in
the current study was 35 and 42 years, respectively.
Other noteworthy finding from our study was the significant association between HTLV-1
infection and increased numbers of direct and indirect sexual contacts in addition to smoking.
Given that smoking is known to impair the function of cervical Langerhans cells, it is possible that
the increased incidence of HTLV-1 in smokers could be related to impaired local immunity which
contributes to increased rates of sexual transmission of the virus [42].
In summary, it is known that the influence of HIV infection on the incidence of HPV related
ICC seems to vary depending on the geographical location of the study [43]. For example, work
carried out in European locations shows an increased incidence of ICC in HIV positive women [43–45],
whereas this has not been observed in other, mainly African, studies [46,47]. In light of our findings,
it is tempting to speculate that the observed differences in ICC incidence rates found in HIV positive
women in different geographical locations may be, at least in part, due to variations in the prevalence
of HTLV-1 infection since this is much more common in Sub-Saharan Africa than Europe. Clearly,
larger studies are needed in order to improve the statistical significance of this finding, which could
also be supplemented with analysis of Th-1 and Th-2 cytokine profiles.
As discussed, there is a paucity of epidemiological data on HTLV-1 in Sub-Saharan Africa, which
also bears the heaviest global HIV burden. The HTLV-1 prevalence found in LBC samples from HIV
positive women (20.4%) suggests this could be higher than anticipated reinforcing the finding that
Kenya may be endemic for HTLV-1 and also confirming the association between HTLV-1 and HIV.
Clearly, there is an urgent need to conduct larger population based studies and to institute public
health measures to curb the continued spread of HTLV-1. For example, addressing the issue of vertical
transmission through breast-feeding (by considering safe replacement feeds for those whose mothers
are carriers), increased condom use to curb sexual transmission and provision of universal HTLV-1
screening on all blood donations, tissue and organ donors. Currently, routine HTLV-1 screening is not
carried out in most African countries including Kenya—a gap which may be promoting the spread of
this virus. Furthermore, there is no curative treatment for HTLV-1 or its associated pathologies and an
effective vaccine is equally unavailable which puts a heavy social and financial burden on sufferers,
their families and the healthcare systems. Thus, public health interventions aimed at counselling and
educating high-risk individuals and the public are of critical significance [10].
Supplementary Materials: The following are available online at www.mdpi.com/1999-4915/8/9/245/s1,
Figure S1: PCR Analysis of HTLV-1 Tax in 220 LBC DNA’s, Figure S2: PCR Analysis of HTLV-1 Tax in 77 ICC
DNA’s, Figure S3: HTLV-1 prevalence and cervical cytology in HIV+ve and −ve patients, Figure S4: Nested
PCR analysis of the Tax 181 pb amplimer in the 26 HTLV-1 positive LBC’s, Table S1: Relationship between
HTLV-1 and WHO HIV staging and HAART, Table S2: HTLV-1 status with respect to patient sociodemographics,
Supplementary_Data_S2: NCBI BLAST of nested Tax amplimer sequences shown in supplementary Figure S4.
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Abstract: Human T-cell lymphotropic virus type 1 (HTLV-1) infection is an endemic condition in
Northeast Iran and, as such, identification of risk factors associated with the infection in this region
seems to be a necessity. All the possible risk factors for HTLV-1 seropositivity among first-time blood
donors were evaluated in Mashhad, Iran, during the period of 2011–2012. Blood donation volunteers
were interviewed for demographic data, medical history, and behavioral characteristics and the
frequencies of risk factors were compared between HTLV-1 positive (case) and HTLV-1 negative
(control) donors. The data was analyzed using Chi square and t-tests. Logistic regression analysis
was performed to identify independent risk factors for the infection. Assessments were carried
out on 246 cases aged 17–60 and 776 controls aged 17–59, who were matched based on their ages,
gender, and date and center of donation. Logistic analysis showed low income (OR = 1.53, p = 0.035),
low educational level (OR = 1.64, p = 0.049), being born in the cities of either Mashhad (OR = 2.47,
p = 0.001) or Neyshabour (OR = 4.30, p < 0001), and a history of blood transfusion (OR = 3.17, p = 0.007)
or non-IV drug abuse (OR = 3.77, p < 0.0001) were significant predictors for infection with HTLV-1.
Lack of variability or small sample size could be reasons of failure to detect some well-known risk
factors for HTLV-1 infection, such as prolonged breastfeeding and sexual promiscuity. Pre-donation
screening of possible risk factors for transfusion-transmissible infections should also be considered as
an important issue, however, a revision of the screening criteria such as a history of transfusion for
more than one year prior to donation is strongly recommended.
Keywords: HTLV-1 infection; risk factors; blood donors; Mashhad; Iran
1. Introduction
Human T-cell lymphotropic virus type 1 (HTLV-1) was the first human retrovirus to have been
discovered in 1980 [1]. Approximately 5 to 10 million people are infected with HTLV-1 worldwide [2].
HTLV-1 infection is observed throughout all parts of the world; however, Southwestern Japan,
Caribbean Basin, South America, and Central Africa have been identified as being endemic regions for
the virus [2]. In addition to these regions, the virus is known to be endemic in Northeast Iran especially
in the cities of Mashhad and Neyshabour [3,4]. HTLV-1 is the etiological agent for adult T-cell leukemia
(ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [2,3]. Despite
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this, more than 95% of infected individuals remain as asymptomatic carriers for the duration of their
lives [5].
The infection can be transmitted through the transfusion of contaminated blood or blood
products, unprotected sexual contact, sharing of contaminated syringes and other instruments, or
via transmission from mother to child [2,6]. Risk of sero-conversion followed by transfusion is
estimated to be between 40%–60% [6]. Receiving red blood cells, platelet, and whole blood compared
to plasma products is also thought to be associated with a higher risk of transmission [7]; however,
this risk decreases after freezing the blood for more than two weeks [6,7]. Routine screenings of blood
volunteers for HTLV antibodies, along with the exclusion of high risk individuals, have contributed in
reducing virus transmission through blood transfusion in endemic areas [7]. In this context, several
preventive measures have been implemented by the Iranian Blood Transfusion Organization as a
means to guarantee blood safety in the country and these include recording medical histories and
physical examinations of the volunteers by trained physicians, encouraging people to donate blood on
a regular basis, exclusion of remunerated or family replacement donations, exclusion of individuals
with histories of possible risk factors such as bloodletting, tattooing, high risk sexual contact, drug
abuse, etc. and screening for blood-borne agents including HBV, HCV, HIV, HTLV, and Treponema
pallidum with sensitive and accurate assays [8]. The first study of Iranian blood donors in 1994 showed
the prevalence of HTLV-1 infection to be 0.29%; 1.97% among Mashhadi blood donors, and 0%–0.5%
in other cities [9]. After that, all donated bloods are screened for HTLV-1 and HTLV-2 antibodies
in some provinces from Northeastern Iran [8]. However, the prevalence of HTLV-1 infection is still
considerable among the general population (2.12%) and blood donors (0.45%) of Mashhad [3,10].
Moreover, remarkable prevalence of the infection has been reported among both blood donors and
frequently blood recipients from other regions of the country as well [11–14].
To our knowledge, no survey has been performed to determine the risk factors for HTLV-1
infection in Iran. Therefore, in the current study the frequency of associated risk factors for HTLV-1
infection was investigated among blood donors in Mashhad, Northeastern Iran. Identification of
individuals with these factors and excluding them from blood donation would result in a reduction of
transfusion-transmitted cases of the infection.
2. Materials and Methods
This case-control epidemiological study was conducted among first-time blood volunteers who
had been referred to blood transfusion centers of Mashhad, Iran between September 2011 and
August 2013. A total of 54,436 individuals donated blood, of which 321 individuals (0.59%; 95% CI:
0.53%–0.66%) had HTLV-1 infection based on screening and subsequent confirmatory test results. The
cases included 316 blood donation volunteers from Mashhad city with confirmed HTLV-1 seropositivity
and the controls were selected randomly from Mashhadi donors who had shown no reactivity for
HTLV-1 antibodies in screening tests. Four controls were individually matched to each case on the
basis of their ages (˘2 years), gender, and date and center of donation. ELISA method (EIAgen HTLV
I-II Ab Kit, Adaltis S.r.l., Rome, Italy) was used as a primary detection tool of HTLV-1 antibodies and
the positive results were confirmed via a Western blot analysis (MP-Diagnostics HTLV-Blot 2.4, MP
Biomedicals Asia Pacific Pte. Ltd., Singapore, Singapore). All blood donors were routinely visited
by the physician of the blood transfusion center before donation and checked for the presence of any
blood-borne infections such as HBV, HCV, HIV, HTLV, and Treponema pallidum. Blood samples from
the control group showed no reactivity to the abovementioned transfusion-transmitted agents.
Participants were interviewed by trained research assistants using a questionnaire on demographic
and socio-economic characteristics, such as age, gender, marital status, education, income, birth
place, family size, weight and height, duration of breastfeeding, medical histories including
sexually-transmitted infections (STIs), blood transfusion, hospitalization, surgery, invasive diagnostic
tests (endoscopy, etc.), dentistry procedures with bleeding (tooth extraction, gum surgery, root canal
treatment, fixed dental prosthesis), suturing, acupuncture, needlestick injuries (in health settings or
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beauty salons), history of risky behaviors such as tattooing, cupping, tatbir (Qama Zani, the act of
striking the head with a sword or knife until blood gushes out as a ritual), body piercing, unsafe sexual
contact, drug abuse, and imprisonment.
This study was approved by The Research and Technology Deputy of Iranian Academic Center
for Education, Culture and Research (ACECR) (Number: 2033-10) with regard to ethical issues. All
participants in the study did so voluntarily, and signed a written consent.
All statistical analyses were performed by SPSS version 16 (Chicago, IL, USA) using a Chi square
test and t-test. Logistic regression analysis was also performed to identify independent risk factors for
HTLV-1 infection. Statistical significance was assumed for p values of less than 0.05.
3. Results
3.1. Demographic Characteristics
From 316 cases, 246 (77.8%) individuals aged 17–60 years had been referred for consulting and
were subsequently interviewed. Moreover, 1241 controls were invited to participate in the study,
of which 776 (62.5%) persons aged 17–59 years, agreed to be interviewed. As Table 1 shows, age
distributions of both cases and controls were not significantly different between studied individuals
and non-participants (p = 0.990 and p = 0.478, respectively). Among the case group, male to female ratio
in participants was considerably less than that in non-participants (p = 0.004), albeit, no differences
in the ratio was observed between referred and non-referred individuals from the control group (p =
0.329).









Non-Participants p Value :
(n = 246) (n = 70) (n = 776) (n = 465)
No (%) No (%) No (%) No (%)
Age (years) 0.990 0.478
<30 52 (21.1) 15 (21.4) 193 (24.9) 132 (28.4)
30–39 68 (27.6) 18 (25.7) 203 (26.2) 124 (26.7)
40–49 77 (31.3) 24 (34.3) 237 (30.5) 133 (28.6)
ě50 49 (19.9) 13 (18.6) 143 (18.4) 76 (16.3)
Gender 0.004 0.329
Male 181 (73.6) 64 (91.4) 613 (79.0) 378 (81.3)
Female 65 (26.4) 6 (8.6) 163 (21.0) 87 (18.7)
: Chi square test.
Table 2. Demographic and socio-economic features associated with HTLV-1 infection in blood donors.
Variable
HTLV-1-Positive
(n = 246) No (%)
HTLV-1-Negative
(n = 776) No (%) p Value :
Age (years) 39.1 ˘ 10.6 * 38.3 ˘ 10.6 * 0.25
Gender
Male 181 (73.6) 613 (79)
0.08Female 65 (26.4) 163 (21)
Marital status
Single 24 (9.8) 98 (12.6)
0.09Married 213 (86.9) 667 (86)
Divorced 8 (3.3) 11 (1.4)
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(n = 246) No (%)
HTLV-1-Negative
(n = 776) No (%) p Value :
Remarriage
Yes 19 (8.7) 25 (3.7)
0.003No 200 (91.3) 652 (96.3)
Education
Illiterate 4 (1.6) 15 (1.9)
<0.0001
Primary school (1–5 years) 67 (27.2) 105 (13.6)
Secondary and high school (6–12 years) 113 (45.9) 406 (52.6)
Academic education 62 (25.2) 250 (32.3)
Income per month
(Million Rials)
<5 100 (40.8) 213 (27.6)
0.001
5–9.9 113 (46.1) 401 (51.9)
10–19.9 27 (11) 131 (17)
ě20 5 (2) 27 (3.5)
Birth place
Mashhad (Khorasan Razavi province) 163 (66.3) 473 (61)
<0.0001Nyshabour (Khorasan Razavi province) 20 (8.1) 28 (3.6)
Other cities of Khorasan Razavi province 43 (17.5) 144 (18.6)
Other provinces 20 (8.1) 131 (16.9)
Family size 3.7 (1.2) * 3.8 (1.3) * 0.20
BMI
<25 79 (33.2) 220 (39.5)
0.7325–30 108 (45.4) 339 (47)
ě30 51 (21.4) 163 (22.6)
Duration of breastfeeding
<6 months 8 (5.2) 47 (7.9)
0.26ě6 moths 144 (94.7) 547 (92.1)
BMI: Body mass index; * mean ˘ SD; : t-test for age and family size, Chi square test for other variables.
Demographic and socio-economic characteristics of donors are shown in Table 2. No significant
difference was observed in the mean age and gender between case and control groups (p = 0.25 and
p = 0.08, respectively). Cases had higher frequency of remarriage compared to controls (p = 0.003). The
proportion of individuals with primary education or less in the case group (28.8%) was higher than
those observed in the control group (15.5%; p < 0.0001). Furthermore, patients with the infection had
significantly lower incomes compared to the controls (p = 0.001). According to Table 2, frequency of
subjects who were born in the cities of Mashhad and Neyshabour in the case group was more than
those in controls (p < 0.0001). In addition, no significant difference was found in the marital status
(p = 0.09), body mass index (p = 0.73), family size (p = 0.21), and duration of breastfeeding (p = 0.26)
between the both groups.
3.2. Medical Conditions
Medical histories of blood donors which were assumed to be associated with the risk of HTLV-1
infection are shown in Table 3. A history of blood or blood products transfusion in the case group was
higher than that in controls (p = 0.005). Fifteen donors, including six cases (3.7%) and nine controls
(1.5%), reported blood reception in the province of Khorasan Razavi (nearly all in Mashhad city) after
the routine screening for HTLV-1 infection was started in this region (p = 0.07).
In addition, history of STIs was very low in both case and control groups (2.4% and 1.8%,
respectively; p = 0.53). On the other hand, no significant differences were found in the history
of hospitalization, surgery, acupuncture, suturing, invasive dental treatment, invasive diagnostic
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procedures, and needlestick between both groups (Table 3). Three cases of HTLV-1-HBV co-infection
and one case of HTLV-1-HCV co-infection were detected but no association with HIV and Treponema
pallidum was observed in the case group.
Table 3. Medical histories of blood donors associated with HTLV-1 infection.
Variable
HTLV-1-Positive HTLV-1-Negative
p Value :(n = 246) (n = 776)
No (%) No (%)
Hospitalization
Yes 128 (51.2) 461 (57.4)
0.10No 122 (48.8) 342 (42.6)
Surgery
Yes 98 (40.8) 327 (42.5)
0.88No 142 (59.2) 444 (57.6)
Blood or blood products transfusion
Yes 13 (5.3) 15 (1.9)
0.005No 233 (94.7) 761 (98.1)
Invasive diagnostic procedure
Yes 18 (7.3) 57 (7.3)
0.99No 227 (92.7) 719 (92.7)
Invasive dental treatment
Yes 188 (76.4) 550 (71.2)
0.11No 58 (23.6) 222 (28.8)
Acupuncture
Yes 2 (0.8) 17 (2.2)
0.16No 244 (99.2) 759 (98.7)
Suturing
Yes 82 (33.6) 245 (31.8)
0.54No 162 (66.4) 527 (68.3)
Needlestick
Yes 13 (5.3) 37 (4.8)
0.74No 233 (94.7) 739 (95.2)
STIs
Yes 6 (2.4) 14 (1.8)
0.53No 240 (97.6) 761 (98.2)
: Chi square test; STIs: sexually-transmitted infections.
3.3. Risky Behaviors
Possible risky behaviors related to HTLV-1 infection are presented in Table 4. Frequency of
cupping, piercing, tattooing, and imprisonment history did not differ between the groups; with only
two cases (0.8%) and three controls (0.4%) having a history of tatbir. On the other hand, a history of
drug abuse in the case group was significantly higher than those found in the controls (p < 0.0001).
However, none of the subjects had stated a history of injecting drug use (IDU). Moreover, history of
pre- and extra-marital sexual contact and number of lifetime sexual partners in both groups were
similar (p = 0.17 and p = 0.28). On the other hand, among 22 cases with a history of pre- or extra-marital
sex, 4.5% had one partner, 31.8% had two partners, and 63.6% had at least three partners. In controls
with a same history, 43.6%, 27.3%, and 29.1% of 55 donors had one, two, and three or more partners,
respectively (p = 0.002).
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Table 4. Risky behaviors associated with HTLV-1 infection among blood donors.
Variable
HTLV-1-Positive
(n = 246) No (%)
HTLV-1-Negative
(n = 776) No (%) p Value :
Cupping
Yes 85 (34.7) 275 (35.4)
0.89No 160 (65.3) 501 (64.6)
Tattooing
Yes 16 (6.5) 35 (4.5)
0.21No 230 (93.5) 741 (95.5)
Piercing
Yes 47 (19.2) 155 (20.1)
0.70No 198 (80.8) 616 (79.9)
Drug abuse
Yes 23 (9.3) 15 (1.9)
<0.0001No 223 (90.7) 761 (98.1)
Pre- and extra-marital sex
Yes 25 (10.2) 58 (7.5)
0.17No 219 (89.8) 715 (92.5)
Number of life time sexual partners
0 22 (9.2) 86 (11.2)
0.281 196 (81.7) 634 (82.3)
ě2 22 (9.2) 50 (6.5)
Imprisonment
Yes 9 (3.7) 25 (3.2)
0.73No 237 (96.3) 751 (96.8)
: Chi square test.
3.4. Regression Analysis of Risk Factors Related to HTLV-1 Infection
All variables with a significant relation to HTLV-1 infection in univariate analysis were entered
into the logistic regression model. As Table 5 shows, significant associations were found between
the infection and low educational levels (OR = 1.64, 95% CI: 1.04–2.69), low income (OR = 1.53, 95%
CI: 1.03–2.26), birth place (OR = 4.30, 95% CI: 1.91–9.67 for those born in the city of Neyshabour
and OR = 2.47, 95% CI: 1.42–4.33 for Mashhad city), a history of blood transfusion (OR = 3.17, 95%
CI: 1.37–7.33), and drug abuse (OR = 3.77, 95% CI: 1.79–7.55).
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Table 5. Results from logistic regression analysis for HTLV-1 associated risk factors in blood donors.
Variable OR 95% CI for OR p-Value
Remarriage
Yes 1.50 0.75–2.99 0.252
No 1.0
Education level
Illiterate or primary school (0–5 years) 1.64 1.04–2.69 0.049
Secondary and high school (6–12 years) 0.73 0.43–1.27 0.266
Academic education 1.0
Monthly income (Million Rials) :
<5 1.53 1.03–2.26 0.035
5–9.9 1.53 0.49–4.73 0.461
10–19.9 1.13 0.35–3.71 0.838
ě20 1.0
Birth City
Mashhad (Khorasan Razavi province) 2.47 1.42–4.23 0.001
Neyshabour (Khorasan Razavi province) 4.30 1.91–9.67 <0.0001
Other cities of Khorasan Razavi province 1.82 0.96–3.45 0.067
Cities of other provinces 1.0
History of blood transfusion
Yes 3.17 1.37–7.33 0.007
No 1.0
History of drug abuse
Yes 3.77 1.79–7.55 <0.0001
No 1.0
OR: Odd ratio; CI: Confidence Interval. : One million Rials was approximately equal to 30 USD in the time
of study.
4. Discussion
This study was conducted to identify possible risk factors related to HTLV-1 infection among
first-time donors who referred to blood centers in Mashhad, Iran. Findings showed that the main risk
factors associated with HTLV-1 infection were low educational levels, low income, being born in the
cities of Mashhad and Neyshabour, and histories of blood transfusion and drug abuse.
In a study conducted on Australian blood donors during 2000–2006, the prevalence of HTLV-1
seropositivity was three per 100,000 donors, of which 5% had at least one unidentified risk factor at the
time of blood donation. In general, no dominant risk factors emerged, but the major identified factors
related to the infection were as follows: the country of birth and parental ethnicity (24%), sex with
individual from overseas (23%), at-risk household contacts (19%), tattooing or piercing (8%), surgery
or endoscopy (8%), blood product transfusion (8%), and other blood contacts, such as needle sticks
(4%) [15].
In the current study, being born in the cities of Mashhad or Neyshabour showed a strong
association with infection of HTLV-1. Very high prevalence of the infection in the general population
of these cities had been previously reported [3,4]. However, studies conducted in other cities of Iran,
had shown that HTLV-1 prevalence was not considerable [13,16].
In the present study, the case group had a significant lower education and income levels compared
to the controls. It seems that low education and income levels among these people would have
reduced their access to health information and may increase the prevalence of risk factors related
to HTLV-1 infection, such as risky sexual behaviors or contact with contaminated blood through
tattooing or piercing among these individuals. In another study on the general population of Mashhad,
HTLV-1 infection was not associated with income, but the highest prevalence of the infection was
observed among illiterates. Nevertheless, regression analysis showed no significant association
between educational level and the infection [3]. Similarly, Custer et al. and Dourado et al. could not
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find any significant association between literacy and income with the infection in blood donors [17,18].
Conversely, in a case-control study by Rouet et al., low educational level was identified to be a main
risk factor for HTLV-1 infection among blood donors in French West Indies [19]. Furthermore, Blas et al.
demonstrated that low literacy was indeed an important risk factor for HTLV-1 infection [20].
Breastfeeding, especially longer than six months, is one of the HTLV-1 transmission routes [21].
The current study, showed high frequencies of breastfeeding for ě 6 months in both groups. However
prolonged breastfeeding was slightly higher in the case group compared to the controls, but this
difference was not statistically significant. Lack of variability about prolonged breastfeeding might
be a reason that we could not find a significant association between mode of feeding in infancy
period and prevalence of the infection. Similarly, Blas et al. could not find a significant association
between the infection and breastfeeding due to very high prevalence of breastfeeding in both HTLV-1
seropositive and seronegative individuals [20]. On the other hand, breastfeeding was reported as one
of the important risk factors for HTLV-1infection among blood donors from Taiwan with an odds
ratio of 4.4 [22].
As expected, this study showed that HTLV-1 infection is significantly associated with a history
of blood reception. Nevertheless, there was no significant difference between the study groups if the
history was limited to reception in Khorasan Razavi blood centers after 1994 when routine screening
for HTLV-1 infection began in this region. A history of blood transfusion during the last year is one of
the deferral criteria for blood donations in Iran and all of the blood donors had not received any blood
for at least one year before the blood donation date. In a survey in Neyshabour, the proportion of the
infection among individuals with a history of the transfusion was four times higher than others [4].
Additionally, in several studies on blood donors from Taiwan, Canada and Brazil a history of blood
transfusion increased the risk of infection by a factor of nine to ten times [22–24]. On the other hand,
HTLV-1 infection was not significantly associated with transfusion among healthy blood donors from
Nigeria [25] and USA [17].
Based on the results of the present study, the risk of infection was not increased in individuals
with a history of surgery, hospitalization, needlestick, cupping, or tattooing. Similarly, in the study
conducted on the general population of Mashhad, HTLV-1 infection was not more prevalent among
individuals with a history of these variables on the regression analysis [3]. In another survey among
blood donors from Taiwan, a history of surgery was also not associated with the infection [22].
This study unexpectedly identified non-IDU as a risk factor for HTLV-1 infection. The frequency
of non-IDU in the case group was significantly higher than in controls (9% and 2%, respectively).
Likewise, Soares et al. showed that HTLV-1 seropositive cases in Brazilian blood donors more often
used non-intravenous illegal drugs (OR = 3.3), while no significant difference was observed between
HTLV-1 seropositive and seronegative groups for the frequency of intravenous drugs use [24]. In Iran,
people who use opium orally or by inhalation (except heroin and crack) could donate their blood but
are permanently excluded from donation if they report at least one IDU or use sharp tools for substance
inhalation. It seems that the other risk factors which are not declared by the participants with a history
of non-IDU or not evaluated by the researchers might have been involved in the infection of HTLV
and other blood-borne viruses [26].
A history of STIs during one last year is a deferral factor for blood donation in Iran, and in the
current study a history of STIs among blood donors was expectedly very low as a result. A history
of extramarital sexual contact was similar among cases and controls, however, among this subgroup,
cases had more lifetime sexual partner than controls. In a study conducted on injecting drug users
in Mashhad prison, no association was found between HTLV-1 infection and a history of STIs and
the frequency of multiple sexual partners did not differ between the HTLV-1 positive and negative
groups [27]. In contrast, several studies have reported that HTLV-1 infection is associated with a
history of STIs or with having multiple sexual partners [23,28,29]. Rouet et al. demonstrated that
a history of STIs and Chlamydia seropositivity are indeed predictive factors for HTLV-1 infection
among blood donors from Guadeloupe, French West Indies [19]. In addition, Melbye et al. showed
278
Viruses 2015, 7, 5736–5745
significant correlation between having more than three partners and HTLV-1 infection among females
in Guinea-Bissau, West Africa. However, they could not find a significant correlation between a history
of gonorrhea and genital ulcer with HTLV-1 infection [30].
5. Conclusions
In summary, a history of blood transfusion, being born in the cities of Mashhad and Neyshabour,
having low education and income levels, and non-IDU were significantly associated to HTLV-1
infection in first-time donors from Mashhad, Iran. Failure to detect other well-known risk factors
linked to HTLV-1 infection such as breastfeeding, sexual promiscuity, and IDU could have been due,
in part, to a lack of variability or the small sample size used. Various blood safety programs, such as
pre-donation screening and deferral policies for blood donors with a history of possible risk factors for
transfusion-transmissible infections, might also have contributed to the reduction of blood donation
volunteers with these risk factors in Iran. However, a revision of the screening criteria such as a history
of transfusion for more than one year prior to donation is strongly recommended.
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Abstract: Background: indeterminate Western blot (WB) patterns are a major concern for diagnosis
of human T-cell lymphotropic virus type 1 (HTLV-1) infection, even in non-endemic areas. Objectives:
(a) to define the prevalence of indeterminate WB among different populations from Argentina; (b) to
evaluate if low proviral load (PVL) is associated with indeterminate WB profiles; and (c) to describe
mutations in LTR and tax sequence of these cases. Results: Among 2031 samples, 294 were reactive
by screening. Of them, 48 (16.3%) were WB indeterminate and of those 15 (31.3%) were PCR+.
Quantitative real-time PCR (qPCR) was performed to 52 HTLV-1+ samples, classified as Group 1
(G1): 25 WB+ samples from individuals with pathologies; Group 2 (G2): 18 WB+ samples from
asymptomatic carriers (AC); and Group 3 (G3): 9 seroindeterminate samples from AC. Median PVL
was 4.78, 2.38, and 0.15 HTLV-1 copies/100 PBMCs, respectively; a significant difference (p=0.003)
was observed. Age and sex were associated with PVL in G1 and G2, respectively. Mutations in the
distal and central regions of Tax Responsive Elements (TRE) 1 and 2 of G3 were observed, though not
associated with PVL.The 8403A>G mutation of the distal region, previously related to high PVL, was
absent in G3 but present in 50% of WB+ samples (p = 0.03). Conclusions: indeterminate WB results
confirmed later as HTLV-1 positive may be associated with low PVL levels. Mutations in LTR and tax
are described; their functional relevance remains to be determined.
Keywords: HTLV-1/2; proviral load; Western blot; indeterminate; mutations
1. Introduction
Human T-cell lymphotropicvirus type 1 and 2 (HTLV-1/2) are distributed worldwide. HTLV-1
infects an estimated 20 million people in the world and is considered the etiologic agent of adult
T-cell leukemia/lymphoma (ATLL), HTLV-associated myelopathy/tropical spastic paraparesis
(HAM/TSP), and HTLV-1 uveitis [1]. HTLV-1 presents foci of endemicity in the Caribbean,
Southeastern Japan, sub-Saharan Africa, the Middle East, and areas of South America, while HTLV-2
is naturally endemic in natives from Africa and aborigines of the Americas [1,2]. Concerning
phylogeny, seven subtypes have been identified within HTLV-1: cosmopolitan (a), Central African
(b and d), Melanesian (c), a variant from Zaire (e), one from Gabon (f), and one from Cameroon (g).
The cosmopolitan subtype, disseminated worldwide, is composed of five subgroups: transcontinental
(A), Japanese (B), West African (C), North African (D), and Black Peruvian (E) [3–5]. In Argentina,
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HTLV-1 cosmopolitan subtype transcontinental subgroup A is the major subgroup detected in the
endemic area of thenorthwest as well as in blood donors, pregnant women, and different at-risk
populations in non-endemic regions [6,7].
Mandatory screening for HTLV-1/2 in blood banks, which includes detection by an enzyme
immunoassay (EIA) or particle agglutination (PA), has been implemented in many countries so far.
According to the current algorithm, a serological confirmation, usually by Western blot (WB), should be
performed after reactive screening results [8]. However, despite improvements made in the WB assay
specificity over the past years, HTLV-indeterminate WB results continue to be frequent in blood donors,
mainly in inter-tropical areas, posing a major challenge for routine diagnosis worldwide [9–11].
It has been observed that the use of screening tests with low specificity significantly increases the
number of indeterminate WB results that are later confirmed negative for the infection by molecular
techniques [12]. Other possible explanations include cross-reactivity against other retroviruses or
microbial agents, as occurs with Plasmodium falciparum in Central Africa, Indonesia, and the
Philippines [13–15]. Regarding seroindeterminate cases later confirmed positive for the infection,
several hypotheses have been proposed such as the presence of defective virus or low copy numbers
of prototypic HTLV-1/2 that could be yielding a light antibody response [16]. Punctual mutations in
key viral genes could be another alternative. Netto et al. have reported an association between G232A
in the Tax Responsive Element (TRE) 1 and an increase in PVL levels [17]. Furthermore, it has been
observed that non-synonymous mutations of the HTLV-1 tax gene could display markedly attenuated
abilities to transactivate the provirus [18].
Over the last decade, a sensitive and specific nested polymerase chain reaction (n-PCR) assay able
to confirm HTLV-1/2 infections in individuals with an indeterminate profile or HTLV positive but
not typeable results by WB became an important tool for diagnosis [19,20]. Years later, quantitation of
HTLV-1 proviral load (PVL) by quantitative real-time PCR (qPCR) was implemented for the follow-up
of patients with associated pathologies worldwide [21–23]. Recently, both qPCR and multiplex
(mqPCR) have been proposed as molecular testing for the confirmation of HTLV-1/2 diagnosis, aimed
to address the issue of indeterminate results. However, according to reported data, these techniques
still show sensibility problems [24,25].
As a consequence of frequent indeterminate WB results leading to difficulties in interpretation
and counseling in our country, this study aims to (i) define the prevalence and banding profile
frequency of cases with indeterminate results by WB among different populations from Argentina;
(ii) evaluate whether a low PVL in HTLV-1 positive individuals is one of the causes of these results;
and (iii) identify the presence of punctual mutations, both in Long Terminal Repeats (LTR) and tax
regions, of indeterminate cases.
2. Results
2.1. Prevalence Studies
Prevalence of WB indeterminate results corresponding to samples from four different populations
of Argentina is shown in Table 1. Three of them, Men who have Sex with Men (MSM), Injecting Drug
Users (IDUs), and Female Sex Workers (FSW), belong to a previous epidemiological study [26]. The
remaining one, the HTLV Diagnosis and Confirmation population (HDC), is composed of individuals
referred from blood banks or hospitals to our Institute. The global methodology, including the number
of samples tested at each step, is illustrated in Figure S1. The total number of WB indeterminate
samples (IS) and, of those, the ones that were later confirmed as HTLV-1 or HTLV-2 positive by
molecular techniques, are also shown in Table 1.
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Table 1. Prevalence of HTLV-1/2 infection and frequency of WB indeterminate patterns in four
populations of Argentina. MSM: Men who have Sex with Men; IDU: Injecting Drug Users; FSW: Female
Sex Workers; HDC: samples received at a Reference Institute for HTLV Diagnosis and Confirmation




















MSM (N=667) 26 11 (1.65) 3 (27.28) 0 (0) 0.45% (3/667) c 0% (0/667)c
IDU (N=173) 36 4 (2.31 ) 4 (100 ) 2 b (100 ) 4.62% (8/173) c 15.6% (27/173) c
FSW (N=613) 25 3 (2.12) 3 (23.10 ) 0 (0 ) 1.46% (9/613) c 0.2% (1/613) c
HDC (N=578) 207 30 (5.19 ) 3 (15.79) a 2 (10.53)a 18.8% (109/578) 5.36% (31/578)
Total 294 48 (16.33) 13 (35.13) 4 (10.81) 6.35% (129/2031) 2.90% (59/2031)
aOut of 30 seroindeterminate samples, only 19 could be tested by molecular techniques, as no DNA was available
for the other 11. bThese two samples were HTLV-1/2 co-infected. cData reported by Berini et al. 2007 [26].
The different WB indeterminate banding patterns are detailed in Table 2 for all samples from
the HDC population (n=30), including positive and negative ones by n-PCR. The banding patterns
corresponding to the other three populations were previously described by Berini et al. 2007 [26].
Table 2. Description of WB indeterminate patterns for positive and negative samples by n-PCR among
578 samples received at a Reference Institute for HTLV Diagnosis and Confirmation (HDC) from blood









GD21 6 3 1 2
GD21 + others 7 3 3 1
rgp46-1 and/or 2 4 1 1 2
p19 2 2 0 0
p19 + p24 4 2 0 2
p19 + others 1 0 0 1
HGIP 6 3 0 3
Total 30 14 5 11
The following experiments were performed in nine out of 13 seroindeterminate confirmed HTLV-1
positive cases found among the four studied populations, as samples from the other four were scarce.
Figure 1 shows the banding pattern in each case.
2.2. Performance of the qPCR
The qPCR quantitation limit was 34 albumin copies/reaction and three pol copies/reaction.
Samples with seroindeterminate results were run together, and an additional dilution was added
to pol standard curve, as lower Threshold Cycle (Ct) values were expected. Acceptance criteria
were accomplished and linearity was maintained (R2> 0.99). The intra-assay coefficient of variation
(CV) was directly proportional to viral load levels: 14% at high load (>10 HTLV-1 copies/100 cells),
9% at medium load (1–10 HTLV-1 copies/100 cells), and 7% at low load (<1 HTLV-1 copy/100 cells);
inter-assay CV at high loads was 24%. Of the 52 samples, PVL was detected in 51 and successfully
quantified in 44 of them, including 25 pathology cases that were not in treatment at the time of
the sample extraction (G1), 15 samples from asymptomatic carriers (AC) (G2), and four from
seroindeterminate cases (G3), also AC. PVL was detected but not quantified in three G2 and four G3
samples, as the acceptance criteria was not met because of variable Ct values for pol gene. This viral
gene was not detected in one of the G3 samples, although it could be amplified by n-PCR.
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Figure 1. Western blot patterns of indeterminate cases confirmed HTLV-1 positive by n-PCR.
Seroreactivity pattern using the MPD HTLV Blot 2.4 kit, which contains a recombinant GD21 (common
for HTLV-1 and HTLV-2) and two synthetic peptides (rpg46-I and rpg46-II), specific either for HTLV-1
or HTLV-2. “HTLV-1”: HTLV-1 positive control. “C-“: negative control. 44–52: banding profile for each
of the nine seroindeterminate cases analyzed.
2.3. PVL Values
Individual PVL values are shown in Table 4. Median PVL values and standard errors were
4.78 (2.4), 2.38 (1.02), and 0.15 (0.07) HTLV-1 copies/100 PBMCs for G1, G2, and G3, respectively;
a significant difference could be observed between the three groups (p = 0.003), as shown in Figure 2a.
The difference was also significant (p = 0.005) when samples with seropositive WB results were
analyzed as a single group [G1 + G2]. As shown in Figure 2b, no significant difference (p = 0.07)
was observed when samples from acute leukemia (ATL; n = 4) were compared with HAM/TSP
ones (n = 21).
2.4. PVL Distribution
Regarding WB indeterminate samples, all successfully detected PVLs (8/9) were lower than
1 HTLV-1 copy/100 cells. Concerning G1 and G2 samples, an overlap in the range of PVL values
was observed (Table 3). In three cases, viral loads below 1 HTLV-1 copy/100 cells were observed in
individuals with pathology (12%).
Table 3. Individual proviral load values (PVL) distribution by groups (G). G1: positive samples by
Western blot (WB) from individuals with pathology; G2: positive samples by WB from asymptomatic
carriers (AC); and G3: indeterminate samples by WB from AC. PVLs are expressed as HTLV-1
copies/100 PBMCs.
PVL Range G1 (n=25) G2 (n=18) G3 (n=8)
<1 12% 44.4% 100%
1–10 52% 44.4% -
>10 36% 11.2% -
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Table 4. Age, gender, and individual proviral load values (PVL) of cases confirmed as HTLV-1 positive
by nested PCR (n-PCR). Samples were classified as Group 1: positive samples by WB from individuals
with pathology that are not on treatment (n = 25), Group 2: positive samples by WB from asymptomatic
carriers (AC) (n = 18), and Group 3: indeterminate samples by WB from AC (n = 9). Codes for 14 LTR
and/or tax sequences are detailed in brackets. Indeterminate patterns for G3 are also described in
brackets. PVLs are expressed as HTLV-1 copies/100 PBMCs.
Sample N˝ (Sequence Code) Group Age Gender PVL
1 1- Leukemia 53 M 33.9768
2 1- Leukemia 66 F 40.1995
3 (ATL1) 1- Lymphoma 48 F 1.2974
4 (ATL2) 1- Leukemia 67 F 12.4920
5 1- HAM/TSP 43 F 0.7081
6 1- HAM/TSP 14 F 8.9051
7 1- HAM/TSP 27 F 3.1244
8 1- HAM/TSP 38 F 1.6633
9 1- HAM/TSP 52 F 8.5679
10 1- HAM/TSP 65 M 5.3882
11 1- HAM/TSP 37 F 1.2808
12 1- HAM/TSP 51 F 4.7829
13 (Neu28) 1- HAM/TSP 42 F 13.0850
14 (Neu14) 1- HAM/TSP 39 F 1.0119
15 1- HAM/TSP 52 M 35.0971
16 1- HAM/TSP 59 F 12.8610
17 1- HAM/TSP 50 M 1.3508
18 1- HAM/TSP 56 F 29.5394
19 1- HAM/TSP NA M 0.1183
20 1- HAM/TSP 26 F 3.1234
21 1- HAM/TSP 71 F 10.4542
22 1- HAM/TSP 35 M 0.5227
23 1- HAM/TSP 67 F 1.6661
24 1- HAM/TSP 52 M 15.5252
25 1- HAM/TSP 49 M 4.0326
26 2 50 M 12.4340
27 2 64 M 1.8929
28 2 50 M 0.0832
29 2 46 F 1.2681
30 (ASYAR3) 2 35 M 4.6143
31 (ASYAR2) 2 26 F 0.7502
32 2 47 F 0.2476
33 2 25 M 8.4668
34 2 33 M 2.3861
35 2 39 F 2.8778
36 (ASYAR1) 2 47 F 0.4813
37 2 52 F <3 copies/ reaction
38 2 NA F <3 copies/ reaction
39 2 38 F 0.1832
40 (BDAR20) 2 38 M 3.9461
41 2 57 M 5.9663
42 2 NA M <3 copies/ reaction
43 2 46 M 10.5358
44 3 (p19) 59 M 0.0013
45 3 (p19) 24 M 0.3365
46 (BDAR21) 3 (GD21) 28 M 0.1493
47 (BDAR18) 3 (p24, GD21) 52 M 0.1452
48 (FSW8) 3 (HGIP) 32 F <3 copies/ reaction
49 (FSW9) 3 (p19) 52 F <3 copies/ reaction
50 (FSW7) 3 (p19) 25 F <3 copies/ reaction
51 (BDAR19) 3 (GD21) 31 M <3 copies/ reaction
52 3 (HGIP) 21 M pol not detected
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Figure 2. Individual proviral load values (PVLs). PVLs are expressed as HTLV-1 copies/100 PBMCs.
(a) Samples are classified as Group 1: positive samples by Western blot (WB) from individuals with
pathology that are not on treatment (n = 25), Group 2: positive samples by WB from asymptomatic
carriers (AC) (n = 15), and Group 3: indeterminate samples by WB from AC (n = 4); PVL values are
shown. A significant difference is observed between the three groups (p = 0.003) (GraphPad Prism
V5). (b) PVLs for samples of Group 1, classified by disease: ATLL (n = 4) or HAM/TSP (n = 21) are
shown, p = 0.07.
2.5. PVL Association with Gender, Age, and Optical Density
A moderate correlation (S=0.56) between PVL values and age at the moment of the sample
extraction was observed in G1, which included patients with pathology who were not in treatment.
Meanwhile, there was a significant association between PVL and gender in G2 (p = 0.01) (Figure 3).
No correlation was observed in G3. Significantly lower optical density values were observed in most
of the seroindeterminatesamples (n = 6/7), when compared with plasma samples from G1 and G2
selected randomly.
Figure 3. Median individual proviral loads (PVL) of G2 samples distrubuted by gender. A significant
association (p =0.01) is observed between PVL and gender in Western blot (WB) positive samples from
asymptomatic carriers (AC) distributed as: Males (n = 9) and Females (n = 6). Median PVL values were
4.61 in males and 0.61 in females. Median values together with interquartile ranges are shown.
2.6. HTLV-1 Phylogeny
A rooted neighbor-joining (NJ) tree of 134 HTLV-1 strains based upon a 458-bp fragment
of the LTR region was performed, including 14 new strains from Argentina (G1: n=4; G2: n = 4;
G3: n = 6); three G3 sequences could not be obtained. Cosmopolitan subtype HTLV-1a was clearly
separated from HTLV-1 subtypes b, c, d, e, f, and g, with a bootstrap value of 69%. Within the
cosmopolitan subtype, five subgroups were identified as previously described [4]. Although all of
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them were consistently separated by NJ, only two subgroups, West African/Caribbean subgroup
C and North African subgroup D were well supported, showing higher bootstrap values than
75% (90% and 96%, respectively). Thirteen strains clustered within the cosmopolitan subtype
transcontinental subgroup A, while the remaining one (N˝ 13, Neu28) from G1 clustered among
sequences from Brazil and Peru previously reported by our group as Divergent Strains (Figure S2).
Of these, five strains (ASYAR2, N˝31; BDAR20, N˝40; ASYAR3, N˝30; ATL2, N˝4; and Neu14, N˝14)
grouped with sequences from the Big Latin American cluster and three sequences (BDAR21, N˝46;
ATL1, N˝3; and BDAR19, N˝51) from the Small Latin American cluster. All eight sequences from the
Latin American clusters grouped with Amerindian strains and other populations from Argentina
previously reported by our group. One of the G3 strains (FSW7, N˝50) grouped in the South African
cluster along with one Argentine blood donor (BD1) and one Peruvian female sex worker (FSW1)
residing in Argentina. The remaining four (BDAR18, N˝47; FSW8, N˝48; FSW9, N˝49; and ASYAR1,
N˝36) clustered within the transcontinental group, near the other Argentine sequences previously
reported by our group but not in any specific cluster.
2.7. Sequence Analysis
LTR and tax genes could be amplified in eight and four of all the seroindeterminate cases analyzed,
respectively. Of those, six LTR and two tax sequences could be obtained with high quality, despite
having repeated the procedure several times and assayed different DNA amounts with the remaining
samples. A total of 25 mutations were detected among LTR sequences from G3 samples, of which
seven were linked to geographical subtypes. Four mutations were observed in more than one sequence
and the remaining 14 in only one, as detailed in Table 5. Of them, one mutation in the TRE-1 domain
was present in the distal (dr) and one in the central (cr) region of the LTR. Regarding the TRE-2,
two punctual mutations (8522T>C, 8545G>A) were observed in sample N˝ 50, while the other three
were present in most Argentine sequences. While not found in any of the LTR sequences from G3,
a mutation was observed in the distal region of TRE-1 (8403A>G) in 50% of the remaining sequences,
which corresponded to samples with positive HTLV-1 results by WB and a significant difference
(p = 0.03) between these frequencies was established. As for sequences from patients with pathology,
eight (2 ATL and 6 HAM/TSP) out of 15 had this same mutation, thus maintaining the significance
(p = 0.04).
Tax sequences showed 12 punctual mutations at the nucleotide level; of them, five were present
in most of the Argentine sequences. Through the analysis of non-synonymous (NS) mutations in
functional domains of the Tax protein, four amino acidic mutations were detected, two of them
corresponding to geographical subtypes (A221V, S304N). The remaining mutations (H43P and M154V)
were detected in sequences N˝ 46 and 47, respectively; H43P is located within the Nuclear Localization
Signal domain, the Zn Finger, and CREB activation by Tax, while M154V is in the NF-κB activation
region and the Dimerization Domain.
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Table 5. Punctual mutations detected in LTR (U-3, R, and U-5) and tax gene sequences of indeterminate
Western Blot samples confirmed as HTLV-1 positive by nested PCR. Six LTR and two tax sequences
from seroindeterminate samples were analyzed, together with four sequences from HTLV-1 patients
with pathology, four from HTLV-1 asymptomatic carriers, and 44 sequences from Argentina, previously
obtained by our group and available in Gene Bank. Geographical: mutation linked to geographical
subtypes; dr: distal region; cr: central region.
Punctual Mutation Sequence N˝ Region Punctual Mutation Sequence N˝ Region
8295G>A 46- 48 LTR; U-3 8718C>T 51 LTR; R
8367C>A Geographical LTR; U-3 8779T>C 47 LTR; R
8381G>A 48 LTR; U-3 8822G>A 46 LTR; R
8391G>A 46 LTR; U-3 8828A>G 47 LTR; R
8392G>A 46 LTR; U-3 8912T>C 46- 47 LTR; U-5
8420C>T 49 LTR; U-3; TRE-1; dr 8955G>A 47 LTR; U-5
8428_8429insA Geographical LTR; U-3; TRE-1 7383C>T 46 tax
8446G>A Geographical LTR; U-3; TRE-1 7398C>T 46- 47 tax
8471G>T 50 LTR; U-3; TRE-1; cr 7401C>T Geographical tax
8509A>G Geographical LTR; U-3; TRE-2 7431G>A 47 tax
8509_8511delA Geographical LTR; U-3; TRE-2 7448A>C 46 tax
8522T>C 50 LTR; U-3; TRE-2 7780A>G 47 tax
8545G>A 50 LTR; U-3; TRE-2 7914T>C Geographical tax
8546T>C Geographical LTR; U-3; TRE-2 7920C>T Geographical tax
8606C>G Geographical LTR; U-3 7933C>T 47 tax
8606C>A 49- 51 LTR; U-3 7982C>T Geographical tax
8632G>A 46 LTR; U-3 8001A>G 46 tax
8655G>T 46 LTR; U-3 8231G>A Geographical tax
8665C>T 46- 48 LTR; R
3. Materials and Methods
3.1. Samples
A retrospective cross-sectional study was carried out on four different populations. Of those,
Injecting Drug Users (IDU; n = 173), Female Sex Workers (FSW; n = 613), and Men who Have
Sex with Men (MSM; n = 667) have been previously recruited and studied by our group; the
corresponding HTLV-1/2 prevalence was reported in Berini et al. [26]. The fourth population included
individuals with previous serological reactive results for HTLV-1/2 and/or with symptoms of HTLV-1
associated pathologies, whose samples have been sent from blood banks and/or hospitals from all
over Argentina to our Institute for HTLV diagnosis or confirmation (HDC) between January 2011 and
January 2014. The prevalence of the former population is reported here. All participants provided
a written informed consent and the project was approved by the Institutional Review Board of
Nexo Civil Association, Argentina. Samples confirmed as HTLV-1 positive by molecular techniques
were classified in three different groups (G). G1 consisted of all the positive samples by WB from
individuals with pathology who were not on treatment received for HDC between 2011 and 2014:
21 HAM/TSP patients and 4 Acute Leukemia Lymphoma (ATLL) patients. G2 included 18 WB positive
samples from asymptomatic carriers (AC), who were chosen randomly for this study. G3 included 9
indeterminate samples by WB, also from AC. Serological and socio-demographic information of all
nine G3 individuals is described in Supplementary Table 1.
3.2. Diagnostic Algorithm
Antibody screening for HTLV-1/2 was performed by particle agglutination technique
(SERODIA-HTLV-I, Fujirebio, Tokyo, Japan) and/or by enzyme-linked immunosorbent assay
(ELISA) (Murex HTLV-I+II, Abbott Laboratories Argentina, Buenos Aires, Argentina or HTLV
I&II Ab v. ULTRA, Dia.Pro, Milan, Italy). Reactive samples were subjected to WB confirmation
(HTLV blot 2.4, Genelabs Diagnostics, Science Park, Singapore). A WB was scored as HTLV-1 or
HTLV-2 positive, untypeable, indeterminate, or negative according to the manufacturer’s criteria.
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For molecular confirmation of indeterminate or HTLV-positive samples by WB, DNA was
extracted from peripheral blood mononuclear cells (PBMCs) by column extraction (ADN PuriPrep-S
kit, Highway, Inbio, Tandil, Argentina) and analyzed with “in-house” n-PCR for HTLV-1 and
2 pol and tax regions as previously described [19,20]. PCR was considered positive when amplicons
from at least one amplification reaction were clearly detectable following agarose gel analysis [11].
Samples with non-reactive results by PA or ELISA were also further confirmed by n-PCR in
order to avoid misdiagnosis in patients on retroviral treatment (because of other infections) and
immune-compromised patients.
3.3. DNA Quantitation
Absolute quantitation of PVL was performed by real-time SYBR Green PCR, using an ABI
Prism 7500Prism System (Applied Biosystems, Foster City, CA, USA).The HTLV-1 pol gene
was amplified using 5 μL DNA, 12.5 μL SYBR Green PCR Master Mix (Applied Biosystems),
and 200 nM of each primer (SK110-1: 5’-CCCTACAATCCAACCAGCTCAG-3’ and SK111-1:
5’-GTGGTGAAGCTGCCATCGGGTTTT-3’). PCR amplification of the albumin gene (ALB-S:
5’-GCTGTCATCTCTTGTGGGCTGT-3’ and ALB-AS: 5’-AAACTCATGGG AGCTGCTGGTT-3’) was
performed as a separate reaction, as an endogenous reference to avoid variation due to differences in
either the PBMC number or the DNA extraction method used. Cycle conditions were the following:
2 min at 50 ˝C and 10 min at 95 ˝C followed by 40 cycles of 15 s at 95 ˝C and 1 min at 65 ˝C. Melting
curves were performed after the end of the amplification cycles to validate the specificity of the
amplified products. Standard curves were generated using 10-fold serial dilutions of DNA from MT2
cells (104–100), and normalized to two copies of the HTLV-1 pol gene and two copies of the cellular
albumin gene per MT2 cell [27]. All standard dilutions, controls, and individual samples were run
in triplicate for both HTLV-1 and albumin DNA quantitation. Standard curves were accepted when
slopes were between –3.10 and –3.74 and the R2 was >0.99 [28]. The accuracy of the diagnostic
test was assessed by measuring intra-assay and inter-assay variability. Intra-assay variability was
evaluated by calculating the coefficient of variation (CV) of three viral load replicates from three
DNA samples in three different ranges defined as low (<1 HTLV-1 copy/100 cells), medium
(1–10 HTLV-1 copies/100 cells), and high (>10 HTLV-1 copies/100 cells). Inter-assay variability was
calculated by measuring the CV for a high PVL sample in three independent runs. CV rather than
standard deviations were used as they are not affected by the PVL absolute value. HTLV-1 proviral
load was reported as [(pol average copy number)/(albumin average copy number/2)]*100 and
expressed as the number of HTLV-1 copies/100 cells.
3.4. Molecular Analysis
Indeterminate samples were subjected to hemi-nPCR, aimed at amplifying LTR
and tax genes. Amplification of the 3’ LTR region was performed using 8200LA
(5’-CTCACACGGCCTCATACAGTACTC-3’) and R2 (5’-GTGCTATAGGATGGGCTGTCGC-3’)
as outer primers and 3VINT (5’-GAACGCRACTCAACCGGCRYGGATGG-3’) and 3LTRf
(5’-TCCCCATTTCTCTATTTTTAACG-3’) as inner primers (528 bp, ATK-1 genome position
8196–8699). Amplification of the tax region was carried out with outer primers HFL75
(5’-GCTATAGTCTCCTCCCCCTGC-3’) and 3VINT (5’-GAACGCRACTCAACCGGCRYGGATGG-3’)
and inner primers TaxF (5’-ATGGCCCACTTCCCAGGGTT-3’) and TaxR (5’-TCAGACTTCTGTTTCTCGGA-3’),
specific for HTLV-1. A slight modification was made to the protocols described elsewhere, in order to
amplify tax and LTR genes in seroindeterminate samples by enhancing the DNA amount [29]. Direct
sequencing reactions were done using a Big Dye Terminator 3.1 Cycle Sequencing RR-100 (Applied
Biosystems). Sequences were generated on a 3500xL Genetic Analyzer AB/HITACHI according to the
manufacturer’s instructions. Sequences were edited manually (Sequencher 4.8) and then aligned using
Clustal W (BioEdit 7.0.4.1 sequence alignment editor). For the sequence analysis of both genes, the
ATK-1 genome was included as a reference prototype sequence and four samples from G1 together
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with four samples from G2 included as controls. Furthermore, 50 LTR sequences were also added, all
of them corresponding to samples from Argentina and available in PubMed. MEGA software v. 5.2.2
was used for translation of tax gene sequences, based on the conventional genetic code.
To construct a comprehensive phylogenetic dataset, 14 of the LTR sequences (six seroindeterminate samples,
four from HTLV-1 patients with pathology, and four from HTLV-1 AC) (See 5.5 “Accession numbers”)
were aligned along with 120 HTLV-1 reference strains obtained from the GenBank database,
preferentially chosen because they were either from Argentina or from neighboring countries with
high migration rates to Argentina. The Mel 5 reference strain (Melanesian origin, subtype c) was used
as an outgroup. Once aligned, the dataset consisted of 458 bp corresponding to the 3´ LTR region. The
phylogenetic analysis was performed by neighbor joining (NJ) using MEGA 5.2 and the tree topology
was visualized with TreeView (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html) [30].
3.5. Accession Numbers
Accession numbers corresponding to all new sequences mentioned here are detailed below.
ASYAR2LTR: KT633516; BDAR20LTR: KT633517; FSW7LTR: KT633518; ASYAR3LTR: KT633519;
BDAR19LTR: KT633520; FSW8LTR: KT633521; Neu14LTR: KT633522; BDAR18LTR: KT633523;
BDAR21LTR: KT633524; FSW9LTR: KT633525; ASYAR1LTR: KT633526; ATL1tax: KT633527; Neu2tax:
KT633528; ASYAR2tax: KT633529; BDAR18tax: KT633530; ATL2tax: KT633531; ASYAR1tax:
KT633532; ASYAR3tax: KT633533; BDAR20tax: KT633534; Neu14tax: KT633535; BDAR21tax:
KT633536. The following numbers correspond to the sequences obtained from GenBank for
the molecular analysis. MEL5 (L02534); Efe1 (Y17014), ITIS (Z32527), PH236 (L76307); 2810YI
(AY818432); Lib2 (Y17017); pyg19 (L76310); HS35 (DI3784), FrGu1 (AY324785), BO (U12804),
Pr52 (U12806), Pr144 (U12807), Bl1.Peru (Y16481), RKl4.Peru (AF054627), BCl2.1 (U32557),
H5 (M37299), Ni1-3.Peru (Y16484, Y16487, Y16485), ATL-YS (U19949), ATK-1 (J02029),
MT4.LB ( Z31661), Br4 (AY324788), Bl3.Peru (Y16483), Neu13 (EU622623), Neu10 (EU622620),
MT2 (L03562), 73RM (M81248), Ar11 (AY324777), FSW6 (EU622605), MSM2 (EU622609),
BD7 (EU622588), Sur229-30 (AY374468, AY374466), BD3 (EU622586), BD10 (EU622590), TBH1-3
(L76026, L76025, L76034), FSW1 (EU622600), BD1 (EU622584), BD8 (EU622589), Gya468 (AY374459),
Gya813 (AY374462), SurHM22 (AY374467), Gya542 (AY374460), BOI (L36905), BD13 (EU622593),
BRRJ136.96 (DQ323759), KUW1-2 (L42253, L42255), IRN2 (U87261), CH26 (D23690), Abl.A (U87264),
BCl1.2 (U32552), BRRP445 (DQ323755), BRRJ276.95 (DQ323750), BRRJ56.00 (DQ323754), BRRJ53.97
(DQ323753), Neu4 (EU622615), PW2 (EU622625), Neu5 (EU622616), MSM4 (EU622611), IDU4
(EU622608), Neu3 (EU622614), BD2 (EU622585), CAM (AF063819), BRRJMDP (DQ323751), ARGSOT
(AF007755), AMA (X88871), CMC (X88872), TBH4 (L76028), BRRP495(DQ323755), FSW4 (EU622603),
Me3.Peru (Y16480), Ar55 (AY324782), FSW5 (EU622604), Sur1597 (AY374465), Gya572 (AY374461),
Neu1 (EU622612), FSW2 (EU622601), JCP (X88875), BRRJFA (DQ323757), Me1.Peru (Y16478), MASU
(X88877), FCR (X88873), BRRJ86.97 (DQ323760), MAQS (X88876), Ar5 (AY324783), Qu2.Peru (Y16476),
Me2.Peru (Y16479), Qu3.Peru (Y16477), J37 (FJ751855), BD16 (EU622596), IDU1-3 (EU622598, EU622606,
EU622607), BD15 (EU622595), BD14 (EU622594), BD12 (EU622592), Neu11 (EU622621), BD11
(EU622591), J77 (FJ758161), J43 (FJ751856), BD4 (EU622587), J68 (FJ751858), J20 (FJ751854), Neu12
(EU622622), Ar49 (AY324793), Ar15 (AY324778), PW1 (EU622624), FSW3 (EU622602), Qu1.Peru
(Y16475), Neu7 (EU622618), ARGDOU (AF007751), Neu8 (EU622619), BD17 (EU622597), J47 (FJ751857),
MSM3 (EU622610), Neu2 (EU622613).
3.6. Statistical Analysis
Data analysis was performed using the Kruskal–Wallis non-parametric method; when two groups
were compared, the Mann–Whitney–Wilcoxon test was used. To evaluate the presence of association
between PVL and age of individuals, correlation was determined based on Spearman coefficient
(S). GraphPad Prism (version 6.03) software was applied and significant differences were defined
as p < 0.05.
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4. Discussion
HTLV indeterminate WB patterns have been reported worldwide, although they are more frequent
in tropical areas [31,32]. Most of these reports refer to blood donors, and seroindeterminate frequency
varies according to HTLV-1/2 endemicity (i.e., the geographical area studied) [27,33]. In this study,
we report for the first time in our country the prevalence of indeterminate WB results among at-risk
populations: 2.31%, 2.12%, and 1.65% for IDUs, FSW, and MSM, respectively. Moreover, the prevalence
of indeterminate WB patterns (5.19%) in the HDC population recruited in our Institute was higher than
the one reported in our country for blood donors (0.1%), as expected due to a biased population [27].
On the other hand, it must be considered that screening in our laboratory has always been performed
with the most efficient assays available in the country. Concerning the indeterminate WB banding
patterns in the HDC population (both positive and negative cases by n-PCR), GD21 (alone or with
other bands) and HGIP were the most frequent. Several studies have demonstrated the presence of
HGIP patterns mostly among blood donors, and it has been suggested that generally these are not
caused by HTLV-1 infection [32]. Nonetheless, as reported previously by our group, two HGIP cases
corresponded to samples that turned out positive for HTLV-1 infection (one blood donor and one
IDU) [10]. Regarding the “N pattern” recently described by Filippone et al., it was not observed neither
in the HDC population, nor in at-risk populations (pattern described in Berini et al [26]) [11].
There are few reports suggesting that low HTLV-1/2 PVL could cause indeterminate WB patterns
in samples from infected individuals [16,34]. Regarding HTLV-1, low PVL levels for these cases were
suggested, especially in the ones in which no PVL could be successfully quantified, although no
direct comparisons with seropositive patients were performed [35–37]. In this study, PVL values were
compared between two groups with positive WB results: G1 (individuals with pathology without
retroviral treatment) and G2 (asymptomatic carriers: AC). A significant difference was observed
between them, in line with previously published data [21,22]. Furthermore, a third group was
included consisting of nine samples from AC with seroindeterminate WB, of which four PVLs could be
determined. Even when considering the small sample size of G3, a significant difference was observed
between these three groups. Although a seroconversion could not be discarded in the indeterminate
cases, these data demonstrate that in some cases indeterminate WB results could be associated with
low HTLV-1 PVL; a low viral replication rate may consequently trigger a weak immune response and
low concentrations of anti-HTLV-1 antibodies.
Regarding age and gender, it was determined that these variables were associated with PVL levels
among G1 and G2, respectively. While Vakili et al. observed no significant association between PVL
in HAM/TSP patients and healthy carriers with age and gender, it has been reported that for both
HTLV-1 and 2 infections, women have lower PVL levels than men, consistent with our results [38–40].
In contrast, Hisada et al. showed no gender differences in PVL [41]. Thus, further studies should
be performed in order to clarify this issue. Regarding serological status, Manns et al. reported in
1999 that the anti-HTLV-1 antibody titer had a positive correlation with PVL levels, and years later,
Akimoto et al. confirmed these results [42,43]. In this study, and similarly to what has been reported
by Filippone et al., the optical density values obtained were lower for most of the seroindeterminate
profile plasma samples when compared to HTLV-1 WB-positive ones [11].
As for phylogeny, all 14 new strains described in this study belonged to the cosmopolitan subtype
and most of them classified within the transcontinental subgroup A (one sample classified as divergent).
Half of the G3 sequences did not group in any specific cluster, while two grouped in the small Latin
American cluster (BDAR19, BDAR21) and one in the South African cluster (FSW7), together with other
sequences previously reported by our group (FSW1 and BD1) [44]. These data confirm our previous
publication concerning the presence of HTLV-1 transcontinental and African strains circulating in
Argentina, although most of the infected individuals in our study were not of black origin, supporting
the hypothesis of multiple introductions of HTLV-1 of the cosmopolitan subtype in the New World [5].
Even though some of the observed mutations in LTR and tax genes were linked to geographical
subtypes, others were further analyzed in order to establish their relevance, as it is well known that
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during replication and transcription the LTR/Tax system is extremely important. The promoter region
LTR responds to the transactivation mediated by the Tax protein, which directly interacts by binding
the DNA or indirectly by binding cellular transcription factors, in the Tax regulation elements known
as TRE-1 and TRE-2 [45]. Although mutations in sequences from G3 were observed both in the
distal and central regions of TRE-1, no significant associations were established given the number of
mutated sequences. The same is valid for the TRE-2 region, which can also mediate transactivation by
Tax-1 [46,47], considering that it contains binding sites for a large number of transcription factors,
including AP-2, HNF-3, Ets family members, NFκB, and Sp1 [48]. Interestingly, we have not observed
the 8403A>G mutation (distal region of TRE-1) in any of the G3 sequences, although it was present
in 50% of the remaining sequences, all of them positive by WB. Therefore, a significant association
was established between the presence of this mutation and seropositivity. Particularly, 53% of
sequences from patients with pathology were mutated in base 8403, consistent with a report from
Brazil, in which this mutation was significantly associated with high PVL values [17]. Regarding
the Tax protein, non-synonymous mutations in the CREB activation domain as well as in the NF-κB
and Zn Finger activation domains were detected. Previous data indicate that mutations in these
regions displayed markedly attenuated abilities to transactivate the provirus and to reduce the
ability to induce nuclear expression of NF-κB [18]. Whether the presence of mutations observed in
this study could explain a diminished transactivation activity of Tax protein and therefore a low
PVL still remains to be determined. Only functional studies would indicate their possible impact on
indeterminate WB profiles.
Considering diagnosis, indeterminate WB results cannot be avoided without an improvement
of serological commercial kits aimed at enhancing sensibility and specificity. Thus, and taking into
account the high prevalence of these seroindeterminate cases worldwide [10,11,49], the usefulness of
serological confirmation is questionable, highlighting the difficulties in interpretation and counseling.
Seroindeterminate results represent a big challenge for health professionals, especially in those
countries with endemic areas and no national programs for controlling HTLV infection. Furthermore,
WB kits are far more expensive than n-PCR, being a relevant factor for the healthcare system. Costa
and Thorstensson et al. have recommended different strategies for reducing costs and improving
the accuracy of the diagnosis [24,50]. While both proposed two EIAs for screening, Costa recommends
qPCR to confirm the infection. Even though qPCR is actually the standard method for PVL
quantitation, other technologies have also been introduced. Recently, an mq-PCR testing algorithm
for the diagnosis of HTLV-1/2 infection has been proposed [25]. Nevertheless, in some serologically
confirmed positive cases, PVL could not be detected, especially in HTLV-2 samples [25,51]. In that
context, Brunetto et al. reported the utility of digital droplet PCR (ddPCR) in the quantitation of
HTLV-1 PVL [52]. They postulate that, even though both methods show a strong correlation and
similar performance, ddPCR exhibits lower inter and intra-assay variability as it is based on a Poisson
algorithm for quantitation of genes instead of the standard curve used in qPCR [52]. On the other
hand, another study showed a higher sensitivity for qPCR compared to ddPCR when detecting
cytomegalovirus in clinical samples [53]. Based on these data, more studies should be performed
in order to establish the most efficient methodology for HTLV-1/2 PVL quantitation. Furthermore,
a consensus regarding qPCR data interpretation and analysis for HTLV-1/2 PVL quantitation, as well
as a universal expression unit, should be achieved in order to avoid confusion and misunderstanding.
Besides, most HTLV-1/2 endemic areas correspond to developing countries and access to qPCR
equipment is not always possible.
Therefore, we propose to re-evaluate the diagnostic algorithm, considering molecular confirmation
by n-PCR for reactive samples, instead of qPCR, right after the combination of two screening tests. This
alternative would avoid serological confirmation by WB, the most expensive stage of the diagnosis
algorithm, until a better confirmation technique is available and standardized. Further studies with
significant panels including HTLV-1, HTLV-2, and indeterminate samples should be carried out in
order to establish whether it is time saving, effective, and less expensive.
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5. Conclusions
This study describes the prevalence of indeterminate WB patterns among different populations
from Argentina and demonstrates that in some cases these profiles may be associated with low HTLV-1
PVL. Mutations in LTR and tax have been described among both indeterminate and positive HTLV-1
cases, highlighting 8403A>G in the distal region of TRE-1, already related to high PVL. Still, the
functional relevance of these mutations remains to be determined.
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